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Resumen 
 
Los 1H-1,2,3-triazoles son compuestos heterocíclicos que durante los últimos 15 
años han atraído un enorme interés debido a sus crecientes aplicaciones en campos tales 
como la química farmacéutica o la ciencia de materiales, así como por su fácil preparación a 
través de cicloadiciones “click” azida-alquino catalizadas por Cu(I) o Ru(II) y mediante 
organocatálisis a partir de compuestos carbonílicos y azidas. Además, su N3-alquilación 
regioselectiva proporciona sales de 1,2,3-triazolio cuya química, menos estudiada, posee 
aplicaciones más específicas. 
 
El propósito general de esta Tesis Doctoral es identificar ámbitos poco explorados 
de la química de los 1,2,3-triazoles y demostrar que sus propiedades estructurales y 
electrónicas así como las de sus sales de N-alquil triazolio pueden aprovecharse para llevar a 
cabo transformaciones, tanto estequiométricas como catalíticas, que permitan acceder a 
nuevos compuestos heterocíclicos. Para ello, se han planteado los siguientes objetivos: 
1. Diseñar y sintetizar 1H-1,2,3-triazoles como plantillas moleculares de fármacos 
reguladores de [Ca
2+
] intraplasmático en músculo esquelético. 
2. Crear una metodología para la transformación de triazoles 1,4-disustituidos en     
1,5-disustituidos via N-desalquilación regiocontrolada de sales de triazolio. 
3. Estudiar la utilidad de los 1,2,3-triazoles como agentes directores en reacciones de 
funcionalización C−H catalizadas por metales de transición. 
Seguidamente se resumen los principales resultados alcanzados durante la 
realización del trabajo experimental. 
 
  
 
1. 1H-1,2,3-triazoles como plantillas moleculares de fármacos reguladores de [Ca2+] 
intraplasmático en músculo esquelético. 
Para alcanzar el primer objetivo, se llevó a cabo un estudio de docking 
computacional con estructuras triazólicas sobre una zona de contacto entre el canal de calcio 
receptor de rianodina RyR1 y la Calstabina-1, su proteína reguladora. Ello permitió 
identificar varios 1H-1,2,3-triazoles 1,4-disustituidos con grupos 1-carboxialquilo y             
4-ariltiometilo, adecuados para el diseño de moduladores de la interacción alostérica 
RyR1/Calstabina-1 que regula la concentración de ión calcio en músculo esquelético. 
 
La síntesis de los triazoles carboxílicos enantiopuros se llevó a cabo con 
rendimientos globales del 45-85% a partir de α-aminoácidos en una transformación         
“one-pot” que incluyó la combinación de una reacción de N-diazotación y otra de 
cicloadición CuAAC de los α-azidoácidos intermedios con alquinos de tipo                          
3-ariloxipropargilo o 3-ariltioprogargilo. Alternativamente, se emplearon α-azidoésteres 
metílicos quirales (p.ej. HPheOMe, HValOMe) como compuestos de partida, pero los ésteres 
triazólicos resultantes sufrieron una racemización parcial cuando se saponificaron para dar 
los α-aminoácidos finales. 
La evaluación biológica de los 11 triazoles carboxílicos sintetizados indicó que 
ninguno de ellos presenta citotoxicidad in vitro frente a cultivos de mioblastos murinos 
(C2C12) ni humanos (LHCN-M2) hasta el rango milimolar. También se demostró que el 
compuesto 1-carboximetil-4-[3-(metoxi)-feniltiometil]-1,2,3-triazol (15) es capaz de 
disminuir en un 75% la concentración de Ca
2+
 intraplasmático en miocitos distróficos, 
disminuye un 30% el número de núcleos centrales en miotubos tras la administración oral 
durante 5 semanas a dosis 0.8 mM e incrementar en un 40% la fuerza de agarre muscular in 
vivo en ratones mdx, modelos de la distrofia muscular de Duchenne.  
De cara a favorecer la capacidad de los nuevos triazoles carboxílicos moduladores 
de RyR1 para atravesar la barrera hematoencefálica (BBB), se ha estudiado mediante 
  
 
técnicas de RMN su complejación con β-ciclodextrina (β-CD) en agua a 25ºC. La 
correlación entre la variación de desplazamientos químicos (Δδi) y la fracción molar de cada 
componente en series de experimentos 
1
H-RMN permitió confirmar la formación de un 
complejo de inclusión β-CD/Trz 15 de estequiometría 1:1 y una constante de asociación 
Ka=428 M
-1
. Además, la topología de la interacción indicó que el compuesto 15 interacciona 
con la cavidad hidrofóbica de la β-CD a través de su fragmento aromático y no por el anillo 
triazólico. 
2. Transformación de triazoles 1,4-disustituidos en 1,5-disustituidos via                      
N-desalquilación regiocontrolada de sales de triazolio. 
En la segunda parte de la Tesis se ha desarrollado una metodología para preparar 
nuevos 1,2,3-triazoles 1,5-disustituidos que incorporan grupos funcionales tales como azidas 
o alquinos terminales, a partir de 1-pivaloiloximetil-1,2,3-triazoles y alcoholes 
funcionalizados siguiendo una estrategia “one-pot” basada en una secuencia de                     
N-alquilación / N-desalquilación regiocontrolada. 
 
La secuencia comenzó con la formación de triflatos de alquilo a partir de alcoholes 
y anhídrido trifluorometanosulfónico en condiciones heterogéneas empleando KHCO3 como 
base. La N3-alquilación de 1-pivaloiloximetil-1,2,3-triazoles con dichos triflatos de alquilo 
en ausencia de disolvente proporcionó las correspondientes sales de 1,2,3-triazolio N1, N3, 
C4-trisustituidas con rendimientos prácticamente cuantitativos. Por su parte, la reacción de 
N-desalquilación del grupo pivaloiloximetilo transcurrió in situ en condiciones básicas 
suaves (K2CO3, MeOH) proporcionando una variedad de 1,2,3-triazoles 1,5-disustituidos y 
1,4,5-trisustituidos funcionalizados con grupos de reactividad latente (azida, alquino 
terminal) en ausencia de metales y con rendimientos globales del 55-74%.  
Un estudio computacional Ab initio (B3LYP/6-31G*) permitió cuantificar una carga 
formal NBO de +0.08 para el carbono metilénico en el grupo pivaloiloximetilo enlazado a un 
  
 
catión triazolio, mientras que un grupo metilo equivalente mostró una carga de -0.48. Este 
incremento de electrofilia se confirmó en los perfiles de energía libre de la reacción SN2 
entre el 3,4-dimetil-1-pivaloiloximetil 1,2,3-triazol y el anión hidróxido a través de un estado 
de transición de ΔG‡ = 4.6 kcal/mol en el que el anillo de triazolio 1,5-disustituido actúa 
como grupo saliente. 
La reactividad latente de varios 1,5-triazoles con sustituyentes conteniendo un grupo 
azido terminal se aprovechó para realizar cicloadiciones CuAAC con alquinos a través del 
mismo. De este modo se obtuvieron sistemas triazólicos dobles 1,4- y 1,5-sustituidos de 
forma no simétrica y enlazados entre sí por cadenas alifáticas. 
Por último, la metodología de N-alquilación / N-desalquilación también se aplicó a 
la obtención de bis(1,2,3-triazoles) enlazados directamente por las posiciones C5-C4’ y     
C5-C5’ mediante la reacción del 1,3-butadiíno con pivalato de azidometilo, seguida de una 
reacción CuAAC con azidas. Los bistriazoles así obtenidos constituyen sendas familias de 
anillos heterocíclicos inéditos hasta la fecha. 
3. Empleo de 1,2,3-triazoles como grupos directores en funcionalizaciones de enlaces 
C−H catalizadas por metales de transición 
En la tercera parte de la Tesis Doctoral se demostró que los 1,2,3-triazoles 
provenientes de reacciones “click” pueden actúar como eficientes grupos directores en 
reacciones de funcionalización de enlaces C(sp
2
)−H catalizadas por metales de transición.  
En primer lugar se llevó a cabo la reacción de acetoxilación y pivaloilación 
catalizada por sales de paladio de anillos aromáticos situados en la posición C4 de diversos 
1,2,3-triazoles. De este modo, se obtuvieron los correspondientes derivados de orto-
aciloxiarilo como mezclas de productos mono- y difuncionalizados con rendimientos que 
oscilaron entre 50-90 %. Es importante remarcar que la monofuncionalización selectiva se 
pudo obtener utilizando 5-yodo 1,2,3-triazoles como grupo director así como empleando 
sustratos con patrón de sustitución orto- y meta- que impiden la doble funcionalización. 
Los productos resultantes de las funcionalizaciones comentadas, pudieron 
transformarse en otros compuestos de mayor complejidad estructural empleando reacciones 
de acoplamiento cruzado (Sonogashira y Heck). 
  
 
 
Seguidamente, el alcance de la reacción de funcionalización se extendió con éxito a 
enlaces C(sp
2
)−H vinilicos. Concretamente, se logró introducir tanto el grupo acetoxilo como 
el pivaloílo en anillos 1-ciclohexenilo con rendimientos del 72-77% asistidos por grupos 
1,2,3-triazol. 
Desafortunadamente, cuando en las reacciones anteriores se intentó sustituir el 
catalizador de paladio por otros más asequibles como el cobre reemplazando 
simultáneamente el grupo director por otro triazol bidentado (TAM), no se pudo conseguir la 
transformación deseada. 
Por último, también se ensayó la acilación catalizada por sales de paladio de enlaces 
C(sp
2
)−H vinílicos con aldehídos. Tras la optimización de diferentes variables de la reacción, 
sólo pudieron obtenerse rendimientos moderados (30-57%). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 List of abbreviations, Acronyms and Symbols 
 
Asp   Aspartic acid 
Arg   Arginine 
ATP   Adenosine triphosphate 
Aq.   Aqueous 
BBB   Blood Brain Barrier  
Boc   tert-Butoxycarbonyl 
BPO   Benzoyl peroxide 
Cav1.1   Calcium channel, voltage-dependent 
CCDC   The Cambridge Crystallographic Data Centre 
CD   Cyclodextrin 
CHP   Cumene hydroperoxide 
CNS   Central Nerve System 
COD   1,5-Cyclooctadiene 
Cp*   Pentamethylcyclopentadiene  
CuAAC   Copper-catalyzed azide alkyne cycloaddition 
d    Doublet (NMR) 
dd    Doublet of doublets (NMR) 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE   1,2-Dichloroethane 
DCP   Dicumyl peroxide 
DFT   Density Functional Theory 
DG   Directing Group 
DIPEA    N,N-Diisopropylethylamine 
DMD   Duchenne Muscular Dystrophy 
DME   Dimethoxyethane 
DMF   N,N-Dimethylformamide 
DNA   Deoxyribonucleic acid 
DTBP   Di-tert-butyl peroxide 
δ   Chemical shift (NMR) 
ΔE‡   Activation Energy 
E-C   Excitation-contraction 
EDG   Electron-donating group 
ESI   Electrospray ionization (Mass spectrometry) 
Equiv.   Equivalent(s) 
EWG   Electron-withdrawing group 
FDA   Food and Drug Administration 
FG   Functionalized group 
FKBP12   FK506 binding protein 12 
FMO   Frontier Molecular Orbital 
Glu   Glutamic acid 
ΔG‡   Activation Gibbs energy 
HMPA   Hexamethylphosphoramide 
HOMO   Highest Occupied Molecular Orbital 
HPLC   High Performance Liquid Chromatography 
HRMS   High Resolution Mass Spectroscopy 
Hz   Hertz   
IR   Infrared 
J    Coupling constant (NMR) 
Ka   Affinity constant or stability constant 
Leu   Leucine 
LUMO   Lowest Unoccupied Molecular Orbital 
Lys   Lysine 
M   Metal 
m    Multiplet (NMR) 
mdx   Duchenne muscular dystrophy mouse model 
MCPBA   3-Chloroperbenzoic acid 
MD   Muscular Dystrophy 
mp   Melting point 
MS   Mass Spectrometry 
NBO   Natural Bonding Orbital 
NBS   N-Bromosuccinimide 
NCS   N-Chlorosuccinimide 
n.d.   Not determined 
NHC   N-Heterocyclic carbene 
NIS   N-Iodosuccinimide 
NMR   Nuclear Magnetic Resonance 
Phe   Phenylalanine 
PIDA   (Diacetoxyiodo)benzene 
PTSA   p-Toluenesulfonic acid 
 q    Quartet (NMR) 
RyR1   Ryanodine receptor channel 
r.t.   Room temperature 
ROESY   Rotating-frame nuclear Overhauser effect correlation spectroscopy 
RuAAC   Ruthenium-catalyzed azide alkyne cycloaddition 
SPAAC   Strain-promoted azide alkyne cycloaddition 
SERCA   Sarco/endoplasmic reticulum Ca2+-ATPase 
SR   Sarcoplasmic reticulum 
t    Triplet (NMR) 
T   Temperature 
TBTA    Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
TBHP   tert-Butyl hydroperoxide 
TBPB   tert-Butyl peroxybenzoate 
TEA   Triethylamine 
TFA   Trifluoroacetic acid 
TfN3   Trifluoromethanesulfonyl azide 
TIP   2,4,6-Triiodophenoxy  
TON   Turnover number 
Trp   Tryptophan 
Trz   Triazole 
Tyr   Tyrosine 
Val   Valine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 Index 
1 General introduction and objectives ......................................................................... 1 
1.1 1,2,3-Triazoles ........................................................................................................... 3 
1.2 Synthesis of 1,2,3-triazoles ........................................................................................ 5 
1.2.1 1,3-Dipolar cycloaddition .................................................................................. 9 
1.2.2 Copper-catalyzed azide-alkyne cycloaddition ................................................. 11 
1.2.3 Ruthenium-catalyzed azide-alkyne cycloaddition ........................................... 15 
1.2.4 Organocatalytic cycloadditions ........................................................................ 17 
1.2.4.1 1,2,3-Triazoles via enamine intermediates .............................................. 18 
1.2.4.2 1,2,3-Triazoles via enolate intermediates ................................................ 19 
1.2.4.3 1,2,3-Triazoles via iminium intermediates .............................................. 21 
1.2.4.4 Miscellaneous reactions towards substituted 1,2,3-triazoles ................... 21 
1.3 General objectives of this PhD thesis ....................................................................... 22 
1.3.1 H-1,2,3-Triazoles as drug scaffolds: intracellular Ca2+ regulation in 
muscle cells  ..................................................................................................... 23 
1.3.2 N-Dealkylation of 1,2,3-triazolium salts. A metal-free route to 1,5-
disubstituted 1,2,3-triazoles and related bistriazoles ........................................ 23 
1.3.3                                         nctionalization events  ....................... 24 
2 1H-1,2,3-Triazoles as drug scaffolds: intracellular Ca2+ regulation in 
muscle cells ............................................................................................................. 27 
2.1 Introduction………………………. ......................................................................... 29 
2.1.1 Skeletal muscle and Duchenne muscular dystrophy (DMD) ........................... 30 
2.2 Hypothesis ................................................................................................................ 35 
2.3 Objectives................................................................................................................. 37 
2.4 Results and discussion.............................................................................................. 38 
2.4.1 Preliminary computational docking studies ..................................................... 38 
2.4.2 Synthesis of 1,4-disubstituted 1H-1,2,3-triazole ligands for RyR1 
modulation ....................................................................................................... 39 
2.4.3 Biological activity of carboxylic triazoles as RyR1 channel 
modulators in myocytes and mdx mouse models ............................................. 50 
2.4.4 Inclusion complexes of 1-(carboxyalkyl)-1,2,3-triazoles and             
β-cyclodextrin .................................................................................................. 54 
2.4.4.1 NMR     y     h  β-CD/triazole 15 host-guest complexation ................ 56 
2.5 Conclusions .............................................................................................................. 61 
2.6 Experimental ............................................................................................................. 63 
2.7 Appendix .................................................................................................................. 87 
3 N-Dealkylation of 1,2,3-triazolium salts. A metal-free route to           
1,5-disubstituted 1,2,3-triazoles and related bistriazoles................................... 115 
3.1 Introduction............................................................................................................. 117 
3.1.1 Synthesis of 1,5-disubstituted triazoles via 1,2,3-triazolium salts..................... 117 
3.1.2 Synthesis of bis(1,2,3-triazoles) containing 1,5-disubstituted triazole 
units ................................................................................................................... 120 
3.2 Hypothesis .............................................................................................................. 123 
3.3 Objectives ............................................................................................................... 124 
3.4 Results and discussion ............................................................................................ 125 
3.4.1 Synthesis of alkyl triflates ................................................................................. 125 
3.4.2 Metal-free synthesis of 1,5-disubstituted 1,2,3-triazoles through    
1,3,4-trisubstituted triazolium intermediates .................................................. 127 
3.4.3 Synthesis of non-symmetrically substituted bistriazoles with full 
positional control. ........................................................................................... 135 
3.4.4 Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles ................................................ 137 
3.5 Conclusions ............................................................................................................ 139 
3.6 Experimental ........................................................................................................... 141 
3.7 Appendix ................................................................................................................ 165 
4 Triazoles as directing groups in C−H functionalization event ............................. 191 
4.1 Introduction............................................................................................................. 193 
4.1.1            m          −                    ...................................................... 194 
4.1.2 DG      −                    .......................................................................... 197 
4.2 Pd-catalyzed C(sp2)−   xy          ..................................................................... 204 
4.2.1 Previous work ................................................................................................... 204 
4.2.2 Results and discussion....................................................................................... 207 
 4.2.2.1 Screening of the reaction conditions ..................................................... 207 
4.2.2.2 Synthesis of the starting triazoles .......................................................... 210 
4.2.2.3   -     y          xy            4-aryl 1,2,3-triazoles ....................... 213 
4.2.2.4 Reaction mechanism .............................................................................. 220 
4.2.2.5 Conclusions ........................................................................................... 222 
4.2.3 Cu-     y     −                             by b         DGs ...................... 222 
4.3 Pd-catalyzed C(sp2)−  y        w  h     hy    ..................................................... 225 
4.3.1 Previous work ................................................................................................... 225 
4.3.2 Results and discussion ...................................................................................... 229 
4.3.3 Conclusions ...................................................................................................... 236 
4.4 Experimental .......................................................................................................... 237 
4.5 Appendix ................................................................................................................ 272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 1 
General introduction and objectives 
  
 
 
 3 
 
1. General introduction and objectives 
1.1 1,2,3-Triazoles 
Despite the 1,2,3-triazole ring does not occur in Nature, organic compounds that 
contain this heterocyclic motif have shown an inordinate interest in the last decades. As a 
result, the 1,2,3-triazole core stands out as a privileged structure of wide presence in a vast 
array of relevant compounds in different research areas such as medicinal chemistry,
1
 
material science,
2
 optoelectronics,
3
 crop protection
4
 and pharmacology.
5
 Their unique 
molecular architecture plays an important role in the development of new disease treatments 
and is thus attractive for designing numerous specific molecules with important biological 
activities such as anticancer,
6
 antimalarial
7
 and antimicrobial
8
 (Figure 1.1). 
                                                          
1  a) Ustyugov, A. A.; Aliev, G. M. Russ. Chem. Bull. 2016, 65, 1151. b) Alfonso, M.; Tárraga, A.; 
Molina, P. Tetrahedron Lett. 2016, 57, 3053. c) El-Sagheer, A. H.; Brown, T. Chem. Soc. Rev. 
2010, 39, 1388.   
2  a) Xiaosong, C.; Yi, S.; Haifeng, G. Synlett 2017, 28, 391. b) Kacprzak, K.; Skiera, I.; Piasecka, 
M.; Paryzek, Z. Chem. Rev. 2016, 116, 5689. c) Flood, A. H. Beilstein J. Org. Chem. 2016, 12, 
611. d) Qin, A.; Lam, J. W. Y.; Tang, B. Z. Chem. Soc. Rev. 2010, 39, 2522.  
3  a) Marrocchi, A.; Facchetti, A.; Lanari, D.; Santoro, S.; Vaccaro, L. Chem. Sci. 2016, 7, 6298. b) 
Dou, L.; Liu, Y.; Hong, Z.; Li, G.; Yang, Y. Chem. Rev. 2015, 115, 12633.  
4  Gonçalves, S. S.; Souza, A. C. R.; Chowdhary, A.; Meis, J. F.; Colombo, A. L. Mycoses 2016, 59, 
198. 
5  a) Akhtar, J.; Khan, A. A.; Ali, Z.; Haider, R.; Yar, M. S. Eur. J. Med. Chem. 2017, 125, 143. b) 
Tiwari, V. K.; Mishra, B. B.; Mishra, K. B.; Mishra, N.; Singh, A. S.; Chen, X. Chem. Rev. 2016, 
116, 3086.  
6  Yadav, P.; Lal, K.; Kumar, A.; Guru, S. K.; Jaglan, S.; Bhushan, S. Eur. J. Med. Chem. 2017, 126, 
944.  
7  a) Singh, A.; Gut, J.; Rosenthal, P. J.; Kumar, V. Eur. J. Med. Chem. 2017, 125, 269. b) Santos, J.; 
Pereira, G. R.; Brandão, G. C.; Borgati, T. F.; Arantes, L. M.; de Paula, R. C.; Soares, L. F.; do 
Nascimento, M. F. A.; Ferreira, M. R. C.; Taranto, A. G.; Varotti, F. P.; de Oliveira, A. B. J. Braz. 
Chem. Soc. 2016, 27, 551.   
8  Abdel-Wahab, B. F.; Khidre, R. E.; Awad, G. E. A. J. Heterocyclic. Chem. 2017, 54, 489. 
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Figure 1.1. Illustrative examples of 1,2,3-triazoles with therapeutic and scientific applications. 
Importantly, the 1,2,3-triazole scaffold is chemically inert against oxidation, 
reduction and hydrolysis both in acidic and basic environment, which makes it an excellent 
mimetic for hydrogen, amide or disulfide bonds thus stabilizing the resulting drugs
9
 or 
                                                          
9  a) Dheer, D.; Singh, V.; Shankar, R. Bioorg. Chem. 2017, 71, 30. b) Sum, T. H.; Sum, T. J.; 
Galloway, W. R. J. D.; Collins, S.; Twigg, D. G.; Hollfelder, F.; Spring, D. R. Molecules 2016, 21, 
1230. c) Whiting, M.; Muldoon, J.; Lin, Y.-C.; Silverman, S. M.; Lindstrom, W.; Olson, A. J.; 
Kolb, H. C.; Finn, M. G.; Sharpless, K. B.; Elder, J. H.; Fokin, V. V. Angew. Chem. Int. Ed. 2006, 
45, 1435. 
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pharmacophores.
10
 Furthermore, they are highly promising moieties for supramolecular 
interactions
11
 upon coordination to the metal centers either by the nitrogen atoms or by 
carbanionic and mesoionic carbenes, with useful applications in metal catalysis.
12
      
In a short period of time the use of triazoles has had a dramatic and diverse impact 
in chemistry and molecular biology. However, although this area of expertise is gaining 
attention exponentially, the powerful and unique properties of 1,2,3-triazoles have not yet 
been fully exploited.  
1.2 Synthesis of 1,2,3-triazoles 
The very first triazole was synthesized in 1893 by Michael;
13
 however, such a 
finding did not attract interest until some years later, when Huisgen
14
 described the 
cycloaddition reaction between organic azides
15
 and internal alkynes named as [3+2] 1,3-
dipolar cycloaddition. Despite the versatility of this technique, its practicality is rather 
limited due to the formation of mixtures of 1,4- and 1,5-regioisomers and the low efficiency 
even at high temperatures. In this respect, a variety of synthetic methods for the assembly of 
1,2,3-triazoles has been widely investigated during the last decade. In 2002, Meldal
16
 and 
Sharpless
17
 independently implemented the use of in situ generated Cu(I) species as efficient 
catalysts to perform the cycloaddition of alkynes and azides in a regioselective fashion 
toward the formation of 1,4-disubstituted 1,2,3-triazoles. This Cu-catalyzed Huisgen 1,3-
dipolar cycloaddition represents one of the early examples of a “click” process and owing to 
                                                          
10  a) Kaushik, R.; Kushwaha, K.; Chand, M.; Vashist, M.; Jain, S. C. J. Heterocyclic Chem. 2017, 54, 
1042. b) Kaushik, R.; Kushwaha, K.; Chand, M.; Vashist, M.; Jain, S. C. J. Heterocyclic Chem. 
2017, 54, 1042. c) Surineni, G.; Yogeeswari, P.; Sriram, D.; Kantevari, S. Bioorg. Med. Chem. Lett. 
2016, 26, 3684.  
11  a) Lim, J. Y. C.; Marques, I.; Thompson, A. L.; Christensen, K. E.; Félix, V.; Beer, P. D. J. Am. 
Chem. Soc. 2017, 139, 3122. b) Lehn, J. M. Science 1993, 260, 1762. 
12  a) Gazvoda, M.; Virant, M.; Pevec, A.; Urankar, D.; Bolje, A.; Kočevar, M.; Košmrlj, J. Chem. 
Commun. 2016, 52, 1571. b) Hollering, M.; Albrecht, M.; Kühn, F. E. Organometallics 2016, 35, 
2980. c) Qureshi, Z.; Kim, J. Y.; Bruun, T.; Lam, H.; Lautens, M. ACS Catal. 2016, 6, 4946. d) 
Huang, D.; Zhao, P.; Astruc, D. Coord. Chem. Rev. 2014, 272, 145.  
13  Michael, A. J. Prakt. Chem. 1893, 48, 94. 
14  Huisgen, R. Angew. Chem. Int. Ed. 1963, 2, 565. 
15  Huanga, D.; Yan, G. Adv. Synth. Catal. 2017, 359, 1600. 
16  Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057. 
17  Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem. Int. Ed. 2002, 41, 
2596. 
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its impressive popularity is often erroneously considered as the “click” chemistry concept 
itself. 
The “click chemistry” concept was introduced by the group of Sharpless and is 
based on the rapid assembly of relevant compounds under specific reaction conditions.
18
 
They defined a “click” transformation as a reaction easy to perform, modular, wide in scope 
and high-yielding. The required features for those events involve: 
 Simple reaction conditions. 
 Readily available starting materials and reagents. 
 Easily removable solvents with particular emphasis on aqueous solvents. 
 Usually exotermic reactions. 
 Most of them include the formation of carbon-heteroatom bonds. 
 In general, they are highly tolerant to the presence of oxygen and water, 
which represents a practical bonus in terms of operational simplicity. 
In this regard, numerous methodologies fulfill the latter criteria and can be referred 
to as a “click” process. They can be classified into four categories including (a) 
cycloadditions, such as Huisgen’s cycloadditions or Diels-Alder reactions, (b) additions to 
multiple carbon-carbon bonds, including epoxidations, aziridinations or Michael additions, 
(c) nucleophilic substitutions like nucleophilic ring opening reactions of strained 
heterocycles and (d) carbonyl chemistry of non-aldol type transformations (Scheme 1.1).   
                                                          
18  Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2001, 40, 2004. 
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Scheme 1.1. General classification of “click” reactions. 
The copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction meets the 
requirements of the Sharpless “click” chemistry concept, as the reaction is easy to perform, 
wide in scope, regiospecific, high yielding, involves readily available alkynes/azides as 
starting materials and copper salts as cost-efficient catalysts, and it is performed in benign 
solvents such as water.  
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Some years later, Fokin and Jia introduced the alternative use of Ru(II) catalysts in 
1,3-dipolar cycloadditions which resulted in the regioselective formation of 1,5-substituted 
1,2,3-triazoles (Scheme 1.2).
19
 Importantly, unlike CuAAC, the parent Ru-catalyzed azide-
alkyne cycloaddition (RuAAC) could be extended to internal alkynes.   
Despite the advances realized, the toxicity of the transition metals to living cells and 
biomolecules like DNA is a limiting factor for the applications of metal-catalyzed “click” 
processes in the field of biomaterial chemistry and chemical biology.
20
 As a result, more 
environmentally friendly protocols are highly desired and significant efforts have been 
directed to the development of metal-free methods to synthetize 1,2,3-triazoles. In 2004, 
Bertozzi and his group reported a pioneering metal-free cycloaddition reaction
21
 between an 
azide and a strained cyclooctyne, also known as strain-promoted azide alkyne cycloaddition 
(SPAAC).  
 
Scheme 1.2. Common approaches for the assembly of 1H-1,2,3-triazoles. 
More recently, the significance of organocatalyzed reactions to synthesize 1,2,3-
triazoles has received an impressive attention. Many of those methods are ingenious 
extensions of previously reported Dimroth reaction, which was first published in 1971 by 
L’abbé22 and described as “the condensation of organic azides with active methylene 
compounds in the presence of an equimolar amount of organic or inorganic base leading to 
highly substituted 1,2,3-triazoles in a regioselective manner” (Scheme 1.3).  
                                                          
19  Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams, I. D.; Sharpless, K. B.; Fokin, V. V.; Jia, G. 
J. Am. Chem. Soc. 2005, 127, 15998. 
20  a) Gaetke, L. M.; Chow, C. K. Toxicology 2003, 189, 147. b) Jomova, K.; Valko, M. Toxicology 
2011, 283, 65. 
21  a) Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.; Chang, P. V.; Miller, I. A.; Lo, A.; 
Codelli, J. A.; Bertozzi, C. R. Proc. Natl. Acad. Sci. USA 2007, 104, 16793. b) Agard, N. J.; 
Prescher, J. A.; Bertozzi, C. R. J. Am. Chem. Soc. 2004, 126, 15046.  
22  L’abbé, G. Ind. Chim. Belge 1971, 36, 3. 
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Scheme 1.3. Dimroth reaction for the synthesis of 1,2,3-triazoles. 
Nevertheless, these procedures usually suffer from modest functional group 
tolerance as well as narrow substrate scope which can be overcome by recent advancements 
based on methodologies such as enamine and dienamine/azide [3+2]-cycloaddition or the use 
of enolates as dipolarophiles, among others.
23
 In the following section, some of the most 
widely utilized procedures for the preparation of 1,2,3-triazoles mentioned before will be 
discussed. 
1.2.1 1,3-Dipolar cycloaddition 
The [3+2] Huisgen 1,3-dipolar cycloaddition reaction or the concerted addition of a 
1,3-dipole to a multiple bond is the most direct route to 1,2,3-triazoles, and provides fast 
access to an enormous variety of heterocycles. However, it has a high activation energy (ca. 
24-26 kcal/mol) and elevated temperatures are needed for the process to occur, thus giving 
place to mixtures of 1,4- and 1,5-regioisomers which are often difficult to separate.  
The azide taking part in a 1,3-dipolar cycloaddition reaction is characterized by the 
presence of an electrophilic nitrogen atom with an electron sextet and a formal positive 
charge, as well as a nucleophilic nitrogen atom with an electron octet and a formal negative 
charge placed at 1- and 3-positions respectively (Figure 1.2).  
 
Figure 1.2. Selected contributing resonance structures of an organic azide. 
The cycloaddition process was classified by Woodward and Hofmann as an 
example of pericyclic cycloaddition which is thermally allowed due to symmetrically and 
geometrically favorable [π4s + π2s] molecular orbital interactions.
24
 Nevertheless, not until 
                                                          
23  For a recent review, see: Lima, C. G. S.; Ali, A.; van Berkel, S. S.; Westermann, B.; Paixão, M. W. 
Chem. Commun. 2015, 51, 10784.  
24 Woodward, R. B.; Hoffmann, R. Angew. Chem. Int. Ed. Engl. 1969, 8, 781. 
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Sustmann
25
 and Houk
26
 did apply the frontier molecular orbital (FMO) model to this process, 
the reaction rates and regisolectivity were rather difficult to predict.
27
 In a few words, this 
computational model suggests that the reaction between the 1,3-dipole (azide) and the 1,3-
dipolarophile (alkyne) proceeds upon interaction of the highest occupied molecular orbital 
(HOMO) of one reactant and the lowest unoccupied molecular orbital (LUMO) of the other 
reactant, being the reaction rate dependent on the corresponding energy gap between them.  
 
Figure 1.3. FMO interaction diagram for the 1,3-dipolar cycloaddition of phenyl azide and phenyl 
acetylene. 
On the one hand, when the azide dipole has a high-lying HOMO which overlaps 
with the LUMO of the alkyne, it is referred to as HOMO-controlled dipole or nucleophilic 
dipole. In this case, the azide HOMO-raising electron-donating groups (EDG) as well as 
alkyne LUMO-lowering electron-withdrawing groups (EWG) will increase the reaction rate 
                                                          
25 a) Sustmann, R. Tetrahedron Lett. 1971, 12, 2717. b) Sustmann, R.; Trill, H. Angew. Chem. Int. Ed. 
Engl. 1972, 11, 838. c) Sustmann, R. Pure Appl. Chem. 1974, 40, 569. 
26 a) Houk, K. N. Acc. Chem. Res. 1975, 8, 361. b) Houk, K. N.; Sims, J.; Duke, R. E.; Strozier, R. 
W.; George, J. K. J. Am. Chem. Soc. 1973, 95, 7287. c) Houk, K. N.; Sims, J.; Watts, C. R.; 
Luskus, L. J. J. Am. Chem. Soc. 1973, 95, 7301. 
27 a) Dewar, M. J. S. Theochem 1989, 200, 301. b) Fukui, K. Science 1982, 218, 747. c) Herndon, W. 
C. Chem. Rev. 1972, 72, 157. d) Klopman, G. J. Am. Chem. Soc. 1968, 90, 223. e) Salem, L. J. Am. 
Chem. Soc. 1968, 90, 553. f) Fukui, K.; Yonezawa, T.; Shingu, H. J. Chem. Phys. 1952, 20, 722. 
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favoring the formation of the 1,4-isomer. On the other hand, an inverse demand FMO 
interaction is possible when the azide dipole has a low-lying LUMO (LUMO-controlled 
dipole or electronic dipole). Figure 1.3 illustrates a typical azide-alkyne FMO interaction for 
the cycloaddition between phenyl azide and phenylacetylene which yields a mixture of 1,4- 
and 1,5-substituted 1,2,3-triazoles in roughly 1:1 ratio.
28
 If the interaction energies ΔE1 and 
ΔE2 are similar, the cycloaddition is said to be synchronous. The presence of EDG or EWG 
substituents in the azide or alkyne reagents usually favors asynchronous FMO interactions, 
resulting in the preferred formation of one of the 1,2,3-triazole regioisomers.  
In general, the quantitative Huisgen reaction rate change is well-predicted by the 
FMO model as a function of the azide and alkyne substituents. However, the observed 
regioselectivity is usually the opposite based on the FMO model, in particular for varying 
azide substituents. With the development of more sophisticated computational methods, new 
approaches have been proposed
29
 such as the distortion/interaction
30
 energy model for 1,3-
dipolar cycloaddition reactivity. According to this model, the reactivity is controlled by the 
stability of the dipolarophile and, in particular, of the 1,3-dipole. 
1.2.2 Copper-catalyzed azide-alkyne cycloaddition 
The copper-catalyzed azide alkyne cycloaddition (CuAAC)
31
 reaction efficiently 
transforms organic azides and terminal alkynes exclusively into the corresponding 1,4-
disubstituted 1,2,3-triazoles, in contrast to the uncatalyzed process which provides mixtures 
of regioisomers. Moreover, the use of copper salts as practical catalysts of the reaction 
increases the rate by a factor of 10
7
 in comparison with the thermal process, even at room 
temperature.  
From the huge number of publications reporting the use of Cu(I) species on these 
“click” processes two main experimental methods have emerged as the most widely used. 
                                                          
28  Kirmse, W.; Horner, L. Liebigs Ann. Chem. 1958, 614, 1. 
29  Heravi, M. M.; Tamimi, M.; Yahyavi, H.; Hosseinnejad, T. Curr. Org. Chem. 2016, 20, 1591.  
30  a) Ess, D. H.; Houk, K. N. J. Am. Chem. Soc. 2008, 130, 10187. b) Ess, D. H.; Houk, K. N. J. Am. 
Chem. Soc. 2007, 129, 10646. 
31  For selected reviews see: a) Singh, M. S.; Chowdhury, S.; Koley, C. Tetrahedron 2016, 72, 5257. 
b) Haldon, E.; Nicasio, M. C.; Pérez, P. J. Org. Biomol. Chem. 2015, 13, 9528. c) Schulze, B.; 
Schubert, U. S. Chem. Soc. Rev. 2014, 43, 2522. d) Hein, J. E.; Fokin, V. V. Chem. Soc. Rev. 2010, 
39, 1302.  
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The first one involves the direct use of Cu(I) salts under strict exclusion of oxygen in order to 
prevent their oxidation to Cu(II) species. In these cases, the addition of supporting ligands 
have been found to have a beneficial impact on the reaction outcome since they are assumed 
to prevent the degradation of Cu(I) species by oxidation or disproportionation.
32
 In particular, 
the tetradentate ligand tris(benzyltriazolylmethyl) amine (TBTA) has shown to be very 
efficient in increasing the rate of CuAAC reactions.
33
 Apart from these nitrogen-based 
compounds, other ligands containing oxygen, phosphorous,
34
 carbon,
35
 and sulfur
36
 as donor 
atoms have also been reported. The use of preformed Cu(I) pre-catalysts is not so extended, 
but it seems to be increasing in the last years.
37
 Metallic copper (wire or turning) also 
catalyzes the CuAAC reaction, although higher catalyst loadings and prolonged reaction 
times are needed in comparison with Cu(II) salts.
38
  
The second common procedure relies on the in situ reduction of Cu(II) salts such as 
CuSO4·5H2O to Cu(I) species with a 3- to 10- fold excess of a reducing agent. Undoubtedly, 
sodium ascorbate is the most utilized reductant but other alternatives have been described 
such as hydrazine,
39
 tris(2-carboxyethyl)phospine
40
 or thiol-grafted cellulose paper,
41
 among 
others. From a practical standpoint, the latter strategy is by far the preferred one since it can 
be performed in water, does not require inert atmosphere, and gives very reliable results, 
hence posing ideal in the field of chemical biology. Besides, it is compatible with the use of 
other Cu(II) salts such as Cu(OAc)2, which can be used even without external reductant. In 
those cases, the formation of Cu(I) species was suggested to be facilitated by either the 
oxidation of alcohols or alkyne homocoupling.
42
  
                                                          
32  Díez-González, S. Catal. Sci. Technol. 2011, 1, 166. 
33  Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V. Org. Lett. 2004, 6, 2853. 
34  Pérez-Balderas, F.; Ortega-Muñoz, M.; Morales-Sanfrutos, J.; Hernández-Mateo, F.; Calvo-Flores, 
F. G.; Calvo-Asín, J. A.; Isac-García, J.; Santoyo-González, F. Org. Lett. 2003, 5, 1951 
35  Díez-Gonzalez, S.; Correa, A.; Cavallo, L.; Nolan, S. P. Chem. Eur. J. 2006, 12, 7558. 
36  Wang, F.; Fu, H.; Jiang, Y.; Zhao, Y. F. Green Chem. 2008, 10, 452. 
37  Lal, S.; Díez-González, S. J. Org. Chem. 2011, 76, 2367. 
38  Appukkuttan, P.; Dehaen, W.; Fokin, V. V.; van der Eycken, E. Org. Lett. 2004, 6, 4223. 
39  Pathigoolla, A.; Pola, R. P.; Sureshan, K. M. Appl. Cat. A 2013, 453, 151. 
40   amantaray, M. K.; Alauzun, J.; Gajan, D.; Kavitake,  .; Mehdi, A.; Veyre, L.; Lelli, M.; Lesage, 
A.; Emsley, L.;  opéret, C.; Thieuleux, C. J. Am. Chem. Soc. 2013, 135, 3193. 
41  Rull-Barrull, J.; d'Halluin, M.; Le Grognec, E.; Felpin, F.-X. Angew. Chem. Int. Ed. 2016, 55, 1. 
42  Brotherton, W. S.; Michaels, H. A.; Simmons, J. T.; Clark, R. J.; Dalal, N. S.; Zhu, L. Org. Lett. 
2009, 11, 4954. 
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Since the initial mechanistic proposal by Fokin and Sharpless, where mononuclear 
Cu-intermediates were assumed as the key species of the process, subsequent in-depth 
kinetic experiments
43
 and computational modeling
44
 evidenced that the intermediacy of 
dinuclear species would be a more plausible scenario. In Scheme 1.4 the up-to-date 
understanding of the CuAAC reaction is depicted.
45
 The reaction begins with the 
coordination of the Cu(I) species to the corresponding alkyne to form intermediate A, which 
increases the CH-acidity of the terminal alkyne allowing thus the subsequent formation of σ, 
π-di (copper) acetylide B.46 In the next step, the acetylide picks up the azide to form the 
azide/alkyne/copper(I) ternary complex C.
47
 Further oxidative coupling afforded 
metallacycle D, in which one Cu(I) center is oxidized to Cu(III) and the metallacycle is 
stabilized by a bimetallic coordination which alleviates the ring strain. The resulting six-
membered metallacycle undergoes reductive elimination in a highly exothermic process, thus 
affording the Cu(I)-bound triazolide E which further undergoes protonolysis with the alkyne, 
hence liberating the triazole and allowing to complete the catalytic cycle. If there is some 
Cu(II) in the media generated via oxidation or disprotonation of Cu(I) species, 
bis(triazoles)
48
 could be formed. This side-process could be prevented by using for example 
additional reducing agents such as sodium ascorbate, and in the absence of oxygen. The 
triazolide E could also give other type of side-reactions, like transmetallations
49
 or 
halogenation events.
50
 Among the Cu-intermediates depicted in the catalytic cycle, both σ, π-
di(copper)acetylide B and the Cu(I)-triazolide E have been fully characterized and verified 
as viable intermediates within the process. Importantly, Fokin and co-workers found that the 
metallacyle D was involved in a rapid equilibrium to scramble the two Cu-centers.      
                                                          
43  a) Presolski, S. I.; Hong, V.; Cho, S.-H.; Finn, M. G. J. Am. Chem. Soc. 2010, 132, 14570. b) 
Rodionov, V. O.; Presolski, S. I.; Díaz, D. D.; Fokin, V. V.; Finn, M. G. J. Am. Chem. Soc. 2007, 
129, 12705. c) Rodionov, V. O.; Fokin, V. V.; Finn, M. G. Angew. Chem. Int. Ed. 2005, 44, 2210.  
44  a) Ahlquist, M.; Fokin, V. V. Organometallics 2007, 26, 4389. b) Straub, B. F. Chem. Commun. 
2007, 3868. 
45  Zhu, L.; Brassard, C. J.; Zhang, X.; Guha, P. M.; Clark, R. J. Chem. Rec. 2016, 16, 1501.    
46  Jin, L.; Tolentino, D. R.; Melaimi, M.; Bertrand, G. Sci. Adv. 2015, 1, e1500304. 
47  a) Nolte, C.; Mayer, P.; Straub, B. F. Angew. Chem. Int. Ed. 2007, 46, 2101. b) Worrell, B. T.; 
Malik, J. A.; Fokin, V. V. Science 2013, 340, 457. 
48  a) González, J.; Pérez, V. M.; Jiménez, D. O.; Lopez-Valdez, G.; Corona, D.; Cuevas-Yañez, E. 
Tetrahedron Lett. 2011, 52, 3514. b) Angell, Y.; Burgess, K. Angew. Chem. Int. Ed. 2007, 46, 
3649.  
49  Liu, S.; Müller, P.; Takase, M. K.; Swager, T. M. Inorg. Chem. 2011, 50, 7598. 
50  Ackermann, L.; Potukuchi, H. K. Org. Biomol. Chem. 2010, 8, 4503. 
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Scheme 1.4. CuAAC proposed mechanism. 
Increasing amount of data have shown that the deprotonation of alkyne to afford the 
target triazole is in fact the turnover-limiting step. It must be mentioned that the 
copper(I)/acetylide/azide complex C have been captured once in mass spectrometric studies 
as a fleeting intermediate.
51 
Additionally, the kinetic significance of alkyne deprotonation in 
the CuAAC reaction leads to the conclusion that alkynes with relatively low pKa values 
undergo faster reactions. This statement can be verified by using alkynes containing electron-
withdrawing substituents, such as 4-nitrophenylacetylene,
52
 ethyl propiolate
53
 and 4-ethynyl 
1,2,3-triazolium salts,
54
 which react very fast in CuAAc reactions.  
                                                          
51  Iacobucci, C.; Reale, S.; Gal, J. F.; De Angelis, F. Angew. Chem. Int. Ed. 2015, 54, 3065. 
52  Kuang, G.-C.; Guha, P. M.; Brotherton, W. S.; Simmons, J. T.; Stankee, L. A.; Nguyen, B. T.; 
Clark, R. J., Zhu, L. J. Am. Chem. Soc. 2011, 133, 13984. 
53  Berg, R.; Straub, J.; Schreiner, E.; Mader, S.; Rominger, F.; Straub, B. F. Adv. Synth. Catal. 2012, 
354, 3445. 
54  Monasterio, Z.; Sagartzazu-Aizpurua, M.; Miranda, J. I.; Reyes, Y.; Aizpurua, J. M. Org. Lett. 
2016, 18, 788. 
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1.2.3 Ruthenium-catalyzed azide-alkyne cycloaddition 
As highlighted before, the use of Ru-catalysts affords the parent 1,5-disubstituted 
1,2,3-triazole derivatives hence complementing the more established CuAAC which provides 
the corresponding 1,4-isomers. Early examples of preparing 1,5-triazole isomers involved the 
use of various metal acetylides (Sn, Ge, Si and Na),
55
 and subsequent studies by Akimova in 
the 1960s
56
 extended the process to the use of highly reactive lithium and magnesium 
acetylides. Those processes are proposed to occur via nucleophilic attack of the metal 
acetylide to the azide followed by ring closure to form the corresponding metallotriazole, 
which upon acidic work-up furnished the corresponding 1,5-disubstituted compounds 
(Scheme 1.5).  
 
Scheme 1.5. Proposed mechanism for triazole formation using Li and Mg acetylides.  
Owing to the undesirable use of stochiometric amounts of metals, the latter 
procedures were incompatible with a wide variety of functional groups. Accordingly, a 
catalytic alternative was actively studied and indeed in 2005 Fokin and Jia solved the 
problem by introducing the use of Ru(II) catalysts in azide-alkyne cycloadditions.
19  
A typical RuAAC involves the reaction of an organic azide with an alkyne in the 
presence of catalytic amounts of a Ru(II) complex containing a [Cp*RuCl] unit in a 
nonprotic solvent.
57
 In general, the more suitable catalyst complexes have the general 
formula Cp*Ru(L)X in which L = phospine or NHC, and X = Cl or OCH2CF3. Although 
heating is often utilized to enshort reaction times, RuAACs at room temperature have been 
also reported when using a very reactive catalyst such as [Cp*RuCl(COD)]. As mentioned 
                                                          
55  a) Himbert, G.; Frank, D.; Regit, M. Chem. Ber. 1976, 109, 370. b) Boyer, N.; Mack, C.; Goebel, 
N.; Morgan, L. J. Org. Chem. 1958, 23, 1051. 
56  a) Akimova, G.; Chistokletov, V.; Petrov, A. Zh. Obshch. Khim. 1968, 4, 389. b) Akimova, G.; 
Chistokletov, V.; Petrov, A. Zh. Obshch. Khim. 1967, 3, 968. c) Akimova, G.; Chistokletov, V.; 
Petrov, A. Zh. Obshch. Khim. 1967, 3, 2241.  
57  a) Johansson, J. R.; Beke-Somfai, T.; Stålsmeden, A. S.; Kann, N. Chem. Rev. 2016, 116, 14726. b) 
Wang, C. L.; Ikhlef, D.; Kahlal, S.; Saillard, J. Y.; Astruc, D. Coord. Chem. Rev. 2016, 316, 1. c) 
Heravi, M. M.; Tamimi, M.; Yahyavi, H.; Hosseinnejad, T. Curr. Org. Chem. 2016, 20, 1591. 
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before, one of the significant features of RuAAC in comparison with CuAAC is the tolerance 
to a variety of internal alkynes, which facilitates the assembly of 1,4,5-trisubstituted 
heterocycles.  
 
Scheme 1.6. Catalytic cycle of the RuAAC for a terminal alkyne. 
Although the mechanism of RuAAC has not been extensively studied, a general 
mechanistic picture is disclosed in Scheme 1.6.
58
 The accepted mechanism is based on the 
well-known cyclotrimerization of alkynes catalyzed by [Cp*RuCl] and similar complexes, 
which is assumed to proceed via ruthenacyclopentadiene intermediates.
59
  
                                                          
58  a) Boren, B. C.; Narayan, S.; Rasmussen, L. K.; Zhang, L.; Zhao, H.; Lin, Z.; Jia, G.; Fokin, V. V. 
J. Am. Chem. Soc. 2008, 130, 8923. b) Lamberti, M.; Fortman, G. C.; Poater, A.; Broggi, J.; 
Slawin, A. M. Z.; Cavallo, L.; Nolan, S. P. Organometallics 2012, 31, 756. c) Boz, E.; Tüzün, N. Ş. 
J. Organomet. Chem. 2013, 724, 167. 
59  Kirchner, K.; Calhorda, M. J.; Schmid, R.; Veiros, L. F. J. Am. Chem. Soc. 2003, 125, 11721. 
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The reaction would start with the generation of a 16-electron Ru complex upon 
ligand dissociation of the precatalyst in the presence of the corresponding alkyne, to form the 
catalytically active π-coordinated complex. Further ligation with the azide through the 
internal nitrogen produces intermediate A, which upon subsequent nucleophilic attack 
provides the six-membered ruthenacycle B. The latter is prone to undergo reductive 
elimination to furnish the triazole-complex C, which further isomerizes to intermediate D. 
Eventually, substitution with the alkyne delivers the target triazole derivative and closes the 
catalytic cycle. It is important to emphasize that the oxidative coupling entirely controls the 
regioselectivity of the overall process. Therefore, the new C−N bond is formed between the 
more electronegative and less sterically-demanding carbon atom of the alkyne and the 
terminal nitrogen atom of the corresponding azide.    
1.2.4 Organocatalytic cycloadditions 
The organocatalytic cycloaddition
23,60
 has recently emerged as a consequence of the 
existing demand towards the development of metal-free selective syntheses of the 1,2,3-
triazole core. These alternative techniques have certain advantages over the metal-catalyzed 
versions, as they are often insensitive to oxygen, eco-friendly, more sustainable, and are 
considered nontoxic in the realm of Biology. Notably, due to the limited availability of 
structurally diverse alkynes, organocatalytic approaches focus on the use of carbonyl 
compounds as versatile coupling counterparts.   
The pioneering work in the field of metal-free cycloaddition reactions came from 
Bertozzi’s lab, where they demonstrated that a strain-promoted azide alkyne cycloaddition 
reaction (SPAAC) resulted in a rapid triazole formation.
21
 While the first discoveries 
suffered from a narrow substrate scope and modest functional group tolerance, the recent 
advancements in the field
61
 can overcome these limitations and also offer an easy access to 
diversely functionalized triazoles that are inaccessible by other means. The significance of 
organocatalyzed events has recently reached an impressive level of performance and 
                                                          
60  For reviews, see: a) Jalani, H. B.; Karagöz, A. Ç.; Tsogoeva, S. B. Synthesis 2017, 49, 29. b) John, 
J.; Thomas, J.; Dehaen, W. Chem. Commun. 2015, 51, 10797.  
61  a) Codelli, J. A.; Baskin, J. M.; Agard, N. J.; Bertozzi, C. R. J. Am. Chem. Soc. 2008, 130, 11486. 
b) Laughlin, S. T.; Baskin, J. M.; Amacher, S. L.; Bertozzi, C. R. Science 2008, 320, 664. c) 
Sletten, E. M.; Bertozzi, C. R. Org. Lett. 2008, 10, 3097.  
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versatility, and the synthesis of functionalized 1,2,3-triazoles through organocatalytic 
reactions is extended in the lines below.  
1.2.4.1 1,2,3-Triazoles via enamine intermediates 
The 1,3-dipolar cycloaddition between enamines and azides constitutes a highly 
regioselective procedure for the assembly of 1,2,3-triazoles. The required enamines that act 
as dipolarophiles are generated from the corresponding carbonyl compounds which can be 
divided into two categories: a) activated carbonyl derivatives including Hagemann’s esters, 
ß-ketoesters, and β-oxo-amines, and b) unactivated carbonyl moieties such as alkyl/allyl 
ketones and aldehydes.
62
 
In 2008 Ramachary and his group reported for the first time a proline-catalyzed 
synthesis of fused triazoles starting from Hagemann’s esters.63 In 2011 Wong and co-
workers implemented the use of diethylamine as organocatalyst for the reaction of aryl 
ketones and keto esters with a variety of azides.
64
 Since these early discoveries numerous 
approaches consisting of an organocatalytic enamine-azide [3+2]-cycloaddition have been 
developed,
65
 but a comprehensive discussion of those methods is beyond the scope of this 
section. In this respect, a general mechanism to rationalize this type of cycloadditions is 
depicted on Scheme 1.7.  
                                                          
62  Dehaen, W.; Bakulev, V. A. Chemistry of 1,2,3-triazoles, Springer International Publishing, New 
York, 1st edn, 2014. 
63  Ramachary, D. B.; Ramakumar, K.; Narayana, V. V. Chem. Eur. J. 2008, 14, 9143. 
64  Danence, L. J. T.; Gao, Y.; Li, M.; Huang, Y.; Wang, J. Chem. Eur. J. 2011, 17, 3584. 
65  a) Thomas, J.; Jana, S.; John, J.; Liekens, S.; Dehaen, W. Chem. Commun. 2016, 52, 2885. b) Wan, 
J.-P.; Cao, S.; Liu, Y. J. Org. Chem. 2015, 80, 9028. c) Li, W.; Du, Z.; Huang, J.; Jia, Q.; Zhang, 
K.; Wang, J. Green Chem. 2014, 16, 3003. d) Ramachary, D. B.; Shashank, A. B. Chem. Eur. J. 
2013, 19, 13175. e) Li, W.; Jia, Q.; Du, Z.; Wang, J. Chem. Commun. 2013, 49, 10187. f) Yeung, 
D. K. J.; Gao, T.; Huang, J.; Sun, S.; Guo, H.; Wang, J. Green Chem. 2013, 15, 2384. g) Belkheira, 
M.; Abed, D. E.; Pons, J.-M.; Bressy, C. Chem. Eur. J. 2011, 17, 12917.  
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Scheme 1.7. General mechanism for the enamine-mediated 1,2,3-triazole synthesis. 
The mechanism for the enamine-based triazole synthesis begins with the 
condensation of the organocatalyst with the corresponding carbonyl compound to generate 
the enamine intermediate A. This enamine compound acts as an electron-rich olefinic partner 
thus reacting with the aryl azide to form the cycloaddition adduct B. The latter undergoes a 
1,3-hydride shift to generate the triazoline intermediate C, which is then converted into the 
zwitterion D. Eventually, the 1,2,3-triazole is obtained upon elimination of the corresponding 
organocatalyst.  
1.2.4.2 1,2,3-Triazoles via enolate intermediates 
In a similar, yet complementary, approach enolates have been successfully 
employed as dipolarophiles in the metal-free synthesis of triazoles. The first reported 
synthesis in 2008 by Kannan and co-workers
66
 provided 1,4,5-trisubstituted 1,2,3-triazoles 
from aromatic azides and acetylacetone utilizing potassium carbonate in excessive amounts. 
Some years later, in 2013 Cui
67
 described the synthesis of 1,5-disubstituted 1,2,3-triazoles in 
a cascade process involving a Michael addition of primary amines to alkynes, followed by 
the addition of tosyl azide and a final deacylative diazo transfer step, which results in the 
                                                          
66  Kamalraj, V. R.; Senthil, S.; Kannan, P. J. Mol. Struct. 2008, 892, 210. 
67  Cheng, G.; Zeng, X.; Shen, J.; Wang, X.; Cui, X. Angew. Chem. Int. Ed. 2013, 52, 13265.  
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cyclization to triazoles. In that process, lithium tert-butoxide is used as the base, and 
remarkably enables the preparation of chiral triazoles when using chiral amines.  
 
Scheme 1.8. Evolution of enolate-mediated triazole synthesis. 
In 2014 Ramachary
68
 described an azide-alkyne [3+2] cycloaddition organo“click” 
reaction between enolizable aldehydes and aryl azides utilizing DBU as catalyst. As 
illustrated in Scheme 1.8, more approaches were discovered along the same year. The 
formation of 1,4-disubstituted 1,2,3-triazoles was described by Paixão,
69
 applying a 1,3-
dipolar cycloaddition strategy which involves the use of alkylidene-malonitriles and aromatic 
azides in the presence of quantitative amounts of DBU. Shortly thereafter, Wang’s group70 
developed an intermolecular azide-zwitterionic reaction catalyzed by DBU for the assembly 
of fully substituted 1,2,3-triazoles, and Ramachary
71
 described an azide ketone [3+2] 
cycloaddition. Likewise, in 2015 the same group
72
 reported an azide-ketone [3+2] 
cycloaddition reaction, which followed by treatment with Raney nickel provided 1,5-
disubstituted 1,2,3-triazoles.   
The proposed general mechanism for the enolate mediated synthesis of 1,2,3-
triazoles from active methylene compounds such as enolizable aldehydes or ketones, and 
substituted acetonitriles is illustrated in the Scheme 1.9. In the first step, the base reacts with 
the acidic C−H bond and the resulting enolate A, upon in situ treatment with Ar-N3, 
selectively furnished the adduct 1,2,3-triazoline B through a concerted [3+2] cycloaddition 
reaction. Eventually, dehydration of adduct B gives access to the corresponding triazole. 
                                                          
68  Ramachary, D. B.; Shashank, A. B.; Karthik, S. Angew. Chem. Int. Ed. 2014, 53, 10420. 
69  Ali, A.; Corrêa, A. G.; Alves, D.; Zukerman-Schpector, J.; Westermann, B.; Ferreira, M. A. B.; 
Paixão, W. P. Chem. Commun. 2014, 50, 11926. 
70  Li, W.; Wang, J. Angew. Chem. Int. Ed. 2014, 53, 14186. 
71  Shashank, A. B.; Karthik, S.; Madhavachary, R.; Ramachary, D. B. Chem. Eur. J. 2014, 20, 16877. 
72  Ramachary, D. B.; Krishna, P. M.; Gujral, J.; Reddy, G. S. Chem. Eur. J. 2015, 21,16775. 
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Scheme 1.9. General mechanism for base-catalyzed 1,2,3-triazole synthesis via enolate intermediates. 
1.2.4.3 1,2,3-Triazoles via iminium intermediates 
The synthesis of trisubstituted triazoles starting from α,β-unsaturated ketones was 
recently reported by Wang.
73
 As shown in Scheme 1.10, piperidine was used as catalyst to 
activate unsaturated ketones and promote their reaction with azides.  
 
Scheme 1.10. 1,2,3-Triazole formation via iminium intermediate. 
The proposed mechanism begins with the formation of the iminium intermediate A 
by reaction of the unsaturated ketone and the catalyst. Then, a cycloaddition reaction takes 
place between the iminium species A and the corresponding azide to generate the triazoline 
intermediate B, which upon hydrolysis of the iminium center and subsequent air oxidation is 
converted into the target triazole C.   
1.2.4.4 Miscellaneous reactions towards substituted 1,2,3-triazoles 
In 1986 Rossi and co-workers
74
 published the synthesis of 1,4,5-trisubstituted 
triazoles utilizing enediamines and aryl azides. In the same year, Sakai and his group
75
 
reported the reaction between ketones and amines for the assembly of 1,4-disubstituted  
1,2,3-triazoles, which Westermann
76
 later improved into a cascade reaction utilizing DIPEA.  
                                                          
73  Li, W.; Du, Z.; Zhang, K.; Wang, J. Green Chem. 2015, 17, 781. 
74  Grassivaro, N.; Rossi, E.; Stradi, R. Synthesis 1986, 1010. 
75  Sakai, K.; Hida, N.; Kondo, K. Bull. Chem. Soc. Jpn. 1986, 59, 179. 
76  Berkel, S. S.; Brauch, S.; Gabriel, L.; Henze, M.; Stark, S.; Vasilev, D.; Wessjohann, L. A.; Abbas, 
M.; Westermann, B. Angew. Chem. Int. Ed. 2012, 51, 5343. 
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The synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from aldehydes, nitroalkanes and 
azides in a one-pot reaction was first described by Dehaen in 2014.
77
 Later on, Wang, Ji and 
co-workers
78
 reported a novel synthetic approach for the assembly of 1,4- and                   
1,5-disubstituted 1,2,3-triazoles starting from arylamines.  
In 2016, the synthesis of fully substituted triazoles using a reaction between 
aldehydes, amines and the Bestmann-Ohira reagent was reported by the group of Mohanan.
79
 
In the same year, Li and co-workers
80
 developed a reaction of ketoamines with azides 
catalyzed by DBU to generate 1,5-disubstituted 1,2,3-triazoles.  
On balance, organocatalytic reactions have led to the generation of highly 
functionalized/fused triazoles which were not possible to obtain by classical or metal- 
catalyzed approaches. These green methods use easily accessible starting materials such as 
carbonyl compounds which render rather advantageous procedures in terms of economics 
and sustainability. However, most of the organocatalytic reactions are rather limited to the 
use of aromatic azides, and their application to aliphatic derivatives is still under 
development. Besides, in-depth mechanistic studies are still required for the better 
understanding of those processes from a fundamental point of view. 
1.3 General objectives of this PhD thesis 
As disclosed in the preceding Section 1.2, a wide variety of strategies have been 
developed for the efficient preparation of 1,2,3-triazole derivatives, which are prevalent 
backbones of paramount medicinal significance. Despite these successful developments, 
there are still some aspects of the chemistry of 1,2,3-triazoles that remain scarcely explored 
and will constitute the main subject of research of this PhD thesis. In particular, our work 
will focus on studying the following topics:  
                                                          
77  Thomas, J.; John, J.; Parekh, N.; Dehaen, W. Angew. Chem. Int. Ed. 2014, 53, 10155. 
78  Bai, H.-W.; Cai, Z.-J.; Wang, S.-Y.; Ji, S.-J. Org. Lett. 2015, 17, 2898. 
79  Ahamad, S.; Kant, R.; Mohanan, K. Org. Lett. 2016, 18, 280. 
80  Zhou, X.; Xu, X.; Liu, K.; Gao, H.; Wang, W.; Li, W. Eur. J. Org. Chem. 2016, 1886. 
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1.3.1 1H-1,2,3-Triazoles as drug scaffolds: intracellular Ca2+ regulation in muscle 
cells (Chapter 2) 
As outlined above, 1,2,3-triazoles are becoming increasingly popular scaffolds for 
drug design in many pharmaceutical areas. Their electronic and structural characteristics are 
similar to the peptide bond but, unlike peptides, they possess excellent pharmacokinetic 
properties. Furthermore, the 1H-1,2,3-triazole ring is inherently nontoxic and stable to 
hydrolytic enzymes. (Figure 1.4). 
Figure 1.4. Design, synthesis and biological evaluation of 1,2,3-triazoles derived from α-amino acids 
as RyR1/Calstabin-1 interaction modulators. 
Few low molecular weight 1,2,3-triazoles have been developed to modulate protein-
protein interactions with therapeutic purposes. In the first part of our work, we will disclose 
the synthesis of a new family of 1,4-disubstituted triazoles derived from natural α-amino 
acids specifically designed to stabilize the interaction between the ryanodine receptor 
channel (RyR1) and its allosteric modulator Calstabin-1. This interaction is crucial to control 
the [Ca
2+
] homeostasis inside skeletal muscle cells (myocytes) and its deregulation is 
involved in the development of some important muscular diseases, like the Duchenne 
muscular dystrophy.  
1.3.2 N-Dealkylation of 1,2,3-triazolium salts. A metal-free route to 1,5-disubstituted 
1,2,3-triazoles and related bistriazoles (Chapter 3) 
In connexion with previous results reported by our group on the alkylation of 1,2,3-
triazoles, we will evaluate the development of a novel procedure for the assembly of less 
common 1,5-disubstituted 1,2,3-triazoles. In particular, we will face the synthesis of 
triazolium salts with a pendant group which can be easily removed and thus render the 
corresponding 1,5-disubstituted heterocycles upon a metal-free process. 
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Scheme 1.11. Synthesis of 1,5-disubstituted 1,2,3-triazoles. 
Furthermore, the practical introduction of azido and terminal alkyne groups with 
latent “click” reactivity along these alkylation processes would facilitate the assembly of new 
bistriazole derivatives of high structural complexity.  
1.3.3 Triazoles as directing groups in C−H functionalization reactions (Chapter 4) 
The use of 1,2,3-triazole units easily prepared upon CuAAC as directing groups 
(DGs) in the field of C−H functionalization has been rarely explored and is still in its 
infancy. In this respect, we will explore the development of practical metal-catalyzed C−H 
functionalization reactions featuring an unconventional role of 1,2,3-triazoles as versatile 
DGs. 
 
Scheme 1.12. Evaluation of “click” triazoles as DGs in    H functionalization reactions.  
Our procedures will complement existing methodologies for the functionalization of 
C(sp
2
)−H bonds and will represent novel late-stage functionalization procedures of “click” 
compounds. In particular, we will study Pd-catalyzed C−H oxygenation and acylation 
reactions which would afford fully decorated triazole derivatives of general structure A 
and B. 
 
Figure 1.5. General structures of fully decorated triazole derivatives.
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2 1H-1,2,3-Triazoles as drug scaffolds: intracellular Ca2+ regulation 
in muscle cells 
2.1 Introduction 
Muscular dystrophies (MDs) were characterized as a family of illnesses in the 19
th
 
century. The progressive weakening of the musculoskeletal system, previously attributed to 
tuberculosis, was comprehensively accounted by the neurologist Guillaume Duchenne, 
which also described an etiology including progressive loss for walking ability and early age 
death. Nowadays, the most common form of such diseases is named “Duchenne muscular 
dystrophy” (DMD)81 after his discoverer. 
In general, muscular dystrophies (MD) refer to a group of more than 30 genetic 
diseases, either inherited or arising from spontaneous mutations, that cause progressive 
weakness and degeneration of skeletal muscles used for voluntary movement. The age the 
disease appears as well as the intensity is variable, depending on the type of muscle that is 
affected. Some dystrophies affect other parts of the body than skeletal muscle, such as the 
heart, gastrointestinal system, respiratory system, eyes, brain and other organs. 
MDs involve mutations in at least one of the genes
82
 encoding proteins that are 
crucial for the integrity of muscles. When a protein is altered, not produced in the adequate 
quantity or missing, the muscles’ cells (myocytes) do not work in the appropriate way. 
Furthermore, MDs-related gene mutations often occur in sex-determining chromosomes and, 
therefore, are transmitted following a sex pattern. For example, the Duchenne muscular 
dystrophy DMD involves a single mutation of the X chromosome that skips the biosynthesis 
of the dystrophin protein and affects exclusively to male animals. 
                                                          
81  For an updated Duchenne Muscular Dystrophy overview and current therapeutic approaches, see: 
a) https://www.mda.org/disease/duchenne-muscular-dystrophy. b) Rao, M. V.; Sindhav, G. M.; 
Mehta, J. J. Ann. Indian Acad. Neur. 2014, 17, 303. c) Mercuri, E.; Muntoni, F. Lancet 2013, 381, 
845. d) Flanigan, K. M. Semin. Neurol. 2012, 32, 255. e) Bushby, K.; Finkel, R.; Birnkrant, D. J.; 
Case, L. E.; Clemens, P. R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; Poysky, J.; 
Shapiro, F.; Tomezsko, J.; Constantin, C. Lancet 2010, 9, 77. f) Emery, A. E. Lancet 2002, 359, 
687.  
82  Koenig, M.; Hoffman, E. P.; Bertelson, C. J.; Monaco, A. F.; Feener, C.; Kunkel, L. M. Cell 1987, 
50, 509. 
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In humans, DMD is the most common muscular dystrophy affecting approximately 
1 in every 3.500-6.000 male births each year in the United States.
83
 It usually becomes 
apparent during the toddler years, progressing rapidly, it causes inability to walk to the 
affected boys around the early age of 12 and, some years later, they need a respirator to 
breathe. Expected lifetime is under 25 years for most DMD patients.
84
 No effective 
therapeutic treatment for DMD is available at present.
85
 
To understand more in detail the structural and molecular basis of the DMD, it is 
necessary to briefly explain how the skeletal muscle is constituted, and how it works under 
normal and pathological conditions.  
2.1.1 Skeletal muscle and Duchenne muscular dystrophy (DMD) 
Skeletal muscles
86
 are formed by muscle fibers
87
 containing myocytes or muscle 
cells (Figure 2.1). Myocytes can contain more than one nucleus and include in their structure 
the myofibrils, which are long protein filaments composed of actin (thin filament) and 
myosin (thick filament). Repeated units of actin and myosin gathered together are called 
sarcomeres, which are the basic functional units of the muscle fiber.  
                                                          
83  Monaco, A. P.; Neve, R. L.; Colletti-Feener, C.; Bertelson, C. J.; Kurnit, D. M.; Kunkel, L. M. 
Nature 1986, 323, 646. 
84  a) Bushby, K. M.; Goodship, J. A.; Nicholson, L. V.; Johnson, M. A.; Haggerty, I. D.; Gardner-
Medwin, D. Neuromusc. Disord. 1993, 3, 57. b) Hoffman, E. P.; Arahata, K.; Minetti, C.; Bonilla, 
E.; Rowland, L. P. Neurology 1992, 42, 967. c) Richards, C. S.; Watkins, S. C.; Hoffman, E. P.; 
Schneider, N. R.; Milsark, I. W.; Katz, K. S.; Cook, J. D.; Kunkel, L. M.; Cortada, J. M. Am. J. 
Hum. Genet. 1990, 46, 672. 
85  Fairclough, R. J.; Wood, M. J.; Davies, K. E. Nat. Rev. Genet. 2013, 14, 373. 
86  Birbrair, A.; Zhang, T.; Wang, Z.-M.; Messi, M. L.; Enikolopov, G. N.; Mintz, A.; Delbono, O. 
Stem Cells Dev. 2012, 22, 2298. 
87  Zammit, P. S.; Partridge, T. A.; Yablonka-Reuveni, Z. J. Histochem. Cytochem. 2006, 54, 1177. 
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Figure 2.1. Structure of skeletal muscles and myocytes (A) Myofibrils are embedded by the 
sarcolemma; they have peripheral nuclei and internal mitochondria to provide energy for contraction 
(B) Sarcomeres are the contractile units of myofibrils. Their length is shortened upon calcium ion 
activated actin/myosin interaction (C) Schematic view of myocyte membrane main calcium channels: 
dihydropyridine receptors channels (Cav1.1), ryanodine receptor channels (RyR1) and SERCA 
channels (ATPase-active calcium ion pumps). 
The interaction between myosin and actin is triggered and modulated by a 
periodical change in the Ca
2+
 ion concentration inside the myocyte’s sarcoplasm fluid and is 
the ultimate responsible for the muscle contraction (high Ca
2+
 concentration) and relaxation 
(low Ca
2+
 concentration). Under resting conditions, the calcium ion is accumulated inside the 
sarcoplasmic reticulum (SR), a membrane complex that forms a tubular network of cisternae 
around each individual myofibril (Figure 2.2).  
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Figure 2.2. Schematic comparison of the excitation-contraction coupling of skeletal muscle in normal 
myocytes (top) and dystrophic DMD myocytes (bottom). A defective RyR1/Calstabin1 coupling 
(bottom-left) results in “Ca+2-leaky RyR1 channels”. In the resting state, DMD myocytes have 
abnormally high sarcoplasmic Ca+2 concentrations, which provokes a poor muscle contractility and, in 
the long term, the cell stress and death. 
In a normal skeletal muscle, the excitation-contraction (E-C) coupling process 
begins in the brain where the signal for the contraction is sent to the T-tubule membrane 
causing the depolarization and activation (opening) of Cav1.1 channels (dihydropyridine 
receptor voltage sensors). This triggers at the same time the large ryanodine receptor 
channels (RyR1),
88
 opens the sarcoplasmic reticulum (SR), and releases large amounts of 
                                                          
88  a) Witherspoon, J. W.; Meilleur, K. G. Acta. Neuropathol. Commun. 2016, 4, 121. b) Fill, M.; 
Copello, J. A. Physiol. Rev. 2002, 82, 893. 
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Ca
2+
 to the sarcoplasm leading ultimately to the muscle contraction.
89
 When the contraction 
is completed, Cav1.1 and RyR1 channels are closed and the intracellular Ca
2+
 is re-uptaken 
to the SR, by an ATPase-active calcium pump (sarco-endoplasmatic reticulum Ca, 
SERCA1a) which results in muscle relaxation
 90
 and preparation for the next excitation-
contraction.
91
  
As mentioned above, the Duchenne’s muscular dystrophy is caused by the absence 
of dystrophin,
92
 which keeps connected the sarcolemma membrane and the actin-myosin 
complex in myocytes. The absence of this protein causes the malfunction of the skeletal 
muscle during the excitation-contraction coupling. In particular, the RyR1 channels are 
hyper-nitrosylated and/or hyper-phosphorylated leading to poor RyR1/Calstabin-1 
interactions. In turn, this results in a failure in the complete closing of the channel during the 
resting step of the E-C coupling, which causes a permanent Ca
2+
 “leak” and, therefore, a 
perturbation in the intracellular Ca
2+
 concentration changes.
93
 In the long term, the 
incomplete calcium ion cycling compromises the contractility of the myocytes (muscle 
performance) makes the cells permanently stressed and, finally, provokes their death by 
apoptosis. 
Although genetic therapeutic approaches are being studied intensively to restore 
dystrophin production in DMD patients, a more profound understanding of the molecular 
basis of the disease is necessary to attain such goal. Alternatively, some therapeutic strategies 
are being actively developed in animal models
94
 seeking to mitigate the pathological 
alterations
95
 caused by the disease. More particularly, the use of low molecular weight 
                                                          
89  a) Petrof, B. J.; Shrager, J. B.; Stedman, H. H.; Kelly, A. M.; Sweeney, H. L. Proc. Natl. Acad. Sci. 
USA 1993, 90, 3710. b) Sandow, A. Yale J. Biol. Med. 1952, 25, 176.  
90  Saladin, K. S. Anat. Physiol. 2010, 405. 
91  Hernandez-Ochoa, E. O.; Pratt, S. J. P.; Garcia-Pelagio, K. P.; Schneider, M. F.; Lovering, R. M. 
Physiol. Rep. 2015, 3, e12366. 
92  Lapidos, K. A.; Kakkar, R.; McNally, E. M. Circ. Res. 2004, 94, 1023. 
93  a) Bellinger, A. M.; Mongillo, M.; Marks, A. R. J. Clin. Invest. 2008, 118, 445. b) Gillis, J. M. J. 
Muscle Res. Cell Motil. 1999, 20, 605. c) Michalak, M.; Fu, S.; Milner, R.; Bussan, J.; Hance, J. 
Biochem. Cell Biol. 1996, 74, 431. 
94  a) Bellinger, A. M.; Reiken, S.; Carlson, C.; Mongillo, M.; Liu, X.; Rothman, L.; Matecki, S.; 
Lacampagne, A.; Marks, A. R. Nat. Med. 2009, 15, 325. b) Muntoni, F.; Wells, D. Curr. Opin. 
Neurol. 2007, 20, 590.  
95  a) Pratt, S. J.; Valencia, A. P.; Le, G. K.; Shah, S. B.; Lovering, R. M. Front. Physiol. 2015, 6, 252. 
b) Mazala, D. A.; Pratt, S. J.; Chen, D.; Molkentin, J. D.; Lovering, R. M.; Chin, E. R. Am. J. 
Physiol. Cell Physiol. 2015, 308, C699. c) Lovering, R. M.; Shah, S. B.; Pratt, S. J. P.; Gong, W.; 
Chen, Y. Muscle Nerve 2013, 47, 588. d) Lovering, R. M.; Michaelson, L.; Ward, C. W. Am. J. 
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compounds to restore the intracellular Ca
2+
 homeostasis and to recover normal skeletal 
muscle function seems very promising. 
Different studies have demonstrated the beneficial effects of RyR1 channel 
stabilizers on animal models of muscular dystrophy.
94a
 In particular, the treatment of 
Duchenne mice models (mdx) with the benzothiazepines JTV-519
96
 and S-107 has shown to 
partially improve the calcium homeostasis by reducing the RyR1 channel leaking, and to 
improve the muscle function and exercise performance in vivo (Figure 2.3).
94,97 
However, 
they have failed to reach a proper preclinical profile and, currently, there is no FDA-
approved treatment for RyR1-related congenital myopathies. 
 
Figure 2.3. Benzothiazepines with sarcoplasmic Ca2+ concentration modulation activity. 
Finally, it should be mentioned that RyR1 channels do not exclusively occur in the 
skeletal muscle tissue, but also in the brain and central nerve system (CNS) of mammals. 
Various authors have reported that alterations of the intracellular Ca
2+
 homeostasis in 
neurons caused by RyR1 channels leaking can be involved in several neurodegenerative 
conditions. Interestingly, some simple 4-chlorophenol-derived compounds, such as 4-chloro-
m-cresol or 4-chloro-3-ethylphenol, have been claimed to consolidate the long-term memory 
stage in young chicks by RyR1 activation and control of the intracellular calcium release.
98
 
                                                                                                                                                      
Physiol. Cell Physiol. 2009, 297, C571. e) Berchtold, M. W.; Brinkmeier, H.; Muntener, M. 
Physiol. Rev. 2000, 80, 1215. f) Tutdibi, O.; Brinkmeier, H.; Rudel, R.; Fohr, K. J. J. Physiol. 1999, 
515, 859. g) McArdle, A.; Edwards, R. J.; Jackson, M. J. Neuromuscul. Disord. 1995, 5, 445. h) 
Florence, J. M.; Fox, P. T.; Planer, G. J.; Brooke, M. H. Neurology 1985, 35, 758.  
96  Wehrens, X. H. T.; Lehnart, S. E.; Reiken, S.; Van der Nagel, R.; Morales, R.; Sun, J.; Cheng, Z.; 
Deng, S.-X.; Windt, L. J.; Landry, D. W.; Marks, A. R. Proc. Natl. Acad. Sci. USA 2005, 102, 
9607. 
97  a) Kreko-Pierce, T.; Azpurua, J.; Mahoney, R. E.; Eaton, B. A. J. Biol. Chem. 2016, 291, 26045. b) 
Bellinger, A. M.; Reiken, S.; Dura, M.; Murphy, P. W.; Deng, S.-X.; Landry, D. W.; Nieman, D.; 
Lehnart, S. E.; Samaru, M.; LaCampagne, A.; Marks, A. R. Proc. Natl. Acad. Sci. USA 2008, 105, 
2198.  
98  Baker, K. D.; Edwards, T. M.; Reiken, S.; Rickard, N. Behav. Brain Res. 2010, 206, 143. 
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Within this context, the research group of Neuromuscular Diseases at the 
BioDonostia Research Institute (San Sebastián, Spain) led by Prof. Adolfo López de Munain 
and Dr. Ainara Vallejo,
99
 established a scientific collaboration with our research group to 
explore the synthesis of novel molecules based on 1H-1,2,3-triazole scaffolds I designed to 
modulate the activity of RyR1 channels in myocytes.  
2.2 Hypothesis 
To the best of our knowledge, the rational design of molecules to stabilize the 
RyR1/Calstabin-1 protein interface has not been studied previously using a combination of 
computational modeling and designed synthesis. This could be attributed to the lack of 
reliable and high-resolution crystallographic information regarding the 3D-structure of the 
huge RyR1 565 kDa-channel, which has been only partially unveiled by Marks in 2015.
100
 In 
contrast, the precise 3D-structure of the 12 kDa-protein Calstabin-1, also named FKBP12, 
was reported more than two decades ago,
101
 establishing that there are four Calstabin-1 
subunits binding the homotetrameric RyR1 protein in a 1:1 manner.  
It is thought that Calstabin-1 promotes the RyR1 channel closure by means of a 
long-range allosteric effect
102
 involving a cascade of conformational changes altering most of 
the domains of the large RyR1 protein (Figure 2.4). Recently, Girgenrath et al
103
 have used 
site-directed fluorescence resonance energy transfer (FRET) techniques to identify two 
segments of RyR1 comprising the amino acids residues 76-619 and 2157-2777, respectively, 
which are likely involved in the interaction with Calstabin-1. Finally, and more importantly, 
Calstabin-1 systematic mutation studies conducted by Galfre et al
 104
 have revealed that    
Trp-59 residue modification efficiently cancels the interaction with RyR1. 
                                                          
99  a) Hernandez-Ochoa, E. O.; Pratt, S. J. P.; Lovering, R. M.; Schneider, M. F. Front. Physiol. 2016, 
6, 1. b) Vallejo-Ilarramendi, A.; Toral-Ojeda, I.; Aldanondo, G.; López de Munain, A. Expert Rev. 
Mol. Med. 2014, 16, e16.  
100 Zalk, R.; Clarke, O. B.; des Georges, A.; Grassucci, R. A.; Reiken, S.; Mancia, F.; Hendrickson, 
W.A.; Frank, J.; Marks, A. R. Nature 2015, 517, 507.  
101 Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thomson, J. A.; Fitzgibbon, M. J.; Fleming, 
M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A. Cell 1995, 82, 507.  
102  Bai, X-Ch.; Yan, Z.; Wu, J.; Li, Z.; Yan, N. Cell. Res. 2016, 26, 995. 
103 Girgenrath, T.; Mahalingam, M.; Svensson, B.; Nitu, F. R.; Cornea, R. L.; Fessenden, J. D. J. Biol. 
Chem. 2013, 288, 16073.  
104 Galfre, E.; Venturi, E.; Pitt, S. J.; Bellamy, S.; Sessions, R. B.; Sitsapesan, R. Biophys. J. 2013, 
104, 443a.  
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On the basis of these observations, we reasoned that 1H-1,2,3-triazole-containing 
analogues could be designed to modulate the protein-protein interaction at the 
RyR1/Calstabin-1 interface around the key Trp-59 Calstabin-1 residue. More particularly, we 
selected triazoles I comprising the combination of a hydrophobic aromatic ring and a polar 
α-amino acid residue to favor the solubilization in physiological media. 
 
Figure 2.4. Schematic representation of the modulation of the long-range allosteric effect of the 
RyR1/Calstabin-1 interaction by triazole compounds I. Only two of four homomers are represented. 
As mentioned above, some RyR1 channels occur in the CNS. Consequently drug 
candidates aimed to modulate the RyR1/Calstabin-1 interaction inside the brain have to cross 
the blood brain barrier (BBB).
105
 Carboxylic acid-containing small molecules often fail to 
traverse the BBB because they form carboxylate anions in the blood plasma, which are 
repealed by the negatively charged membrane of the cerebral endothellium. As a possible 
solution to this problem, we considered the formation of inclusion complexes of triazoles I 
with cyclodextrins (CD), which have recently shown to have the ability to cross the BBB.
106
 
 
 
                                                          
105  Mensh, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. J. Pharm. Sci. 2009, 98, 4429. 
106  a) Shityalov, S.; Salmas, R. E.; Salvador, E.; Roewer, N.; Broscheit, J.; Foerster, C. J. Toxicol. Sci. 
2016, 41, 175. b) Gil, E. S.; Wu, L.; Xu, L.; Lowe, T. L. Biomacromolecules 2012, 13, 3533. 
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2.3 Objectives 
In order to test the hypotheses disclosed above, the first part of this doctoral thesis 
will be focused on the following activities: 
1. A docking computational study of several 1H-1,2,3-triazoles I at the RyR1/Calstabin-1 
interface close to the Trp-59 residue using the Autodock FR package and the CCDC X-
ray data available for Calstabin-1.
101
 The resulting virtual library of triazole modulators 
will be used to select the best candidates to be synthesized. 
2. The synthesis of a representative series of 1H-1,2,3-triazoles I starting from phenols, 
thiophenols and natural α-amino acids, by following standard CuAAC “click” 
procedures or adapted versions developed in our research group.
107
   
 
Some of the compounds synthesized will be tested at BioDonostia Research Institute to 
establish their toxicity profile, the effect on intracellular calcium ion concentration in 
myocytes, and “in vivo” effect on mdx mice models of Duchenne muscular dystrophy. 
3. The formation of inclusion complexes of some selected 1H-1,2,3-triazoles I with β-
cyclodextrin in water solution will be investigated using NMR techniques to measure 
the corresponding association constants (Ka) and propose a plausible interaction model. 
 
                                                          
107  a) Aizpurua, J. M.; Fratila, R. M.; Monasterio, Z.; Pérez-Esnaola, N.; Andreieff, E.; Irastorza, A.; 
Sagartzazu-Aizpurua, M. New J. Chem. 2014, 38, 474. b) Aizpurua, J. M.; Sagartzazu-Aizpurua, 
M.; Azcune, I.; Miranda, J. I.; Monasterio, Z.; García-Lecina, E.; Fratila, R. M. Synthesis 2011, 17, 
2737. c) Aizpurua, J. M.; Azcune, I.; Fratila, R. M.; Balentova, E.; Sagartzazu-Aizpurua, M.; 
Miranda, J. I. Org. Lett. 2010, 12, 1584.  
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2.4 Results and discussion 
2.4.1 Preliminary computational docking studies 
To address the first objective, a computational docking study was conducted in 
collaboration with Dr. Jose Ignacio Miranda from SGIker (General Research Services of the 
University of the Basque Country) using the Autodock FR
108
 software package. Structures of 
the RyR1/Calstabin-1 tetramer complex (code 3J8H)
109
 were obtained from the Protein Data 
Bank. Only one monomeric RyR1/Calstabin-1 pair was used for the calculations. Triazole 
ligand structures Ia-c, formally derived from substituted thiophenols and glycine, were 
selected to confirm their binding ability with the RyR1/Calstabin-1 complex and to estimate 
the effect of electron-donating and electron-withdrawing groups on such interactions. 
Proteins and triazole ligands Ia-c were prepared following the standard protocols using the 
AutoDock Tools 1.5.7 software. Selection of the docking area and mobile side-chains in the 
Calstabin-1 was achieved using the AutoGrid FR software and was limited to the residues 
Tyr-26, Asp-37, Arg-42, Lys-44, Lys-47, Phe-48, Lys-52 and Glu-54, which were all 
surrounding the key Trp-59 amino acid placed in the center of a characteristic groove-like 
structure (see Figure 2.5 D). Likewise, the RyR1 protein docking surface was limited to the 
1778-1784 residues comprising a peptide loop interacting with the Calstabin-1 groove. Each 
ligand was docked 5 times to give an average interaction energy. 
As shown in Figure 2.5, an excellent matching of the triazoles Ia-c and the 
RyR1/Calstabin-1 complex in the expected interface region was anticipated by the docking 
results. The ligand repeatedly docked inside the Calstabin-1 groove and placed itself in front 
of the RyR1 loop segment after each docking run. In view of this result and the docking 
energy range (≈12-13 kcal/mol), we reasonably presumed that triazole ligands I could 
modulate the long-range allosteric effect elicited by Calstabin-1 on the activation/closure of 
the RyR1 channel and, therefore, we expected to have a significant activity on the control of 
the sarcoplasmic calcium ion concentration in myocytes. Finally, the presence of an electron-
                                                          
108  a) Ravindranath, P. A.; Forli, S.; Goodsell, D. S.; Olson, A. J.; Sanner, M. F. PLOS Comput. Biol. 
2015, 11, e1004586. b) Zhao, Y.; Stoffler, D.; Sanner, M. Bioinformatics 2006, 22, 2768.  
109  Yan, Z.; Bai, X.-C.; Yan, C.; Wu, J.; Li1, Z.; Xie, T.; Peng, W.; Yin, C.-C.; Li, X.; Scheres, S. H. 
W.; Shi, Y.; Yan, N. Nature 2015, 517, 50. 
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donating substituent (MeO) at the aromatic ring appeared to exert a sizeable enhancing effect 
on the docking energy, when compared to electron-withdrawing substituents (F). 
 
Figure 2.5. RyR1/Calstabin-1 tetramer complex, (A) top view; (B) side view. (C) Monomer complex 
RyR1 (blue)/Calstabin-1 (purple). (D) Structure of the triazole ligand I-a docked at the 
RyR1/Calstabin-1 complex; deep-blue side-chains correspond to the RyR1 segment of residues 1778-
1784; purple surface corresponds to Calstabin-1. 
2.4.2 Synthesis of 1,4-disubstituted 1H-1,2,3-triazole ligands for RyR1 modulation 
To get a library of representative carboxylic triazole RyR1 ligands, we planned a 
simple two-step reaction sequence comprising a standard CuAAC “click” reaction of alkynes 
and α-azido esters, followed by the saponification of the intermediate triazole esters under 
basic conditions (Scheme 2.1). 
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Scheme 2.1. “Click” synthetic approach to carboxylic 1H-1,2,3-triazole RyR1 ligands. 
First, we prepared a set of alkynes 1a-d containing either electron-donating or 
electron-withdrawing groups at the aromatic moiety by reacting a few commercially 
available thiophenols and phenols with propargyl bromide under phase transfer reaction 
conditions (Table 2.1). The aryl ethers or thioether products were obtained in high yields and 
were pure enough to be used directly in the next CuAAC cycloaddition reactions. 
Table 2.1. Preparation of alkynes 1 from thiophenols and phenols. 
 
Next, a set of α-azido esters 2 was readily synthesized from α-amino acid ester 
hydrochlorides following the N-diazotation method described by Pelletier
110
 (Table 2.2). 
Accordingly, the α-amino ester was liberated in situ with triethylamine and reacted at room 
temperature in dichloromethane with a solution of triflyl azide (TfN3), freshly prepared from 
sodium azide and Tf2O. The N-diazotation was efficiently catalyzed by Cu(II) salts to 
provide practically quantitative yields of the corresponding α-azido esters 2 without 
appreciable epimerization when enantiopure starting α-amino esters were used.  
Attempted isolation and purification of some of the azido compounds (e.g. (S)-2c 
and (R)-2c) resulted in a significant yield lowering, probably due to partial decomposition 
during the purification by column chromatography. For this reason, we decided to avoid such 
operation and use immediately the crude α-azido esters 2 in the subsequent cycloaddition 
                                                          
110  Lundquist, J. T.; Pelletier, J. C. Org. Lett. 2001, 3, 781. 
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reactions with alkynes 1. Finally, it should be mentioned that the achiral methyl 
azidoglycinate 2a was more conveniently prepared using a different method. Thus, reacting 
methyl bromoacetate with NaN3 in DMF at room temperature followed by extraction with 
diethyl ether and careful evaporation provided the azido ester 2a in 95 % yield. 
Table 2.2. Preparation of α-azido esters by N-diazotation of α-amino esters. 
 
aAzidoglycinate 2a was obtained from BrCH2CO2Me and NaN3 in DMF, r.t. 2h. 
bYield of isolated 
compounds after column chromatography. cCompound not purified, used in situ in CuAAC reaction 
with alkynes 1. 
With alkynes 1 and α-azido esters 2 in hand, we studied their CuAAC coupling 
reaction using the Sharpless standard reaction conditions (Table 2.3). Thus, when equimolar 
quantities of both compounds were reacted in the presence of 0.2 equivalents of copper(II) 
sulfate and 0.4 equivalents of sodium ascorbate in a mixture of THF, tBuOH and water, the 
desired triazoles 3-13 were obtained in good to excellent yields after chromatographic 
purification. Interestingly, a one-pot cycloaddition procedure using in situ generated chiral α-
azido esters 2c-d proved to be particularly efficient to prepare the triazoles 8-13, which were 
assumed to undergo no racemization owing to the mild and neutral reaction conditions used.  
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Table 2.3. “Click” synthesis of 1-(methoxycarbonylalkyl) 1,2,3-triazoles 3-13. 
 
aFrom pure azidoglycinates 2a and 2b. bOne-pot procedure was followed from in situ generated α-azido 
esters 2c-e. 
Triazole ring formation was easily assessed in all instances by 
1
H-NMR analysis. 
For example, Figure 2.6 shows the spectrum of the reaction crude product of compound 3, 
which exhibits a characteristic 1H-1,2,3-triazole C5−H peak at 7.38 ppm. Similarly, 
consistent sets of spectroscopic data were found for all the synthesized triazole esters. 
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Figure 2.6. 1H-NMR (500MHz, CDCl3) spectrum of the crude product triazole ester 3. 
 
 
Figure 2.7. 1H-NMR (500MHz, MeOH-d4) spectrum of carboxylic triazole compound 14. 
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The final synthetic step to get the desired RyR1 triazole modulators consisted in the 
saponification of triazolic methyl esters 3-13. This transformation was achieved treating each 
compound with LiOH·H2O in a mixture of THF and water at room temperature. An acidic 
extraction of the aqueous solution afforded the triazolic carboxylic acids 14-24 in 54-94 % 
isolated yields (Table 2.4). Again, the saponification reaction was confirmed by the 
comparison of the 
1
H-NMR spectra of the methyl esters 3-13 and the free carboxylic acids 
14-24. For example, the spectra in Figures 2.6 and 2.7 correspond to the saponification of 4 
to 14, and show how the signal at 3.78 ppm vanished completely after the reaction. 
Table 2.4. Synthesis of 1-(carboxylalkyl)-1,2,3-triazoles 14-24. 
 
In order to use chiral carboxylic triazoles 19-24 (Table 2.4) as RyR1 ligands, it was 
essential to determine their enantiomeric purity arising from the degree of preservation of the 
chiral integrity during the N-diazotation/CuAAC cycloaddition/saponification sequences 
described above. To achieve this purpose, we first repeated these reactions starting from 
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racemic mixtures of (±)-H-Phe-OMe, (±)-H-Leu-OMe and (±)-H-Val-OMe, to prepare the 
corresponding pairs of triazoles (19+20), (21+22) and (23+24), respectively. Neat separation 
of all the racemic carboxylic triazole pairs was confirmed using HPLC chromatography on 
chiral stationary phase (Figure 2.8, left columns). The optimized conditions were achieved 
using a Chiracel IC50 column together with an eluent mixture composed of hexane (80 %), 
isopropanol (20 %) and trifluoroacetic acid (0.1 %).  
Next, we injected compounds 19-24 and compared the chromatograms with the 
respective racemic mixtures. In the case of the phenylalanine-derived carboxylic triazoles 19 
and 20 (Figure 2.8, row A), a similarly low enantiomeric purity (e.e. ≈ 40 %) was measured 
for each compound, which clearly suggested a partial racemization reaction at one or several 
of the synthetic steps leading to the final products. A very similar behavior was observed for 
the valine-derived carboxylic triazoles 23-24 (Figure 2.8, row C), which yielded an even 
lower enantiomeric purity (e.e. ≈ 20 %). 
To our surprise, however, no racemization at all was observed for the leucine-
derived carboxylic triazoles 21-22 (Figure 2.8, row B). In this case, 98 % e.e. purity values 
were recorded for each enantiomer, precluding the occurrence of the racemization reactions 
in any of the synthetic steps. 
The above results clearly suggested that the observed racemization was strongly 
dependent on the nature of the substituent group at the α-amino acid moiety, but it did not 
explained at which particular reaction step of the synthesis the racemization actually took 
place. In order to clarify this point, we first tried to confirm the enantiomeric purity of the 
precursor triazole esters 8-9 and 12-13 (Table 2.3) using the same chiral HPLC techniques 
described above for the carboxylic analogues. Unfortunately, none of the racemic triazole 
ester pairs derived from H-Phe-OMe and H-Val-OMe could be separated under a variety of 
chromatographic conditions. 
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Figure 2.8. HPLC chromatograms of chiral carboxylic triazoles obtained from HPheOMe (A), 
HLeuOMe (B) and HValOMe (C). Left column: racemic mixtures. Center: S major isomers. Right: R 
major isomers. Conditions: Chiracel IC50 column, eluent: hexane (80 %), isopropanol (20 %), 
trifluoroacetic acid (0.1 %), wavelength λ = 210 nm. 
Owing to the strong basic conditions needed to conduct the saponification step, we 
assumed that this reaction was more likely responsible for the racemization observed for 
phenylanine- and valine-derived chiral triazoles. In an attempt to avoid such base-induced 
racemization, we tried to perform the methyl ester deprotection of compound 9 under neutral 
conditions (Scheme 2.2). Unfortunately, neither the in situ generated iodotrimethylsilane
111
 
nor the iodide anion
112
 was able to promote the desired demethylation reaction (Scheme 2.2). 
In the first case, an extensive degradation of the starting material was observed under a 
variety of conditions, while in the second case the ester 9 remained unreactive. 
 
                                                          
111  Miller, A. R. J. Org. Chem. 1979, 44, 889. 
112  Bentley, T. W.; Carter, G. E.; Harris, H. C. J. Chem. Soc., Chem. Commun. 1984, 387.   
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Scheme 2.2. Attempted deprotection of compound 9 under non-basic conditions. 
At this point, we decided to modify the original synthetic approach by replacing the 
methyl ester groups of the starting materials by free-carboxylic acid groups. Wittmann and 
co-workers
113
 have demonstrated that free α-amino acids can be directly transformed into α-
azido acids with triflyl azide under slightly basic conditions using a mixture of methanol and 
water to solubilize the substrates. Furthermore, the authors proved that such transformation 
was totally racemization-free for a large array of α-amino acids. 
As shown in the examples of Scheme 2.3, the N-diazotation reaction of the free 
phenylalanine and valine α-amino acids provided α-azido acid intermediates which were 
reacted in situ with the alkyne 1b under CuAAC conditions to afford the desired carboxylic 
triazoles in a one-pot operation. The overall yields were excellent and the whole 
transformation, including the purification of the final products, could be performed in a 
single working day. 
 
Scheme 2.3. Two-step one-pot synthesis of carboxylic triazoles 19, 20, 23 and 24. 
To our delight, the HPLC analysis on chiral stationary phase revealed a total 
preservation of the stereogenic integrity in all the instances tested (Figure 2.9). For each pair 
of enantiomers analyzed, the measured enantiomeric purities gave e.e. values above 99 %. 
                                                          
113  Beckmann, H. S. G.; Wittmann, V. Org. Lett. 2007, 9, 1. 
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Figure 2.9. HPLC chromatograms of chiral carboxylic triazoles obtained from HPheOH (top), and 
HValOH (bottom). Left column: racemic mixtures. Center: S major isomers. Right: R major isomers. 
Conditions: Chiracel IC50 column, eluent: hexane (80 %), isopropanol (20 %), trifluoroacetic acid 
(0.1 %), wavelength λ = 210 nm. 
Finally, we decided to demonstrate that carboxylic triazoles designed to be RyR1 
channel modulator ligands could be easily modified into related compounds with potential 
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pharmacological interest. More particularly, we tested the S-oxidation reaction of the sulfide 
moiety using MCPBA reagent (Scheme 2.4). 
 
Scheme 2.4. S-oxidation of compound 15. 
In a preliminary experiment, we were pleased to confirm that a clear oxidation of 
compounds 15 to the corresponding sulfone 25 could be achieved under standard conditions 
in a nonoptimized yield of 40 %. These oxidation reactions are currently being studied in our 
laboratory to prepare novel families of calcium channel modulator candidates. 
2.4.3 Biological activity of carboxylic triazoles as RyR1 channel modulators in 
myocytes and mdx mouse models 
Samples of the carboxylic triazoles 14-24 were provided to the BioDonostia 
Research Institute to establish their toxicity profile, the effect on intracellular calcium ion 
concentration in myocytes, and in vivo effect on mdx mouse model of Duchenne muscular 
dystrophy. Nevertheless, due to the long time necessary to grow mdx mice colonies large 
enough to provide statistically significant results in vivo, it was decided to conduct the initial 
trials using only the ligand 16. This task was achieved by Dr. Garazi Aldanondo as part of 
her PhD thesis work.
114
 Similar evaluations are now underway for all the remaining 
carboxylic triazole samples and the results will be discussed elsewhere. 
As mentioned previously (see Section 2.1.1), benzothiazepine S-107 is one of the 
most active RyR1 modulator known at present. For this reason, we decided to synthesize 
such compound following the procedure described by Villeneuve et al.
115
 (Figure 2.10). 
                                                          
114  Aldanondo, G. PhD Thesis UPV-EHU 2017 “Effect of novel ryanodine receptor modulators in 
mouse and human models of Duchenne muscular dystrophy.” 
115  Yan, J.; Belvedere, S.; Webb, Y.; Bertrand, M.; Villeneuve, N. Patent WO-2013156505 A1. 2013. 
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Figure 2.10. Chemical structures of triazole 15 and S-107 used in the biological evaluations conducted 
in this work.114 
Figures 2.11-2.13 collect the main results obtained after the completion of 4 
representative biological assays. Brief comments of the nature of such assays and the 
conclusions that can be drawn from these results follow: 
1. Triazole 15 shows very low or undetectable in vitro toxicity towards mouse C2C12 
myoblast and human LHCN-M2 myoblast cultures, whereas compound S107 is 
strongly cytotoxic to both types of myoblasts at concentrations above 1 mM (Figure 
2.11). Triazole compounds 14 and 16-24 were also essentially not toxic in the same 
concentration range. 
2. Intracellular Ca2+ concentrations are determined using the calcium ratiometric red 
color dye Fura-2AM in combination with a computer-assisted pseudocolor image 
analysis. Compound 15 or compound S107 normalize up to 75 % the resting 
intracellular sarcoplasmic Ca
2+
 levels of isolated muscle fibers from dystrophic mdx 
mice after in vivo treatment (Figure 2.12). 
3. In mdx mice, 5-week treatments with compounds 15 as well as S107 reduce 
histopathological and biochemical evidence of muscle damage and ameliorate overall 
muscle weakness. In contrast, these RyR1 modulators do not have any obvious effect 
in wild-type mice. This effect can be evidenced by the reduction of the pathologic 
central nuclei proportion after the drug treatment (Figure 2.13). 
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4. After a 5-week treatment with compound 15 as well as S107 at oral doses of 0.8 mM, 
mdx mice increase the in vivo grip strength in up to 40 % when they are submitted to 
controlled exercise (Figure 2.14). 
 
 
Figure 2.11. Concentration dependent 24 hours in vitro cytotoxicity of compounds 15 and S107 in: (A) 
7 days-old C2C12 mouse myoblasts and (B) LHCN-M2 immortalized human myoblasts. Data are 
represented as average of the percentage of cell death ± SEM, n = quadruplicates per condition in 3 
independent cultures.114 
 
 
Figure 2.12. Intracellular Ca2+ basal levels measured in vitro in mouse muscle fibers using the calcium 
ratiometric red color dye Fura-2AM. (A) Single fiber isolated from flexor digitorum brevis muscle, 
showing characteristic striation pattern. (B) Representative pseudocolor images of Fura-2AM loaded 
fibers from: control wild-type (WT), non-treated mdx (MDX ND), mdx treated with compound 15 
(MDX 15), and mdx treated with S-107 (MDX S107); a deeper red color corresponds to a higher 
intracellular Ca2+ concentration. (C) Relative intracellular calcium levels in resting myocyte muscle 
fibers. A lower intracellular Ca2+ level indicates a more normalized activity.114 
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Figure 2.13. Muscle histopathology: representative cryostat sections from control and dystrophic 
diaphragms stained with DAPI for collagen IV (green) and to show nuclei (blue). (A) Diaphragm 
cryostat sections from wild-type (WT) and (B) mdx mice (MDX) stained for collagen IV (green) and 
nuclei (blue) showing central nucleation in dystrophic muscle. Scale bar 100 µm. (C) Quantification of 
myofiber central nucleation in diaphragm muscles from wild-type (WT), non-treated mdx (MDX ND), 
15-treated mdx (MDX 15) and S107-treated mdx (MDX S107) mice after 5 weeks of treatment. Data 
are represented as average ± SEM, n = 3 WT, n = 9 MDX ND, n = 7 MDX 15, and n = 6 MDX S107.  
P <0.05 (one-way ANOVA, Tukey´s Post hoc test). [DAPI: 4’,6-Diamidine-2’-phenylindole 
hydrochloride].114 
 
Figure 2.14. Protective in vivo effect of triazole ligands 15 and S-107 on muscle function in dystrophic 
mdx mice after 5 weeks of oral administration (0.25 mg/mL). (A) Dynamometric grip strength 
determination apparatus. (B) Forelimb grip strength of wild-type (WT), non-treated mdx (MDX ND), 
15-treated mdx (MDX 15) and S107-treated mdx (MDX S107) mice after 5 weeks of treatment. Data 
are represented as average ± SEM, n = 10 WT, n = 11 MDX ND, n = 10 MDX 15, and n = 6 MDX 
S107. P <0.05 (one-way ANOVA, Tukey´s Post hoc test).114  
In conclusion, the novel carboxylic triazole 15 has proved to be a highly efficient 
intracellular calcium homeostasis regulator in skeletal muscle upon oral administration to 
dystrophic mdx mice. The efficacy of 15 is comparable to S107, but the former is 
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significantly less toxic. Accordingly, these novel carboxylic triazoles
116
 are promising 
candidates to develop protective therapies for Duchenne muscular dystrophy and other 
related diseases. 
2.4.4 Inclusion complexes of 1-(carboxyalkyl)-1,2,3-triazoles and β-cyclodextrin 
As discussed previously in this chapter (Section 2.2), some cyclodextrins have been 
used to enhance carboxylic drug transportation across the blood-brain barrier. In order to 
complete the third objective of this chapter, we studied the supramolecular interaction of a 
model cyclodextrin with the carboxylic triazole 15 in aqueous solution. 
Cyclodextrins
117
 (CD) are cyclic oligosaccharides produced by enzymatic degradation 
of starch and they are constituted of 6 (α), 7 (β) or 8 (γ) glucopyranose units connected by α-
[1,4]-linkages. They present a truncated cone structure, in which the internal cavity diameter 
increases as a function of the number of glucopyranose units from 5.7 to 7.8 and 9.5 Å, when 
the height of the truncated cone is 7.8 Å.  
 
Figure 2.15. Chemical structure and approximate dimensions of β-cyclodextrin (β-CD). 
                                                          
116  Vallejo, A.; López de Munain, A. J.; Toral, I.; Aldanondo, G.; Aizpurua, J. M.; Irastorza, A.; 
Ferrón, P.; Miranda, J. I. Spanish Patent Application ES : P201630671, 2016. 
117  a) Duchêne, D.; Bochot, A. Int. J. Pharm. 2016, 514, 58. b) Wang, X.; Luo, Z.; Xiao, Z. 
Carbohydr. Polym. 2014, 101, 1027. c) Benk, M.; Király, Z. J. Chem. Therm. 2012, 54, 212. d) 
Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. Aaps Pharmscitech 2005, 6, E329. e) Huang, D.; Ou, B.; 
Hampsch-Woodill, M.; Flanagan, J. A.; Deemer, E. K. J. Agric. Food Chem. 2002, 50, 1815. f) 
Szejtli, J. Chem. Rev. 1998, 98, 1743. g) Wenz, G. Angew. Chem. Int. Ed. Engl. 1994, 33, 803. h) 
Saenger, W. Angew. Chem. Int. Ed. Engl. 1980, 19, 344. 
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The hydroxyl groups of the glucopyranose ring are located on the outside of the 
molecular cavity, which renders the CDs hydrophilic and soluble in water. In contrast, the 
internal cavity is hydrophilic and can reversibly trap apolar molecules (or part of molecules), 
leading to an inclusion complex.
118
 The inclusion complex (host-guest complex) results from 
the chemical equilibrium between the cyclodextrin host and the inclusion molecules to form 
typically 1:1, 1:2 or 2:1 clusters depending on the molecules involved. The equilibrium 
constant Ka is also known as affinity constant or stability constant. It must be mentioned that 
cyclodextrin complexes are routinely used in food,
119
 cosmetics
120
 and chemical industries,
121
 
agriculture and environmental engineering
122
 and also in pharmaceutical technology.
123
 
Triazoles have been extensively used for the chemical modification of cyclodextrins 
via CuAAC reactions, facilitated by the higher reactivity of the primary hydroxyl groups, 
which can be easily turned into “clickable” azido or alkyne groups.124 However, the ability of 
1H-1,2,3-triazoles to act as “aromatic-like” heterocyclic guest molecules of cyclodextrins has 
been only partially investigated.
125
 In this respect, we decided to study the supramolecular 
interaction of the RyR1 regulator carboxylic triazole 15 and β-cyclodextrin (β-CD), which 
has been recognized as the more suitable to the purpose of controlling drug delivery.
126
 
                                                          
118  a) Kumar, A. R.; Ashok, K.; Brahmaiah, B.; Nama, S.; Baburano, C. Int. J. Pharm. Res. Bio-sci. 
2013, 2, 291. b) Brinker, U. H.; Mieusset, J.-L. John Willey & Sons, Chichester, UK 2010. c) 
Duchêne, D. John Willey & Sons, Hobboken, USA 2001, 3.  
119  a) Cheng, J.; Hu, Y.; Luo, Z.; Chen, W.; Chen, H.; Peng, X. Food Chem. 2017, 218, 116. b) 
Fenyvesia, É.; Vikmona, M. A.; Szente, L. Crit. Rev. Food Sci. Nutr. 2016, 56, 1981. c) Nazi, M.; 
Malek, R. M. A.; Kotek, R. Carbohydr. Polym. 2012, 88, 950. d) Inoue, M.; Hashizaki, K.; 
Taguchi, H.; Saito, Y. Chem. Pharm. Bull. 2008, 56, 668. e) Huang, D.; Ou, B.; Hampsch-Woodill, 
M.; Flanagan, J. A.; Deemer, E. K. J. Agric. Food Chem. 2002, 50, 1815.  
120  Wang, C. X.; Chen, S. L. J. Ind. Text. 2005, 34, 157. 
121  Szejtli, J. Chem. Rev. 1998, 98, 1743. 
122  a) Li, Y.; Zhao, Y.; Chan, W.; Wang, Y.; You, Q.; Liu, C.; Zheng, J.; Li, J.; Yang, S.; Yang, R. 
Anal. Chem. 2015, 87, 584. b) Soheilmoghaddam, M.; Sharifzadeh, G.; Pour, R. H.; Wahit, M. U.; 
Whye, W. T.; Lee, X. Y. Mater. Lett. 2014, 135, 210.  
123  a) Menuela, S.; Jolyb, J.-P.; Courcotc, B.; Elyséec, J.; Ghermanid, N.-E.; Marsuraa, A. Tetrahedron 
2007, 63, 1706. b) Loftsson, T.; Masson, M. Int. J. Pharm. 2001, 225, 15. c) Tabushi, I. Acc. Chem. 
Res. 1982, 15, 66. 
124  a) Legros, V.; Vanhaverbeke, C.; Souard, F.; Len, C.; Desire, J. Eur. J. Org. Chem. 2013, 2583. b) 
Hänni, K. D.; Leigh, D. A. Chem. Soc. Rev. 2010, 39, 1240. 
125  a) Farcas, A.; Fifere, A.; Stoica, I.; Farcas, F.; Resmerita, A. M. Chem. Phys. Lett. 2013, 514, 74. b) 
Menuel, S.; Azaroual, N.; Landy, D.; Six, N.; Hapiot, F.; Monflier, E. Chem. Eur. J. 2011, 17, 
3954. 
126  Cheong, A. M.; Tan, K. W.; Tan, C. P.; Nyam, K. L. Food Hydrocoll. 2016, 52, 934. 
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2.4.4.1 NMR study on the β-CD/triazole 15 host-guest complexation 
NMR is the technique of choice to investigate the supramolecular interactions of 
cyclodextrins with organic molecules.
127
 Standardized titration 
1
H-NMR experiments on 
series of samples with different concentrations of the host β-CD and guest compounds, 
allows the accurate measurement of variations of the chemical shift (Δδi) of the protons of 
both molecules involved in the interaction. From this data, three valuable kinds of 
information can be obtained: a) the stoichiometry of the interaction, b) the association 
constant (Ka) and, in some cases, c) the topology of the binding, revealing which side of the 
guest molecule is interacting with the β-cyclodextrin inner moiety.  
To implement these titration experiments, we selected the method described by 
C. Jaime.
128
 Accordingly, we prepared a set of 11 NMR sample tubes containing β-CD/15 
mixtures of variable molar fractions (Xβ-CD and X14) ranging from 0 to 1 at 0.1 intervals 
(Table 2.5).  
Table 2.5. NMR sampling of β-CD and triazole 15 mixtures in D2O.
a 
Tube (nº) 1 2 3 4 5 6 7 8 9 10 11 
Vβ-CD (mL) 0.5 0.45 0.4 0.35 0.3 0.25 0.2 0.15 0.1 0.05 0 
VTrz (mL) 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 
X15  0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
Xβ-CD  1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 
aTwo 5 mM mother solutions of β-CD and triazole 15 were prepared in D2O. Then, different volumes 
from each mother solution were mixed at 0.05 mL volume intervals to give 11 samples with a total 
volume of 0.5 mL in each case and (Xβ-CD) molar fractions ranging from 1 to 0 at 0.1 intervals. 
Next, we recorded the 
1
H NMR spectra of the 11 samples, which are collected in 
Figure 2.16 in a stacked representation. Evidences of a strong interaction between the 
triazole 15 and β-CD were apparent from the significant variations of the chemical shift (Δδi) 
                                                          
127  a) Fielding, L.; McKellar, S. M.; Florence, A. J. Magn. Reson. Chem. 2011, 49, 405. b) Pean, C.; 
Cheminon, C.; Grassi, J.; Pradelles, P.; Perly, B.; Djedaini-Pilard, F. J. Inclusion Phenom. 
Macrocycl. Chem. 1999, 33, 307.  
128  Salvatierra, D.; Díez, C.; Jaime, C. J. Inclusion Phenom. 1997, 27, 215. 
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observed both for the Hg proton of the triazole ring and the β-CD protons H3 and H5 located 
at the inner hydrophobic hole of the β-cyclodextrin. Proton Hg shifted to lower fields as the 
β-CD concentration was increased in the mixture, whereas H3 and specially H5 shifted to 
higher fields. 
 
     
Figure 2.16. 1H-NMR (500 MHz, D2O) proton-assigned spectra of mixtures of β-CD and triazole 15 
registered at 25ºC. Spectrum n=1 (Xβ-CD = 0, bottom). Spectrum n=11 (Xβ-CD = 1, top). 
The stoichiometry of the β-CD/15 complex was easily determined from the 1H-NMR 
chemical shift values at different molar fractions by representing a Job’s plot.129 Figure 2.17 
shows the variations of the chemical shifts (Δδi) for all the protons of the β-CD (left) and the 
triazole 15 (right) as a function of Xβ-CD and X14 , respectively. In both cases, the maximum 
chemical shift variation occurs at Xβ-CD ≈ X14 ≈ 0.5 for the protons Hg and H5 directly 
involved in the supramolecular interaction, which means a 1:1 complex stoichiometry. 
                                                          
129  Fielding, L. Tetrahedron 2000, 56, 6151. 
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Figure 2.17. Job’s plot of the β-CD/15 complex measured in D2O at 25 ºC. 
Next, we measured the Ka association constant for the β-CD/15 complex, according 
to the formation equilibrium quoted below. Given the 1:1 stoichiometry determined 
experimentally, such constant can be expressed as a function of the initial concentrations of 
β-CD and triazole Trz15 and their molar fractions as follows:  
β-CD + Trz 15 ⇄  β-CD / Trz 15 
    
    
                         
 
The same equation can be re-written as a function of the variations of the chemical 
shifts of the interaction protons at the triazole (Δδi) and at the inclusion complex (Δδc):129 
    
       
                               
 
Application of the curve fitting method to the equation using the CLAK algorithm 
software
128
 allowed a good assessment of Ka (428 M
-1) for the β-CD/15 complex, which can 
be considered an interaction of medium stability.  
After the confirmation of the stability of the inclusion complex β-CD/15 in water, we 
investigated its structure assuming two possible topologies of 1:1 stoichiometry with the      
β-CD inner hole interacting with: a) the triazole moiety or, b) the thioaryl moiety (Scheme 
2.5, top). The striking variation of the chemical shift of the triazole C5-H proton in the 
titration experiments (Hg in Figure 2.15) suggested a direct interaction of the β-CD 
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hydrophobic protons and the triazole ring. Unfortunately, several attempts to get long range 
2D ROESY
130
 cross-peaks between the triazole Hg proton and β-CD met with failure. 
At this point, we reasoned that studying the complexation of β-CD with the triazole 
31,
131
 which is similar to 15 but lacking the aromatic moiety, could provide interesting 
information on the inherent ability of 1-carboxymethyl-1,2,3-triazoles to form inclusion 
complexes with β-cyclodextrin (Scheme 2.5, bottom). Unfortunately, when 1H-NMR titration 
experiments were conducted with mixtures of β-CD and triazole 31 in D2O at 25 ºC, no 
chemical shift variation of the triazole C5-H proton was observed at all. Therefore, we 
concluded that a typical cyclodextrin/thioaryl hydrophobic interaction would likely account 
for the stability and structural topology of the β-CD/15 complex. 
 
Scheme 2.5. Likely structure of the β-CD/ 15 inclusion complex in D2O at 25 ºC. 
Next, we extended the β-CD complexation studies to the three pair of enantiomers 19-
24 (Figure 2.19) to investigate the effect of chirality on their supramolecular 
diastereoisomeric interactions with β-cyclodextrin. According to the recorded Job’s plots 
                                                          
130  Bax, A.; Davies, D. G. J. Magn. Reson. 1985, 65, 355. 
131  a) Buckley, B. R.; Dann, S. E.; Heaney, H.; Stubbs, E. C. Eur. J. Org. Chem. 2011, 770. b) Carmo, 
A. M. L.; Stroppa, P. H. F.; Corrales, R. C. N. R.; Barroso, A. B. N.; Ferreira-Leitãob, V. S.; Silva, 
A. D. J. Braz. Chem. Soc. 2014, 25, 2088. 
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(see experimental section for details), all of them formed stable 1:1 β-CD/Trz inclusion 
complexes. In all instances, the titration experiments resulted in a significant variation of the 
chemical shift of the triazole C5-H proton (Hg) and the β-CD inner protons H3 and H5. An 
inspection of the Ka association constants of the chiral carboxylic triazoles gathered in 
Figure 2.18 seems to discard the existence of a general correlation between their 
configuration and the Ka values. 
 
Figure 2.18. Association constants (Ka) of β-CD/triazole complexes measured in D2O at 25 ºC. 
Finally, it is worth mentioning that a careful inspection of the titration spectra of these 
chiral compounds revealed some β-CD concentration dependent signal coalescence and 
splittings, which could be tentatively attributed to the emergence of conformational barriers 
near the triazole ring groups. For example (Figure 2.20), the C5-H proton (Hg) of triazole 20 
experienced a splitting into two signals as the β-CD concentration increases, and the 
diastereotopic Hf protons shift at different rates. This phenomenon could be rationalized as a 
gradual blocking of the rotation around the methylene group linked to the triazole ring. 
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Figure 2.19. 1H-NMR titration spectra of β-CD/20 in D2O at 25ºC showing β-CD-dependent peak 
coalescence (Top). Molecular interpretation of the β-CD-induced conformational barrier. 
In summary, the cyclodextrin/carboxylic triazole supramolecular strategy seems 
practicable to provide novel inclusion complexes designed to interact with the blood-brain 
barrier. Nevertheless, the triazole interaction topology observed for the β-CD complexes in 
aqueous media is likely to keep the negatively charged carboxylate moiety exposed to the 
hydrophilic region in physiological media and, therefore, in an unsuitable configuration to 
cross the negatively charged blood brain barrier. 
2.5 Conclusion 
1. 1,4-Disubstituted 1H-1,2,3-triazoles comprising 1-carboxyalkyl- and 4-
arylthiomethyl- groups are effective templates for the design of modulators of the 
RyR1/Calstabin-1 interface.  
2. Certain triazoles (19,20,23 and 24) can be synthesized in enantiopure form and high 
overall yields from α-amino acids in a one-pot operation comprising the 
combination of an N-diazotation reaction and a “click” CuAAC cycloaddition with 
a 3-aryloxypropargyl or a 3-arylthiopropargyl alkyne.  
3. 1-Carboxymethyl-4-[3-(methoxy)phenylthiomethyl]-1,2,3-triazole (compound 15) 
is a non cytotoxic molecule which efficiently lowers the intracellular sarcoplasmatic 
calcium ion concentration in dystrophic myocytes in vitro. It also enhances in vivo 
the muscle performance on mdx mice models of Duchenne muscular dystrophy. 
4. Compound 15 forms an inclusion complex with β-cyclodextrin in water solutions at 
25 ºC, likely through a hydrophobic interaction of the cyclodextrin with the 
aromatic ring, but not with the triazole moiety. 
 
 
 62 
 
 
 
Experimental 
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Experimental  
General 
All reagents and solvents were obtained from commercial sources (Aldrich, Acros, 
Alfa Aesar, Merck and Fluka) and were used without further purification unless stated 
otherwise. Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried through PS-MD-
2columns. Extra pure dichloromethane (CH2Cl2), acetonitrile (MeCN), hexane (Hex) and 
ethyl acetate (EtOAc) were bought from Sharlau.  
Moisture sensitive reactions were carried out under an atmosphere of nitrogen in 
oven or flame-dried glassware with magnetic stirring. 
The solvents produced in reactions or chromatography were evaporated in Büchi    
R-210 rotapavors under reduced pressure. 
Purification of reaction products was carried out by flash chromatography using 
silica gel 60 (230-400 mesh). Analytical thin layer chromatography was performed on 
0.25 mm silica gel 60-F plates and visualization was accomplished with UV light 
(λ = 254 nm) or KMnO4 as TLC stain.  
1
H NMR spectra were recorded on Bruker avance spectrometers operated at 500 and 
400 MHz; and 
13
C NMR spectra were recorded at 125 and 101 MHz. The chemical shifts are 
reported as δ values (ppm) relative to residual deuterated solvent as internal standards: for 
CDCl3 δH (7.26 ppm) and δC (77.16 ppm), respectively; for MeOH-d4 δH (3.31 ppm) and 
δC (49.0 ppm), respectively; for MeCN-d3 δH (1.94 ppm) and δC (118.26 ppm, 1.32 ppm), 
respectively; for DMSO-d6 δH (2.50 ppm) and δC (39.52 ppm), respectively.  
High resolution mass spectra were performed by SGIker and were acquired on a 
time of flight (TOF) mass spectrometer (SYNAPT G2 HDMS from Waters, Milford, MA, 
USA) equipped with an electrospray source in positive mode (ESI
+
). Melting points were 
measured with a Büchi SMP-20 melting point apparatus and are uncorrected. Infrared spectra 
were recorded on a Bruker Alpha P. Optical rotations were measured on an Jasco P-200  
polarimeter using a sodium lamp (589 nm, D line) at 25 ± 0.2 °C and concentrations are 
reported in g/100mL units.  
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Analytical HPLC was performed on a Waters 1525 Binary HPLC pump (dual 
wavelength detector), using a Diacel Chiralpak IC 50 column. The mobile phase was iPrOH 
(% 0.1 TFA)/Hex 20:80 with a flow rate of 1 mL/min monitored by UV detection at 210 nm. 
2.1 Synthesis of the starting materials 
2.1.1 General procedure for the synthesis of alkynes 
The corresponding thiophenol (10.00 mmol) was dissolved in H2O (20 mL) and 
KOH (15.00 mmol, 840 mg) was added. The mixture was stirred at room temperature for 
1 h. Then, it was cooled down to 0 ºC and a solution formed by propargyl bromide (15.00 
mmol, 1.80 g), toluene (20 mL) and a catalytic amount of tetrabutylammonium iodide 
(1.50 mmol, 0.55 g) was added dropwise. Then, the reaction mixture was further stirred at 
room temperature for 2 h 30 min. The organic layer was separated, dried with MgSO4 and 
the solvent was evaporated under reduced pressure. 
 
4-Methoxyphenyl propargyl sulfide (1a).
132
 General procedure 2.1.1 was followed starting 
from 4-methoxybenzenethiol (10.0 mmol, 1.22 mL) to provide 1.95 g (99 % yield) of 1a as 
an orange solid. 
1
H NMR (500 MHz, CDCl3): δ 7.30-7.22 (m, 1H), 7.07-6.99 (m, 2H), 6.81 
(dd, J = 7.6, 2.4 Hz, 1H), 3.83 (s, 3H), 3.65 (s, 2H), 2.27 (t, J = 2.6 Hz, 1H). 
 
3-Methoxyphenyl propargyl sulfide (1b).
132
 General procedure 2.1.1 was followed starting 
from 3-methoxybenzenethiol (10.0 mmol, 1.22 mL) to provide 1.66 g (93 % yield) of 1b as 
an orange liquid. 
1
H NMR (500 MHz, CDCl3): δ 7.48 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.8 
Hz, 2H), 3.81 (s, 3H), 3.49 (d, J = 2.6 Hz, 2H), 2.22 (s, 1H). 
 
 
                                                          
132  Yadagiri, D.; Anbarasan, P. Chem. Sci. 2015, 6, 5847. 
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3-Clorophenyl propargyl sulfide (1c). General procedure 2.1.1 was followed starting from 
3-clorobenzenethiol (4.68 mmol, 0.54 mL) to provide 0.70 g (82 % yield) of 1c as a 
yellowish liquid. 
1
H NMR (400 MHz, CDCl3): δ 7.43 (t, J = 1.9 Hz, 1H), 7.31 (dt, J = 7.5, 
1.7 Hz, 1H), 7.28-7.24 (m, 1H), 7.24-7.20 (m, 1H), 3.62 (d, J = 2.6 Hz, 2H), 2.26 (t, J = 2.6 
Hz, 1H). 
13
C NMR (101 MHz, CDCl3): δ 137.1, 134.7, 130.0, 129.3, 127.7, 127.0, 79.3, 
72.1, 22.3. IR (cm
-1
): 3295, 1576, 1460, 1407, 772, 636. MS (ESI
-
) m/z (%) 180 (M-H). 
HRMS calcd. for (C9H6SCl): 180.9879, found 180.9886. 
 
3-Methoxyphenyl propargyl ether (1d).
133
 Propargyl bromide (30.00 mmol, 3.30 mL) was 
added to a suspension of 3-methoxyphenol (20.00 mmol, 2.20 mL) and K2CO3 (30.00 mmol, 
4.17 g) in acetone (30 mL) at 0 ºC. The mixture was heated at 60 ºC and stirred over 17 h. 
Then the solvent was evaporated and extracted with EtOAc (15 mL x 3). The organic 
combined layer was washed with brine (15 mL x 2), dried over Mg2SO4 and concentrated 
under vacuum to provide 3.00 g (93 % yield) of 1d as a yellow oil. 
1
H NMR (400 MHz, 
CDCl3): δ 7.20 (t, J = 8.2 Hz, 1H), 6.75-6.45 (m, 3H), 4.68 (d, J = 1.7 Hz, 2H), 3.79 (s, 3H), 
2.52 (s, 1H). 
2.1.2 Typical procedure for the preparation of α-amino acid methyl ester 
hydrochlorides 
 
Methyl D-leucinate hydrochloride.
134
 To a suspension of the D-leucine (5.00 mmol, 656 
mg) in MeOH (14 mL) at 0 ºC under inert atmosphere, acetyl chloride (12.00 mmol, 0.85 
mL) was dropwise added and the solution was heated to reflux during 2h. Then, the solution 
                                                          
133  Nocentini, A.; Ferraroni, M.; Carta, F.; Ceruso, M.; Gratteri, P.; Lanzi, C.; Masini, E.; Supuran, C. 
T. J. Med. Chem. 2016, 59, 10692. 
134  Steinmetz, H.; Li, J.; Fu, C.; Zaburannyi, N.; Kunze, B.; Harmrolfs, K.; Schmitt, V.; Herrmann, J.; 
Reichenbach, H.; Höfle, G.; Kalesse, M.; Müller, R. Angew. Chem. Int. Ed. 2016, 55, 10113. 
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was cooled down to room temperature, and the solvent was evaporated under reduced 
pressure. The solid was washed with dry Et2O and was stored in a desiccator as a white solid 
(91 mg, 99 % yield). 
1
H NMR (500 MHz, D2O): δ 4.17 (t, J = 6.5 Hz, 1H), 3.86 (s, 3H), 
1.94-1.84 (m, 1H), 1.76 (tt, J = 14.5, 7.2 Hz, 2H), 0.98 (s, 6H). 
2.1.3 Preparation of azides 
 
Methyl azidoacetate (2a).
135
A solution of methyl bromoacetate (21.30 mmol, 3.20 g) and 
sodium azide (22.50 mmol, 1.50 g) in dry DMF (5 mL) was stirred at room temperature for 
3 h. The solution was quenched with an equivalent quantity of water (21.30 mmol, 384 µL) 
and the resulting mixture was extracted with Et2O (3 x 10 mL). The organic layer was 
washed three times with water and dried over MgSO4. The solvent was carefully removed 
under reduced pressure to provide 2.32 g (95 % yield) of 2a as a colorless liquid. 
1
H NMR 
(500 MHz, CDCl3): δ 3.89 (s, 2H), 3.79 (s, 3H).  
2.1.3.1 General procedure for the synthesis of α-azido esters 
To a solution of the corresponding α-amino acid methyl ester hydrochloride (1.00 
mmol) in MeCN (5 mL) at 0 ºC were added CuSO4·5H2O (0.01 mmol) and Et3N (1.73 
mmol) followed by the dropwise addition of freshly prepared solution of TfN3 (1.50 mmol) 
in CH2Cl2. The mixture was stirred at room temperature overnight. The solvent was 
evaporated under reduced pressure and the resulting product was purified by column 
chromatography. 
 
Triflyl azide.
136
 Tf2O (0.57 mmol, 0.10 mL) was added dropwise to a solution of sodium 
azide (2.80 mmol, 183 mg) in a mixture of H2O:CH2Cl2 (1.5 mL:2.5 mL) at 0 ºC and the 
mixture was vigorously stirred for 2h. Then, the resulting mixture was extracted with CH2Cl2 
                                                          
135  Bonacorsoa, H. G.; Liberoa, F. M.; Dal Fornoa, G. M.; Pittalugaa, E. P.; Backb, D. F.; Hörnerc, M.; 
Martinsa, M. A. P.; Zanattaa, N. Tetrahedron Lett. 2016, 57, 4568. 
136  Lundquist IV, J. T.; Pelletier, J. C. Org. Lett. 2001, 3, 781. 
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(2 mL x 2). The combined organic fraction was washed with a saturated aqueous solution of 
Na2CO3 and used directly in the next reaction without further purification.  
 
Methyl (S)-2-azido-3-phenylpropanoate (2b*S).
137
 General procedure 2.1.3.1. was 
followed starting from methyl L-phenylalaninate hydrochloride (7.00 mmol, 1.50 g). The 
product was purified by column chromatography (Hex:EtOAc 3:1) to provide 0.96 g (67 % 
yield) of 2b*S as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.37-7.26 (m, 5H), 4.11 (dd, J 
= 8.7, 5.4 Hz, 1H), 3.80 (s, 3H), 3.21 (dd, J = 14.0, 5.4 Hz, 1H), 3.04 (dd, J = 14.0, 8.8 Hz, 
1H). 
 
Methyl (R)-2-azido-3-phenylpropanoate (2b*R).
138
 General procedure 2.1.3.1. was 
followed starting from methyl D-phenylalaninate hydrochloride (7.00 mmol, 1.50 g). The 
product was purified by column chromatography (EtOAc:Hx 1:3) to provide 0.81 g (56 % 
yield) of 2b*R as a yellow oil.
 
The 
1
H-NMR spectroscopic data were identical to those of the 
previous compound. 
 
Methyl (S)-2-azido-4-methylpentanoate (2c*S).
139
 General procedure 2.1.3.1. was 
followed starting from methyl L-leucinate hydrochloride (5.74 mmol, 833 mg). The resulting 
crude product solution was used directly in the next step of the “click” reaction. 1H NMR 
(500 MHz, CDCl3): δ 3.78 (s, 3H), 2.16 (s, 1H), 1.76 (dd, J = 13.4, 6.9 Hz, 1H), 1.66 (td, J = 
13.6, 11.4, 7.0 Hz, 2H), 0.94 (dd, J = 10.6, 6.6 Hz, 6H). 
                                                          
137  Stanleya, N. J.; Pedersenb, D. S.; Nielsenb, B.; Kvistb, T.; Mathiesenb, J. M.; Bräuner-Osborneb, 
H.; Taylorc, D. K.; Abella, A. D. Bioorg. Med. Chem. Lett. 2010, 20, 7512. 
138  Paul, A.; Bittermann, H.; Gmeiner, P. Tetrahedron 2006, 62, 8919. 
139  Hoffman, R. V.; Kim, H.-O. Tetrahedron 1992, 48, 3007. 
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Methyl (R)-2-azido-4-methylpentanoate (2c*R).
139
 General procedure 2.1.3.1. was 
followed starting from methyl D-leucinate hydrochloride (7.00 mmol, 1.02 g). The solution 
was used directly in the next step of the “click” reaction. The 1H-NMR spectroscopic data 
were identical to those of the previous compound. 
 
Methyl (S)-2-azido-3-methylbutanoate (2d*S).
139
 General procedure 2.1.3.1. was followed 
starting from methyl L-valinate hydrochloride (7.00 mmol, 1.17g). The solution was used 
directly in the next step of the “click” reaction. 1H NMR (500 MHz, CDCl3): δ 3.79 (s, 3H), 
2.19 (dq, J = 13.2, 6.7 Hz, 1H), 0.98 (dd, J = 10.0, 6.8 Hz, 6H).  
 
Methyl (R)-2-azido-3-methylbutanoate(2d*R).
139
 General procedure 2.1.3.1. was followed 
starting from methyl D-valinate hydrochloride (7.00 mmol, 1.17 g). The solution was used 
directly in the next step of the “click” reaction. The 1H-NMR spectroscopic data were 
identical to those of the previous compound. 
 
Methyl 2-azido-2-methylpropanoate (2e).
139
 General procedure 2.1.3.1. was followed 
starting from methyl α-aminoisobutyrate hydrochloride (2.00 mmol, 307 mg). The solution 
was used directly in the next step of the “click” reaction. 1H NMR (400 MHz, MeOH-d4): 
δ 3.09 (q, J = 7.1 Hz, 3H), 1.26 (t, J = 7.2 Hz, 6H). 
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2.2 General procedure for the synthesis of 1H-1,2,3-triazoles.16 
To a solution of the corresponding alkyne (2.00 mmol, 356 mg) and azide (2.00 
mmol, 230 mg) in a mixture of THF/tBuOH (1:1, 4 mL), CuSO4·5H2O (0.40 mmol, 63 mg) 
in H2O (1 mL) were subsequently added and sodium ascorbate (0.80 mmol, 158 mg) in H2O 
(1 mL) under inert atmosphere. The reaction mixture was stirred at room temperature 
overnight. Then, the solvent was partially evaporated under reduced pressure, sat. aq. 
NH4OH (5 mL) was added and the resulting mixture was extracted with CH2Cl2 (3 x 20 mL) 
and washed with brine, dried over MgSO4 and evaporated under reduced pressure. The crude 
residue was purified by flash column chromatography. 
 
1-Methoxycarbonylmethyl-4-[4-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (3). The 
general procedure 2.2 was followed starting from 4-methoxyphenyl propargyl sulfide (2.00 
mmol, 356 mg) and methyl 2-azidoacetate (2.00 mmol, 230 mg). The resulting product was 
purified by column chromatography (EtOAc:Hx 3:7) to provide 477 mg (78 % yield) of 3 as 
a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.38 (s, 1H), 7.30 (d, J = 8.7 Hz, 2H), 6.81 (d, J 
= 8.7 Hz, 2H), 5.09 (s, 2H), 4.12 (s, 2H), 3.78 (s, 3H), 3.77 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3): δ 166.7, 159.4, 145.8, 134.0, 125.4, 123.5, 114.7, 55.4, 53.1, 50.8, 30.9. IR (cm
-1
): 
2953, 2837, 1750, 1219, 1174. MS (ESI
+
) m/z (%) 294 (M+H). HRMS calcd. for 
(C13H16N3O3S): 294.0912, found 294.0916. 
 
1-Methoxycarbonylmethyl-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (4). The 
general procedure 2.2 was followed starting from 3-methoxyphenyl propargyl sulfide (6.00 
mmol, 1.10 g) and methyl azidoacetate (6.43 mmol, 504 mg). The resulting crude product 
was purified by column chromatography (EtOAc:Hx 3:7) to provide 1.40 g (79 % yield) of 4 
as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.51 (s, 1H), 7.18 (t, J = 8.0 Hz, 1H), 6.92 (d, 
J = 7.7 Hz, 1H), 6.88 (t, J = 2.1, 1.5 Hz, 1H), 6.76-6.70 (m, 1H), 5.11 (s, 2H), 4.26 (s, 2H), 
3.78 (s, 3H), 3.77 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 166.7, 159.9, 145.7, 136.8, 129.9, 
123.6, 121.5, 114.6, 112.5, 55.4, 53.1, 50.8, 28.7. IR (cm
-1
): 2953, 2837, 1749, 1220, 1180. 
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MS (ESI
+
) m/z (%) 294 (M+H). HRMS calcd. for (C13H16N3O3S): 294.0912, found 
294.0917. 
 
1-Methoxycarbonyl-4-[3-(methoxy)phenoxymethyl]-1H-1,2,3-triazole (5). The general 
procedure 2.2 was followed starting from 3-methoxyphenyl propargyl ether (4.34 mmol, 704 
mg) and methyl azidoacetate (4.34 mg, 500 mg). The crude product was purified by column 
chromatography (EtOAc:Hx 1:1) to provide 0.91 g (76 % yield) of 5 as a white solid. Mp 71-
75 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.76 (s, 1H), 7.19 (t, J = 8.2 Hz, 1H), 6.74-6.46 (m, 
3H), 5.23 (s, 2H), 5.18 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H). 
13
C NMR (101 MHz, DMSO-d6): δ 
161.4, 155.6, 154.2, 139.4, 124.8, 118.9, 101.8, 101.6, 96.1, 56.7, 50.0, 47.8, 45.5. IR (cm
-1
): 
3156, 1747, 1591, 1493, 1200, 1152, 1015, 815. MS (ESI
+
) m/z (%) 278 (M+H). HRMS 
calcd. for (C13H16N3O4): 278.1141, found 278.1148. 
 
4-[3-(Chloro)phenylthiomethyl]-1-methoxycarbonylmethyl-1H-1,2,3-triazole (6). The 
general procedure 2.2 was followed starting from 3-clorophenyl propargyl sulfide (3.00 
mmol, 535 mg) and methyl azidoacetate (3.00 mmol, 345 mg). The crude product was 
purified by column chromatography (EtOAc:Hx 1:3) to provide 0.71 g (79 % yield) of 6 as a 
yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 7.52 (s, 1H), 7.34-7.10 (m, 4H), 5.12 (s, 2H), 4.26 
(s, 2H), 3.79 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 166.7, 145.2, 137.7, 134.8, 130.2, 
129.0, 127.4, 126.7, 123.6, 53.2, 50.9, 28.7. IR (cm
-1
): 3135, 1743, 1577, 1459, 1347, 1226, 
774. MS (ESI
+
) m/z (%) 298 (M+H). HRMS calcd. for (C12H13N3O2SCl): 298.0417, found 
298.0416. 
 
4-[3-(Methoxy)phenylthiomethyl]-1-(1-methyl-1-methoxycarbonylethyl)-1H-1,2,3-
triazole (7). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (2.00 mmol, 356 mg) and methyl 2-azido-2-methylpropanoate (2.00 mmol, 
286 mg). The crude product was purified by column chromatography (EtOAc:Hx 2:6) to 
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provide 290 mg (45 % yield) of 7 as a yellowish oil. 
1
H NMR (400 MHz, CDCl3): δ 7.44 (s, 
1H), 7.11 (t, J = 7.7 Hz, 1H), 6.95-6.75 (m, 2H), 6.67 (d, J = 7.6 Hz, 1H), 4.17 (s, 2H), 3.69 
(s, 3H), 3.62 (s, 3H), 1.82 (s, 6H). 
13
C NMR (101 MHz, CDCl3): δ 171.8, 159.9, 144.4, 
136.9, 129.8, 121.8, 121.2, 114.9, 112.4, 64.4, 55.3, 53.2, 28.9, 25.7. IR (cm
-1
): 2953, 1743, 
1588, 1575, 1282, 1190, 1153, 1041. MS (ESI
+
) m/z (%) 322 (M+H). HRMS calcd. for 
(C15H20N3O3S): 322.1225, found 322.1222. 
 
(S)-1-(1-Methoxycarbonyl-2-phenylethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-
triazole (8). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (3.60 mmol, 642 mg) and methyl (S)-2-azido-3-phenylpropanoate (3.60 
mmol, 740 mg). The crude product was purified by column chromatography (EtOAc:Hx 3:7) 
to provide 1.24 g (89 % yield) of 8 as a yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 7.47 (s, 
1H), 7.27-6.62 (m, 9H), 5.50 (dd, J = 8.5, 6.2 Hz, 1H), 4.12 (q, J = 14.9 Hz, 2H), 3.75 (s, 
3H), 3.73 (s, 3H), 3.46 (dd, J = 14.0, 5.8 Hz, 1H), 3.36 (dd, J = 13.9, 9.2 Hz, 1H). 
13
C NMR 
(101 MHz, CDCl3): δ 168.6, 159.9, 145.1, 136.8, 134.7, 129.9, 128.9, 127.6, 122.4, 121.5, 
114.5, 112.5, 64.3, 55.4, 53.2, 38.9, 28.7. IR (cm
-1
): 2952, 2836, 1744, 1228, 1172. MS 
(ESI
+
) m/z (%) 384 (M+H). HRMS calcd. for (C20H22N3O3S): 384.1382, found 384.1382. 
[α] = -56.11 (c 1.01, CH2Cl2).  
 
(R)-1-(1-Methoxycarbonyl-2-phenylethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-
triazole (9). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (2.00 mmol, 384 mg) and methyl (R)-2-azido-3-phenylpropanoate (2.00 
mmol, 358 mg). The crude product was purified by column chromatography (EtOAc:Hx 3:7) 
to provide 653 mg (85 % yield) of 9 as a yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 7.47 (s, 
1H), 7.27-6.62 (m, 9H), 5.50 (dd, J = 8.5, 6.2 Hz, 1H), 4.12 (q, J = 14.9 Hz, 2H), 3.75 (s, 
3H), 3.73 (s, 3H), 3.46 (dd, J = 14.0, 5.8 Hz, 1H), 3.36 (dd, J = 13.9, 9.2 Hz, 1H). 
13
C NMR 
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(101 MHz, CDCl3): δ 168.6, 159.9, 145.1, 136.8, 134.7, 129.9, 128.9, 127.6, 122.4, 121.5, 
114.5, 112.5, 64.3, 55.4, 53.2, 38.9, 28.7. IR (cm
-1
): 2952, 2836, 1744, 1228, 1172. MS 
(ESI
+
) m/z (%) 384 (M+H). HRMS calcd. for (C20H22N3O3S): 384.1382, found 384.1382. 
[α] = +39.38 (c 2.71, CH2Cl2). 
 
(S)-1-(1-Methoxycarbonyl-3-methyl-butyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-
triazole (10). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (2.00 mmol, 384 mg) and methyl (S)-2-azido-4-methylpentanoate (2.00 
mmol, 342 mg). The crude product was purified by column chromatography (EtOAc:Hx 1:3) 
to provide 678 mg (97 % yield) of 10 as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.51 (s, 
1H), 7.16 (t, J = 8.0 Hz, 1H), 6.90 (d, J = 7.7 Hz, 1H), 6.87 (s, 1H), 6.72 (dd, J = 8.2, 1.8 Hz, 
1H), 5.38 (t, J = 8.0 Hz, 1H), 4.24 (q, J = 14.8 Hz, 2H), 3.76 (s, 3H), 3.73 (s, 3H), 1.94 (t, J = 
7.5 Hz, 2H), 1.19 (dt, J = 13.4, 6.7 Hz, 1H), 0.90 (d, J =6.5 Hz, 3H), 0.84 (d, J = 6.6 Hz, 
3H). 
13
C NMR (126 MHz, CDCl3): δ 169.8, 159.9, 145.3, 136.6, 129.8, 122.1, 115.1, 112.7, 
61.1, 55.3, 53.1, 41.4, 29.1, 24.7, 22.7, 21.3. IR (cm
-1
): 2940, 2550, 1726, 1570, 1329, 967, 
775, 550. MS (ESI
+
) m/z (%) 350 (M+H). HRMS calcd. for (C17H24N3O3S): 350.1538, found 
350.1550. [α] = +10.67 (c 1.00, CH2Cl2). 
 
(R)-1-(1-Methoxycarbonyl-3-methyl-butyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-
triazole (11). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (4.50 mmol, 810 mg) and methyl (R)-2-azido-4-methylpentanoate (4.50 
mmol, 793 mg). The crude product was purified by column chromatography (EtOAc:Hx 1:3) 
to provide 1.45 g (93 % yield) of 11 as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.51 (s, 
1H), 7.16 (t, J = 8.0 Hz, 1H), 6.90 (d, J = 7.7 Hz, 1H), 6.87 (s, 1H), 6.72 (dd, J = 8.2, 1.8 Hz, 
1H), 5.38 (t, J = 8.0 Hz, 1H), 4.24 (q, J = 14.8 Hz, 2H), 3.76 (s, 3H), 3.73 (s, 3H), 1.94 (t, J = 
7.5 Hz, 2H), 1.19 (dt, J = 13.4, 6.7 Hz, 1H), 0.90 (d, J =6.5 Hz, 3H), 0.84 (d, J = 6.6 Hz, 
3H). 
13
C NMR (126 MHz, CDCl3): δ 169.8, 159.9, 145.3, 136.6, 129.8, 122.1, 115.1, 112.7, 
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61.1, 55.3, 53.1, 41.4, 29.1, 24.7, 22.7, 21.3. IR (cm
-1
): 2940, 2550, 1726, 1570, 1329, 967, 
775, 550. MS (ESI
+
) m/z (%) 350 (M+H). HRMS calcd. for (C17H24N3O3S): 350.1538, found 
350.1550. [α] = -12.09 (c 1.03, CH2Cl2).  
 
(S)-1-(1-Methoxycarbonyl-2-methyl-propyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3 
-triazole (12). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (4.70 mmol, 840 mg) and methyl (S)-2-azido-3-methylbutanoate (4.67 
mmol, 734 mg). The crude product was purified by column chromatography (EtOAc:Hx 2:8) 
to provide 1.44 g (92 % yield) of 12 as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 7.63 (s, 
1H), 7.16 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.88 (s, 1H), 6.72 (d, J = 6.8, 1H), 
5.06 (d, J = 8.7 Hz, 1H), 4.24 (q, J = 14.7 Hz, 2H), 3.76 (s, 6H), 2.44-2.30 (m, 1H), 0.96 (d, 
J = 6.6 Hz, 3H), 0.73 (d, J = 6.6 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 168.8, 159.6, 
144.7, 136.3, 129.5, 121.9, 115.0, 112.3, 68.5, 55.0, 52.5, 32.0, 28.8, 18.9, 18.1. IR (cm
-1
): 
2940, 1865, 1501, 1365, 1210, 1020, 754. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. for 
(C16H22N3O3S): 336.1382, found 336.1388. [α] = +21.49 (c 1.03, CH2Cl2).  
 
(R)-1-(1-Methoxycarbonyl-2-methyl-propyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3 
-triazole (13). The general procedure 2.2 was followed starting from 3-methoxyphenyl 
propargyl sulfide (4.67 mmol, 832 mg) and methyl (R)-2-azido-3-methylbutanoate (4.67 
mmol, 734 mg). The crude product was purified by column chromatography (EtOAc:Hx 2:8) 
to provide 1.45 g (93 % yield) of 13 as a yellowish oil. 
1
H NMR (500 MHz, CDCl3): δ 7.63 
(s, 1H), 7.16 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.88 (s, 1H), 6.72 (d, J = 6.8, 1H), 
5.06 (d, J = 8.7 Hz, 1H), 4.24 (q, J = 14.7 Hz, 2H), 3.76 (s, 6H), 2.44-2.30 (m, 1H), 0.96 (d, 
J = 6.6 Hz, 3H), 0.73 (d, J = 6.6 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 168.8, 159.6, 
144.7, 136.3, 129.5, 121.9, 115.0, 112.3, 68.5, 55.0, 52.5, 32.0, 28.8, 18.8, 18.1. IR (cm
-1
): 
2940, 1865, 1501, 1365, 1210, 1020, 754. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. for 
(C16H22N3O3S): 336.1382, found 336.1388. [α] = -19.47 (c 1.06, CH2Cl2).  
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4-Hydroxymethyl-1-methoxycarbonylmethyl-1H-1,2,3-triazole (30).
131a
 The reaction was 
carried out under nitrogen atmosphere in a flame-dried flask, with magnetical stirring. 
Propargyl alcohol (2.00 mmol, 112 mg), methyl azidoacetate (2.00 mmol, 230 mg) and CuI 
(2.00 mmol, 381 mg) were suspended in MeCN (10 mL). DIPEA (6.00 mmol, 1.04 mL) was 
added and the reaction mixture was stirred at room temperature for 5 h. The mixture was 
filtered through a pad of celite and the filtrate was dried with magnesium sulfate and 
evaporated under reduced pressure to provide 147 mg (86 % yield) of 30 as a yellow oil. 
1
H NMR (500 MHz, MeOH-d4): δ 7.95 (s, 1H), 5.33 (s, 2H), 4.70 (s, 2H), 3.79 (s, 3H).  
2.3 General procedure for the synthesis of 1-(carboxyalkyl)-1H-1,2,3-
triazoles 
To a solution of the corresponding triazolic methyl ester (1.00 mmol) in THF/H2O 
(1:1, 8 mL), LiOH·H2O (2.00 mmol, 82 mg) was added and the mixture was stirred at room 
temperature for 1h. The solvent was evaporated, the resulting solution was acidified with 1M 
HCl, and it was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
over MgSO4 and the solvents were evaporated under reduced pressure. The crude products 
were purified by crystallization in a mixture of EtOAc:Hx. 
 
1-Carboxymethyl-4-[4-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (14). The general 
procedure 2.3 was followed starting from 1-methoxycarbonylmethyl-4-[4-
(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (1.70 mmol, 500 mg) to provide 0.42 g (88 % 
yield) of 14 as a white solid. Mp 168-170 ºC. 
1
H NMR (500 MHz, MeOH-d4): δ 7.66 (s, 1H), 
7.28 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 5.19 (s, 2H), 4.07 (s, 2H), 3.76 (s, 3H). 
13
C 
NMR (126 MHz, MeOH-d4): δ 169.7, 161.1, 146.3, 135.6, 126.3, 125.9, 115.7, 55.8, 51.6, 
31.5. IR (cm
-1
): 2923, 2848, 1730, 1223, 1188. MS (ESI
+
) m/z (%) 280 (M+H). HRMS 
calcd. for (C12H14N3O3S): 280.0756, found 280.0760.  
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1-Carboxymethyl-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (15). The general 
procedure 2.3 was followed starting from 1-methoxycarbonylmethyl-4-[3-
(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (2.22 mmol, 652 mg) to provide 0.58 g (94 % 
yield) of 15 as a white solid. Mp 118-119 ºC. 
1
H NMR (500 MHz, MeOH-d4): δ 7.80 (s, 1H), 
7.18 (t, J = 8.0 Hz, 1H), 6.96-6.86 (m, 2H), 6.79-6.70 (m, 1H), 5.19 (s, 2H), 4.23 (s, 2H), 
3.75 (s, 3H). 
13
C NMR (126 MHz, MeOH-d4): δ 169.7, 161.4, 146.1, 138.0, 130.9, 125.9, 
123.1, 116.1, 113.6, 55.7, 51.7, 29.3. IR (cm
-1
): 2999, 2971, 1707, 1229. MS (ESI
+
) m/z (%) 
280 (M+H). HRMS calcd. for (C12H14N3O3S): 280.0756, found 280.0753.  
 
1-Carboxymethyl-4-[3-(methoxy)phenoxymethyl]-1H-1,2,3-triazole (16). The general 
procedure 2.3 was followed starting from 1-methoxycarbonylmethyl-4-[3-(methoxy)phenoxy 
methyl]-1H-1,2,3-triazole (1.90 mmol, 530 mg) to provide 0.35 g (70 % yield) of 16 as a 
white solid. Mp 108-110 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.77 (s, 1H), 7.20 (t, J = 8.5 Hz, 
1H), 6.66-6.42 (m, 3H), 5.23 (s, 2H), 5.08 (s, 2H), 3.79 (s, 3H). 
13
C NMR (101 MHz, 
CDCl3): δ 172.5, 165.7, 164.6, 147.6, 135.2, 131.3, 112.1, 111.8, 106.2, 66.3, 60.3, 56.6. IR 
(cm
-1
): 3411, 3184, 1666, 1589, 1491, 1415, 1196, 1152, 1040, 830. MS (ESI
+
) m/z (%) 264 
(M+H). HRMS calcd. for (C12H14N3O4): 264.0984, found 264.0980.  
 
1-Carboxymethyl-4-[3-(chloro)phenylthiomethyl]-1H-1,2,3-triazole (17). The general 
procedure 2.3 was followed starting from 1-methoxycarbonylmethyl-4-[3-
(chloro)phenylthiomethyl]-1H-1,2,3-triazole (0.53 mmol, 157 mg) to provide 0.19 g (67 % 
yield) of 17 as a white solid. Mp 146-148 ºC. 
1
H NMR (500 MHz, CDCl3): δ 7.86 (s, 1H), 
7.38 (s, 1H), 7.27 (d, J = 6.8 Hz, 2H), 7.21 (d, J = 1.9 Hz, 1H), 5.22 (s, 2H), 4.28 (s, 2H). 
13
C 
NMR (126 MHz, MeOH-d4): δ 168.4, 144.2, 137.9, 134.4, 130.0, 128.8, 127.6, 126.3, 124.7, 
50.4, 27.7. IR (cm
-1
): 2928, 2850, 1731, 1224, 1184. MS (ESI
+
) m/z (%) 284 (M+H). HRMS 
calcd. for (C11H10ClN3O2S): 284,0182, found 284,0190.  
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1-(1-Carboxy-1-methylethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (18). 
The general procedure 2.3 was followed starting from 1-(1-methoxycarbonyl-1-methylethyl)-
4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (0.45 mmol, 145 mg) to provide 138 mg 
(99 % yield) of 18 as a brown solid. Mp 119-121 ºC. 
1
H NMR (400 MHz, MeOH-d4): δ 7.77 
(s, 1H), 7.09 (t, J = 7.8 Hz, 1H), 6.90-6.73 (m, 2H), 6.67 (d, J = 7.7 Hz, 1H), 4.12 (s, 2H), 
3.65 (s, 3H), 1.78 (s, 6H). 
13
C NMR (101 MHz, MeOH-d4): δ 174.2, 161.3, 145.3, 137.9, 
130.8, 123.4, 116.5, 113.7, 65.9, 55.7, 29.5, 25.9. IR (cm
-1
): 2931, 1589, 1573, 1283, 1229, 
1178, 1030. MS (ESI
+
) m/z (%) 308 (M+H). HRMS calcd. for (C14H18N3O3S): 308.1069, 
found 308.1074.  
 
(S)-1-(1-Carboxy-3-methylbutyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(21). The general procedure 2.3 was followed starting from methyl (S)-1-(1-
methoxycarbonyl-3-methylbutyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (1.44 
mmol, 501 mg) to provide 0.36 g (77 % yield) of 21 as a white solid. Mp 103-105 ºC. 
1
H NMR (500 MHz, CDCl3): δ 11.88 (s, 1H), 7.54 (s, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.95-
6.77 (m, 2H), 6.75-6.62 (m, 1H), 5.38 (dd, J = 10.7, 5.0 Hz, 1H), 4.35-4.15 (m, 2H), 3.70 (s, 
3H), 2.33-1.75 (m, 2H), 1.17 (dq, J = 13.2, 6.5 Hz, 1H), 0.88 (d, J = 6.5 Hz, 3H), 0.82 (d, J = 
6.5 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 171.2, 159.8, 144.7, 136.0, 129.8, 122.6, 122.4, 
115.6, 112.9, 61.8, 55.3, 41.2, 28.5, 24.7, 22.7, 21.1. IR (cm
-1
): 2958, 2513, 1726, 1588, 
1478, 1229, 1037, 773, 685. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. for 
(C16H22N3O3S): 336.1382, found 336.1389. [α] = +9.31 (c 1.11, CH2Cl2).  
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(R)-1-(1-Carboxy-3-methylbutyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(22). The general procedure 2.3 was followed starting from methyl (R)-1-(1-
methoxycarbonyl-3-methylbutyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (1.00 
mmol, 349 mg) to provide 301 mg (86 % yield) of 22 as a white solid. Mp 102-104 ºC. 
1
H NMR (500 MHz, CDCl3): δ 11.88 (s, 1H), 7.54 (s, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.95-
6.77 (m, 2H), 6.75-6.62 (m, 1H), 5.38 (dd, J = 10.7, 5.0 Hz, 1H), 4.35-4.15 (m, 2H), 3.70 (s, 
3H), 2.33-1.75 (m, 2H), 1.17 (dq, J = 13.2, 6.5 Hz, 1H), 0.88 (d, J = 6.5 Hz, 3H), 0.82 (d, J = 
6.5 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 171.2, 159.8, 144.7, 136.0, 129.8, 122.6, 122.4, 
115.6, 112.9, 61.8, 55.3, 41.2, 28.5, 24.7, 22.7, 21.1. IR (cm
-1
): 2958, 2513, 1726, 1588, 
1478, 1229, 1037, 773, 685. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. for 
(C16H22N3O3S): 336.1382, found 336.1389. [α] = -12.06 (c 0.95, CH2Cl2).  
 
1-Carboxymethyl-4-hydroxymethyl-1H-1,2,3-triazole (31).
131b
 The general procedure 2.3 
was followed starting from 4-(hydroxymethyl)-1-methoxycarbonyl methyl-1H-1,2,3-triazol-
1-yl) acetate (1.00 mmol, 171 mg) to provide 143 mg (99 % yield) of 31 as a white solid. 
1
H NMR (500 MHz, MeOH-d4): δ 8.05 (s, 1H), 5.32 (s, 2H), 4.73 (s, 2H). 
2.3.1 Synthesis of chiral 1H-1,2,3-triazoles. 
To a solution of the corresponding α-aminoacid (1.00 mmol) in H2O/MeOH (1:2, 
9 mL), KHCO3 (1.50 mmol, 197 mg) and CuSO4·5H2O (1 mol %, 2.5 mg) were added, 
followed by dropwise addition of freshly prepared TfN3 (3.00 mmol) in CH2Cl2 (see page 
68). The mixture was stirred at room temperature for 3 h. Then, the alkyne (1.2 mmol), 
CuOAc (5 mol %, 6 mg), NaOAc (5.00 mmol, 410 mg) and Na Ascorbate (1.00 mmol, 
200 mg) were added to the reaction mixture and the solution was stirred at 45 ºC for 3h. The 
solvent was evaporated, the resulting mixture was basified with Na2CO3, and the aqueous 
solution was extracted with EtOAc (2 x 10 mL). The aqueous phase was acidified with HCl 
3M and extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over 
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Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was 
purified by crystallization in a mixture of CH2Cl2:Et2O. 
 
(S)-1-(1-Carboxy-2-phenylethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(19). The general procedure 2.3.1. was followed starting from L-phenylalanine (1.00 mmol, 
165 mg) and 3-methoxyphenyl propargyl sulfide (1.20 mmol, 213 mg) to provide 270 mg 
(73 % yield) of 19 as a white solid. Mp 81-83 ºC. 
1
H-NMR (500 MHz, MeOH-d4): δ 7.77 (s, 
1H), 7.20-6.71 (m, 9H), 5.56 (dd, J = 10.8, 4.6 Hz, 1H), 4.15 (s, 2H), 3.73 (s, 3H), 3.56 (dd, 
J = 14.3, 4.5 Hz, 1H), 3.40 (dd, J = 14.3, 10.9 Hz, 1H). 
13
C NMR (126 MHz, MeOH-d4): 
δ 171.1, 161.4, 145.9, 138.0, 137.2, 130.9, 129.9, 129.6, 128.1, 124.8, 122.9, 115.9, 113.5, 
65.8, 55.7, 39.0, 29.1. IR (cm
-1
): 2931, 1727, 1246, 1229. MS (ESI
+
) m/z (%) 384 (M+H). 
HRMS calcd. for (C19H20N3O3S): 370.1147, found 370.1145. [α] = -23.31 (c 1.12, CH2Cl2).  
 
(R)-1-(1-Carboxy-2-phenylethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(20). The general procedure 2.3.1 was followed starting from D-phenylalanine (1.00 mmol, 
165 mg) and 3-methoxyphenyl propargyl sulfide (1.20 mmol, 213 mg) to provide 280 mg 
(76 % yield) of 20 as a white solid. Mp 85-86 ºC. 
1
H NMR (500 MHz, CDCl3): δ 10.11 (s, 
1H), 7.49 (s, 1H), 7.14 (d, J = 7.4 Hz, 4H), 6.89 (d, J = 6.6 Hz, 2H), 6.82 (d, J = 6.7 Hz, 2H), 
6.72 (d, J = 7.4 Hz, 1H), 5.53 (dd, J = 9.4, 4.8 Hz, 1H), 4.31-4.08 (m, 2H), 3.70 (s, 3H), 3.52 
(dd, J = 14.3, 4.6 Hz, 1H), 3.36 (dd, J = 14.1, 9.8 Hz, 1H). 
13
C NMR (126 MHz, MeOH-d4): 
δ 171.1, 161.4, 145.9, 138.0, 137.2, 130.9, 129.9, 129.6, 128.1, 124.8, 122.9, 115.9, 113.5, 
65.8, 55.7, 39.0, 29.1. IR (cm
-1
): 2930, 1727, 1246, 1230. MS (ESI
+
) m/z (%) 384 (M+H). 
HRMS calcd. for (C19H20N3O3S): 370.1147, found 370.1145. [α] = +16.50 (c 0.98, CH2Cl2).  
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(S)-1-(1-Carboxy-3-methylpropyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(23). The general procedure 2.3.1 was followed starting from L-valine (1.00 mmol, 117 mg) 
and 3-methoxyphenyl propargyl sulfide (1.20 mmol, 213 mg) to provide 210 mg (65 % 
yield) of 23 as a white solid. Mp 119-121 ºC. 
1
H NMR (500 MHz, CDCl3): δ 11.53 (s, 1H), 
7.68 (s, 1H), 7.12 (t, J = 7.8 Hz, 1H), 6.91-6.80 (m, 2H), 6.70 (d, J = 6.8 Hz, 1H), 5.13 (d, J 
= 7.6 Hz, 1H), 4.38-4.15 (m, 2H), 3.71 (s, 3H), 2.59-2.28 (m, 1H), 0.96 (d, J = 6.4 Hz, 3H), 
0.75 (d, J = 6.4 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 170.7, 159.9, 144.6, 136.1, 129.9, 
123.0, 122.8, 115.8, 113.0, 69.3, 55.4, 32.2, 28.7, 19.3, 18.3. IR (cm
-1
): 2966, 2461, 1907, 
1591, 1573, 1479, 1281, 1228, 1206, 1037, 783, 721, 687. MS (ESI
+
) m/z (%) 336 (M+H). 
HRMS calcd. for (C15H20N3O3S): 332.1227, found 332.1225. [α] = +4.52 (c 1.06, CH2Cl2). 
 
(R)-1-(1-Carboxy-3-methylpropyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole 
(24). The general procedure 2.3.1. was followed starting from D-valine (1.00 mmol, 117 mg) 
and 3-methoxyphenyl propargyl sulfide (1.20 mmol, 213 mg) to provide 220 mg (69 % 
yield) of 24 as a white solid. Mp 120-123 ºC. 
1
H NMR (500 MHz, MeOH-d4): δ 7.81 (s, 1H), 
7.16 (t, J = 7.9 Hz, 1H), 7.03-6.82 (m, 2H), 6.82-6.66 (m, 1H), 5.06 (d, J = 8.1 Hz, 1H), 4.22 
(s, 2H), 3.73 (s, 3H), 2.46 (dt, J = 13.5, 6.7 Hz, 1H), 0.95 (d, J = 6.7 Hz, 3H), 0.74 (d, J = 6.7 
Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 170.7, 159.9, 144.6, 136.1, 129.9, 123.0, 122.8, 
115.8, 113.0, 69.3, 55.4, 32.2, 28.7, 19.3, 18.3. IR (cm
-1
): 2966, 2461, 1907, 1591, 1573, 
1479, 1281, 1228, 1206, 1037, 783, 721, 687. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. 
for (C15H20N3O3S): 332.1227, found 332.1225. [α] = -6.68 (c 1.01, CH2Cl2).  
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2.3.2 Synthesis of sulfonyl triazole  
 
1-Carboxymethyl-4-[3-(methoxy)phenylsulfonylmethyl]-1H-1,2,3-triazole (25). To a 
solution of 1-(carboxymethyl)-4-[3-(methoxy)phenylthiomethyl]-1H-1,2,3-triazole (0.25 
mmol, 70.7 mg) in a mixture of CDCl3:MeCN (1:1, 1 mL), 3-chloroperbenzoic acid (0.63 
mmol, 110 mg) was added. The reaction was stirred overnight at room temperature. The 
solvent was evaporated, and the product was purified by column chromatography 
DCM:MeOH (95:5) to provide 31 mg (40 % yield) of 25 as a white solid. Mp 113-115 ºC. 
1
H NMR (400 MHz, MeOH-d4): δ 7.93 (s, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.4 Hz, 
1H), 7.32-7.21 (m, 2H), 4.98 (s, 2H), 4.70 (s, 2H), 3.84 (s, 3H). 
13
C NMR (101 MHz, 
MeOH-d4): δ 172.5, 161.4, 140.2, 136.5, 131.6, 128.2, 121.7, 121.5, 114.0, 56.3, 54.4, 54.0. 
IR (cm
-1
): 2960, 2521, 1858, 1499, 1473, 1317, 1140, 1050, 780. MS (ESI
+
) m/z (%) 312 
(M+H). HRMS calcd. for (C12H14N3O5S): 312.0654, found 312.0662.  
2.4 Synthesis of compound S107115 
 
2-[(4-Methoxyphenyl)thio]ethan-1-amine (26).
115 
4-Methoxythiophenol (100.00 mmol, 
14.00 g), 2-chloroethylamine monohydrochloride (96.00 mmol, 11.00 g) and diisopropyl 
ethylamine (0.05 mmol, 9.00 mL) were mixed in THF (55 mL), and after degasification the 
reaction was refluxed overnight under nitrogen. The solvent was evaporated, and water 
(85 mL) was added. The mixture was extracted with CH2Cl2 (3 x 50 mL), and washed with a 
solution of NaOH 3M. The organic solution was dried over Na2SO4, and evaporated under 
reduced pressure to provide 16.8 g (95 % yield) of 26 as a colorless liquid. 
1
H NMR (400 
MHz, CDCl3): δ 7.36 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 3.79 (s, 3H), 2.88 (d, J = 
5.8 Hz, 2H), 2.83 (d, J = 5.8 Hz, 2H). 
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Benzyl [2-(4-methoxyphenyl)thioethyl] carbamate (27).
115 
To a flask containing 2-[(4-
methoxyphenyl)thio]ethan-1-amine (92.00 mmol, 16.80 g), sodium bicarbonate (300.00 
mmol, 25.00 g), water (200 mL) and CH2Cl2 (400 mL) were added. The mixture was cooled 
down to 0 ºC, and a solution of benzyl chloroformate (100.00 mmol, 14.00 mL) in 
dichloromethane (200 mL) was added dropwise. The mixture was stirred overnight at room 
temperature. The organic layer was collected and the aqueous solution was extracted with 
dichloromethane. The combined organic phases were dried over Na2SO4, and the solvent was 
evaporated under reduced pressure. The resulting solid was triturated with 300 mL of 
THF/hexane (1:10), and then it was collected and dried to provide 26.2 g (90 % yield) of 27 
as a white solid. 
1
H NMR (400 MHz, CDCl3): δ 7.37-7.32 (m, 9H), 6.84 (d, J = 8.2 Hz, 1H), 
5.09 (s, 2H), 3.79 (s, 3H) 3.38-3.28 (m, 2H), 2.94 (t, J = 6.4 Hz, 2H).  
 
Benzyl 7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carboxylate (28).
115 
A 
mixture of benzyl [2-(4-methoxyphenyl)thioethyl] carbamate (83.00 mmol, 26.20 g), 
paraformaldehyde (0.83 mmol, 25.00 g) and p-toluenesulfonic acid (27.00 mmol, 5.20 g) in 
toluene (600 mL) was stirred at 70 ºC overnight. After cooling to room temperature, it was 
filtered, and the resulting organic phase was cleaned with sat. sodium carbonate (200 mL), 
dried over anhydrous Na2SO4, and evaporated to provide 24.60 g (93 % yield) of 28 as an 
orange liquid. 
1
H NMR (400 MHz, CDCl3): δ 7.45 (d, J = 8.3 Hz, 1H), 7.36-7.30 (m, 5H), 
6.75-6.66 (m, 2H), 5.07 (d, J = 2.8 Hz, 2H), 4.58 (s, 2H), 3.57 (s, 3H), 2.78 (t, J = 4.9 Hz, 
2H), 2.72 (t, J = 4.9 Hz, 2H). 
 
7-Methoxy-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine hydrobromide (29).
115 
A solution 
of HBr (33 % in acetic acid, 60 mL) was added to benzyl 7-methoxy-2,3-
dihydrobenzo[f][1,4] thiazepine-4(5H)-carboxylate. After the addition, carbon dioxide was 
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generated and a white solid formed. The resulting mixture was stirred for 2 h at room 
temperature. Then, diethyl ether (500 mL) was added to the mixture and stirred for 30 min. 
The resulting solid was collected by filtration, washed with diethyl ether and dried under 
vacuum to provide 18.00 g (85 % yield) of 29 as a white solid. 
1
H NMR (400 MHz, DMSO-
d6): δ 9.01 (s, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.26 (s, 1H), 6.94 (dd, J = 8.4, 3.0 Hz, 1H), 4.41 
(s, 2H), 3.78 (s, 3H), 3.50 (s, 2H), 2.96 (s, 2H).  
 
7-Methoxy-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (S-107).
115 
To 7-methoxy-
2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine hydrobromide (65.00 mmol, 18.00 g) in MeOH 
(600 mL) a solution of 30 % CH2O (100 mL), and sodium cyanoborohydride (NaBH3CN) 
(450 mmol, 28.30 g) were added. The reaction mixture was stirred at room temperature, 
maintaining the pH of the solution at around pH 4-5 by addition of a few drops of 1N HCl. 
After 3 hours, the solvent was removed under reduced pressure. The residue was dissolved in 
ethyl acetate (300 mL) and washed with H2O and saturated NaHCO3 (2 x 200 mL). The 
solvent was removed and the product purified by column chromatography to provide 12.30 g 
(90 % yield) of S-107 as a white solid. 
1
H NMR (400 MHz, CDCl3): δ 7.48 (d, J = 8.5 Hz, 
1H), 7.05 (d, J = 2.8 Hz, 1H), 6.85 (dd, J = 8.5, 2.8 Hz, 1H), 4.75 (d, J = 13.7 Hz, 1H), 4.39 
(dd, J = 13.7, 4.9 Hz, 1H), 3.79 (s, 3H), 3.72-3.64 (m, 1H), 3.53 (d, J = 11.6 Hz, 1H), 3.11-
2.87 (m, 2H), 2.62 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 160.2, 134.8, 134.2, 127.2, 119.1, 
115.6, 76.8, 58.6, 57.5, 55.8, 27.2. 
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2.5 NMR study of the inclusion complexes of triazoles 15-24 and β-
cyclodextrin (β-CD).  
Stock 5mM solutions of each triazole 15-24 and β-cyclodextrin (β-CD) were 
prepared in D2O (5 mL) by dissolving 28.4 mg (0.025 mmol) of β-CD and 0.025 mmol of the 
corresponding triazole. Next, 10 solutions of 0.5 mL total volume were prepared for each 
triazole in 10 NMR test tubes in order to reach the molar fractions collected in Table 2.6. Vβ-
CD and VTrz represent the volumes of β-CD and triazole mother solutions, respectively. The 
molar fraction of β-CD (Xβ-CD) is given by the ratio: 
      
    
         
 
Table 2.6. Volume combinations of 5mM mother solutions of β-CD and triazoles 15-24 to get the 
different titration samples used in the NMR study. 
Tube (nº) 1 2 3 4 5 6 7 8 9 10 11 
Xβ-CD 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Vβ-CD (mL) 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 
VTrz (mL) 0.5 0.45 0.4 0.35 0.3 0.25 0.2 0.15 0.1 0.05 0 
XTRZ 0 0.05 0.1 0.015 0.2 0.25 0.3 0.35 0.4 0.45 0.5 
The 
1
H-NMR spectra were registered at 500 MHz, in D2O, and the association 
constants were determined with the method described by C. Jaime.
128
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APPENDIX 1: 
1
H NMR and 
13
C NMR Spectra 
 
 
Spectrum 2.1. 1H NMR (500 MHz, CDCl3) spectrum of compound 3. 
 
 
Spectrum 2.2. 13C NMR (126 MHz, CDCl3) spectrum of compound 3. 
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Spectrum 2.3. 1H NMR (500 MHz, CDCl3) spectrum of compound 4. 
 
 
Spectrum 2.4. 13C NMR (126 MHz, CDCl3) spectrum of compound 4. 
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Spectrum 2.5. 1H NMR (400 MHz, CDCl3) spectrum of compound 5. 
 
 
Spectrum 2.6. 13C NMR (101 MHz, DMSO-d6) spectrum of compound 5. 
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Spectrum 2.7. 1H NMR (400 MHz, CDCl3) spectrum of compound 6. 
 
 
Spectrum 2.8. 13C NMR (101 MHz, CDCl3) spectrum of compound 6. 
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Spectrum 2.9. 1H NMR (400 MHz, CDCl3) spectrum of compound 7. 
 
 
Spectrum 2.10. 13C NMR (101 MHz, CDCl3) spectrum of compound 7. 
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Spectrum 2.11. 1H NMR (400 MHz, CDCl3) spectrum of compound 9. 
 
 
Spectrum 2.12. 13C NMR (101 MHz, CDCl3) spectrum of compound 9. 
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Spectrum 2.13. 1H NMR (500 MHz, CDCl3) spectrum of compound 10. 
 
 
Spectrum 2.14. 13C NMR (126 MHz, CDCl3) spectrum of compound 10. 
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Spectrum 2.15.1H NMR (500 MHz, CDCl3) spectrum of compound 13. 
 
 
Spectrum 2.16. 13C NMR (126 MHz, CDCl3) spectrum of compound 13. 
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Spectrum 2.17. 1H NMR (500 MHz, MeOH-d4) spectrum of compound 14. 
 
 
Spectrum 2.18. 13C NMR (126 MHz, MeOH-d4) spectrum of compound 14. 
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Spectrum 2.19. 1H NMR (500 MHz, MeOH-d4) spectrum of compound 15. 
 
 
Spectrum 2.20. 13C NMR (126 MHz, MeOH-d4) spectrum of compound 15. 
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Spectrum 2.21. 1H NMR (400 MHz, CDCl3) spectrum of compound 16. 
 
 
Spectrum 2.22. 13C NMR (101 MHz, CDCl3) spectrum of compound 16. 
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Spectrum 2.23. 1H NMR (500 MHz, CDCl3) spectrum of compound 17. 
 
 
Spectrum 2.24. 13C NMR (126 MHz, MeOH-d4) spectrum of compound 17. 
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Spectrum 2.25. 1H NMR (400 MHz, MeOH-d4) spectrum of compound 18. 
 
 
Spectrum 2.26. 13C NMR (101 MHz, MeOH-d4) spectrum of compound 18. 
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Spectrum 2.27. 1H NMR (500 MHz, CDCl3) spectrum of compound 21. 
 
 
Spectrum 2.28. 13C NMR (126 MHz, CDCl3 ) spectrum of compound 21. 
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Spectrum 2.29. 1H NMR (500 MHz, CDCl3) spectrum of compound 20. 
 
 
Spectrum 2.30. 13C NMR (126 MHz, MeOH-d4) spectrum of compound 20. 
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Spectrum 2.31. 1H NMR (500 MHz, MeOH-d4) spectrum of compound 24. 
 
 
Spectrum 2.32. 13C NMR (126 MHz, CDCl3) spectrum of compound 24. 
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Spectrum 2.33.  1H NMR (400 MHz, MeOH-d4) spectrum of compound 25. 
 
 
Spectrum 2.34. 13C NMR (101 MHz, MeOH-d4) spectrum of compound 25. 
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Spectrum 2.35. 1H NMR (400 MHz, CDCl3) spectrum of compound 26. 
 
 
Spectrum 2.36. 1H NMR (400 MHz, CDCl3) spectrum of compound 27. 
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Spectrum 2.37. 1H NMR (400 MHz, CDCl3) spectrum of compound 28. 
 
 
Spectrum 2.38. 1H NMR (400 MHz, DMSO-d6) spectrum of compound 29. 
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Spectrum 2.39. 1H NMR (400 MHz, CDCl3) spectrum of compound S-107. 
 
 
Spectrum 2.40. 13C NMR (101 MHz, CDCl3) spectrum of compound S-107. 
 
 
 109 
 
APPENDIX 2: Job Plots of Compounds 19-24 (D2O, 25 ºC) 
 
 
 110 
 
 
 
 111 
 
APPENDIX 3: Stacked 
1
H NMR Titration Spectra of Compounds 19-24 (D2O, 25 ºC) 
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3 N-Dealkylation of 1,2,3-triazolium salts. A metal-free route to 1,5-
disubstituted 1,2,3-triazoles and related bistriazoles 
3.1 Introduction 
To address the second general objective of this PhD thesis consisting in the 
transformation of 1,4-disubstituted triazoles into their 1,5-disubstituted counterparts or 
related bistriazoles (Section 1.2.3), we selected to explore a synthetic route involving the use 
of triazolium cationic intermediates.  
3.1.1 Synthesis of 1,5-disubstituted triazoles via 1,2,3-triazolium salts 
During the past decade, 1,2,3-triazolium salts have attracted increasing interest as a 
result of their easy synthetic accessibility from the corresponding “click” 1,4-disubstituted 
1,2,3-triazoles by N-alkylation. The alkylation process can be carried out using alkyl 
halides,
140
 tosylates or triflates
141
 (RX, ROTs or ROTf, respectively) or trimethyloxonium 
tetrafluoroborates (Meerwein’s reagent, R3OBF4).
142
 This transformation usually occurs with 
total N3-regioselectivity and quasi-quantitative yields for simple R alkyl groups. 
As Figure 3.1 illustrates, 1,2,3-triazolium salts have been successfully used to 
design ionic liquids
143
 by incorporating at least one flexible substituent (R
2
) and a bulky 
hydrophobic anion (BF4, TfO, PF6, NTf2) which makes the crystalline accommodation 
difficult. Additionally, the introduction of chiral substituents (R
1
) also provides structures 
                                                          
140  a) Cao, Q.-Y.; Pradhan, T.; Lee, M. H.; No, K.; Kim, J. S. Analyst 2012, 137, 4454. b) Chhatra, R. 
K.; Kumar, A.; Pandey, P. S. J. Org. Chem. 2011, 76, 9086. c) Schulze, B.; Friebe, C.; Hager, M. 
D.; Günther, W.; Köhn, U.; Jahn, B. O.; Görls, H.; Schubert, U. S. Org. Lett. 2010, 12, 2710. d) 
Mathew, P.; Neels, A.; Albrecht, M. J. Am. Chem. Soc. 2008, 130, 13534. e) Kumar, A.; Pandey, P. 
S. Org. Lett. 2007, 10, 165.  
141  a) Sanghi, S.; Willett, E.; Versek, C.; Tuominenb, M.; Coughlin, E. B. RSC Advances 2012, 2, 848. 
b) Bernet, L.; Lalrempuia, R.; Ghattas, W.; Mueller-Bunz, H.; Vigara, L.; Llobet, A.; Albrecht, M. 
Chem. Commun. 2011, 47, 8058. c) Lalrempuia, R.; McDaniel, N. D.; Müller-Bunz, H.; Bernhard, 
S.; Albrecht, M. Angew. Chem. Int. Ed. 2010, 49, 9765.  
142  a) Cao, Q.-Y.; Wang, Z.-C.; Li, M.; Liu, J.-H. Tetrahedron Lett. 2013, 54, 3933. b) Spence, G. T.; 
Pitak, M. B.; Beer, P. D. Chem. Eur. J. 2012, 18, 7100. c) Mullen, K. M.; Mercurio, J.; Serpell, C. 
J.; Beer, P. D. Angew. Chem. Int. Ed. 2009, 48, 4781.  
143  a) M'sahel, M.; Obadia, M. M.; Medimagh, R.; Serghei, A.; Zina, M. S.; Drockenmuller, E. New J. 
Chem. 2016, 40, 740. b) Li, H.-Y.; Chen, C.-Y.; Cheng, H.-T.; Chu, Y.-H. Molecules 2016, 21, 
1355. c) Jeong, Y.; Ryu, J.-S. J. Org. Chem. 2010, 75, 4183. d) Hanelt, S.; Liebscher, J. Synlett 
2008, 1058. e) Yacob, Z.; Shah, J.; Leistner, J.; Liebscher, J. Synlett 2008, 2342.  
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potentially suitable to promote asymmetric organocatalysis.
143e,144
 Their acidic C5  H bond 
can be preserved to participate in supramolecular assemblies
145
 or to prepare polymer 
electrolytes,
146
 although its deprotonation can form mesoionic N-heterocyclic carbene ligands 
for transition metal complexes.
107c,147
  
 
Figure 3.1. Some examples of 1,2,3-triazolium salts and their applications. 
Despite the high potential of triazolium salts to participate in organic reactions as 
powerful and versatile electrophiles, they have received very limited attention as synthetic 
intermediates to prepare novel neutral 1,2,3-triazole derivatives. At the beginning of our 
work, the only example describing the use of 1,3,4-trisubstituted 1,2,3-triazolium cations to 
prepare 1,5-disubstituted 1,2,3-triazoles was reported by Koguchi
148
 (Scheme 3.1). The 
                                                          
144  a) Ohmatsu, K.; Kiyokawa, M.; Ooi, T. J. Am. Chem. Soc. 2011, 133, 1307. b) Khan, S. S.; Shah, 
J.; Liebscher, J. Tetrahedron 2011, 67, 1812. c) Khan, S. S.; Shah, J.; Liebscher, J. Tetrahedron 
2010, 66, 5082. d) Shah, J.; Khan, S. S.; Blumenthal, H.; Liebscher, J. Synthesis 2009, 3975.  
145  a) Clavel, C.; Romuald, C.; Brabet, E.; Coutrot, F. Chem. Eur. J. 2013, 19, 2982. b) Zhang, Z.-J.; 
Han, M.; Zhang, H.-Y.; Liu, Y. Org. Lett. 2013, 15, 1698. c) Gilday, L. C.; White, N. G.; Beer, P. 
D. Dalton Trans. 2012, 41, 7092. d) Coutrot, F.; Busseron, E. Chem. Eur. J. 2008, 14, 4784.  
146  Obadia, M. M.; Drockenmuller, E. Chem. Commun. 2016, 52, 2433. 
147  a) Mendoza-Espinosa, D.; González-Olvera, R.; Negrón-Silva, G. E.; Angeles-Beltrán, D.; Suárez-
Castillo, O. R.; Álvarez-Hernández, A.; Santillan, R. Organometallics 2015, 34, 4529. b) 
Eisenberger, P.; Bestvater, B. P.; Keske, E. C.; Crudden, C. M. Angew. Chem. Int. Ed. 2015, 54, 
2467. c) Hettmanczyk, L.; Manck, S.; Hoyer, C.; Hohloch, S.; Sarkar, B. Chem. Commun. 2015, 
51, 10949.  
148  a) Koguchi, S.; Izawa, K. ACS Comb. Sci. 2014, 16, 381. b) Koguchi, S.; Izawa, K. Synthesis 2012, 
44, 3603. 
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procedure involves a sacrificial 3,4-dimethoxybenzyl group (DMB) attached to the N1-
position of triazoles 32, which is cleaved from triazolium salts 33 upon treatment with either 
ammonium nitrate or ceric ammonium nitrate. This method provides 1,5-disubstituted 1,2,3-
triazoles 34 in fair to good yields for simple alkyl or aryl substituents but, unfortunately, it 
requires relatively harsh DMB-deprotection oxidative conditions which are unsuitable for 
triazoles bearing sensitive functional groups.  
 
Scheme 3.1. Synthesis of 1,5-disubstituted 1,2,3-triazoles from N3-alkyl-1,2,3-triazolium salts. 
Two critical aspects to make the above approach synthetically attractive are: a) the 
use of an alternative sacrificial group attached at the N1 position that can be removed under 
mild conditions and b) the extension of the N3-alkylation scope to a wider range of 
functionalized alkyl groups. It is worth mentioning that N3-alkylation of 1,2,3-triazoles is 
strongly dependent on the steric hindrance of the alkylating reagent and limited to primary 
alkyl groups, such as small groups (methyl, ethyl) or activated groups (allyl, benzyl). In 
general, a large excess of the alkylating agent is required to achieve acceptable yields. 
Importantly, a wide variety of functional groups such as ethers, amides,
143d
 carbamates
149
 and 
even sulfides
150
 are well-accommodated at the N1 and C4 substituents of the 1,2,3-triazoles.  
An improved method for the N3-alkylation of 1,4-disubstituted 1,2,3-triazoles with 
complex alkylating agents has been recently developed in our group by Dr. Zaira 
Monasterio.
151
 It involves the use of alkyl triflates, freshly prepared from functionalized 
primary alcohols, to alkylate 1,2,3-triazoles 35 under solvent-free conditions (Scheme 3.2). 
In fact, the absence of solvent during the reaction turned out to be crucial to reach full 
conversion. As depicted in Scheme 3.2, “clickable” azide and terminal alkyne groups were 
                                                          
149  Karthikeyan, T.; Sankararaman, S. Tetrahedron Lett. 2009, 50, 5834. 
150  Mendoza-Espinosa, D.; González-Olvera, R.; Osornio, C.; Negrón-Silva, G. E.; Santillan, R. New 
J. Chem. 2015, 39, 1587. 
151  Monasterio, Z. PhD Thesis UPV-EHU 2015 “Synthesis, applications and reactivity of 1,2,3-
triazolium salts.” 
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successfully incorporated into 1,2,3-triazolium salts 36 bearing numerous functional groups, 
such as ethers, esters, carboxylic acids or carbamates. 
 
Scheme 3.2. N-alkylation of 1,2,3-triazoles with functionalized alkyl triflates.                                    
(TIP = 2,4,6-triiodophenoxy group). 
3.1.2 Synthesis of bis(1,2,3-triazoles) containing 1,5-disubstituted triazole units 
Bis(1,2,3-triazoles) have gained significant attention due to their potential 
application in supramolecular, pharmaceutical, biological and organometallic chemistry.
152
 
However, currently available bis(1,2,3-triazole) molecules share two common structural 
limitations: a) they are based almost exclusively on 1,4-disubstituted 1,2,3-triazoles units
153
 
and b) they invariably possess symmetrical substitution patterns.
154
 This is not surprising 
                                                          
152  Zheng, Z.-J.; Wang, D.; Xu, Z.; Xu, L.-W. Beilstein J. Org. Chem. 2015, 11, 2557.  
153  Damodiran, M.; Muralidharan, D.; Perumal, P. T. Bioorg. Med. Chem. Lett. 2009, 19, 3611. 
154  Aucagne, V.; Leigh, D. A. Org. Lett. 2006, 8, 20. 
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because they all rely on CuAAC procedures which involve the use of α,ω-diazides155 or    
α,ω-dialkynes and the performance of chemoselective “click” reactions over difunctionalized 
substrates towards the assembly of bis(1,2,3-triazoles) is still rather difficult.
156
   
In recent years, few methods for the synthesis of nonsymmetrically substituted 4,4’-
bitriazoles 37 (Figure 3.2) have been reported consisting in a “one-pot” sequential double 
CuAAC reactions of 1,3-butadiyne with different azides.
107c,157
 Some nonsymmetrically 1,4-
disubstituted bis(1,2,3-triazoles) 4,4’-tethered with short alkylene chains have also been 
prepared using alkyl azides bearing additional criptoazide groups.
158
  
Since the seminal report by Burgess
48b
 describing the formation of symmetrically 
substituted 5,5’-bistriazoles 38 (Figure 3.2) as byproducts in CuAAC reactions, numerous 
procedures to selectively prepare such heterocyclic products in good yields have been 
described.
48a,159
 In particular, the combination of oxidative conditions with the use of a 
carbonate base and supporting ligands proposed by Zhu and coworkers
159a
 has shown to be 
rather useful to give 5,5’-bistriazoles in high conversion, good selectivity and substrate scope 
extensible to aromatic azides. 
  
                                                          
155  Wang, Z.-X.; Zhao, Z.-G. J. Heterocyclic Chem. 2007, 44, 89. 
156  Elamari, H.; Meganem, F.; Herscovici, J.; Girard, C. Tetrahedron Lett. 2011, 52, 658. 
157  a) Doak, B. C.; Scanlon, M. J.; Simpson, J. S. Org. Lett. 2011, 13, 537. b) Fiandanese, V.; 
Bottalico, D.; Marchese, G.; Punzi, A.; Capuzzolo, F. Tetrahedron 2009, 65, 10573.  
158  Guiard, J.; Fiege, B.; Kitov, P. I.; Peters, T.; Bundle, D. R. Chem. Eur. J. 2011, 17, 7438. 
159  a) Brassard, C. J.; Zhang, X.; Brewer, C. R.; Liu, P.; Clark, R. J.; Zhu, L. J. Org. Chem. 2016, 81, 
12091. b) del Hoyo, A. M.; Latorre, A.; Díaz, R.; Urbano, A.; Carreño, M. C. Adv. Synth. Catal. 
2015, 357, 1154. c) Wang, C.-Y.; Zou, J.-F.; Zheng, Z.-J.; Huang, W.-S.; Lia, L.; Xu, L.-W. RSC 
Adv. 2014, 4, 54256. d) Li, L.; Fan, X.; Zhang, Y.; Zhu, A.; Zhang, G. Tetrahedron 2013, 69, 9939. 
e) Zheng, Z.-J.; Ye, F.; Zheng, L.-S.; Yang, K.-F.; Lai, G.-Q.; Xu, L.-W. Chem. Eur. J. 2012, 18, 
14094. f) Oladeinde, O. A.; Hong, S. Y.; Holland, R. J.; Maciag, A. E.; Keefer, L. K.; Saavedra, J. 
E.; Nandurdikar, R. S. Org. Lett. 2010, 12, 4256.  
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Figure 3.2. Bistriazole structures containing 1,4-disubstituted 1,2,3-triazole units (37-38) and 1,5-
disubstituted 1,2,3-triazole units (39-42). 
Despite the advancements disclosed above, the synthetic access to bis(1,2,3-
triazoles) containing 1,5-disubstituted components 39-42 (Figure 3.2) remains challenging. 
In 2013 Cui
160
 reported a single example of the preparation of triazole 43 containing 
simultaneously a 1,5-disubstitution pattern and a latent “clickable” azide group which could 
be further used to add the second triazole ring following a CuAAC methodology 
(Scheme 3.3). Unfortunately, the two-step procedure required the use of cumbersome 
starting materials and involved the diazotation of a preformed α-benzoyl-β-enamine 
intermediate with tosyl azide under strongly basic conditions. 
 
Scheme 3.3. Synthesis of a functionalized 1,5-disubstituted 1,2,3-triazole bearing a “clickable” N1-
azidoalkyl group. 
In view of the scarce precedents covering the synthesis of bis(1,2,3-triazoles) 
containing non-symmetrically substituted 1,5-triazole units, we decided to face the 
development of a novel and efficient protocol for the preparation of such appealing 
heterocyclic backbones.  
  
                                                          
160  Cheng, G.; Zeng, X.; Shen, J.; Wang, X.; Cui, X. Angew. Chem. Int. Ed. 2013, 52, 13265. 
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3.2 Hypothesis 
On the basis of the precedent discussion, we considered the use of the novel 
triazolium salts 44 (Scheme 3.4) as an interesting alternative to overcome the existing 
synthetic limitations to prepare bistriazoles comprising non-symmetrically substituted 1,5-
substituted 1,2,3,-triazole units 39-42 (Figure 3.2). We surmised that the incorporation of 
“clickable” functionalized groups via N-alkylation with functionalized alkyl triflates as 
described by our research group
151
 would overcome the above-mentioned limitations. 
Moreover, the subsequent N-dealkylation of triazolium salts 44 could be conducted in a 
totally site-selective manner if proper electronwithdrawing groups were used to enhance the 
electrophilicity of one of the N-alkyl substituents. In particular, we selected the                     
N-pivaloyloxymethyl group described by Sharpless and Fokin
161
 to prepare N-unsubstituted 
1,2,3-triazoles 45 as a valuable candidate for our synthetic purposes. 
 
Scheme 3.4. Site-selective N3-alkylation / N1-dealkylation strategy to prepare 1,5-disubstituted 
triazoles and bistriazoles. 
 
 
                                                          
161
  a) Saftić, D.; Vianello, R.; Žinić, B. Eur. J. Org. Chem. 2015, 7695. b) Loren, J. C.; Krasi, A.; 
Fokin, V. V.; Sharpless, K. B. Synlett 2005, 2847.  
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3.3 Objectives 
To confirm the above hypotheses, we established two objectives consisting in the 
study of the following chemical transformations: 
1. Conversion of 1-pivaloyloxymethyl 1,2,3-triazoles into 1,5-disubstituted triazoles, 
following a site-selective N3-alkylation / N1-dealkylation sequence.  
 
2. Extension of the former methodology to the synthesis of unprecedented bistriazole 
systems involving 1,5-disubstituted 1,2,3-triazoles. 
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3.4 Results and discussion 
To address the proposed objectives, we divided our working plan into four tasks. 
First, the preparation of alkyl triflates from primary alcohols bearing functionalized groups 
such as azide or terminal alkynes. Second, to use the resulting functionalized alkyl triflates to 
alkylate 1,4-disubstituted 1,2,3-triazoles. Then, to study the N-dealkylation of the resulting 
triazolium salts with different nucleophiles or bases to obtain 1,5-disubstituted 1,2,3-
triazoles, and finally to perform the CuAAC reaction in order to obtain bistriazoles that are 
beyond reach by other methods. 
3.4.1 Synthesis of alkyl triflates 
Alkyl triflates are excellent alkylating reagents, but their preparation and isolation 
as pure compounds is not trivial. They are often prepared from alcohols by reaction with 
triflic anhydride in the presence of sterically hindered organic bases like 2,6-di-tert-butyl-
pyridine
162
 or poly(vinylpyridine).
163
 However, mild basic aqueous washing is required to 
separate the reaction byproducts, which often results in partial hydrolysis of alkyl triflates 
rendering their purification unpractical.  
Hanack and Collins took advantage of using heterogeneous reaction conditions to 
prepare enol triflates from ketones.
164
 Following this approach, we found that treating an 
alcohol with equimolar amounts of triflic anhydride and anhydrous KHCO3 in CH2Cl2 
resulted in quantitative conversion to the desired alkyl triflate (Table 3.1).  
 
 
 
 
                                                          
162 Kramer, J. R.; Deming, T. J. Biomacromolecules 2012, 13, 1719. 
163 Ross, S. A.; Pitíe, M.; Meunier, B. J. Chem. Soc., Perkin Trans. 2000, 571. 
164  Hanack, M.; Fuchs, K.-A.; Collins, C. J. J. Am. Chem. Soc. 1983, 105, 4008. 
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Table 3.1. Synthesis of alkyl triflates from alcohols. 
 
Entry R Product Yield (%) 
1
165
 
  
47a 94
a 
2 
  
47b >95
b 
3   47c >95
b 
4   47d 0
 
5
166
   47e >95
b 
6
167
   47f >95
b 
7   47g >95
b 
aIsolated yield. bNot isolated. Conversion determined by 1H NMR.  
After a simple filtration of the heterogeneous reaction mixture, solutions of practically 
pure alkyl triflates 47 were obtained ready for use in subsequent N-alkylation reactions as 
shown in Table 3.1. The method was useful to prepare not only simple alkyl triflates (entry 2), 
but also functionalized ones including groups such as azide (entries 5 and 6) or halogens 
(entry 3).  
Although we tried to synthesize the alkyl triflate including a cyano group (entry 4), the 
reaction failed. Remarkably, alkyl triflate 47g which incorporates the acid-sensitive alkynyl 
                                                          
165  Radek, O.; Nemecek, O. Czech Patent CS 118450, 1966. 
 
166  Dowlut, M.; Hall, D. G.; Hindsgaul, O. J. Org. Chem. 2005, 70, 9809. 
167  Aucagne, V.; Hänni, K. D.; Leigh, D. A.; Lusby, P. J.; Walker D. B. J. Am. Chem. Soc. 2006, 128, 
2186. 
 127 
 
group (entry 7) was also uneventfully prepared and the 2,4,6-triiodophenol derivative 47a 
(entry 1) could be isolated and stored at -20 ºC for months without appreciable decomposition. 
3.4.2 Metal-free synthesis of 1,5-disubstituted 1,2,3-triazoles through 1,3,4-
trisubstituted triazolium intermediates 
In order to select the most suitable 3-N-alkyl-1,2,3-triazolium salts to provide the 
target 1,5-disubstituted 1H-1,2,3-triazoles upon site-selective N-dealkylation, several test 
experiments and computational calculations were conducted. Accordingly, we studied the N3-
demethylation reaction of several model 3-methyl-1,2,3-triazolium triflates under basic and 
nucleophilic substitution conditions. 
Bertrand first established that the base-promoted N-demethylation of triazolium salt 
48 to the C5-methylated triazole 50 likely occurred through the intermolecular nucleophilic 
attack of a mesoionic carbene formed by C5-H deprotonation of the triazolium salt 
(Scheme 3.5).
168
  
 
Scheme 3.5. N-Dealkylation of a triazolium salt 48 under basic conditions. 
To avoid the carbene formation, we tested several nucleophilic reagents and found 
that a much milder N-dealkylation of the N1-benzyl-N3-methyl-1,2,3-triazole 51 occurred 
using potassium thiophenoxide to cleave the C−N bond, albeit with very poor site-selectivity 
(Scheme 3.6). 
 
Scheme 3.6. N-Dealkylation of 1,3-dialkyl-triazolium triflate 51 under nucleophile attack conditions. 
                                                          
168  Bouffard, J.; Keitz, B. K.; Tonner, R.; Guisado-Barrios, G.; Frenking, G.; Grubbs, R. H.; Bertrand, 
G. Organometallics 2011, 30, 2617. 
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As shown in Figure 3.3, the assigned 
1
H-NMR spectrum of the crude reaction mixture 
shows the signals of the dealkylated compound 52 and the 1,5-disubstituted triazole 53, which 
is the major product in a 68 % yield.  
 
Figure 3.3. 1H NMR (500 MHz, MeCN-d3) spectra of the triazolium salt 51 (top) and the reaction 
crude of the non-selective N-dealkylation reaction of 51 with thiophenol and K2CO3 (bottom). 
We concluded that the poor site-discrimination observed during the N-dealkylation 
reaction could be attributed to the similar electrophilicity of the two carbon substituents (Me 
and Bn groups) placed at the N1 and N3 positions of the 1,2,3-triazole ring, respectively.  
As mentioned above
161
 (see, section 3.2), the pivaloyloxymethyl group is particularly 
suitable for the N-protection of triazoles because it can be removed with nucleophilic or basic 
reagents. In order to get a quantitative estimation of the relative electrophilicity of the methyl, 
benzyl and pivaloyloxymethyl groups attached to triazolium rings, we decided to perform 
computational studies with triazolium cations A and B (Figure 3.4).
169
 We also compared the 
mechanisms of the nucleophilic attack of the hydroxide ion to the pivaloyloxymethyl group of 
the cationic triazolium structure B and the neutral counterpart C. Each reaction was studied 
assuming two possible pathways involving the cleavage of the O−CH2 bond [paths (1) and (3)] 
and the cleavage of the CH2−N bond [paths (2) and (4)], respectively. 
                                                          
169  Computational studies conducted by Dr. Jose Ignacio Miranda. 
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Figure 3.4. “Ab initio” natural bond orbital (NBO) charges of triazolium cations A and B (top). 
Comparison of the SN2 reaction pathways (1)-(4) for the nucleophilic reaction of hydroxide anion with 
the pivaloyloxymethyl group of the triazolium cation B and the triazole C (bottom). 
First, we computed the natural bonding (NBO)
170
 charges of the N1-benzyl and N3-
methyl carbon atoms of the triazolium structure A. We found negative formal charge values of 
-0.26 and -0.48, respectively, indicating a poor electrophilicity in both cases, but pointing at a 
higher reactivity for the benzyl methylene compared to the methyl group. Indeed, this result 
was in excellent agreement with the experimentally observed N-dealkylation ratio 
(Secheme 3.6).  
In contrast to benzyl and methyl groups, the pivaloyloxymethyl group in the 
triazolium structure B showed a positive formal charge of +0.08 at the methylene carbon. This 
result strongly suggested that N-pivaloyloxymethyl group could be clearly discriminated from 
other N-alkyl groups using site-selective nucleophilic N-dealkylation reactions. To confirm this 
                                                          
170
  NBO 6.0. Software: Glendening, E. D.; Badenhoop, J. K.; Reed, A. E.; Carpenter, J. E.; Bohmann, 
J. A.; Morales, C. M.; Landis, C. R.; Weinhold, F. Theoretical Chemistry Institute, University of 
Wisconsin, Madison, 2013. 
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observation, we computed the SN2 reaction pathways (1)-(4) to calculate the activation barriers 
(ΔG‡) leading to the corresponding triazole four products D-G. The free energy profiles of the 
hydroxide-promoted N-dealkylation of the 1,2,3-triazolium salt B and the 1,2,3-triazole C are 
represented in Scheme 3.7.  
As expected, the SN2 hydroxylation reaction was significantly more favored in the 
case of triazolium electrophile B, which could evolve through pathways (1) and (2) reaching 
computationally characterizable transition states of 5.0 kcal/mol and 4.6 kcal/mol activation 
barriers, respectively. In contrast, equivalent pathways (3) and (4) from the neutral triazole C 
involved transition states with comparatively higher activation barriers of 10.4 kcal/mol and 
16.9 kcal/mol.  
It should be mentioned that pathway (2), anticipated as the more likely by our 
computational study, involved the participation of a triazolium cation as the leaving group of 
the reaction to give rise to the uncharged 1,5-disubstituted triazole E. This transformation of 
charged reactants into neutral products, makes pathway (2) thermodynamically very favored                          
(ΔGºE = -67.8 kcal/mol) and could be considered the driving force of the reaction. 
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Scheme 3.7. Transition states and reaction products computed at B3LYP/6-31G* level of theory for the 
nucleophilic N-dealkylation of 1,2,3-triazolium salt B (top) and 1,2,3-triazole C (bottom) to the triazole 
products D-G. Relative ΔG‡ energies in kcal/mol calculated at 25 ºC in MeOH. 
In agreement with these calculations, we further synthesized the 1-pivaloyloxymethyl 
substituted 1,2,3-triazoles 55 and 56 upon Cu-catalyzed cycloaddition of azidomethyl pivalate 
with phenylacetylene and 1-hexyne (Scheme 3.8).   
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Scheme 3.8. Preparation of model 1-pivaloyloxymethyl triazoles. 
With the 1-pivaloyloxymethyl-1,2,3-triazoles in hand, we studied their alkylation 
reaction to form the intermediate 1,3,4-trisubstituted 1,2,3-triazolium triflates and submit them 
to the site-selective N-dealkylation reaction in order to obtain the desired 1,5-disubstituted 
1,2,3-triazoles. In general, triazolium salts were not isolated and the products were obtained in 
a one-pot two-step reaction. Two different alkylating methods were used; the introduction of 
the methyl group was performed utilizing commercially available methyl 
trifluoromethanesulfonate in dichloromethane (Scheme 3.9), while the N3-alkylation with 
larger or functionalized groups was achieved employing previously synthesized alkyl triflates 
(Table 3.1) in the absence of solvent (Scheme 3.10).  
As shown in the Scheme 3.9, 1,5-disubstituted 1,2,3-triazoles 53 and 57 were obtained 
in good overall yields, both from aromatic and aliphatic substituted triazoles. The operational 
simplicity of the method is worth mentioning, since practically pure products were obtained 
after a simple filtration of the final reaction mixture and evaporation of the solvent. 
 
Scheme 3.9. One-pot two-step synthesis of 1-methyl-5-substituted-1,2,3-triazoles following a N3-
alkylation / N1-dealkylation reaction sequence. 
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Figure 3.5. 1H NMR (400 MHz, CDCl3) spectra of the N-methylation reaction of 55 with MeOTf 
followed by N-depivaloyloxymethylation reaction in the presence of K2CO3 and MeOH. 
As depicted in Figure 3.5, upon methylation of triazole 55, the signal corresponding 
to the heterocyclic proton 1 was shifted from 7.96 ppm to 8.52 ppm and a methyl group 
singlet appeared at 4.25 ppm. When the subsequent dealkylation took place, the pivaloyloxy 
group signal vanished and the 1,5-substituted triazole 8 proton shifted back to higher field as 
a result of the recovery of a neutral triazole nature.  
Alternatively, to achieve equivalent transformations with more hindered or 
functionalized alkyl triflates, the alkylation step was conducted in neat conditions attained by 
the slow evaporation of an equimolar solution of the triflate and the triazole in dichloromethane 
under a very smooth nitrogen gas stream. The reaction was stirred at room temperature 
overnight and then it was dissolved in MeOH and K2CO3 was added to promote the 
dealkylation step.  
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Scheme 3.10. 1,5-Disubstituted 1,2,3-triazoles prepared from 1-pivaloyloxy triazoles following a two-
step “one-pot” N-alkylation / N-dealkylation sequence. aObtained from 58c by substitution with NaCN. 
As depicted in Scheme 3.10, the method gave the corresponding 1,5-disubstituted 
1,2,3-triazoles in moderate to good yields from functionalized alkyl triflates bearing halogen 
(compound 58c), terminal alkyne (compound 58e) and azide groups (compounds 58f and 58g). 
As mentioned before, we were unable to synthesize 3-cyanopropyl triflate (compound 4d in 
Table 3.1) from the corresponding alcohol and therefore, compound 58d could not be prepared 
directly from 55 using the alkylation/dealkylation method. Alternatively, the nitrile 58d was 
obtained in 70 % yield from bromide 58c by substitution reaction with sodium cyanide. It is 
worth noting that after the completion of our work, Page et al. reported the N-debenzylation 
reaction of triazolium salts bearing nonfunctionalized alkyl and aryl groups utilizing KOtBu in 
THF at 0 ºC to provide 1,5-disubstituted 1,2,3-triazoles.
171
 
                                                          
171  Page, P. C. B.; Stephenson, G. R.; Harveya, J.; Slawinb, A. M. Z. Synlett 2016, 27, 2500. 
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3.4.3 Synthesis of non-symmetrically substituted bistriazoles with full positional 
control. 
Following our working plan, the previously synthesized 1,5-disubstituted 1,2,3-
triazoles containing latent reactivity (compounds 58f and 58g) were further reacted with 
alkynes under CuAAC conditions as shown in Scheme 3.11. As expected, azide groups 
incorporated by N-alkylation reacted with phenylacetylene and propargyl alcohol to provide the 
corresponding 1,5- and 1,4-substituted bis(1,2,3-triazoles) 59 and 60 in excellent yields.   
 
Scheme 3.11. Synthesis of 1,5- and 1,4-substituted bistriazoles linked by alkyl chains. 
Encouraged by these results, we next explored the poorly studied, yet unknown, 
synthesis of, 4,5’- and 5,5’-tethered bistriazoles. To face this challenge, we began with the 
synthesis of the key triazole 61 containing the 4-alkyne group (Scheme 3.12). 
 
Scheme 3.12. Synthesis of 5,4’-tethered and 5,5’-tethered bistriazoles from 1-pivaloyloxymethyl-1,2,3-
triazole precursors. 
We first tried to synthesize triazole 61 starting from a “click” reaction between the 
pivaloyloxymethyl azide and propargyl alcohol to obtain a 4-hydroxymethyl triazole 
intermediate which was immediately oxidized under Swern reaction conditions in nearly 
quantitative yield (Scheme 3.13). The resulting aldehyde derivative 63 was further treated with 
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the Bestmann-Ohira reagent but the desired 4-ethynyl compound was not obtained, regardless 
of the reaction conditions. In this respect, different types of bases as well as temperature and 
reaction time variations were tried with no evidence of the formation of 61. As the initial 
product was consumed, the reaction was followed by 
1
H-NMR and we observed that a 
competitive attack of the base to the pivaloyloxymethyl group occurred instead of the desired 
Bestmann-Ohira reaction. Therefore, we decided to evaluate the synthesis of triazole 67 using 
alternative routes. 
 
Scheme 3.13. Attempted synthesis of 4-ethynyl-1,2,3-triazole 61 via Bestmann-Ohira reaction. 
After a short literature survey, we decided to use butadyine as the starting material for 
the synthesis of ethynyl triazole 61. Butadiyne is not commercially available, but it can be 
readily prepared by heating 1,4-dichlorobut-2-yne in a mixture of DMSO and water with 
potassium hydroxide at 70 ºC.
172
 The resulting product evolved as a gas via cannula to a trap 
containing dry THF cooled at -78 ºC giving a solution that could be stored in the fridge.  
Triazoles 61 and 62 were synthesized from pivaloyloxymethyl azide 54 via CuAAC 
reactions using an excess of butadiyne or stoichiometric amounts of reactants, respectively. In 
the former case, mixtures of mono- and bistriazole products were obtained, which were readily 
separated by column chromatography to give the major alkyne 61 in moderate yield 
(Scheme 3.14).  
To demonstrate the usefulness of our methodology, we next prepared 5,4’-tethered 
bis(1,2,3-triazole) backbones through an alkylation/“click”/deprotection sequence. As shown in 
Scheme 3.14, nonsymmetrically substituted bis(1,2,3-triazoles) 39a, 39b and 39c were 
obtained in overall yields ranging from good to excellent. To the best of our knowledge, this is 
the first time that these types of biheterocyclic systems have been prepared. 
                                                          
172  Janka, M.; Anderson, G. K.; Rath, N. P. Organometallics 2004, 23, 4382. 
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Alternatively, to get 5,5’-tethered bis(1,2,3-triazoles), we performed the double 
methylation of the 4,4’-bistriazole 62 with methyl triflate, followed by in situ N-dealkylation 
with potassium carbonate to get the target product 40 in 61 % yield (Scheme 3.14).  
 
 
Scheme 3.14. Synthesis of 5,4’- and 5,5’-tethered bis(1,2,3-triazoles). 
3.4.4 Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 
We also extended the N-alkylation/activation methodology to the preparation of 
multisubstituted monocyclic triazoles. To accomplish this task, we studied the in situ 
deuteration and halogenation of the intermediate triazolium salts at the reactive C5-H position 
before the N-dealkylation of the pivaloyloxymethyl group.  
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As depicted in Scheme 3.15, triazole 55 could be easily converted into the C5-
deuterated triazole 64 through an alkylation/deuteration sequence by simply replacing the 
regular methanol solvent with the deuterated analog. Although the reaction mechanism was not 
studied in detail, this outcome suggested the formation of a triazolydine carbene intermediate 
prior to the dealkylation reaction. 
 
Scheme 3.15. Synthesis of fully substituted 1,2,3-triazoles. (TIP = 2,3,6-triiodophenyl). 
In order to support the latter statement, we trapped the intermediate carbene from the 
N3-methyl-triazolium salt of 55 with silver oxide to form the corresponding silver carbene 
complex, which was reacted in situ with cyanogen iodide to iodinate the C5-H bond. The 
subsequent deprotection of the pivaloyloxymethyl group with potassium carbonate in methanol 
provided fully substituted 1,2,3-triazole 65 in good yields, in agreement with the suggested 
hypothesis.      
Finally, we synthesized the C5-iodo derivative 66, substituted with the pivaloyl group 
in the N1 position. In this case, the alkylation and deprotection processes were found 
compatible with the presence of a iodine atom as the reaction proceeded in good yield to give 
the product 67 in 64 % isolated yield.   
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3.5 Conclusions 
The assembly of a variety of 1,5-disubstituted 1,2,3-triazoles incorporating “click” 
compatible functional groups has been easily conducted starting from 1-pivaloyloxymethyl-
1,2,3-triazoles and functionalized alcohols, following a one-pot site-selective N-alkylation / N-
dealkylation sequence.
173
   
A two-step protocol consisting in the heterogeneous triflation of alcohols followed by 
a solvent-free N3-alkylation of 1,2,3-triazoles, provided N1, N3, C4-trisubstituted 1,2,3-
triazolium salts in excellent yields and with great operational simplicity. The following            
N-dealkylation reaction of the pivaloyloxymethyl group provided a wide variety of 1,5-
disubstituted 1,2,3-triazoles or 1,4,5-trisubstituted 1,2,3-triazoles following a metal-free 
protocol that takes advantage of the electrophilicity enhancement generated by the triazolium 
moiety on the 1-(pivaloxyloxymethyl)-1,2,3-triazolium intermediates. 
The latent reactivity of some N3-azide-1,2,3-triazoles has been demonstrated by 
achieving their CuAAC coupling with alkynes to transform them into double 1,4- and 1,5- 
multisubstituted 1,2,3-triazoles. 
Finally, 5,5’- and 5,4’-tethered-bistriazoles have been successfully prepared upon 
reaction of buta-1,3-diyne and azidomethyl pivalate and subsequent CuAAC processes. To the 
best of our knowledge, our approach represents the first straightforward access to those 
appealing bistriazoles. 
 
 
 
 
 
 
 
                                                          
173
  Monasterio, Z.; Irastorza, A.; Miranda, J. I.; Aizpurua, J. M. Org. Lett. 2016, 18, 2511. 
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Experimental  
General 
All reagents and solvents were obtained from commercial sources (Aldrich, Acros, 
Alfa Aesar, Merck, and Fluka) and were used without further purification unless stated 
otherwise. Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried through PS-MD-
2columns. Extra pure dichloromethane (CH2Cl2), acetonitrile (MeCN), hexane (Hex) and 
ethyl acetate (EtOAc) were bought from Sharlau.  
Moisture sensitive reactions were carried out under an atmosphere of nitrogen in 
oven or flame-dried glassware with magnetic stirring. 
The solvents produced in reactions or chromatography were evaporated in Büchi R-
210 rotapavors under reduced pressure. 
Purification of reaction products was carried out by flash chromatography using 
silica gel 60 (230-400 mesh). Analytical thin layer chromatography was performed on 0.25 
mm silica gel 60-F plates and visualization was accomplished with UV light (λ = 254 nm) or 
KMnO4 as TLC stain.  
1
H NMR spectra were recorded on Bruker avance spectrometers operated at 500 and 
400 MHz; and 
13
C NMR spectra were recorded at 125 and 101 MHz. The chemical shifts are 
reported as δ values (ppm) relative to residual deuterated solvent as internal standards: for 
CDCl3 δH (7.26 ppm) and δC (77.16 ppm), respectively; for MeOH-d4 δH (3.31 ppm) and 
δC (49.0 ppm), respectively; for MeCN-d3 δH (1.94 ppm) and δC (118.26 ppm, 1.32 ppm), 
respectively; for DMSO-d6 δH (2.50 ppm) and δC (39.52 ppm), respectively.  
High resolution mass spectra were performed by SGIker and were acquired on a 
time of flight (TOF) mass spectrometer (SYNAPT G2 HDMS from Waters, Milford, MA, 
USA) equipped with an electrospray source in positive mode (ESI
+
). Melting points were 
measured with a Büchi SMP-20 melting point apparatus and are uncorrected. Infrared spectra 
were recorded on a Bruker Alpha P.  
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3.1 Synthesis of the starting materials 
3.1.1 Synthesis of alkylazides 
 
2-Azidoethan-1-ol (46e).
171
 2-Bromoethanol (3.00 mmol, 375 mg) was dissolved in H2O (2 
mL) and NaN3 (3.30 mmol, 214 mg) was subsequently added. The mixture was stirred at 80 
ºC for 8 h, then cooled down at room temperature and the solution was extracted with Et2O 
(2 mL x 3). The organic layer was dried over MgSO4 and the solvent was evaporated under 
reduced pressure to provide 222 mg (87 %) of 46e as a colorless oil. 
1
H NMR (400 MHz, 
CDCl3): δ 3.81 (q, J = 5.4 Hz, 2H), 3.48 (t, J = 5.1 Hz, 2H). 
 
3-Azidopropan-1-ol (46f).
167
 A mixture of 3-bromopropan-1-ol (7.19 mmol, 0.65 mL) and 
NaN3 (14.38 mmol, 935 mg) in H2O (20 mL) was stirred at 80 ºC for 18 h, then cooled down 
to room temperature and the solution was extracted with EtOAc (20 mL x 5). The combined 
organic layers were washed with brine (20 mL), dried over MgSO4 and concentrated under 
reduced pressure to provide 698 mg (96 % yield) of 46f as a colorless oil. 
1
H NMR (400 
MHz, CDCl3): δ 3.76 (t, J = 5.7 Hz, 2H), 3.45 (t, J = 6.3 Hz, 2H), 1.83 (p, J = 5.9 Hz, 2H). 
 
Azidomethyl pivalate (54).
174
 A mixture of chloromethyl pivalate (1.33 mmol, 20 μL), 
NaN3 (2.00 mmol, 130 mg) and NaI (10 mg) in H2O (0.20 mL) was stirred at 90 ºC for 12h, 
then cooled down to room temperature and extracted with DCM (5 mL x 3). The organic 
layer was dried over MgSO4 and concentrated under reduced pressure to provide 174 mg 
(83 % yield) of 54 as a colorless liquid. 
1
H NMR (400 MHz, CDCl3): δ 5.14 (s, 2H), 1.25 (s, 
9H). 
                                                          
174  Jogireddy, R.; Rullkötter, J.; Christoffers, J. Synlett 2007, 18, 2847. 
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3.1.2 General procedure for the preparation of alkyl trifluoromethanesulfonates 
Trifluoromethanesulfonic anhydride Tf2O (1.20 mmol) was added dropwise over a 
period of 5 min to a vigorously stirred solution of the corresponding alcohol (1.00 mmol) and 
anhydrous KHCO3 (1.40 mmol) in dry CH2Cl2 (8.6 mL) cooled to 0 ºC and the reaction 
mixture was stirred for 5-18 hours at ambient temperature. The suspension was filtered 
through a 0.2 µm PTFE filter and the resulting alkyl trifluoromethanesulfonate solution was 
used in the next alkylation reactions without further purification. Alternatively, the pure 
product could be isolated by evaporating the solvent at reduced pressure. 
 
2-(2,4,6-Triiodophenoxy)ethyl trifluoromethanesulfonate (47a). The general procedure 
3.1.2 was followed starting from 2-(2,4,6-triiodophenoxy)ethanol (0.58 mmol, 300 mg), 
KHCO3 (0.81 mmol, 81 mg) and Tf2O (0.70 mmol, 117 µL) in CH2Cl2 (5 mL). The reaction 
mixture was stirred for 18 hours and provided 355 mg (94 % yield) of 47a as a white solid. 
Mp 62-63 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.10 (s, 2H), 4.95 (t, J = 4.2 Hz, 2H), 4.32 (t, J 
= 4.2 Hz, 2H). 
13
C NMR (101 MHz, CDCl3): δ 156.6, 147.5, 118.6 (q, J = 320.5, 319.9 Hz), 
91.5, 90.3, 74.5, 69.2. IR (cm
-1
): 1238, 1200, 1141, 930, 863, 612. 
 
Phenethyl trifluoromethanesulfonate (47b).
175
 The general procedure 3.1.2 was followed 
starting from 2-phenylethan-1-ol (0.14 mmol, 20 μL), KHCO3 (0.20 mmol, 20 mg) and Tf2O 
(0.17 mmol, 30 µL) in CH2Cl2 (5 mL). The reaction mixture was stirred for 18 hours to 
provide a solution of the product in practically quantitative yield, as checked from the 
1
H-
NMR analysis of a sample. 
1
H NMR (400 MHz, CDCl3): δ 7.21-7.19 (m, 5H), 3.86 (t, J = 
7.2 Hz, 2H), 2.87 (t, J = 7.3 Hz, 2H). A freshly prepared solution of the alkyl triflate was 
directly used for the N-alkylation of triazoles.  
 
 
                                                          
175  Dang, H.; Mailig, M.; Lalic, G. Angew. Chem. Int. Ed. 2014, 53, 6473. 
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3-Bromopropyl trifluoromethanesulfonate (47c).
176
 The general procedure 3.1.2 was 
followed starting from 3-bromopropan-1-ol (0.14 mmol, 13 μL), KHCO3 (0.20 mmol, 20 
mg) and Tf2O (0.17 mmol, 30 µL) in CH2Cl2 (5 mL). The reaction mixture was stirred for 18 
hours to provide a solution of the product in practically quantitative yield, as checked from 
the 
1
H-NMR analysis of a sample. 
1
H NMR (400 MHz, CDCl3): δ 4.02 (t, J = 7.1 Hz, 2H), 
3.50 (t, J = 7.1 Hz, 2H), 1.90 (q, J = 7.1 Hz, 2H). A freshly prepared solution of the alkyl 
triflate was directly used for the N-alkylation of triazoles.  
 
2-Azidoethyl trifluoromethanesulfonate (47e).
177
 The general procedure 3.1.2 was 
followed starting from 2-azidoethan-1-ol (4.00 mmol, 360 mg), KHCO3 (5.60 mmol, 560 
mg) and Tf2O (4.80 mmol, 0.80 mL) in CH2Cl2 (5 mL). The reaction mixture was stirred for 
18 hours to provide a solution of the product in practically quantitative yield, as checked 
from the 
1
H-NMR analysis of a sample. 
1
H NMR (400 MHz, CDCl3): δ 3.60 (t, J = 7.6 Hz, 
2H), 1.70 (t, J = 7.4 Hz, 2H). A freshly prepared solution of the alkyl triflate was directly 
used for the N-alkylation of triazoles.  
 
3-Azidopropyl trifluoromethanesulfonate (47f).
162
 The general procedure 3.1.2 was 
followed starting from 3-azidopropan-1-ol (0.14 mmol, 14 mg), KHCO3 (0.20 mmol, 20 mg) 
and Tf2O (0.17 mmol, 30 µL) in CH2Cl2 (5 mL). The reaction mixture was stirred for 18 
hours to provide a solution of the product in practically quantitative yield, as checked from 
the 
1
H-NMR analysis of a sample. 
1
H NMR (400 MHz, CDCl3): δ 4.02 (t, J = 7.5 Hz, 2H), 
1.52-1.48 (m, 6H). A freshly prepared solution of the alkyl triflate was directly used for the 
N-alkylation of triazoles.  
 
 
 
                                                          
176  Hugelshofer, C. L.; Mellem, K. T.; Myers, A. G. Org. Lett. 2013, 15, 3134. 
177  Vourloumis, D.; Winters, G. C.; Simonsen, K. B.; Takahashi, M.; Ayida, B. K.; Shandrick, S.; 
Zhao, Q.; Han, Q.; Hermann, T. ChemBioChem 2005, 6, 58.  
   
147 
 
 
Pent-4-yn-1-yl trifluoromethanesulfonate (47g).
178
 The general procedure 3.1.2 was 
followed starting from pent-4-yn-1-ol (0.14 mmol, 13 μL), KHCO3 (0.20 mmol, 20 mg) and 
Tf2O (0.17 mmol, 30 µL) in CH2Cl2 (5 mL). The reaction mixture was stirred for 18 hours to 
provide a solution of the product in practically quantitative yield, as checked from the 
1
H-
NMR analysis of a sample. 
1
H NMR (400 MHz, CDCl3): δ 4.02 (t, J = 7.1 Hz, 2H), 2.93 (t, J 
= 4.2, 1H), 2.51-2.44 (m, 2H), 1.65 (q, J = 7.6 Hz, 2H). A freshly prepared solution of the 
alkyl triflate was directly used for the N-alkylation of triazoles.  
3.2 Synthesis of 1,4-disubstituted and 1,4,5-trisubstituted-1H-1,2,3-triazoles 
General procedure : To a solution of the corresponding azide (1.00 mmol) and alkyne (1.10 
mmol) in a mixture of deoxygenated 
t
BuOH/THF 1:1 (1 mL/mmol), a deoxygenated aq. 
solution of CuSO4·5H2O (20 mol %, 1mL/mmol) followed by a deoxygenated aq. solution of 
sodium ascorbate (40 mol %, 1mL/mmol) was added. The resulting mixture was stirred 
under inert atmosphere at room temperature overnight. The solvent was partially evaporated 
under reduced pressure and the resulting solution was washed with aq. NH3, extracted with 
EtOAc and washed with brine. The combined organic layers were dried over MgSO4, and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (hexanes/EtOAc 7/3) unless otherwise noted. 
 
4-Phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole (55).
174
 The general procedure 3.2 was 
followed starting from azidomethyl pivalate 54 (7.50 mmol, 1.18 g) and phenylacetylene 
(7.50 mmol, 0.82 mL) to provide 1.60 g (82 % yield) of 55 as a yellowish solid. 
1
H NMR 
(500 MHz, CDCl3): δ 7.96 (s, 1H), 7.78 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.28 (d, 
J = 7.4 Hz, 1H), 6.21 (s, 2H), 1.12 (s, 9H).  
 
                                                          
178  Reyes-Gutiérrez, P. E.; Jirásek, M.; Severa, L.; Novotná, P.; Koval, D.; Sázelová, P.; Vávra, J.; 
Meyer, A.; Císařová, I.; Šaman, D.; Pohl, R.; Štěpánek, P.; Slavíček, P.; Coe, B. J.; Hájek, M.; 
Kašička, V.; Urbanová, M.; Teplý, F. Chem. Commun. 2015, 51, 1583.  
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4-Butyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole (56). The general procedure 3.2 was 
followed starting from azidomethyl pivalate 54 (12.3 mmol, 1.90 g) and hept-1-yne (13.50 
mmol, 1.55 mL) to provide 1.90 g (66 % yield) of 56 as a yellowish oil. 
1
H NMR (400 MHz, 
CDCl3): δ 7.46 (s, 1H), 6.10 (s, 2H), 2.60 (t, J = 7.7 Hz, 2H), 1.54 (p, J = 7.6 Hz, 2H), 1.25 
(q, J = 7.6 Hz, 2H), 1.06 (s, 9H), 0.80 (t, J = 7.4 Hz, 3H). 
13
C NMR (101 MHz, CDCl3): 
δ 177.5, 148.7, 121.8, 69.5, 38.6, 31.2, 26.6, 25.0, 22.0, 13.6. IR (cm-1): 2960, 1744, 1458, 
1243, 1118, 1031, 776. MS (ESI
+
) m/z (%) 240 (M+H). HRMS calcd. for C12H22N3O2: 
240.1712; found: 240.1720. 
 
4-Ethynyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole (61). A solution of KOH (65 mmol, 
4.30 g) in water (10 mL) and DMSO (2.5 mL) was heated at 75 °C for 30 min in a three-
necked flask equipped with a condenser and a dropping funnel. The top of the condenser was 
connected, via a tube to a trap containing dry THF, which was cooled at -20 °C. 1,4-
dichloro-2-butyne (16 mmol, 1.60 mL) was added dropwise over a period of 30 min, while 
the temperature was maintained at 75 °C. A stream of argon was passed through the 
apparatus, which forced the butadiyne gas into the cold THF trap. The tube was extracted, 
and azidomethyl pivalate 54 (3.30 mmol, 512 mg), sodium acetate (9.90 mmol, 812 mg) and 
CuOAc (0.66 mmol, 120 mg) were added and the mixture was stirred at ambient temperature 
for 3-4 hours. Then, the solution was filtered through a celite pad, and the solvents were 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (silica gel, Hex/EtOAc 7:3) to provide 301 mg (44 % yield) of 61 as a white 
solid. Mp 192-195 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 6.31 (s, 2H), 3.35 (s, 
1H), 1.25 (s, 9H). 
13
C NMR (126 MHz, CDCl3): δ 177.7, 140.3, 122.2, 75.6, 69.9, 38.9, 27.0. 
IR (cm
-1
): 2976, 1730, 1279, 1144, 1089, 994, 829, 727. MS (ESI
+
) m/z (%) 208 (M+H). 
HRMS calcd. for C10H14N3O2: 208.1086; found: 208.1096. 
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4-Butyl-5-iodo-1-(pivaloyloxymethyl)-1H-1,2,3-triazole (66). To a suspension of CuI (5.50 
mmol, 1.10 g) in MeCN (15 mL) under argon at room temperature a solution of N-
bromosuccinimide (6.00 mmol, 1.10 g) in MeCN (15 mL) was added and the mixture was 
stirred 5 min at room temperature. Later on, azidomethyl pivalate 54 (5.00 mmol, 786 mg), 
hept-1-yne (5.50 mmol, 0.63 mL) and DIPEA (5.50 mmol, 1 mL) were subsequently added 
and the resulting mixture was stirred at room temperature overnight. Next, the mixture was 
washed with HCl 10 %, aq. NH3, extracted with EtOAc and washed with brine. The 
combined organic layers were dried over MgSO4, and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (hexanes/EtOAc 1/1) to 
provide 729 mg (40 % yield) of 66 as a yellowish solid. Mp 57-58 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 6.14 (s, 2H), 2.56 (t, J = 7.5 Hz, 2H), 1.57 (p, J = 7.5 Hz, 2H), 1.26 (h, J = 7.1 Hz, 
2H), 1.09 (s, 9H), 0.82 (t, J = 7.2 Hz, 3H). 
13
C NMR (101 MHz, CDCl3): δ 176.1, 152.4, 
78.8, 70.7, 38.5, 30.6, 26.6, 25.3, 21.9, 13.5. IR (cm-1): 2958, 2933, 1742, 1458, 1276, 1120, 
1031, 985, 827. MS (ESI
+
) m/z (%) 208 (M+H). HRMS calcd. for C12H21N3O2I: 366.0678; 
found: 366.0685. 
3.3 Synthesis of 1,5-disubstituted-1H-1,2,3-triazoles 
General Procedure A: A solution of the corresponding 1,2,3-triazole (1.00 mmol) and 
MeOTf (1.10 mmol) in anhydrous CH2Cl2 (5 mL) was stirred under nitrogen atmosphere at 
room temperature for 18 hours. The solvents were removed under reduced pressure. The 
crude was dissolved in MeOH (5 mL) and K2CO3 (2.00 mmol) was added. The mixture was 
stirred at ambient temperature for 5 hours. The solvents were removed under reduced 
pressure and the crude product was dissolved in CH2Cl2 and filtered using a PTFE filter. 
General Procedure B: To a solution of the corresponding 1,2,3-triazole (1.00 mmol) in 
CH2Cl2 (8.6 mL) the selected alkyl trifluoromethanesulfonate (1.20 mmol) was added and 
the mixture was slowly evaporated by passing a slow stream of dry nitrogen through the 
solution. After 18 hours at 30 ºC the resulting viscous mixture was dissolved in MeOH (5 
mL) and K2CO3 (2.00 mmol) was added. The mixture was stirred at ambient temperature for 
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5 hours. The solvents were removed under reduced pressure and purified by column 
chromatography (silica gel, Hex/EtOAc 1:1). 
 
1-Methyl-5-phenyl-1H-1,2,3-triazole (53). The general procedure A was followed starting 
from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.60 mmol, 150 mg), MeOTf 
(0.64 mmol, 70 µL) and CH2Cl2 (2.50 mL) to provide 43 mg (79 % yield) of 53 as a yellow 
oil. 
1
H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H), 7.47 (d, J = 7.4 Hz, 3H), 7.42-7.35 (m, 2H), 
4.04 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 138.4, 133.3, 129.5, 129.1, 128.6, 127.0, 35.6. 
IR (cm
-1
): 3423, 2917, 1749, 1483, 1244, 1016, 765, 696. MS (ESI
+
) m/z (%) 160 (M+H). 
HRMS calcd. for C9H10N3: 160.0875; found: 160.0869. 
 
5-Butyl-1-methyl-1H-1,2,3-triazole (57). The general procedure A was followed starting 
from 4-butyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 56 (0.63 mmol, 150 mg), MeOTf 
(0.69 mmol, 80 µL) and CH2Cl2 (2.50 mL) to provide 73 mg (83 % yield) of 57 as a yellow 
oil. 
1
H NMR (400 MHz, CDCl3): δ 7.34 (s, 1H), 3.87 (s, 3H), 2.54 (t, J = 7.8 Hz, 2H), 1.60-
1.51 (m, 2H), 1.33 (q, J = 7.5 Hz, 2H), 0.87 (t, J = 7.4 Hz, 3H). 
13
C NMR (101 MHz, 
CDCl3): δ 137.4, 131.9, 34.1, 29.9, 22.7, 22.1, 13.6. IR (cm
-1
): 2956, 2872, 1749, 1458, 
1238, 1031. MS (ESI
+
) m/z (%) 140 (M+H). HRMS calcd. for C7H14N3: 140.1188; found: 
140.1173. 
 
5-Phenyl-1-[2-(2,4,6-triiodophenoxy)ethyl]-1H-1,2,3-triazole (58a). The general 
procedure B was followed starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 
55 (0.24 mmol, 60 mg) and 2-(2,4,6-triiodophenoxy)ethyl trifluoromethanesulfonate 47a 
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(0.29 mmol, 187 mg). The product was purified by column chromatography (silica gel, 
CH2Cl2/MeOH 95:5) to provide 105 mg (68 % yield) of 58a as a white solid. Mp 141-144 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.99 (s, 1H), 7.73 (s, 2H), 7.60-7.53 (m, 2H), 7.48 (d, J = 
5.7 Hz, 3H), 4.79 (t, J = 5.4 Hz, 2H), 4.41 (t, J = 5.4 Hz, 2H). 
13
C NMR (101 MHz, CDCl3): 
δ 156.8, 147.4, 139.3, 133.1, 129.7, 129.6, 129.1, 127.0, 91.8, 90.1, 70.9, 47.5. IR (cm-1): 
1421, 1234, 1024, 768, 697. MS (ESI
+
) m/z (%) 644 (M+H). HRMS calcd. for C16H13N3OI3: 
643.8193; found: 643.8207. 
 
1-(2-Phenethyl)-5-phenyl-1H-1,2,3-triazole (58b). The general procedure B was followed 
starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.12 mmol, 30 mg) and 
phenethyl trifluoromethanesulfonate 47b (0.14 mmol, 35 mg). The product was purified by 
column chromatography (silica gel, Hex/EtOAc 7:3) to provide 22 mg (74 % yield) of 58b as 
a white solid. Mp 110-112 ºC. 
1
H NMR (400 MHz, MeOH-d4): δ 8.15 (s, 1H), 7.83 (d, J = 
7.6 Hz, 2H), 7.44 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 7.30-7.09 (m, 6H), 3.74 (t, J = 
7.2 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H). 
13
C NMR (101 MHz, MeOH-d4): δ 140.3, 131.2, 130.0, 
130.0, 129.9, 129.5, 129.3, 127.1, 127.0, 64.3, 40.3. IR (cm
-1
): 1450, 960, 768, 690. MS 
(ESI
+
) m/z (%) 250 (M+H). HRMS calcd. for C16H16N3: 250.1344; found: 250.1327. 
 
1-(3-Bromopropyl)-5-phenyl-1H-1,2,3-triazole (58c). The general procedure B was 
followed starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.24 mmol, 60 
mg) and 3-bromopropyl trifluoromethanesulfonate 47c (0.28 mmol, 76 mg). The product was 
purified by column chromatography (silica gel, Hex/EtOAc 7:3) to provide 33 mg (52 % 
yield) of 58c as a yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H), 7.55-7.46 (m, 3H), 
7.44-7.35 (m, 2H), 4.50 (t, J = 6.8 Hz, 2H), 3.36 (t, J = 6.3 Hz, 2H), 2.53-2.31 (m, 2H). 
13
C 
NMR (101 MHz, CDCl3): δ 138.2, 133.2, 129.7, 129.3, 128.9, 126.9, 46.5, 32.7, 29.6. IR 
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(cm
-1
): 2960, 1482, 1455, 1274, 1245, 1014, 959, 833, 763, 697. MS (ESI
+
) m/z (%) 186 
(M+H). HRMS calcd. for C11H12N3: 186.1031; found: 186.1018. 
 
1-(4-Cyanopropyl)-5-phenyl-1H-1,2,3-triazole (58d). The general procedure B was 
followed starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.50 mmol, 
130 mg) and 3-bromopropyl trifluoromethanesulfonate 47c (0.60 mmol, 163 mg). The 
product was purified by column chromatography (silica gel, Hex/EtOAc 7:3). After that, the 
resulting, 1-(3-bromopropyl)-5-phenyl-1H-1,2,3-triazole 58c (0.24 mmol, 64 mg) was 
dissolved in EtOH/H2O 7:3 (3 mL) and KCN (0.65 mmol, 43 mg) was added. The mixture 
was stirred for 45 min at 90 ºC, and then cooled down to room temperature and stirred 
overnight. The solvent was evaporated under reduced pressure, and the aqueous phase was 
extracted with EtOAc (10 mL x 3). The combined organic layers were dried over MgSO4 and 
the solvent was evaporated under reduced pressure. The product was purified by column 
chromatography (silica gel, Hex/EtOAc 1:1) to provide 36 mg (70 % yield) of 64d as a white 
solid. Mp 55-57 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H), 7.61-7.46 (m, 3H), 7.45-
7.31 (m, 2H), 4.47 (t, J = 6.6 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.22 (p, J = 6.9 Hz, 2H). 
13
C 
NMR (101 MHz, CDCl3): δ 138.2, 133.4, 129.9, 129.4, 128.8, 126.6, 118.3, 46.4, 25.8, 14.8. 
IR (cm
-1
): 1738, 1483, 1233, 964, 840, 769, 696, 537. MS (ESI
+
) m/z (%) 213 (M+H). 
HRMS calcd. for C12H13N4: 213.1140; found: 213.1134. 
 
1-(Pent-4-yn-1-yl)-5-phenyl-1H-1,2,3-triazole (58e). The general procedure B was 
followed starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.24 mmol, 60 
mg) and pent-4-yn-1-yl trifluoromethanesulfonate 47g (0.28 mmol, 61 mg). The product was 
purified by column chromatography (silica gel, Hex/EtOAc 7:3) to provide 14 mg (27 % 
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yield) of 58e as a colorless oil. 
1
H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H), 7.54-7.37 (m, 
5H), 4.47 (t, J = 7.0 Hz, 2H), 2.21 (td, J = 6.9, 2.4 Hz, 2H), 2.09 (p, J = 6.9 Hz, 2H), 1.89 (t, 
J = 2.6 Hz, 1H). 
13
C NMR (101 MHz, CDCl3): δ 133.2, 129.6, 129.2, 129.0, 127.2, 82.3, 
69.8, 61.2, 47.0, 28.8, 15.9. IR (cm
-1
): 3293, 2948, 1283, 1413, 1240, 1208, 965, 764, 697, 
637. MS (ESI
+
) m/z (%) 212 (M+H). HRMS calcd. for C13H14N3: 212.1188; found: 
212.1195. 
 
1-(3-Azidopropyl)-5-phenyl-1H-1,2,3-triazole (58f). The general procedure B was 
followed starting from 4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.12 mmol, 30 
mg) and 3-azidopropyl trifluoromethanesulfonate 47f (0.14 mmol, 32.6 mg). The product 
was purified by column chromatography (silica gel, Hex/EtOAc 1:1) to provide 11 mg (40 % 
yield) of 58f as a colorless oil. 
1
H NMR (400 MHz, CDCl3): δ 7.72 (s, 1H), 7.57-7.46 (m, 
3H), 7.45-7.34 (m, 2H), 4.44 (t, J = 6.9 Hz, 2H), 3.34 (t, J = 6.4 Hz, 2H), 2.12 (p, J = 6.7 Hz, 
2H). 
13
C NMR (101 MHz, CDCl3): δ 138.3, 133.2, 129.8, 129.4, 128.9, 126.9, 48.3, 45.5, 
29.3. IR (cm
-1
): 2094, 1482, 1455, 1238, 964, 764, 697. MS (ESI
+
) m/z (%) 229 (M+H). 
HRMS calcd. for C11H13N6: 229.1202; found: 229.1187. 
 
1-(3-Azidoethyl)-5-phenyl-1H-1,2,3-triazole (58g). The general procedure B was followed 
starting from 4-butyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 56 (1.70 mmol, 407 mg), and 
2-azidoethyl trifluoromethanesulfonate 47e (2.00 mmol, 438 mg). The product was purified 
by column chromatography (silica gel, Hex/EtOAc 1:1) to provide 198 mg (60 % yield) of 
58g as a colorless oil. 
1
H NMR (400 MHz, CDCl3): δ 7.48 (s, 1H), 4.36 (t, J = 5.9 Hz, 2H), 
3.86 (t, J = 5.9 Hz, 2H), 2.71-2.62 (m, 2H), 1.67 (p, J = 7.5 Hz, 2H), 1.43 (dq, J = 14.6, 7.4 
Hz, 2H), 0.97 (t, J = 7.3 Hz, 3H). 
13
C NMR (101 MHz, CDCl3): δ 137.7, 131.2, 50.1, 46.0, 
29.5, 22.1, 21.6, 13.1. IR (cm
-1
): 2958, 2933, 2097, 1455, 1286, 1237, 827. MS (ESI
+
) m/z 
(%) 195 (M+H). HRMS calcd. for C18H15N6: 195.1358; found: 195.1360. 
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3.4 Synthesis of 1,4- and 1,5-substituted bistriazoles  
 
5-Phenyl-1-[3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl]-1H-1,2,3-triazole (59). The general 
procedure 3.2 was followed starting from 1-(3-azidopropyl)-5-phenyl-1H-1,2,3-triazole 58f 
(0.07 mmol, 16.5 mg) and phenylacetylene (0.09 mmol, 10 µL) to provide 22 mg (99 % 
yield) of 59 as a white solid. Mp 113-115 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.84-7.74 (m, 
3H), 7.71 (s, 1H), 7.49-7.24 (m, 8H), 4.44 (t, J = 6.2 Hz, 2H), 4.41-4.33 (m, 2H), 2.59-2.42 
(m, 2H). 
13
C NMR (101 MHz, CDCl3): δ 173.0, 147.8, 130.4, 129.9, 129.4, 128.9, 128.7, 
128.3, 126.5, 125.8, 120.6, 47.1, 44.9, 30.3, 22.7. IR (cm
-1
): 764, 696. MS (ESI
+
) m/z (%) 
331 (M+H). HRMS calcd. for C19H19N6: 331.1671; found: 331.1664. 
 
1-[2-(5-Butyl-1H-1,2,3-triazol-1-yl)ethyl]-4-hydroxymethyl-1H-1,2,3-triazole (60). The 
general procedure 3.2 was followed starting from 1-(2-azidoethyl)-5-butyl-1H-1,2,3-triazole 
58g (1.87 mmol, 364 mg) and propargyl alcohol (2.10 mmol, 0.12 mL) to provide 415 mg 
(89 % yield) of 60 as a yellowish oil. 
1
H NMR (400 MHz, CDCl3): δ 7.35 (s, 1H), 7.26 (s, 
1H), 5.03 (s, 1H), 4.85 (t, J = 5.9 Hz, 2H), 4.65 (t, J = 5.9 Hz, 2H), 4.56 (s, 2H), 2.21 (t, J = 
7.8 Hz, 2H), 1.37 (p, J = 7.9, 7.3 Hz, 2H), 1.26-1.13 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H). 
13
C 
NMR (101 MHz, CDCl3): δ 148.1, 138.3, 131.5, 123.1, 55.4, 49.0, 46.8, 29.5, 21.8, 21.8, 
13.3. IR (cm
-1
): 3346, 2931, 1667, 1455, 1236, 1039, 823, 765. MS (ESI
+
) m/z (%) 251 
(M+H). HRMS calcd. for C11H19N6O: 251.1620; found: 251.1623. 
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1,1’-[Di(pivaloyloxymethyl)]-4,4’-bis(1H-1,2,3-triazole) (62). KOH (4.30 g, 65.00 mmol), 
water (10 mL), and DMSO (2.5 mL) were heated to 75 °C for 30 min in a three-necked flask 
equipped with a condenser and a dropping funnel. The top of the condenser was connected 
via a tube to a trap containing dry THF, which was cooled to -20 °C. 1,4-dichloro-2-butyne 
(1.60 mL, 16 mmol) was added dropwise over a period of 30 min, while the temperature was 
maintained at 75 °C. A stream of argon was passed through the apparatus, which forced the 
butadiyne into the cold THF trap. The tube was extracted, and azidomethyl pivalate 54 (1.02 
g, 6.60 mmol), sodium acetate (1.60 g, 19.80 mmol) and CuOAc (240 mg, 1.32 mmol) were 
added at ambient temperature for 4 hours. The solution was filtered through a celite pad, and 
the solvents were evaporated under reduced pressure. The crude product was purified by 
column chromatography (silica gel, Hex/EtOAc 7:3) to provide 1.06 g (85 % yield) of 62 as 
a white solid. Mp 201-203 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.01 (s, 2H), 6.26 (s, 4H), 1.20 
(s, 18H). 
13
C NMR (126 MHz, CDCl3): δ 177.6, 140.3, 122.2, 69.9, 38.9, 26.9. IR (cm-1): 
2971, 1731, 1279, 1144, 1057, 828. MS (ESI
+
) m/z (%) 365 (M+H). HRMS calcd. for 
C16H25N6O4: 365.1937; found: 365.1950. 
 
1,1’-Dimethyl-5,5’-bis(1,2,3-triazole) (40). The general procedure 3.3.A was followed 
starting from 1,1’-[di(pivaloyloxymethyl)]-4,4’-bis(1H-1,2,3-triazole) 62 (0.22 mmol, 
80 mg) and MeOTf (1.2 mmol, 160 µL) to provide 22 mg (61 % yield) of 40 as a white solid. 
Mp 140-142 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.89 (s, 2H), 4.07 (s, 6H). 
13
C NMR (101 
MHz, CDCl3): δ 134.5, 124.7, 35.8. IR (cm-1): 3133, 1664, 1452, 1252, 1149, 1024, 954, 
858, 679. MS (ESI
+
) m/z (%) 165 (M+H). HRMS calcd. for C6H9N6: 165.0889; found: 
165.0892. 
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1-Benzyl-1’-methyl-4,5’-bis(1H-1,2,3-triazole) (39a). A solution of 4-ethynyl-1-
(pivaloyloxymethyl)-1H-1,2,3-triazole 61 (0.24 mmol, 50 mg) and MeOTf (0.36 mmol, 41 
µL) in CH2Cl2 (2.50 mL) was stirred under nitrogen atmosphere at room temperature for 
1 hour and, on completion, the solvent was removed under reduced pressure. Then, 
benzylazide (0.24 mmol, 32 mg), CuSO4·5H2O (0.05 mmol, 12 mg), sodium ascorbate (0.10 
mmol, 19 mg) and NaOAc (0.24 mmol, 20 mg) in THF/tBuOH/H2O 1:1:1 (2 mL) were 
added and the mixture was stirred at ambient temperature for 18 hours. Finally, the volatiles 
were removed under reduced pressure, the crude product was dissolved in MeOH (2.50 mL) 
and K2CO3 (0.48 mmol, 66 mg) was added. The resulting mixture was stirred at ambient 
temperature for 3 hours. The solvents were removed under reduced pressure to provide 
43.5 mg (75 % yield) of 39a as a yellow solid. Mp 113-115 ºC. 
1
H NMR (400 MHz, CDCl3): 
δ 7.79 (s, 1H), 7.75 (s, 1H), 7.46-7.23 (m, 5H), 5.58 (s, 2H), 4.30 (s, 3H). 13C NMR (101 
MHz, CDCl3): δ 136.1, 134.0, 132.5, 129.3, 129.2, 128.5, 128.3, 122.2, 54.5, 37.0. IR (cm
-1
): 
3079, 1426, 1243, 1025, 827, 731. MS (ESI
+
) m/z (%) 241 (M+H). HRMS calcd. for 
C6H9N6: 241.1202; found: 241.1203. 
 
1-Methyl-1’-phenyl-5,4’-bis(1,2,3-triazole) (39b). A solution of 4-ethynyl-1-
(pivaloyloxymethyl)-1H-1,2,3-triazole 61 (0.24 mmol, 50 mg) and MeOTf (0.36 mmol, 41 
µL) in CH2Cl2 (2.50 mL) was stirred under nitrogen atmosphere at ambient temperature for 1 
hour. After that, the solvent was removed under reduced pressure. Then, phenylazide (0.24 
mmol, 29 mg), CuSO4·5H2O (0.05 mmol, 12 mg), sodium ascorbate (0.10 mmol, 19 mg) and 
NaOAc (0.24 mmol, 20 mg) in THF/tBuOH/H2O 1:1:1 (2 mL) were added and the mixture 
was stirred at ambient temperature for 18 hours. Finally, the volatiles were removed under 
reduced pressure, the crude product was dissolved in MeOH (2.50 mL) and K2CO3 (0.48 
mmol, 66 mg) was added. The resulting mixture was stirred at ambient temperature for 
3 hours. The solvents were removed under reduced pressure to provide 54 mg (99 % yield) 
of 39b as a white solid. Mp 129-130 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.38 (s, 1H), 7.90 (s, 
1H), 7.76 (d, J = 7.8 Hz, 2H), 7.52 (t, J = 7.7 Hz, 2H), 7.46 (d, J = 7.2 Hz, 1H), 4.35 (s, 3H). 
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13
C NMR (101 MHz, CDCl3): δ 136.1, 136.0, 129.5, 128.9, 120.7, 120.2, 116.4, 36.8. IR 
(cm
-1
): 3119, 2962, 2920, 1599, 1509, 1458, 1418, 1248, 1176, 1030 749. MS (ESI
+
) m/z 
(%) 227 (M+H). HRMS calcd. for C11H11N6: 227.1045; found: 227.1040. 
 
1-Benzyl-1’-[2-(2,4,6-triiodophenoxy)ethyl]-5,4’-bis(1,2,3-triazole) (39c). To a solution of 
4-ethynyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazole 61 (0.29 mmol, 60 mg) in CH2Cl2 (0.50 
mL), 2-(2,4,6-triiodophenoxy)ethyl trifluoromethanesulfonate 53a (0.35 mmol, 225 mg) was 
added and evaporated under reduced pressure. After 18 hours at 30 ºC, benzylazide (0.29 
mmol, 39 mg), CuSO4·5H2O (0.06 mmol, 14 mg), sodium ascorbate (0.12 mmol, 23 mg) and 
NaOAc (0.29 mmol, 24 mg) in THF/tBuOH/H2O 1:1:1 (2 mL) were added and the mixture 
was stirred at ambient temperature for 18 hours. Finally, the volatiles were removed under 
reduced pressure, the crude product was dissolved in MeOH (3.00 mL) and K2CO3 (0.6 
mmol, 80 mg) was added. The resulting mixture was stirred at ambient temperature for 
3 hours. The solvents were removed under reduced pressure and the crude product was 
purified by column chromatography (silica gel, Hex/EtOAc 7/3) to provide 166 mg (79 % 
yield) of 39c as a white solid. Mp 75-76 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.96-7.90 (m, 
3H), 7.85 (s, 1H), 7.35-7.23 (m, 5H), 5.57 (s, 2H), 5.13 (t, J = 5.2 Hz, 2H), 4.36 (t, J = 5.1 
Hz, 2H). 
13
C NMR (101 MHz, CDCl3): δ 156.6, 147.3, 135.9, 134.1, 132.8, 129.3, 129.1, 
128.2, 122.9, 91.8, 90.0, 71.1, 54.5, 48.9. IR (cm
-1
): 3123, 1425, 1229, 1045, 717, 695. MS 
(ESI
+
) m/z (%) 725 (M+H). HRMS calcd. for C19H16N6OI3: 724.8520; found: 724.8529. 
3.5 Synthesis of 1,4,5-trisubstituted-1H-1,2,3-triazoles 
 
1-Methyl-5-phenyl-1H-1,2,3-triazole-4-d (64). To a solution of 4-phenyl-1-
(pivaloyloxymethyl) 1H-1,2,3-triazole 55 (0.18 mmol, 48 mg) and MeOTf (0.20 mmol, 22 
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µL) in CDCl3 (2.50 mL) was stirred under nitrogen atmosphere at ambient temperature for 
18 hours. The volatiles were removed under reduced pressure. The crude was dissolved in 
MeOH-d4 (2.50 mL) and K2CO3 (0.15 mmol, 21 mg) was added. The mixture was stirred at 
ambient temperature for 5 hours. The solvents were removed under reduced pressure and the 
crude product was dissolved in CH2Cl2 and filtered through a PTFE filter to provide 9 mg 
(75 % yield) of 64 as a colorless oil. 
1
H NMR (400 MHz, CDCl3): δ 7.54 (m, 5H), 4.10 (s, 
3H). 
13
C NMR (101 MHz, CDCl3): δ 139.9, 130.7, 130.2, 129.8, 127.9, 127.0, 36.1. IR (cm
-
1
): 2933, 1460, 1259, 1028, 772. MS (ESI
+
) m/z (%) 161 (M+H). HRMS calcd. for 
C9H9DN3: 161.0937; found: 161.0929. 
 
4-Iodo-1-methyl-5-phenyl-1H-1,2,3-triazole (65). To a solution of 4-phenyl-1-
(pivaloyloxymethyl)-1H-1,2,3-triazole 55 (0.40 mmol, 104 mg) in CH2Cl2 (2 mL), MeOTf 
(0.44 mmol, 50 µL) was added and the mixture was stirred for 5 hours at ambient 
temperature. Then, triflate exchange was carried out by using an anion exchange resin (I
-
form) following a procedure reported in the literature,
179
 and using MeCN as solvent. After 
that, a mixture of 3-methyl-4-phenyl-1-(pivaloyloxymethyl)-1H-1,2,3-triazolium iodide, 
Ag2O (0.24 mmol, 48 mg) and cyanogen halide (0.80 mmol, 122 mg) in CH2Cl2/MeCN 1:1 
(3 mL) was stirred at ambient temperature for 6 hours. The mixture was filtered through a 
celite/silice 1:1 pad which was successively washed with CH2Cl2 and MeCN. Finally, the 
product was dissolved in MeOH (2 mL) and K2CO3 (0.80 mmol, 110 mg) was added. The 
mixture was stirred at ambient temperature for 5 hours. The solvents were removed under 
reduced pressure and the product was purified by column chromatography (silica gel, 
Hex/EtOAc 1:1) to provide 114 mg (99 % yield) of 65 as a yellowish solid. Mp 122-124 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.54-7.47 (m, 3H), 7.40-7.33 (m, 2H), 3.99 (s, 3H). 
13
C NMR 
(101 MHz, CDCl3): δ 140.2, 130.1, 129.6, 129.1, 126.0, 89.7, 36.3. IR (cm
-1
): 2949, 1481, 
1449, 1258, 1031, 980, 772, 697, 542. MS (ESI
+
) m/z (%) 286 (M+H). HRMS calcd. for 
C9H9N3I: 285.9841; found: 285.9833. 
                                                          
179  Dinarès, I.; Mesquida, N.; Ibáñez, A.; Alcalde, E. Arkivoc 2014, ii, 85. 
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5-Butyl-4-iodo-1-[2-(2,4,6-triiodophenoxy]ethyl-1H-1,2,3-triazole (67). The general 
procedure 3.3.B was followed starting from 4-butyl-5-iodo-1-(pivaloyloxymethyl)-1H-1,2,3-
triazole 66 (0.24 mmol, 60 mg) and 2-(2,4,6-triiodophenoxy)ethyl trifluoromethanesulfonate 
47a (0.29 mmol, 187 mg). The product was purified by column chromatography (silica gel, 
Hex/EtOAc 1:1) to provide 192 mg (64 % yield) of 67 as a white solid. Mp 123-124 ºC.      
1
H NMR (400 MHz, CDCl3): δ 8.00 (s, 2H), 4.76 (t, J = 5.2 Hz, 2H), 4.32 (t, J = 5.1 Hz, 2H), 
2.85-2.76 (m, 2H), 1.61 (p, J = 7.7 Hz, 2H), 1.40 (q, J = 7.3 Hz, 2H), 0.94 (t, J = 7.2 Hz, 
3H). 
13
C NMR (101 MHz, CDCl3): δ 156.5, 147.4, 141.4, 91.8, 90.3, 89.4, 71.0, 48.4, 30.6, 
23.4, 22.5. IR (cm
-1
): 2923, 1524, 1462, 1423, 1377, 1220, 1028, 1005, 852, 651. MS (ESI
+
) 
m/z (%) 750 (M+H). HRMS calcd. for C14H16N3OI4: 749.7472; found: 749.7486. 
3.6 Computational calculations 
3.6.1 Computational methods 
Density functional theory calculations were performed by use of Gamess 5 DEC 
2014 (R1) from Iowa State University suite of programs.
180
  Full geometry optimizations and 
harmonic analyses were carried out by use of the B3LYP hybrid functional [39] and the 6-
31G* basis set. Solvent effects were computed by the C-PCM solvation model (MeCN, ε = 
35.68) (MeOH ε = 32.63) and Grimme empirical dipersion DFTD3 v1.2181 Free energies 
were computed at 298.15 K. The charges of compound D,E were obtained using NBO6.0 
software.
182
                                                          
180  Schmidt, M. W.;  Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, 
S.; Matsunaga, N.; Nguyen, K. A.; Su, S. J.; Windus T. L.; Together with Dupuis, M.; Montgomery 
J. A. J. Comput.Chem. 1993, 14, 1347. 
181  Grimme, S.; Antony, J.; Ehrlich S.; Krieg, H. J. Chem. Phys 2010, 132, 154104. 
182  NBO 6.0. Glendening, E. D.; Badenhoop, J. K.; Reed, A. E.; Carpenter, J. E.; Bohmann, J. A.; 
Morales, C. M.; Landis, C. R.; Weinhold F. Theoretical Chemistry Institute University of 
Wisconsin, Madison, WI, 2013. 
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3.6.2 Electronic energies and cartesian coordinates for structures D and E NBO 
charges 
 
E(R-B3LYP)= -395.8693148 
 
N    -3.52800   0.90638   1.87401 
C    -3.85657   0.85272   0.54402 
C    -4.93113   1.70737  -0.05106 
H    -5.91839   1.43181   0.33867 
H    -4.95377   1.60035  -1.13939 
H    -4.76586   2.76402   0.18775 
C    -3.04633  -0.09140  -0.05104 
N    -2.27133  -0.56833   0.95692 
N    -2.56603   0.05412   2.11937 
H    -2.96325  -0.44897  -1.06631 
C    -1.15900  -1.51408   0.88944 
O    -0.01363  -0.95527   0.30064 
H    -1.46134  -2.35383   0.26134 
H    -0.99553  -1.85539   1.91677 
H     0.35598  -0.30174   0.91838 
 
 
E(R-B3LYP)=  -435.6024226 
 
C    -4.56044   1.30706   2.96381 
N    -3.76700   0.67755   1.90367 
H    -4.47477   2.39078   2.86902 
H    -4.15525   0.97898   3.91935 
H    -5.60220   0.99501   2.86177 
C    -3.91180   0.84224   0.55268 
C    -4.92635   1.73797  -0.06704 
H    -5.93787   1.47245   0.25852 
H    -4.87778   1.65445  -1.15422 
H    -4.74048   2.78188   0.20988 
C    -2.92977   0.04507   0.00622 
N    -2.29154  -0.52408   1.05982 
N    -2.78656  -0.14939   2.21969 
H    -2.64478  -0.13562  -1.01785 
C    -1.15022  -1.49053   1.00459 
O    -0.22247  -1.08314   0.06131 
H    -1.56155  -2.44690   0.67772 
H    -0.77862  -1.56128   2.03041 
H     0.31934  -0.36279   0.42695 
 
E(R-B3LYP)=  -346.3516447 
 
C    -3.43321   1.02169  -0.03115 
C    -1.89356   0.99968  -0.03257 
C    -3.91898   2.12996   0.92152 
C    -3.97164  -0.33788   0.43133 
C    -3.93344   1.37269  -1.47884 
H    -3.57523   1.94985   1.95010 
H    -5.01638   2.17946   0.94023 
H    -3.54167   3.10174   0.58877 
H    -1.49711   0.82134   0.97730 
H    -1.50548   1.95449  -0.40022 
H    -1.51129   0.20339  -0.68555 
H    -3.61350  -0.58312   1.44145 
H    -3.65338  -1.13066  -0.25373 
H    -5.06668  -0.33893   0.44070 
O    -4.70135   0.54877  -2.04592 
O    -3.52873   2.47474  -1.94915 
 
 
E(R-B3LYP)=  -280.9080632 
 
C    -8.03373   1.16105  -0.04309 
C    -6.74744   0.68841   0.20185 
C    -9.34640   0.43119  -0.02589 
H    -9.76437   0.29747  -1.03412 
H   -10.10230   0.96855   0.56179 
H    -9.23091  -0.56662   0.41318 
N    -7.92439   2.48157  -0.33173 
N    -6.61562   2.79844  -0.25960 
N    -5.87883   1.71987   0.06056 
H    -6.41881  -0.31162   0.46556 
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E(R-B3LYP)=  -666.3245292 
 
N    -3.61447   1.15351   1.68237 
C    -3.94243   0.90750   0.37252 
C    -5.06986   1.61110  -0.31456 
H    -6.04014   1.27244   0.06852 
H    -5.04653   1.42411  -1.39194 
H    -5.00920   2.69240  -0.14985 
C    -3.08065  -0.05673  -0.10129 
N    -2.27242  -0.34618   0.95426 
N    -2.60332   0.40476   2.03076 
H    -2.97846  -0.54401  -1.05896 
C    -1.14052  -1.24636   0.99429 
O    -0.08555  -0.76819   0.15909 
H    -1.42347  -2.21522   0.58558 
H    -0.82501  -1.32960   2.03377 
C     0.74815   0.17607   0.69694 
O     0.65782   0.54120   1.84876 
C     1.73644   0.70036  -0.34036 
C     0.93120   1.53016  -1.36876 
C     2.43955  -0.47722  -1.04954 
C     2.76936   1.59031   0.36944 
H     0.18173   0.91396  -1.87522 
H     1.61639   1.93377  -2.12233 
H     0.42187   2.37147  -0.88472 
H     2.28504   2.43328   0.87133 
H     3.48153   1.98382  -0.36384 
H     3.32586   1.02160   1.12186 
H     1.72287  -1.10960  -1.58074 
H     2.98668  -1.10057  -0.33283 
H     3.15871  -0.08323  -1.77599 
 
  
 
E(R-B3LYP)=  -75.8256250 
 
O    -6.46996   2.62939   0.00000 
H    -5.49344   2.62939   0.00000 
 
 
 
 
  
 
E(R-B3LYP)= -706.0548936 
 
C    -4.44729   1.42405   2.90879 
N    -3.74346   0.75165   1.81261 
H    -4.23541   2.49442   2.85661 
H    -4.07852   1.01091   3.84619 
H    -5.51923   1.24621   2.80772 
C    -3.96565   0.90804   0.46951 
C    -5.02890   1.78291  -0.09499 
H    -6.01645   1.48874   0.27646 
H    -5.03209   1.70446  -1.18343 
H    -4.85594   2.82973   0.17906 
C    -3.01111   0.11392  -0.12595 
N    -2.31166  -0.44669   0.89566 
N    -2.74267  -0.06209   2.08046 
H    -2.78680  -0.06388  -1.16588 
C    -1.17336  -1.38007   0.79890 
O    -0.15950  -0.81174   0.00409 
H    -1.50834  -2.27927   0.28596 
H    -0.85308  -1.58739   1.81971 
C     0.62549   0.15077   0.61490 
O     0.44008   0.47569   1.76412 
C     1.67292   0.69765  -0.34508 
C     0.95018   1.29289  -1.57576 
C     2.59930  -0.45850  -0.78583 
C     2.48095   1.78583   0.37911 
H     0.39434   0.52511  -2.12167 
H     1.69299   1.72719  -2.25370 
H     0.25541   2.08811  -1.28174 
H     1.83155   2.59854   0.71972 
H     3.22684   2.20221  -0.30604 
H     3.00133   1.37699   1.25107 
H     2.04014  -1.24224  -1.30526 
H     3.11045  -0.90641   0.07389 
H     3.36067  -0.06565  -1.46869 
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E(R-B3LYP)=  -320.6871625 
 
C    -8.02575   1.15772   0.07805 
C    -6.73160   0.67121   0.09182 
C    -9.35712   0.50156   0.23026 
H    -9.98632   0.65762  -0.65464 
H    -9.90242   0.89415   1.09753 
H    -9.22758  -0.57455   0.36984 
N    -7.85948   2.49224  -0.12226 
N    -6.54881   2.81361  -0.22723 
N    -5.86385   1.70315  -0.09589 
H    -6.39464  -0.34781   0.22380 
C    -8.88824   3.51617  -0.22786 
H    -9.52098   3.32780  -1.09997 
H    -8.38955   4.47931  -0.33824 
H    -9.50542   3.52260   0.67478 
 
  
 
E(R-B3LYP)=  -461.3095115 
 
O    -4.90632   0.35947  -0.14724 
C    -4.83780   1.59135   0.49083 
O    -3.51795   2.19555   0.39692 
H    -5.09854   1.53340   1.55316 
H    -5.48894   2.28688  -0.03754 
C    -2.54622   1.56311   1.08952 
O    -2.75122   0.52378   1.69712 
C    -1.20628   2.29268   1.00877 
C    -1.38134   3.71187   1.59456 
C    -0.78501   2.38587  -0.47502 
C    -0.15846   1.50960   1.81301 
H    -2.12143   4.28497   1.02859 
H    -0.42464   4.24560   1.55596 
H    -1.70328   3.67010   2.64189 
H    -0.43765   1.44842   2.86985 
H     0.81118   2.01478   1.74148 
H    -0.04736   0.48946   1.43200 
H    -1.52220   2.94198  -1.06135 
H    -0.67070   1.38939  -0.91794 
H     0.17892   2.90245  -0.54915 
H    -4.42910  -0.27002   0.42288 
 
 
 
  
 
E(R-B3LYP)=  -742.1496967 
Freq= -564.970 
 
N    -0.35275   2.09125  -1.65515 
C    -0.93499   1.47305  -2.72832 
C    -2.14591   2.02047  -3.41807 
H    -3.04178   1.92231  -2.79225 
H    -2.33034   1.48703  -4.35538 
H    -2.01990   3.08479  -3.64658 
C    -0.21621   0.32474  -2.99240 
N     0.75980   0.30514  -2.05478 
N     0.67686   1.38094  -1.25236 
H    -0.31505  -0.44647  -3.74036 
C     1.80677  -0.63270  -1.90024 
O     2.97895   0.13847  -2.96170 
H     1.73083  -1.53647  -2.47129 
H     2.35756  -0.56857  -0.98162 
C     4.00731   0.70755  -2.38347 
O     4.26377   0.65776  -1.17679 
C     4.91714   1.46207  -3.38294 
C     4.07642   2.52962  -4.11363 
C     5.46512   0.44543  -4.40641 
C     6.07657   2.13130  -2.63133 
H     3.23622   2.06876  -4.64004 
H     4.69619   3.06393  -4.84465 
H     3.67709   3.26691  -3.40661 
H     5.70188   2.84628  -1.89195 
H     6.72283   2.66671  -3.33777 
H     6.68108   1.38928  -2.10040 
H     4.64700  -0.05473  -4.93339 
H     6.09654   0.95399  -5.14563 
O     0.45386  -1.84423  -0.73324 
H     6.07450  -0.32169  -3.91243 
H     1.13375  -2.37718  -0.28288 
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E(R-B3LYP)=  -742.1393969 
Freq= -584.592 
 
O    -1.65442   2.73367   0.65321 
N     1.65517   0.68671   0.24845 
C     0.02627   1.55272   0.46757 
C     3.37190  -0.65775   0.11352 
C     4.32845  -1.81127   0.18329 
H     4.91835  -1.88795  -0.73749 
H     3.79267  -2.75605   0.32429 
H     5.03689  -1.70564   1.01593 
C     2.05135  -0.57202   0.53551 
N     2.65577   1.35753  -0.32002 
H     1.39136  -1.29357   0.99510 
C    -1.41250  -0.08438  -0.39079 
O    -1.18096   0.24535  -1.53710 
C    -2.57330  -0.96931   0.04889 
C    -3.74659   0.03739   0.21375 
C    -2.29393  -1.67660   1.38665 
C    -2.89133  -1.99870  -1.04620 
H    -3.40514   0.92646   0.75784 
H    -4.57613  -0.43881   0.74896 
H    -4.10835   0.36446  -0.76786 
H    -3.02594  -1.50828  -2.01444 
H    -3.81413  -2.53281  -0.79362 
H    -2.08516  -2.73589  -1.14303 
H    -2.15780  -0.95898   2.19952 
H    -3.14241  -2.32422   1.63643 
H    -1.39571  -2.30264   1.32650 
H    -2.01446   2.60706  -0.24064 
N     3.71545   0.55006  -0.41069 
H     0.31464   2.06812   1.36392 
H     0.09807   1.99741  -0.50714 
O    -0.73108   0.40570   0.67404 
 
 
 
 
 
 
 
 
 
 
 
 
 
E(R-B3LYP)=  -781.9102850 
 
C    -5.23442   1.01341   2.69764 
N    -3.99719   1.13000   1.93633 
H    -5.99119   1.66410   2.26045 
H    -5.05173   1.30280   3.73408 
H    -5.50699  -0.04622   2.62699 
C    -3.85838   1.45714   0.60262 
C    -4.89203   2.18806  -0.18388 
H    -5.82414   1.61436  -0.24180 
H    -4.53073   2.35678  -1.20097 
H    -5.11959   3.16090   0.26666 
C    -2.62025   0.99404   0.25637 
N    -2.09222   0.43941   1.39724 
N    -2.98067   0.40487   2.37753 
H    -2.07529   1.04037  -0.67216 
C    -1.08452  -0.62397   1.45928 
O    -0.13374  -0.44315   0.43204 
H    -1.64942  -1.54616   1.28400 
H    -0.63107  -0.60022   2.45083 
C     0.86894   0.46670   0.67682 
O     0.94031   1.07779   1.71887 
C     1.80938   0.58643  -0.51722 
C     0.99335   1.09825  -1.72745 
C     2.40608  -0.80314  -0.83577 
C     2.92497   1.58203  -0.16617 
H     0.20509   0.39080  -2.00316 
H     1.66013   1.22176  -2.58782 
H     0.53417   2.07094  -1.51357 
H     2.51381   2.56861   0.07014 
H     3.60737   1.68514  -1.01691 
H     3.50019   1.23846   0.69951 
H     1.62312  -1.52369  -1.08792 
H     2.97653  -1.19251   0.01538 
H     3.08673  -0.71626  -1.69010 
O    -3.89608  -1.66590   1.72784 
H    -3.73674  -1.93041   2.64911 
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E(R-B3LYP)=  -857.7509630 
Freq= -569.53 
 
C    -3.92947   1.87696   2.67785 
N    -3.28536   1.11945   1.61120 
H    -4.59647   2.61804   2.23654 
H    -3.16096   2.37385   3.27352 
H    -4.45975   1.06362   3.24701 
C    -3.75295   0.87918   0.34907 
C    -4.81732   1.68358  -0.31572 
H    -5.78759   1.53913   0.17222 
H    -4.91105   1.38037  -1.36101 
H    -4.57808   2.75221  -0.28655 
C    -3.02790  -0.20383  -0.09002 
N    -2.21774  -0.54917   0.94514 
N    -2.35542   0.24985   1.98228 
H    -3.02925  -0.73532  -1.02733 
C    -1.27181  -1.61570   0.98156 
O    -0.03432  -0.87490   0.03083 
H    -1.44011  -2.41970   0.29128 
C     0.74043  -0.00878   0.65050 
O     0.73894   0.18277   1.86630 
C     1.66363   0.76906  -0.31351 
C     0.79840   1.41431  -1.41612 
C     2.65864  -0.22643  -0.94669 
C     2.42189   1.85419   0.46359 
H     0.26318   0.65121  -1.98741 
H     1.43189   1.98946  -2.10266 
H     0.05749   2.09976  -0.98561 
H     1.72589   2.56535   0.92127 
H     3.08778   2.40663  -0.21073 
H     3.02545   1.41578   1.26441 
H     2.12975  -1.01909  -1.48484 
H     3.28917  -0.69284  -0.17967 
H     3.31614   0.29520  -1.65337 
O    -4.79002  -0.77999   3.46916 
H    -3.86111  -0.93693   3.70348 
O    -2.79651  -2.70420   1.95647 
H    -3.47427  -2.06964   2.26145 
H    -0.76966  -1.75116   1.91891 
 
 
 
E(R-B3LYP)=  -857.7460529 
Freq= -576.08 
 
C    -4.64183   0.80303   3.27476 
N    -3.77806   0.66853   2.10750 
H    -4.87291   1.86412   3.40254 
H    -4.06973   0.45735   4.13886 
H    -5.61121   0.16439   3.16316 
C    -3.85205   1.35684   0.93005 
C    -4.79730   2.48450   0.68890 
H    -5.83624   2.17246   0.83976 
H    -4.68914   2.84636  -0.33642 
H    -4.59616   3.32013   1.37029 
C    -2.88718   0.77268   0.13054 
N    -2.31232  -0.20684   0.86432 
N    -2.84574  -0.28511   2.06403 
H    -2.57141   0.98656  -0.87868 
C     0.42315   0.04640  -0.80712 
O    -0.32460   0.05965  -1.76305 
C     1.85118   0.57565  -0.77206 
C     2.21747   1.10862  -2.16518 
C     2.77880  -0.59973  -0.37883 
C     1.94822   1.70542   0.27725 
H     2.17811   0.31161  -2.91475 
H     3.23376   1.51711  -2.14665 
H     1.52973   1.90111  -2.47730 
H     1.30205   2.55047   0.01191 
H     2.98111   2.06859   0.32699 
H     1.66088   1.34707   1.27023 
H     2.52576  -1.50175  -0.94547 
H     2.66888  -0.84066   0.68288 
H     3.82280  -0.32439  -0.56636 
O    -6.91727  -0.84494   3.24762 
H    -6.35391  -1.46759   3.74070 
O     0.33229  -2.91078  -0.23370 
H     1.04243  -2.69205   0.38991 
C    -1.00750  -1.34740   0.39953 
H    -1.43213  -1.64630  -0.54077 
H    -1.08216  -1.96527   1.27598 
O     0.05797  -0.46163   0.40519 
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APPENDIX: 
1
H NMR and 
13
C NMR Spectra 
 
 
Spectrum 3.1. 1H NMR (400 MHz, CDCl3) spectrum of compound 47a. 
 
 
Spectrum 3.2. 13C NMR (101 MHz, CDCl3) spectrum of compound 47a. 
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Spectrum 3.3. 1H NMR (400 MHz, CDCl3) spectrum of compound 56. 
 
 
Spectrum 3.4. 13C NMR (101 MHz, CDCl3) spectrum of compound 56. 
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Spectrum 3.5. 1H NMR (400 MHz, CDCl3) spectrum of compound 61. 
 
 
Spectrum 3.6. 13C NMR (126 MHz, CDCl3) spectrum of compound 61. 
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Spectrum 3.7. 1H NMR (400 MHz, CDCl3) spectrum of compound 66. 
 
 
Spectrum 3.8. 13C NMR (101 MHz, CDCl3) spectrum of compound 66. 
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Spectrum 3.9. 1H NMR (400 MHz, CDCl3) spectrum of compound 53. 
 
 
Spectrum 3.10. 13C NMR (101 MHz, CDCl3) spectrum of compound 53. 
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Spectrum 3.11. 1H NMR (400 MHz, CDCl3) spectrum of compound 57. 
 
 
Spectrum 3.12. 13C NMR (101 MHz, CDCl3) spectrum of compound 57. 
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Spectrum 3.13. 1H NMR (400 MHz, CDCl3) spectrum of compound 58a. 
 
 
Spectrum 3.14. 13C NMR (101 MHz, CDCl3) spectrum of compound 58a. 
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Spectrum 3.15. 1H NMR (400 MHz, MeOH-d4) spectrum of compound 58b. 
 
 
Spectrum 3.16. 13C NMR (101 MHz, MeOH-d4) spectrum of compound 58b. 
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Spectrum 3.17. 1H NMR (400 MHz, CDCl3) spectrum of compound 58c. 
 
 
Spectrum 3.18. 13C NMR (101 MHz, CDCl3) spectrum of compound 58c. 
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Spectrum 3.19. 1H NMR (400 MHz, CDCl3) spectrum of compound 58d. 
 
 
Spectrum 3.20. 13C NMR (101 MHz, CDCl3) spectrum of compound 58d. 
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Spectrum 3.21. 1H NMR (400 MHz, CDCl3) spectrum of compound 58e. 
 
 
Spectrum 3.22. 13C NMR (101 MHz, CDCl3) spectrum of compound 58e. 
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Spectrum 3.23. 1H NMR (400 MHz, CDCl3) spectrum of compound 58f. 
 
 
Spectrum 3.24. 13C NMR (101 MHz, CDCl3) spectrum of compound 58f. 
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Spectrum 3.25. 1H NMR (400 MHz, CDCl3) spectrum of compound 58g. 
 
 
Spectrum 3.26. 13C NMR (101 MHz, CDCl3) spectrum of compound 58g. 
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Spectrum 3.27. 1H NMR (400 MHz, CDCl3) spectrum of compound 59. 
 
 
Spectrum 3.28. 13C NMR (101 MHz, CDCl3) spectrum of compound 59. 
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Spectrum 3.29. 1H NMR (400 MHz, CDCl3) spectrum of compound 60. 
 
 
Spectrum 3.30. 13C NMR (101 MHz, CDCl3) spectrum of compound 60. 
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Spectrum 3.31. 1H NMR (400 MHz, CDCl3) spectrum of compound 62. 
 
 
Spectrum 3.32. 13C NMR (126 MHz, CDCl3) spectrum of compound 62. 
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Spectrum 3.33. 1H NMR (400 MHz, CDCl3) spectrum of compound 40. 
 
 
Spectrum 3.34. 13C NMR (101 MHz, CDCl3) spectrum of compound 40. 
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Spectrum 3.35. 1H NMR (400 MHz, CDCl3) spectrum of compound 39a. 
 
Spectrum 3.36. 13C NMR (101 MHz, CDCl3) spectrum of compound 39a. 
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Spectrum 3.37. 1H NMR (400 MHz, CDCl3) spectrum of compound 39b. 
 
 
Spectrum 3.38. 13C NMR (101 MHz, CDCl3) spectrum of compound 39b. 
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Spectrum 3.39. 
1
H NMR (400 MHz, CDCl3) spectrum of compound 39c. 
 
Spectrum 3.40. 13C NMR (101 MHz, CDCl3) spectrum of compound 39c. 
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Spectrum 3.41. 1H NMR (400 MHz, CDCl3) spectrum of compound 64. 
 
 
Spectrum 3.42. 13C NMR (101 MHz, CDCl3) spectrum of compound 64. 
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Spectrum 3.43. 1H NMR (400 MHz, CDCl3) spectrum of compound 65. 
 
 
Spectrum 3.44. 13C NMR (101 MHz, CDCl3) spectrum of compound 65. 
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Spectrum 3.45. 1H NMR (400 MHz, CDCl3) spectrum of compound 67. 
 
Spectrum 3.46. 13C NMR (101 MHz, CDCl3) spectrum of compound 67. 
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4. Triazoles as directing groups in C−H functionalization events 
4.1 Introduction  
Transition metal-catalyzed cross-coupling techniques are powerful tools in modern 
organic chemistry. Among the many strategies available, commonly used methods rely on 
the use of reactive functional groups, such as halides or unsaturated bonds, able to interact 
with a metal to form new C−M bonds which undergo a wide variety of chemical processes. 
In these cases, however, several steps are needed to synthesize the required substrates from 
readily available starting materials, and the production of a substantial amount of by-product 
waste often accompanies these reactions. During the last years a new dimension has been 
opened in the field of synthetic organic chemistry with the activation of carbon−hydrogen 
bonds utilizing transition metal catalysts.
183
 The direct catalytic cleavage and transformation 
of C−H bonds, which are ubiquitous in organic molecules, avoids the need for preparing 
functionalized intermediates, allowing the assembly of the desired products in fewer steps 
and thus offering a virtually unlimited library of simple starting materials as well as new 
perspectives in retrosynthesis. Accordingly, the development of new synthetic strategies in 
which C−H bonds can be activated and further used as a simple functional group represents 
one of the most stimulating and promising areas of research in the field of organic chemistry.  
Direct C−H bond functionalization reactions are limited by two fundamental 
challenges: (a) the inert nature of most carbon−hydrogen bonds and (b) the requirement to 
control site-selectivity in molecules that contain various C−H motifs. Numerous studies have 
addressed the first challenge by introducing transition metals which can react with C−H 
bonds to form new C−M bonds in a process known as “C−H activation”.184 The resulting 
C−M bonds are far more reactive than their C−H counterparts and they can be further 
                                                          
183  For selected reviews, see: a) Dong, Z.; Ren, Z.; Thompson, S. J.; Xu, Y.; Dong, G. Chem. Rev. 
DOI: 10.1021/acs.chemrev.6b00574. b) Roudesly, F.; Oble, J.; Poli, G. J. Mol. Catal. A: Chem. 
2017, 426, 275. c) Gensch, T.; Hopkinson, M. N.; Glorius, F.; Wencel-Delord, J. Chem. Soc. Rev. 
2016, 45, 2900. d) Santoro, S.; Kozhushkov, S. I.; Ackermann, L.; Vaccaro, L. Green Chem. 2016, 
18, 3471. e) Hartwig, J. F. J. Am. Chem. Soc. 2016, 138, 2. f) Girard, S. A.; Knauber, T.; Li, C.-J. 
Angew. Chem. Int. Ed. 2014, 53, 74. g) Wencel-Delord, J.; Glorius, F. Nat. Chem. 2013, 5, 369. h) 
Newhouse, T.; Baran, P. S. Angew. Chem. Int. Ed. 2011, 50, 3362. i) Liu, C.; Zhang, H.; Shi, W.; 
Lei, A. Chem. Rev. 2011, 111, 1780. j) Godula, K.; Sames, D. Science 2006, 312, 67. 
 
184  a) Xue, X.-S.; Ji, P.; Zhou, B.; Cheng, J.-P. Chem. Rev. DOI: 10.1021/acs.chemrev.6b00664. b) 
Hartwig, J. F. Nature 2008, 455, 314.  
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converted into new functional groups. Given the large number and variety of C−H bonds that 
are usually present in an organic molecule, the ability to control the regioselectivity of the 
reaction is considered an ongoing challenge of high synthetic significance.  
4.1.1 Transition metals in C−H functionalization 
The introduction of transition metals in the field of C−H activation was described in 
the literature as early as the 1960s (Scheme 4.1). Some years later, Trofimenko
185
 introduced 
the term “cyclometalation” to describe the activation reaction between the metal and the 
C−H bond in an intramolecular fashion. These reactions are known to proceed by different 
mechanisms depending on the metal species, kind of substrate, and the reaction conditions, 
including oxidative addition, electrophilic activation, concerted metalation/deprotonation, 
and σ-bond metathesis.186 In 1963 Kleiman and Dubeck reported the first nickelacycle I.187 
Similar reactivity was discovered by Cope and Siekman when they used Pd(II) and Pt(II) 
salts to give complexes II and III, respectively.
188
 Bennett and Milner observed that ortho-
C−H bonds of triphenylphospine ligands underwent oxidative addition to give [Ir(III)-H] 
species IV,
189
 and other metals were found to exhibit analogous reactivity with both 
phospines and phosphonites (V and VI).
190
 Although different transition metals such as 
Ru,
191
 Rh,
192
 Pt
193
 and Pd
194
 have been used in a vast array of C−H activation reactions, the 
most widely used metal is by far Pd owing to its unique characteristics. Remarkably, having 
only three oxidation states facilitates the understanding of the reaction mechanisms, as well 
as the isolation ease of the corresponding intermediates in comparison with other metals.  
                                                          
185  Trofimenko, S. Inorg. Chem. 1973, 12, 1215. 
186  Labinger, J. A.; Bercaw, J. E. Nature 2002, 417, 507. 
187
  Kleiman, J. P.; Dubeck, M. J. Am. Chem. Soc. 1963, 85, 1544. 
188  Cope, A. C.; Siekman, R. W. J. Am. Chem. Soc. 1965, 87, 3272. 
189  Bennett, M. A.; Milner, D. L. Chem. Commun. (London) 1967, 581.   
190  a) Keim, W. J. Organomet. Chem. 1968, 14, 179. b) Knoth, W. H.; Schunn, R. A. J. Am. Chem. 
Soc. 1969, 91, 2400. 
191  a) Ruiz, S.; Sayago, F. J.; Cativiela, C.; Urriolabeitia, E. P. J. Mol. Catal. A: Chem. 2017, 426, 407. 
b) Yamamoto, K.; Qureshi, Z.; Tsoung, J.; Pisella, G.; Lautens, M. Org. Lett. 2016, 18, 4954. 
192  a) Nicolaou, K. C.; Pulukuri, K. K.; Yu, R.; Rigol, S.; Heretsch, P.; Grove, C. I.; Hale, C. R. H.; 
ElMarrouni, A. Chem. Eur. J. 2016, 22, 8559. b) Chidipudi, S. R.; Burns, D. J.; Khan, I.; Lam, H. 
W. Angew. Chem. Int. Ed. 2015, 54, 13975.  
193  a) Kumar, M. K.; Ramaprabhu, S. J. Phys. Chem. B 2006, 110, 11291. b) Pastine, S. J.; Youn, S. 
W.; Sames, D. Tetrahedron 2003, 59, 8859. 
194  a) He, J.; Wasa, M.; Chan, K. S. L.; Shao, Q.; Yu, J.-Q. Chem. Rev. DOI: 
10.1021/acs.chemrev.6b00622. b) Jiang, H.; Zhang, Y.; Chen, D.; Zhou, B.; Zhang, Y. Org. Lett. 
2016, 18, 2032.   
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Scheme 4.1. Some examples of metalacyles with different transition metals.  
Palladium complexes are particularly attractive catalysts in the realm of C−H 
functionalization for several reasons. The first one, ligand-directed C−H functionalization at 
Pd centers can be utilized to build-up a vast array of different bonds, including 
carbon−oxygen, carbon−halogen, carbon−nitrogen, carbon−sulfur, and carbon−carbon 
unions. Few other catalysts allow such diverse bond constructions, and this versatility is 
predominantly the consequence of two main characteristics (a) the compatibility of many 
Pd
II
 catalysts with oxidants, and (b) the ability to selectively functionalize cyclopalladated 
intermediates. The second feature is that palladium can take part in the cyclometalation 
process with a wide variety of directing groups and, unlike many other transition metals, 
easily promotes C−H activation at both sp2 and sp3 C−H sites. At last but not least, Pd-
catalyzed directed C−H functionalization processes can be usually carried out in the presence 
of air, making the reaction exceptionally practical for further applications in organic 
synthesis. The groups of Fujiwara,
195
 Yu,
196
 Sanford,
197
 Gaunt,
198
 and Shi,
199
 among others, 
have contributed to the development of this area of expertise during the last decade. 
Palladium-catalyzed C−H functionalization processes can proceed through either a 
Pd(0)/Pd(II) or Pd(II)/Pd(IV) catalytic cycle. The first one begins with the ligand-directed 
C−H activation, which takes place at PdII center to afford a cyclopalladated intermediate. 
Then, a ligand exchange followed by a reductive elimination process delivers the product. 
                                                          
195  Jia, C.; Kitamura, T.; Fujiwara, Y. Acc. Chem. Res. 2001, 34, 633. 
196  Giri, R.; Shi, B.-F.; Engle, K. M.; Maugel, N.; Yu, J.-Q. Chem. Soc. Rev. 2009, 38, 3242. 
197  Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147.  
198  Beck, E. M.; Gaunt, M. J. Top. Curr. Chem. 2010, 292, 85. 
199  Sun, C.-L.; Li, B.-J.; Shi, Z.-J. Chem. Commun. 2010, 46, 677. 
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The resulting Pd
0
 species is subsequently oxidized to regenerate the active Pd
II
 catalyst 
(Scheme 4.2). 
 
Scheme 4.2. PdII/Pd0 and PdII/PdIV catalytic cycles.  
The second pathway presumably starts with the C−H activation at Pd(II) center by 
electrophilic attack, followed by oxidation of the resulting Pd(II) intermediate and ligand 
transfer to afford a Pd(IV) complex or the corresponding Pd
III
~Pd
III
 dimer.
200
 Then, reductive 
elimination delivers the coupling product and regenerates the Pd(II) catalyst to facilitate the 
catalytic cycle (Scheme 4.2). The diversity of bond-forming reductive elimination processes 
from Pd(IV) complexes allows the installation of a wide range of functionalities starting 
from C−H bonds.  
An oxidant is essential for both Pd
II
/Pd
0
 and Pd
II
/Pd
IV
 catalysis.
201
 In Pd
II
/Pd
0
 
catalysis, the oxidant is used to regenerate the active Pd
II
 catalyst from the Pd
0
 generated 
within the reaction and the most common oxidants include BQ/O2, Ag
I
 salts and Cu
II
 salts. It 
                                                          
200  a) Powers, D. C.; Geibel, M. A. L.; Klein, J. E. M. N.; Ritter, T. J. Am. Chem. Soc. 2009, 131, 
17050. b) Campbell, M. G.; Zheng, S.-L.; Ritter, T. Inorg. Chem. 2013, 52, 13295. 
201  Connelly, N. G.; Geiger, W. E. Chem. Rev. 1996, 96, 877. 
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is worth noting that many C−Y (Y = F, Cl, Br, I, O, N) bond-forming processes from the 
corresponding Pd
II
 centers are normally sluggish.
202
 Conversely, in transformations involving 
Pd
II
/Pd
IV 
catalysis, the oxidant is used to convert Pd
II
 to Pd
IV 
species. The oxidants utilized in 
these cases include PhI(OAc)2, NCS, NBS, NIS, peroxide, Ce(IV), F
+
, K2S2O8 and oxone, 
among others.
203
  
The second key issue in C−H functionalization is the control of the regioselectivity 
considering the wide variety of C−H bonds that are usually present in an organic molecule. 
This issue can be circumvented by employing molecules bearing C−H bonds of different 
reactivity, which has already been applied in the functionalization of various heterocycles 
that possess at least one position of special reactivity as a result of the presence of one or 
more heteroatoms.
204
 However, in benzene derivatives, the discrepancy in reactivity between 
the C−H bonds is generally less pronounced and other regioselectivity-controlling elements 
are required. In this respect, the most common manner to achieve the regioselectivity of a 
single C−H bond involves the use of functional groups or atoms, often named directing 
groups (DGs).  
4.1.2 DGs in C−H functionalization 
Functional groups or commonly named directing groups (DGs) are able to 
coordinate or bind to a metal center and thus deliver the catalyst to a proximal C−H bond, in 
most cases ortho to the DG.
205
 The stabilizing interaction formed between the π system of the 
                                                          
202  a) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem. Int. Ed. 2009, 48, 5094. b) 
Muñiz, K. Angew. Chem. Int. Ed. 2009, 48, 9412. 
203  a) Neufeldt, S. R.; Sanford, M. S. Acc. Chem. Res. 2012, 45, 936. b) Xu, L.-M.; Li, B.-J.; Yang, Z.; 
Shi, Z.-J. Chem. Soc. Rev. 2010, 39, 712. 
204  a) Phillips, D.; France, D. J. Asian J. Org. Chem. 2017, 6, 27. b) Wilton, D. A. A. C−H Bond 
Activation in Organic Synthesis, CRC Press 2015, 267. c) Li, S.-S.; Qin, L.; Dong, L. Org. Biomol. 
Chem. 2016, 14, 4554. d) Zhang, Z.; Tanaka, K.; Yu, J.-Q. Nature 2017, 543, 538. e) Sun, B.; 
Yoshino, T.; Kanai, M.; Matsunaga, S. Angew. Chem. Int. Ed. 2015, 54, 12968.    
205  For recent discoveries in remote meta- and para-C  H functionalization events, see: a) Bag, S.; 
Jayarajan, R.; Mondal, R.; Maiti, D. Angew. Chem. Int. Ed. 2017, 56, 1. b) Wang, P.; Farmer, M. 
E.; Yu, J.-Q. Angew. Chem. Int. Ed. 2017, 56, 5125. c) Liang, S.; Bolte, M.; Manolikakes, G. 
Chem. Eur. J. 2017, 23, 96. d) Dey, A.; Maity, S.; Maiti, D. Chem. Commun. 2016, 52, 12398. e) 
Zhao, Y.; Yan, H.; Lu, H.; Huang, Z.; Lei, A. Chem. Commun. 2016, 52, 11366. f) Patra, T.; Bag, 
S.; Kancherla, R.; Mondal, A.; Dey, A.; Pimparkar, S.; Agasti, S.; Modak, A.; Maiti, D. Angew. 
Chem. Int. Ed. 2016, 55, 7751. g) Bag, S.; Patra, T.; Modak, A.; Deb, A.; Maity, S.; Dutta, U.; Dey, 
A.; Kancherla, R.; Maji, A.; Hazra, A.; Bera, M.; Maiti, D. J. Am. Chem. Soc. 2015, 137, 11888. 
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arene or alkene and the transition metal center is presumably a key factor for facilitating the 
activation of otherwise unreactive C−H bonds. In general, the process happens via the 
formation of a thermodynamically stable five- or six-membered metalacycle intermediate 
(Scheme 4.3).
206
 One of the most important drawbacks is the additional synthetic steps which 
are required to both install and cleave the desired DG in the substrate and product, 
respectively. However, when the DG itself can play a key role in further applications of the 
resulting products practical and elegant late-stage functionalization approaches can be 
designed in the field of medicinal chemistry.  
 
Scheme 4.3. DG-assisted C−H functionalization strategy. 
The first example of a transition metal-catalyzed regioselective functionalization of 
a C−H bond was described in 1955 by Murahashi, which involved the insertion of carbon 
monoxide into C(sp
2
)−H bonds catalyzed by cobalt.207 However, the reaction mechanism 
was not defined until 1963, when Kleiman and Dubeck published the first characterization of 
a cyclometalated complex.
187
 This complex, a five-membered ortho-nickelacycle, highlights 
the ability of some functional groups to promote the insertion of a transition metal into an 
ortho-C(sp
2
)−H bond. Although important advances were achieved in the field in the next 
years, the main limitation came from using stoichiometric amounts of metal which rendered 
the process unpractical from a sustainable point of view.  
                                                          
h) Wang, P.; Farmer, M. E.; Huo, X.; Jain, P., Shen, P.-X.; Ishoey, M.; Bradner, J. E.; Wisniewski, 
S. R.; Eastgate, M. D.; Yu, J.-Q. J. Am. Chem. Soc. 2016, 138, 9269. 
206  For selected reviews, see: a) Rouquet, G.; Chatani, N. Angew. Chem. Int. Ed. 2013, 52, 11726. b) 
Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. Angew. Chem. Int. Ed. 2012, 51, 
10236. c) Ackermann, L. Chem. Rev. 2011, 111, 1315.  
207  Murahashi, S. J. Am. Chem. Soc. 1955, 77, 6403.   
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In 1993 a highly efficient and selective ortho-alkylation reaction of aromatic 
ketones with olefins catalyzed by ruthenium salts was reported by the group of Murai 
(Scheme 4.4).
208
  
 
Scheme 4.4. Ruthenium-catalyzed ortho-alkylation of aromatic ketones with olefins. 
Inspired by this major breakthrough, a huge number of publications subsequently 
appeared involving related transformations such as arylations, vinylations or oxidations with 
a vast array of DGs. As shown in Scheme 4.5, nitrogen-based DGs including imines, 
pyridines, oxime ethers, azobenzene derivatives as well as some carbonyl containing DGs 
such as ketones, aldehydes and carboxylate derivatives were reported as efficient chelating 
mioeties. Moreover, it should be mentioned that some DGs, especially those derived from 
carboxylic acids and the carboxylic acids themselves, have been proven to be versatile 
functionalities for further transformations.
209
 In addition, significant attention has been 
focused on the development of easily modifiable or removable DGs.
210
  
                                                          
208  Murai, S.; Kakiuchi, F.; Sekine, S.; Tanaka, Y.; Kamatani, A.; Sonoda, M.; Chatani, N. Nature 
1993, 366, 529. 
209  Drapeauand, M. P.; Gooßen, L. J. Chem. Eur. J. 2016, 22, 18654. 
210  a) Rousseau, G.; Breit, B. Angew. Chem. Int. Ed. 2011, 50, 2450. b) Wang, C.; Huang, Y. Synlett 
2013, 24, 145. c) Yadav, M. R.; Rit, R. K.; Shankar, M.; Sahoo, A. K. Asian J. Org. Chem. 2015, 4, 
846. 
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Scheme 4.5. Some examples of monodentate DGs. 
Considering the important advances that have been developed to date in a large 
variety of catalytic reactions involving C(sp
2
)−H bonds of arenes, heteroarenes and alkenes, 
directed C−H bond functionalization can be considered a reliable strategy for the 
transformation of a C−H bond into a new C−X bond (X = C, O, N, F, Cl, Br, I, Si). In this 
manner, classical catalytic cross-coupling reactions involving the coupling of organohalides 
with organometallic species R−M (M = Li, MgX, ZnX, BR2, SnR3, SiR3, etc.) can be 
replaced in certain cases by more atom-economical and sustainable C−H functionalization 
processes. Besides, benzylic or C(sp
3
)−H bonds in α position to a heteroatom also undergo 
functionalization relatively easily, probably due to the lone pair of electrons which has 
stabilizing orbital interactions with the metal, or because of the influence of a proximal 
aromatic system.
194a,206c,211
 However, directed functionalization of unactivated C(sp
3
)−H 
bonds remains comparatively less explored. With the aim of extending the concept of 
directed C−H bond functionalization beyond its limits, the development of new types of DGs 
poses a promising strategy for achieving catalytic transformations that cannot be completed 
with the methods currently available.  
In this regard, Daugulis introduced the utilization of novel bidentate DGs in 2005
212
 
which via the formation of a stable metalacycle C(sp
3
)−H and C(sp2)−H were elegantly 
functionalized. The DG of choice was 8-aminoquinoline, and its coordination to the metal 
center in a bidentate fashion during the formation of the corresponding intermediate was 
                                                          
211 For selected reviews, see: a) Dastbaravardeh, N.; Christakakou, M.; Haider, M.; Schnürch, M. 
Synthesis 2014, 46, 1421. b) Jazzar, R.; Hitce, J.; Renaudat, A.; Sofack-Kreutzer, J.; Baudoin, O. 
Chem. Eur. J. 2010, 16, 2654. 
212  Zaitsev, V. G.; Shabashov, D.; Daugulis, O. J. Am. Chem. Soc. 2005, 127, 13154. 
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prepared within the Pd-catalyzed arylation of β-C−H bonds of various aliphatic and aromatic 
amides (Scheme 4.6).   
 
Scheme 4.6. Palladium-catalyzed arylation of C−H bonds promoted by a bidentate DG. 
In addition to 8-aminoquinoline DG, other bidentate DGs have been reported in the 
literature as well (Scheme 4.7).     
 
Scheme 4.7. Some examples of bidentate DGs. 
More recently, 1,2,3-triazole-containing bidentate DGs have been introduced by 
Ackermann,
213
 Shi
214
 and Ding,
215
 and they have demonstrated the great potential that 
triazoles can offer as versatile DGs in the field of C−H functionalization. The group led by 
Ackermann reported iron- and ruthenium-catalyzed reactions, such as arylations and 
                                                          
213  a) Cera, G.; Haven, T.; Ackermann, L. Chem. Eur. J. 2017, 23, 3577. b) Santrač, D.; Cella, S.; 
Wang, W.; Ackermann, L. Eur. J. Org. Chem. 2016, 5429. c) Cera, G.; Haven, T.; Ackermann, L. 
Angew. Chem. Int. Ed. 2016, 55, 1484. d) Al Mamari, H. H.; Diers, E.; Ackermann, L. Chem. Eur. 
J. 2014, 20, 9739. e) Gu, Q.; Al Mamari, H. H.; Graczyk, K.; Diers, E.; Ackermann, L. Angew. 
Chem. Int. Ed. 2014, 53, 3868. 
214  a) Ye, X.; Shi, X. Org. Lett. 2014, 16, 4448. b) Ye, X.; He, Z.; Ahmed, T.; Weise, K.; Akhmedov, 
N. G.; Petersen, J. L.; Shi, X. Chem. Sci. 2013, 4, 3712. 
215  Zhang, G.; Xie, X.; Zhu, J.; Li, S.; Ding, C.; Ding, P. Org. Biomol. Chem. 2015, 13, 5444. 
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alkylations of arenes, heteteroarenes and alkenes utilizing a bidentate DG containing a 
triazole scaffold named TAM (Scheme 4.8).  
 
Scheme 4.8. TAM as DG in C−C bond formation. 
Alternatively, Shi
214
 and Ding
215 
reported the Pd-catalyzed formation of new C−O 
and C−C bonds, respectively, assisted by other types of bidentate DGs. The group of Shi 
utilized DGs such as TA-Ph and TA-Py to perform olefination and acetoxylation reactions, 
and Ding achieved C(sp
3)−H arylations of aminoacid derivatives directed by the bidentate 
TAH moiety (Scheme 4.9). 
 
Scheme 4.9. Selected examples of triazole-containing DGs. 
Despite the efficiency of those bidentate triazole-containing DGs, the mayor 
drawback relies on their structural complexity, which sometimes limited their synthetic 
scope. In this regard, the use of alternative and simple triazole derivatives easily installed 
within the arene ring in a straightforward fashion and acting as monodentate DGs would be 
of utmost synthetic practical value. In that sense, 4-aryl-1,2,3-triazoles resulting from the 
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atom economical CuAAC stand out as ideal substrates to develop novel C−H 
functionalization events. However, competitive functionalization of the heterocycle core 
poses a major limitation. Indeed, metal-catalyzed arylations and alkenylations selectively 
occurring at the acidic C−H bond are well-documented (Scheme 4.10, routes a and b).216 On 
the one hand, C−H arylation processes generally involving Pd- and Cu-NHC systems 
promote the construction of C−C bonds from arenes or heteroarenes using aryl bromides and 
chlorides. On the other hand, alkenylation processes described by Jiang are carried out 
utilizing palladium salts and terminal conjugated alkenes in order to perform the 
corresponding C−H functionalization event in the C5 of the 1,2,3-triazole ring. 
Our approach involves a distinct binding mode of the metal catalyst within the 
triazole and further activation of a specific C−H bond in the arene while leaving the C5−H 
bond intact (Scheme 4.10, route d). Whereas ruthenium complexes have allowed triazole-
assisted direct arylations to selectively proceed at the arene (Scheme 4.10, route c),
217
 at the 
time this work started Pd-catalyzed processes remained virtually unexplored.
218
 In particular, 
we envisioned the use of triazoles as DG in challenging C−O bond-forming processes as well 
as in C−C bond-forming events such as acylation reactions. 
 
Scheme 4.10. Metal-catalyzed C−H functionalization processes using 4-phenyl-1,2,3-triazoles. 
                                                          
216  a) Lesieur, M.; Lazreg, F.; Cazin, C. S. J. Chem. Commun. 2014, 50, 8927. b) Tao, H.; Min, W.; 
Pinhua, L.; Lei, W. Chin. J. Chem. 2012, 30, 979. c) Ackermann, L.; Vicente, R. Org. Lett. 2009, 
11, 4922. d) Ackermann, L.; Vicente, R.; Born, R. Adv. Synth. Catal. 2008, 350, 741. e) Jiang, H.; 
Feng, Z.; Wang, A.; Liu, X.; Chen, Z. Eur. J. Org. Chem. 2010, 1227. 
217  Ackermann, L.; Novák, P.; Vicente, R.; Pirovano, V.; Potukuchi, H. K. Synthesis 2010, 13, 2245.  
218  Very recently, other “click”-triazole directed C−H functionalization events have been reported, see 
for example: a) Zhao, F.; Chen, Z.; Ma, X.; Huang, S.; Jiang, Y. Tetrahedron Lett. 2017, 58, 614. 
b) Zhao, F.; Chen, Z.; Huang, S.; Jiang, Y. Synthesis 2016, 48, 2105.  
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4.2 Pd-catalyzed C(sp2)−H oxygenations 
4.2.1 Previous work 
The field of Pd-catalyzed C−H functionalization has undergone an impressive 
development during the past decade and, in particular, C−H oxidations have received a great 
deal of attention. The C−H acetoxylation of benzene was first described in the presence of 
strong oxidants such as K2Cr2O7 and K2S2O8, albeit with low catalytic turnover and 
significant formation of the biphenyl product (homocoupling).
219
 In 1996 Crabtree 
introduced a ligand-directed Pd(OAc)2-catalyzed arene acetoxylation with PhI(OAc)2 as the 
terminal oxidant.
220
 The transformation proceeded with poor site-selectivity and both alkanes 
and electron-deficient arenes showed low reactivity. Although some efforts were done to 
improve the catalyst performance, in general it was found limited by harsh reaction 
conditions, low TON (turnover number), low functional group tolerance, significant 
formation of byproducts, and large excesses of substrate relative to oxidant were typically 
required.
221
 In 2004 Sanford and co-workers circumvented some of the latter issues by 
describing a C−H acetoxylation protocol using a series of different nitrogen-containing DGs 
and PhI(OAc)2 as the stoichiometric oxidant.
222
 
 
Scheme 4.11. Pd(OAc)2-catalyzed C(sp
2)−H acetoxylation with PhI(OAc)2. 
As depicted in scheme 4.11, they achieved the successful Pd-catalyzed C−H 
oxygenation of benzo[h]quinoline as a single isomer. The method was further extended at 
                                                          
219  For Pd-catalyzed C−H acetoxylation of arenes using K2S2O8 as oxidant, see: a) Eberson, L.; 
Jonsson, L. J. Chem. Soc. Chem. Commun. 1974, 885. b) Eberson, L.; Jonsson, L. Acta Chem. 
Scand. Ser. B 1974, 28, 771. c) Eberson, L.; Jonsson, L. Acta Chem. Scand. Ser. B 1976, 30, 361. d) 
Eberson, L.; Jonsson, L. Justus Liebigs Ann. Chem. 1977, 233. For Pd-catalyzed C−H 
acetoxylation of arenes using chromates as oxidant, see: e) Stock, L. M.; Tse, K.; Vorvick, L. J.; 
Walstrum, S. A. J. Org. Chem. 1981, 46, 1757. f) Henry, P. M. J. Org. Chem. 1971, 36, 1886. 
220  Yoneyama, T.; Crabtree, R. H. J. Mol. Catal. A 1996, 108, 35. 
221  a) Shilov, A. E.; Shul'pin, G. B. Chem. Rev. 1997, 97, 2879. b) Stahl, S. S.; Labinger, J. A.; 
Bercaw, J. E. Angew. Chem. Int. Ed. 1998, 37, 2180. c) Mukhopadhyay, S.; Bell, A. T. Angew. 
Chem. Int. Ed. 2003, 42, 2990. 
222  Dick, A. R.; Hull, K. L.; Sanford, M. S. J. Am. Chem. Soc. 2004, 126, 2300.  
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both sp
2
 and sp
3
 C−H bonds, as well as to the use of numerous DGs including pyridine, 
pyrimidine, pyrazine, pyrazole, azobenzene, imine, pyrrolidinone, oxime ether and acetate, 
isoxazole, amide and carbene derivatives.
223
 Apart from the latter, other types of DGs have 
been reported including alcohols,
224
 carboxylates
225
 and sulfur derivatives such as sulfonyl,
226
 
silanol
227
 or sulfoxide
228
 groups, as well as alkene groups.
229
 The reaction also proceeded in 
high yields with different types of oxidants such as oxone and K2S2O8. Noteworthy, when 
employing protic solvents such as MeOH, 
i
PrOH and CF3CH2OH, the corresponding ethers 
were obtained.  
The generally accepted mechanism for this type of Pd-catalyzed C−H acetoxylation 
events starts with a site-selective C−H cleavage step to form palladacycle I. Then, such 
Pd(II) intermediate undergoes oxidation to provide the corresponding Pd(IV) intermediate II, 
which have been also proposed to exist as a Pd
III
~Pd
III
 dimer.
200
 Eventually, C−O bond 
forming reductive elimination furnishes the acetoxylated product and the active Pd(II) 
catalyst.
230
  
                                                          
223  a) Desai, L. V.; Hull, K. L.; Sanford, M. S. J. Am. Chem. Soc. 2004, 126, 9542. b) Kalyani, D.; 
Sanford, M. S. Org. Lett. 2005, 7, 4149. c) Desai, L. V.; Malik, H. A.; Sanford, M. S. Org. Lett. 
2006, 8, 1141. d) Kalberer, E. W.; Whitfield, S. R.; Sanford, M. S. J. Mol. Catal. A 2006, 251, 108. 
e) Desai, L. V.; Stowers, K. J.; Sanford, M. S. J. Am. Chem. Soc. 2008, 130, 13285. f) Neufeldt, S. 
R.; Sanford, M. S. Org. Lett. 2010, 12, 532. g) Gary, J. B.; Cook, A. K.; Sanford, M. S. ACS Catal. 
2013, 3, 7  . h) Tato,  .;  arc  a-Dom  nguez, A.; Cárdenas, D. J. Organometallics 2013, 32, 7487. 
i) Cook, A. K.; Emmert, M. H.; Sanford, M. S. Org. Lett. 2013, 15, 5428. 
224  a) Ren, Z.; Schulz, J. E., Dong, G. Org. Lett. 2015, 17, 2696. b) Lu, Y.; Wang, D.-H.; Engle, K. M.; 
Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 5916. 
225  Wang, D.-H.; Engle, K. M.; Shi, B.-F.; Yu, J.-Q. Science 2010, 327, 315. 
226  García-Rubia, A.; Fernández-Ibáñez, M. A.; Gómez Arrayás, R.; Carretero, J. C. Chem. Eur. J. 
2011, 17, 3567. 
227  Wang, C.; Ge, H. Chem. Eur. J. 2011, 17, 14371. 
228  Wang, B.; Shen, C.; Yao, J.; Yin, H.; Zhang, Y. Org. Lett. 2014, 16, 46. 
229  Gandeepan, P.; Cheng, C.-H. J. Am. Chem. Soc. 2012, 134, 5738. 
230  For discussions of the intermediacy of monomeric PdIV or closely related dimeric PdIII-PdIII/ PdIV-
PdIV intermediates in these reactions, see: a) Dick, A. R.; Kampf, J. W.; Sanford, M. S. 
Organometallics 2005, 24, 482. b) Racowski, J. R.; Dick, A. R.; Sanford, M. S. J. Am. Chem. Soc. 
2009, 131, 10974. c) Deprez, N. R.; Sanford, M. S. J. Am. Chem. Soc. 2009, 131, 11234. d) Ye, Y.; 
Ball, N. D.; Kampf, J. W.; Sanford, M. S. J. Am. Chem. Soc. 2010, 132, 14682. e) Ariafard, A.; 
Hyland, C. J. T.; Canty, A. J.; Sharma, M.; Yates, B. F. Inorg. Chem. 2011, 50, 6449. f) Ariafard, 
A.; Hyland, C. J. T.; Canty, A. J.; Sharma, M.; Brookes, N. J.; Yates, B. F. Inorg. Chem. 2010, 49, 
11249. g) Powers, D. C.; Ritter, T. Acc. Chem. Res. 2012, 45, 840. 
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Scheme 4.12. Catalytic cycle for ligand-directed C−H acetoxylation 
The selectivity of the acetoxylation reaction is dictated by more than one factor. In 
general, the C−H functionalization occurs via the formation of a five- or six-membered 
palladacycle, although reactions proceeding via seven-membered and even larger 
palladacyclic intermediates have been also reported.
231
 Interestingly, multiple oxygenation 
processes can be performed when utilizing substrates with 2 or 3 identical C−H bonds in the 
presence of large amounts of oxidant. Remarkably, if two sterically distinct ortho C−H sites 
are available, high selectivity is typically observed for the functionalization in the less 
hindered position (Scheme 4.13, product A). 
 
Scheme 4.13. Sterically inequivalent ortho C−H sites 
As mentioned before, Shi and co-workers have recently reported the utilization of 
1,2,3-triazole-containing DGs in Pd-catalyzed C−H oxygenations (Scheme 4.14).214b In 
particular, the use of TA-Py as DG facilitated the selective functionalization of both 
C(sp
2
)−H and C(sp3)−H bonds. Despite the remarkable importance of the method, the 
requirement of a structurally complex triazole-containing moiety as DG clearly limited the 
synthetic scope of the process. Inspired by their findings, we envisioned the alternate use of 
more simple triazoles as DGs in such C−H acetoxylation processes. 
                                                          
231  Li, J.-J.; Giri, R.; Yu, J.-Q. Tetrahedron 2008, 64, 6979. 
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Scheme 4.14. TA-Py DG reported by Shi. 
In this regard, the implementation of simple 1,2,3-triazoles as DGs prepared in a 
practical fashion upon “click” chemistry could open up new doors in this field of expertise. If 
successful, such procedures could complement existing methodologies for the assembly of 
acetoxylated arenes and represent likewise elegant late-stage functionalization events of 
“click” compounds. 
4.2.2 Results and discussion 
4.2.2.1 Screening of the reaction conditions 
In order to test the feasibility of our approach, we first selected 68a as the model 
substrate owing to its easy access in multi-gram scale following a reported CuAAC process 
from commercially available phenylacetylene and previously prepared benzyl azide. Thus, 
the desired 4-phenyl-1,2,3-triazole derivative 68a was prepared in excellent yield 
(Scheme 4.15). 
 
Scheme 4.15. Synthesis of triazole 68a upon CuAAC.  
With substantial amounts of 68a in hand, we set out a systematic evaluation of the 
experimental variables such as metal, oxidant, solvent, additives and reaction temperatures. 
We started our screening process by varying the nature of the solvent and pleasingly found 
that Pd(OAc)2 (10 mol %), PIDA (2.0 equiv.) and AcOH (2.0 equiv.) in THF (1 mL) at 90 ºC 
provided the desired acetoxylated product 69a in 33 % yield (Table 4.1, entry 2). Although 
the oxygenated product was obtained in low yield, it demonstrated the viability of our 
hypothesis on the active role of “click” triazoles as D s in C−H  functionalization. 
 208 
 
We next found out that the use of DCE as solvent provided the target product 69a in 
slightly higher yield (entry 1), along with traces of diacetoxylated product. Other solvents 
such as PhCl, PhCl2, C2Cl4, dioxane, DMF, DMA, MeCN and TFA were found unsuitable 
for the process to occur (entries 3-10). With the aim to improve the acetoxylation process,
222c
 
a co-solvent such as AcOH, DME and Ac2O was added to the reaction mixture (entries 11-
13). To our delight, the use of a mixture of DCE-Ac2O in a 1:1 ratio favored the reaction 
obtaining 78 % yield of a mixture of mono- and diacetoxylated products (1.2:1 ratio) (Table 
4.1, entry 13). This positive effect of Ac2O has been justified by the presumable regeneration 
of the active catalyst.
223g,i,232
 
Table 4.1. Screening of solvents.a 
 
Entry Solvent Yield
b
 (%) Entry Solvent Yield
b
 (%) 
1 DCE 37 8 Dioxane 0 
2 THF 33 9 MeCN 0 
3 PhCl 0 10 TFA 0 
4 PhCl2 0 11 DCE-AcOH n.d. 
5 C2Cl4 0 12 DCE-DME n.d. 
6 DMF n.d. 13 DCE-Ac2O 78 (1.2:1)
c
 
7 DMA n.d.    
aReaction conditions: 68a (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), DCE (1 mL) at 90 ºC for 24 h. bYield of isolated product after column chromatography. cRatio 
of mono- vs diacetoxylated product (69a/69a’). 
Encouraged by these results, we further analyzed the influence of other Pd sources 
and oxidants, but we experimentally observed that Pd(OAc)2 and PhI(OAc)2, respectively, 
were the most efficient ones affording the target product in higher yields.   
 
                                                          
232  Cook, A. K.; Sanford, M. S. J. Am. Chem. Soc. 2015, 137, 3109. 
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Table 4.2. Pd-catalyzed C(sp2)−H acetoxylation of 68aa 
 
Entry Variation from standard conditions Yield
b
 (%) 
1 none 78 (1.2:1)
c
 
2 without Pd(OAc)2 0 
3 without PhI(OAc)2 0 
4 under air 60 (1.1:1)
c
 
5 without Ac2O 27 (1.1:1)
c
 
6 p-TsOH·H2O instead of AcOH traces 
7 K2S2O8 instead of PhI(OAc)2 traces 
8 110 ºC instead of 90 ºC 79 (1.1:1)
c
 
9 5 mol % of Pd(OAc)2 instead of 10 mol % 61 (1.1:1)
c
 
aReaction conditions: 68a (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), AcOH (2.0 equiv.), DCE/Ac2O (1:1, 1mL) at 90 ºC for 24 h. 
bYield of isolated product after 
column chromatography. cRatio of mono- vs diacetoxylated product (69a/69a’). 
We further performed several control experiments (Table 4.2). As expected, the 
reaction did not proceed in the absence of either metal (entry 2) or oxidant (entry 3) and the 
addition of both AcOH and Ac2O was crucial for the process to occur in high yields (entries 
5-6).
203a,233
 It is worth noting that the yield was not improved either at higher temperature 
(entry 8) or by adding pyridine derivatives which are known to enhance the rate of Pd-
catalyzed C−H acetoxylations.223g,i,232 Importantly, the process could take place in a 
remarkable 60 % yield even under air atmosphere (entry 4). Curiously, whereas the use of 
K2S2O8 under the standard conditions resulted in the formation of just traces of the 
acetoxylated product (entry 7), Jiang and co-workers have recently reported related Pd-
catalyzed acetoxylations of “click” triazoles using K2S2O8 as oxidant instead of PIDA.
218a
 
                                                          
233  Giri, R.; Liang, J.; Lei, J.-G.; Li, J.-J.; Wang, D.-H.; Chen, X.; Naggar, I. C.; Guo, C.; Foxman, B. 
M.; Yu, J.-Q. Angew. Chem. Int. Ed. 2005, 44, 7420.  
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4.2.2.2 Synthesis of the starting triazoles 
Having established the optimized reaction conditions, we continued our studies by 
preparing a wide range of 4-aryl-1,2,3,-triazoles to evaluate the influence of the nature of the 
heterocyclic motif on the ortho-acetoxylation. One of the most common strategies for the 
synthesis of triazoles is the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition between 
alkynes and azides (CuAAC), which has been previously described in chapter 1. This method 
provides exclusive regioselectivity toward the formation of 1,4-substituted 1,2,3-triazoles, 
and occurs under mild reaction conditions and very high yields, which constitutes a practical 
bonus for our synthetic goals. Accordingly, a variety of alkynes and azides were reacted in 
the presence of CuSO4·5H2O and sodium ascorbate to provide the corresponding triazoles 
68a-v in moderate to good yields (Table 4.3).  
Similarly, another set of 1,2,3-triazoles 68w-zc were obtained in a two-step 
sequence. Although organic azides are generally safe compounds, those of low molecular 
weight can be unstable and, therefore, difficult to handle. In those cases, we followed a one-
pot, two-step procedure described in the literature,
234
 where the alkyl azides were in situ 
generated and reacted with CuI and DIPEA to obtain the corresponding triazoles in overall 
good yields (Table 4.4).  
Additionally, fully substituted 1,2,3-triazoles were synthesized in a different manner 
depending on the type of substituent in the C5 position. On the one hand, the 5-iodo-1,2,3-
triazoles were synthesized in a one-pot, two-step procedure where the alkyl azides were 
generated in situ and reacted with CuI, NBS and DIPEA in MeCN to afford the 
corresponding triazoles in good yields (Table 4.5).
235
 On the other hand, when the substituent 
was a phenyl group, the reaction was carried out through a metal-free Huisgen cycloaddition 
process which provided the target product 68zj in low yield (Scheme 4.17).
236
  
                                                          
234  Feldman, A. K.; Colasson, B.; Fokin, V. V. Org. Lett. 2004, 6, 3897. 
235  Wu, Y.-M.; Deng, J.; Li, Y.; Chen, Q.-Y. Synthesis 2005, 1314. 
236  Wang, Z.-X.; Qin, H.-L. Chem. Commun. 2003, 2450.    
 211 
 
Table 4.3. Synthesis of 1,2,3-triazoles 68a-va,b 
 
aReaction conditions: alkyne (1.0 equiv.), R-N3 (1.1 equiv.), CuSO4·5H2O (0.2 equiv.), Na Ascorbate 
(0.4 equiv.), THF/tBuOH (1:1, 30 mL) and H2O (15 mL) under N2 at room temperature. 
bYield of 
isolated product after column chromathography. 
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Table 4.4. Synthesis of 1,2,3-triazoles 68w-zca,b 
 
aReaction conditions: i) alkyl bromide (1.0 equiv.), R2-N3 (1.1 equiv.), HMPA (0.60 mL/mmol) under 
N2, for 5h; ii) alkyne (1.0 equiv.), CuI (0.2 equiv.), DIPEA (5.0 equiv.), under N2 overnight at room 
temperature. bYield of isolated product after column chromathography. 
Table 4.5. Synthesis of 1,4,5-trisubstituted 1,2,3-triazolesa,b 
 
aReaction conditions: i) alkyl bromide (1.0 equiv.), R2-N3 (1.1 equiv.), HMPA (0.60 mL/mmol) under 
N2, for 5h; ii) CuI (1.0 equiv.) in MeCN (2.4 mL/mmol) and NBS (1.2 equiv.) in MeCN (2.4 
mL/mmol)  for 5min; azide (previously prepared), alkyne (1.0 equiv.) and DIPEA (1.1 equiv.), under 
N2 overnight at room temperature. 
bYield of isolated product after column chromathography. 
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Scheme 4.16. Synthesis of 1,4,5-triphenyl-1H-1,2,3-triazole. 
4.2.2.3 Pd-catalyzed C  H oxygenation of 4-aryl-1,2,3-triazoles 
With a vast array of 1,2,3-triazoles in hand, we next explored the scope of the 
reaction evaluating the influence of differently substituted triazoles as DGs. As depicted in 
Table 4.6, a variety of triazoles including those bearing both aliphatic and aromatic motifs 
were found to be effective DGs to afford the corresponding oxygenated products as separable 
mixtures of mono- and diacetoxylated isomers in good to high yields (up to 88 % yield). 
Remarkably, a variety of functional groups such as cyano (69c,i), ester, (69e-g), bromide 
(69d) and ether (69j) were perfectly accommodated, as well as other bulky groups including 
silicon (69x) and mesityl (69k) groups.  
As depicted in Table 4.6, when certain aliphatic chains were introduced in the N1 
atom (69f,g,w) the yield was increased considerably. Additionally, we observed that sterical 
hindrance played a crucial role in selectivity and diacetoxylation was significantly enhanced 
when using triazoles bearing sterically demanding substituents on the N1 atom (69f’,k’,x’).  
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Table 4.6. Influence of the nature of triazole ring on the Pd-catalyzed C(sp2)−H acetoxylation.a,b 
 
aReaction conditions: 68 (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), DCE/Ac2O (1:1, 1 mL) at 90 ºC for 24 h. 
bYield of isolated product after column 
chromatography, average of at least two independent runs. cRatio of mono- vs diacetoxylated product 
(69/69’). d110 ºC. 
Remarkably, in all the cases C(sp
2
)−H acetoxylation exclusively occurred at the 
ortho-position of the arene moiety leaving the heterocyclic C(sp
2
)−H bond intact. Although 
merely speculative, the regioselectivity toward the acetoxylation reaction may be related to 
the more feasible formation of the required palladacycle under acidic conditions, whereas 
C−H functionalization of the more acidic heterocyclic position generally occurs under basic 
conditions.
216  
 215 
 
Taking into account the crucial role that bulky groups can play within 
regioselectivity, we decided to prepare sterically demanding triazoles by introducing 
different substituents in the C5 of the triazole in order to evaluate their effect. To our 
surprise, iodinated compounds 68zd and ze resulted in the exclusive formation of 
monoacetoxylated arenes 69zd and ze in excellent yields. We tentatively hypothesized that 
the iodine atom could block the free-rotation of the arene thus positioning the directing 
triazole unit away from the second ortho C−H bond. In striking contrast, the introduction of a 
less sterically demanding phenyl group resulted in a total loss of selectivity towards the 
monoacetoxylation and the corresponding oxygenated product was obtained as a separable 
mixture of isomers (69zj/zj’) (Table 4.7). 
Table 4.7. Influence of C5-substituted triazoles on Pd-catalyzed C(sp2)−H acetoxylation.a,b 
 
aReaction conditions: 68 (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), DCE/Ac2O (1:1, 1 mL) at 90 ºC for 24 h. 
bYield of isolated product after column 
chromatography, average of at least two independent runs. cRatio of mono- vs diacetoxylated product 
(69/69’). 
Notably, an added benefit from using such 5-iodo-1,2,3-triazoles as DGs is that the 
resulting products constitute versatile synthetic intermediates in the cross-coupling arena. As 
shown in Scheme 4.17, when compound 69zd was reacted with an alkyne in THF utilizing 
PdCl2(PPh3)2 as catalyst and K2CO3 as base at 80 ºC, the corresponding Sonogashira reaction 
effectively yielded 1,4,5-trisubstituted 1,2,3-triazole 70 in high yield. Likewise, the Pd-
 216 
 
catalyzed Heck reaction on 5-iodo-1,2,3-triazole 69zd with methyl acrylate afforded the 
corresponding product 71 in good yield.
237
       
 
Scheme 4.17. Sonogashira and Heck couplings to 1,4,5-trisubstituted 1,2,3-triazoles. 
Having demonstrated the key role of 5-iodo-1,2,3-triazoles as efficient DGs, we 
next evaluated the synthetic scope of the process. To our delight, both DG-and substrate-
controlled selectivity was achieved, and this transformation was found to be highly efficient 
for the exclusive monoacetoxylation of a wide range of substrates as depicted in Table 4.8. 
The use of 5-iodotriazoles facilitated the selective ortho-oxygenation of substituted arenes 
(69zf,zg) upon a DG-controlled reaction pathway. Notably, substrate-controlled selectivity 
was also observed even with simple triazoles (R
2
=H); ortho-substituents did not hamper the 
process and indeed allowed the oxygenation to occur in high yields (69y,z). Conversely, in 
certain reported protocols the presence of ortho-substituents was found detrimental for the 
reaction to occur.
238
 Likewise, meta-substituted substrates such as 69l, 69m and 69za 
displayed excellent regioselectivity in the less hindered ortho-position producing the 
corresponding acetoxylated products as single regioisomers in 50 %, 72 % and 82 % yields, 
respectively. Remarkably, comparatively less explored vinylic C−H bonds smoothly 
underwent the acetoxylation process to furnish the desired products 69n, 69o, 69p and 69zb 
with high yields.  
                                                          
237  a) Hein, J. E.; Tripp, J. C.; Krasnova, L. B.; Sharpless, K. B.; Fokin, V. V. Angew. Chem. Int. Ed. 
2009, 48, 8018. b) Deng, J.; Wu, Y.-M.; Chen, Q.-Y. Synthesis 2005, 2730. 
238  a) Huang, C.; Chernyak, N.; Dudnik, A. S.; Gevorgyan, V. Adv. Synth. Catal. 2011, 353, 1285. b) 
Chernyak, N.; Dudnik, A. S.; Huang, C.; Gevorgyan, V. J. Am. Chem. Soc. 2010, 132, 8270. 
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Table 4.8. Pd-catalyzed C(sp2)−H ortho-acetoxylation of arenes and alkenes.a,b 
 
aReaction conditions: 68 (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), DCE/Ac2O (1:1, 1 mL) at 90 ºC for 24 h. 
bYield of isolated product after column 
chromatography, average of at least two independent runs. c110 ºC. 
In an attempt to see the synthetic usefulness of the developed method, we tried to 
convert the acetoxylated product into a more versatile functionality. As depicted in Scheme 
4.18, the acetoxylated product 69a was easily hydrolyzed to produce the corresponding free-
hydroxy derivative under mild reaction conditions.   
 
Scheme 4.18. Mild hydrolysis of acetoxylated compound 69a. 
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In order to study the feasibility of our protocol for the introduction of other related 
oxygenated moieties, we next performed the Pd-catalyzed C−H functionalization process 
utilizing PhI(OPiv)2. After careful control experiments, we observed that AcOH had to be 
replaced by PivOH. Likewise, Ac2O had to be removed from the reaction media to avoid 
competitive ortho-acetoxylation which could be attributed to the in situ formation of more 
reactive PhI(OAc)2 by a reasonable ligand exchange on the hypervalent iodine species.
239
 
Gratifyingly, Pd-catalyzed ortho-pivaloxylation was successfully achieved to yield 73p, 
73za, and 73zd in 77 %, 70 % and 73 % yield, respectively (Table 4.9). It is worth 
highlighting that the selective introduction of pivaloxy group is of great synthetic importance 
owing to its broad opportunities in Ni-catalyzed cross-coupling events.
240
  
Table 4.9. Pd-catalyzed C(sp2)−H ortho-pivaloxylation of arenes and alkenes.a,b 
 
aReaction conditions: 68 (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OPiv)2 (2.0 equiv.), PivOH (2.0 
equiv.), DCE (1 mL) at 90 ºC for 24 h. bYield of isolated product after column chromatography, 
average of at least two independent runs. 
Next, we examined the feasibility of the Pd-catalyzed oxygenation process in 
substrates with a longer tether between the arene and the directing triazole. As depicted in 
Table 4.10, 4-benzyl-1,2,3-triazoles 68zc and 68t provided the corresponding acetoxylated 
products 69zc and 69t, respectively, as separable mixtures of mono- and difunctionalized 
products. Interestingly, whereas when using 4-phenyl-1,2,3-triazoles the corresponding 
monoacetoxylated products were obtained as the major isomers, in the latter cases the 
                                                          
239  a) Narayan, R.; Manna, S.; Antonchick, A. P. Synlett 2015, 26, 1785. b) Zhdankin, V. V.; Stang, P. 
J. Chem. Rev. 2008, 108, 5299. 
240  See for example: a) Correa, A.; Martin, R. J. Am. Chem. Soc. 2014, 136, 7253. b) Muto, K.; 
Yamaguchi, J.; Itami, K. J. Am. Chem. Soc. 2012, 134, 169. c) Rosen, B. M.; Quasdorf, K. W.; 
Wilson, D. A.; Zhang, N.; Resmerita, A.-M.; Garg, N. K.; Percec, V. Chem. Rev. 2011, 111, 1346.  
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diacetoxylated products were mostly obtained, which could be tentatively attributed to the 
higher flexibility of the presumable formation of 6-membered palladacyclic intermediates. 
Remarkably, the introduction of both ortho- (69q, 69r) and meta-substituents (69s) into the 
arene ring enabled the selective monooxygenation process to occur in good yields. Likewise, 
the monopivaloxylation of the arene bearing a meta- substituent 73s was also achieved in 
good yield. Impressively, when 5-iodo derivatives 68zh and 68zi were utilized, an 
unexpected selectivity was achieved. Instead of the monoacetoxylated compounds, 
diacetoxylated products 69zh’ and 69zi’ were exclusively obtained in high yields. In an 
attempt to see if the monoacetoxylated product could be obtained, the amount of PhI(OAc)2 
was reduced providing the monosubstituted product 69zi as the major compound. We 
hypothesized that the triazole motif could bind to the Pd center via the formation of a more 
flexible 6-membered palladacycle, and hence the iodine atom may not block the free rotation 
of the benzyl group as when a phenyl ring is used. As a result, previous selectivity toward 
monoacetoxylation (Table 4.7, 69zd,ze) is not observed, and selective diacetoxylation is 
achieved instead, which remains unclear to rationalize at this stage. 
Table 4.10. Pd-catalyzed C(sp2)−H ortho-acetoxylation of arenes 68q-zi.a,b 
 
aReaction conditions: 68 (0.25 mmol), Pd(OAc)2 (10 mol %), PhI(OAc)2 (2.0 equiv.), AcOH (2.0 
equiv.), DCE/Ac2O (1:1, 1 mL) at 90 ºC for 24 h. 
bYield of isolated product after column 
chromatography, average of at least two independent runs. cPhI(OPiv)2 (2.0 equiv), PivOH (2.0 equiv) 
in DCE (1 mL). dRatio of mono- vs diacetoxylated product. ePhI(OAc)2 (1.0 equiv). 
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Finally, in order to extend the synthetic scope of the process for the practical 
functionalization of arenes bearing the required DG in a longer distance to the corresponding 
C−H bond, triazoles 68u-v were easily prepared through CuAAC. In those cases, the process 
would involve the formation of less common 7- and 8-membered palladacycles. 
Unfortunately, triazoles 68u-v remained unreactive under the standard reaction conditions 
and not even traces of the target products were detected. Therefore, the process seems to be 
limited to the use of 4-phenyl and 4-benzyl triazole derivatives. 
 
Scheme 4.19. Unsuccessful attempts with triazoles 68u-v. 
4.2.2.4 Reaction mechanism 
As mentioned in the introduction section, C−H functionalization reactions catalyzed 
by palladium salts are commonly proposed to proceed via either Pd(0)/Pd(II) or 
Pd(II)/Pd(IV) redox cycles.
241
 Pd(IV) intermediates have been suggested in Pd-catalyzed 
aromatic C−H oxidation reactions since 1971,242 and Pd(II)/Pd(IV) catalysis cycles have 
subsequently become generally accepted as the operative mechanisms for a large class of Pd-
catalyzed oxidation reactions. In this regard, our group has recently reported a related Pd-
catalyzed C−H bromination procedure assisted by “click” triazoles, where D T studies 
supported the intermediacy of Pd(IV) species within the catalytic cycle. In particular, a 
palladacycle involving a “click”-triazole as DG was successfully characterized by X-Ray 
analysis verifying its bimetallic nature (Scheme 4.20).
243
  
                                                          
241  Yu, J.-Q.; Giri, R.; Chen, X. Org. Biomol. Chem. 2006, 4, 4041. 
242  Henry, P. M. J. Org. Chem. 1971, 36, 1886. 
243  Goitia, A.; Gómez-Bengoa, E.; Correa, A. Org. Lett. 2017, 19, 962.   
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Scheme 4.20. Synthesis of “click” 1,2,3-triazole complex A. 
In-depth DFT studies demonstrated that the oxidation of the Pd(II)-intermediate was 
more energetically favored to occur under the monomeric species rather than the bimetallic 
one, and hence dissociation of the palladacycle is believed to proceed prior to the 
corresponding oxidation step. Accordingly, we reasonably assumed that a similar reaction 
mechanism for the present Pd-catalyzed C−H oxygenation procedure may be operative. In 
this regard, although further mechanistic studies are clearly required to confirm the 
mechanistic scenario, a plausible reaction pathway is proposed in Scheme 4.21. 
 
Scheme 4.21. Proposed reaction mechanism. 
The reaction would start by a cyclopalladation step to furnish the corresponding 
palladacyclic intermediate IA which has been confirmed by DFT studies in related studies by 
our group to be more stable as its dimeric species IB. Based on DFT studies which revealed a 
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less favored oxidation step upon such bimetallic intermediate IB, a dissociation step was 
proposed to occur before its corresponding oxidation by treatment with a brominating agent. 
Accordingly, herein we also propose that the corresponding oxidation step would be more 
likely to happen on the monomeric palladacycle IA to afford the corresponding Pd(IV) 
intermediate IC. Some reports support such Pd(IV) complexes as active intermediates in Pd-
catalyzed C−H acetoxylations via oxidation of Pd(II) complexes with PhI(OAc)2.
223b,244
 
Eventually, C−O bond-forming reductive elimination from the monomeric Pd(IV) species 
would deliver the target product and regenerate the active Pd catalyst. 
4.2.2.5 Conclusions 
1. “Click” triazoles have been demonstrated to act as versatile and practical D s in Pd-
catalyzed C−H oxygenation reactions. Both acetoxy and pivaloxy groups can be 
efficiently introduced in a wide variety of substituted arenes and alkenes by our 
protocol. 
2. DG- and substrate-controlled selectivity towards monoacetoxylated products was 
achieved. The use of iodo-substituted DGs facilitated the ortho-oxygenation of 
C(sp
2
)−H bonds upon a DG-controlled pathway. Additionally, substrate-controlled 
selectivity was performed employing ortho- and meta- substituted arenes as well as 
vinylic compounds. 
3. The usefulness of the developed method was highlighted by the synthetically practical 
transformations that the prepared triazoles can undergo in cross-coupling reactions.
245
 
4.2.3 Cu-catalyzed C−H functionalization directed by bidentate DGs 
Despite the successful use of “click” triazoles as D s in Pd-catalyzed C−H 
oxygenation reactions, the use of Pd salts has been replaced by other sustainable metals in 
the last years. In this respect, we faced the implementation of cost-efficient Cu-catalysts in 
these C−H oxidation processes. If successful, such procedures would be clearly more 
appealing in terms of economics and sustainability. 
                                                          
244  a) Canty, A. J.; Denney, M. C.; van Koten, G.; Skelton, B. W.; White, A. H. Organometallics 2004, 
23, 5432. b) Dick, A. R.; Kampf, J. W.; Sanford, M. S. J. Am. Chem. Soc. 2005, 127, 12790. 
245  Irastorza, A.; Aizpurua, J. M.; Correa, A. Org. Lett. 2016, 18, 1080. 
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In this respect, we hypothesized that the use of bidentate DGs would result in the 
formation of a more robust catalyst in combination with copper salts (Scheme 4.22). For that 
purposes, we decided to synthesize TAM-derivative 76, which has been extensively utilized 
by Ackermann in a variety of C−C bond-forming processes,213 but its use in C−H oxidation 
reactions remains unexplored.  
 
Scheme 4.22. Cu-catalyzed C−H oxygenation strategy. 
Accordingly, we chose 76 as our model substrate since it could be prepared in 
multi-gram scale in essentially two steps from commercially available 2-methylbut-3-yn-
2-amine and freshly prepared benzyl azide under CuAAC conditions. The resulting triazole 
75, was then reacted with commercially available benzoyl chloride and triethylamine in 
DCM to obtain the desired compound 76 in 94 % yield.
213e
     
 
Scheme 4.23. Synthesis of compound 76. 
With substantial amounts of 76 in hand, we set out to investigate the viability of our 
hypothesis by testing a variety of experimental variables such as metals, ligands, additives, 
solvents and temperatures. Our initial reactions were performed using compound 76 in the 
presence of several copper catalysts such as Cu(OTf)2, Cu(OAc)2, CuBr2, CuCl2, CuF2, 
CuBr, CuCl, Cu(NO3)2·H2O, CuO and CuSO4·5H2O utilizing PIDA as oxidant and AcOH as 
additive in DCE at 110 ºC. Taking into consideration the mechanism proposed by several 
authors,
246
 both Cu(I) and Cu(II) are plausible for the reaction to occur.  
                                                          
246  a) Bhadra, S.;  Matheis, C.; Katayev, D.; Gooßen, L. J. Angew. Chem. Int. Ed. 2013, 52, 9279. b) 
Khemnar, A. B.; Bhanage, B. M. Org. Biomol. Chem. 2014, 12, 9631. c) Kumar, S.; Guin, R. S.; 
Gogoi, A.; Majji, G.; Patel, B. K. Org. Lett. 2014, 16, 1614. 
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Table 4.11. Screening of different copper salts. 
 
Entry [Cu] 77 (yield, %) Entry [Cu] 77 (yield, %) 
1 Cu(OTf)2 78 (60 %) 6 CuBr 0 
2 Cu(OAc)2 0 7 CuCl 0 
3 CuBr2 0 8 Cu(NO3)2·H2O 0 
4 CuCl2 0 9 CuO 0 
5 CuF2 0 10 CuSO4·5H2O 0 
 
As shown in Table 4.11, the target acetoxylated product 77 was not detected and 
starting material was recovered instead, except when utilizing Cu(OTf)2 as catalyst (entry 1) 
that compound 78 was obtained in 60 % yield. The formation of that olefinic derivative 
could be explained by first coordination of the hypervalent iodine reagent on the amide 
moiety and subsequent cleavage under acidic conditions. 
In order to favor the formation of the acetoxylated product 77 over the undesired 
formation of 78 as side-product, we further conducted a careful screening process of several 
reaction parameters such as oxidants, acetate sources, solvents, chelating ligands and a wide 
variety of additives.  
 
Scheme 2.24. Screening process with triazole 76. 
Unfortunately, all attempts were unfruitful and the target acetoxylation process was 
not favored under any tested reaction conditions. At this stage, we wondered whether the use 
of triazole derivative 79 bearing an extra methylene unit would render a more flexible system 
that could provide us more promising results. Accordingly, we successfully prepared triazole 
79 following a similar CuAAC/N-protection sequence in good overall yield.  
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Scheme 4.25. Synthesis of compound 79. 
In this case, regardless of the reaction conditions utilized, we neither obtained the 
corresponding acetoxylated derivative and either the starting material 79 was recovered or 
the undesired cleavage of the starting material was observed instead (Scheme 4.26).  
 
Scheme 4.26. Screening of reaction conditions for compound 79. 
At this stage, we concluded that whereas Pd salts were found to be efficient catalyst 
systems in C−H acetoxylations upon “click” triazoles, the use of more cost-efficient Cu-
catalysts was found unsuccessful and the corresponding acetoxylation process was not 
achieved so far. Further studies are currently ongoing in our laboratories in order to develop 
more sustainable C−H acetoxylation procedures with “click” triazoles.  
4.3 Pd-catalyzed C(sp2)−acylations with aldehydes  
4.3.1 Previous work 
Diaryl ketones are important motifs in the pharmaceutical, fragrance, dye, and 
agrochemical industries.
247
 Among numerous known methodologies for diaryl and aryl alkyl 
ketone synthesis, the most accepted procedure is Friedel-Crafts acylation, which involves the 
use of a stoichiometric amount of a Lewis acid and has poor functional group compatibility 
                                                          
247  a) Hruszkewycz, D. P.; Miles, K. C.; Thiel, O. R.; Stahl, S. S. Chem. Sci. 2017, 8, 1282. b) Benites, 
J.; Valderrama, J. A.; Ríos, D.; Lagos, R.; Monasterio, O.; Buc Calderon, P. Mol. Cell Toxicol. 
2016, 12, 237. c) Kohtani, S.; Nishioka, S.; Yoshioka, E.; Miyabe, H. Catal. Commun. 2014, 43, 
61. 
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and untenable regioselectivity.
248
 The oxidation of a secondary alcohol is also a powerful 
tool to access ketones, but stoichiometric amounts of oxidant are generally required.
249
 The 
reactions of carboxylic acid derivatives, such as nitriles, Weinreb amides, anhydrides, or acid 
chlorides with lithium, magnesium, or aluminum reagents are also important methods for the 
synthesis of the corresponding ketones.
250
 However, these transformations require either 
highly basic and nucleophilic or acidic conditions, resulting in low compatibility with most 
functional groups. Thus, the construction of elaborated ketones generally involves further 
functionalization steps that are time-consuming and occur with low yields. To circumvent 
these drawbacks, various alternative methods have been developed including the 
hydroacylation of olefins,
251
 acylation of aryl halides,
252
 carbonylative coupling,
253
 and 
arylboronate acylation with aldehydes.
254
 However, the transition metal-catalyzed acylation 
of the C−H bond of arenes has emerged as a new approach which represents another direct 
and promising pathway for the synthesis of the desired target products. 
In 2009, the Cheng group
255
 reported for the first time the palladium-catalyzed 
regioselective acylation of aromatic C−H bonds utilizing aldehydes in the presence of air as 
ideal oxidant (Scheme 4.27). 
 
Scheme 4.27. Direct acylation reaction with benzaldehyde 
                                                          
248  Olah, G. A. Friedel-Crafts Chemistry; Wiley. New York, 1973. 
249  a) Hudlicky, M. Oxidation in Organic Chemistry; American Chemical Society: Washington DC, 
1990. b) Tojo, G.; Fernandez, M. In Oxidation of Alcohols to Aldehyde and Ketones: A Guide to 
Current Common Practice; Tojo, G., Ed.; Springer: New York, 2006. 
250  a) Larock, R. C. Comprehensive Organic Transformations; VCH: New York, 1989, 685. b) March, 
J. Advanced Organic Chemistry, 3rd ed.; Wiley: New York, 1985, 433 and 824. 
251  a) Park, Y. J.; Park, J.-W.; Jun, C.-H. Acc. Chem. Res. 2008, 41, 222. b) Willis, M. C. Chem. Rev. 
2010, 110, 725.  
252  Ruan, J.; Xiao, J. Acc. Chem. Res. 2011, 44, 614.  
253  a) Wu, X.-F.; Neumann, H.; Beller, M. Chem. Soc. Rev. 2011, 40, 4986. b) Sharma, P.; Rohilla, S.; 
Jain, N. J. Org. Chem. 2017, 82, 1105. 
254  a) Pucheault, M.; Darses, S.; Genet, J.-P. J. Am. Chem. Soc. 2004, 126, 15356. b) Li, H.; Xu, Y.; 
Shi, E.; Wei, W.; Suo, X.; Wan, X. Chem. Commun. 2011, 47, 7880. 
255  Jia, X.; Zhang, S.; Wang, W.; Luo, F.; Cheng, J. Org. Lett. 2009, 11, 3120. 
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Shortly afterwards, Li and co-workers
256
 developed an efficient palladium-catalyzed 
pyridine-directed oxidative acylation of sp
2
 C−H bonds with aldehydes utilizing tert-butyl 
hydroperoxide as oxidant under neat conditions. In contrast to the previous synthetic method, 
this methodology enabled cross-couplings with both aromatic and aliphatic aldehydes. 
Subsequently, Deng and co-workers reported the practical acylation of arene C−H bonds 
using benzylic and aliphatic alcohols, which were in situ oxidized to the corresponding 
aldehydes and used as acylation reagents.
257
 In 2010, Yu and co-workers
258
 utilized oximes 
as DGs for the direct C−H bond acylation between aromatic oximes and aldehydes using 
tert-butyl hydroperoxide as oxidant. At almost the same time, the groups of Wang,
259
 
Kwong,
260
 and Yu
261
 developed the palladium-catalyzed ortho-acylation of acetanilides with 
aldehydes. Thereafter, aldehydes,
262
 α-oxocarboxylic acids,263 alcohols,264 toluene,265 and 
benzylic ethers
266
 were used as acylating reagents in direct ortho-acylations of aromatic C−H 
bonds.  
Taking palladium-catalyzed acylation of 2-phenylpyridine as a model example, a 
plausible reaction mechanism is depicted in Scheme 4.28. The reaction would be initiated by 
ortho-C−H activation/cyclopalladation of 2-phenylpyridine with palladium to form a 
bimetallic Pd
II
 complex I. The aldehyde would undergo its transformation to the radical II in 
the presence of the oxidant (TBHP in this case). Then, intermediate I would capture the acyl 
radical through an oxidative addition step to give intermediate III, which might be a Pd(IV) 
                                                          
256  Baslé, O.; Bidange, J.; Shuai, Q.; Li, C.-J. Adv. Synth. Catal. 2010, 352, 1145. 
257  Xiao, F.; Shuai, Q.; Zhao, F.; Baslé, O.; Deng, G.; Li, C.-J. Org. Lett. 2011, 13, 1614. 
258  Chan, C.-W.; Zhou, Z.; Chan, A. S. C.; Yu, W.-Y. Org. Lett. 2010, 12, 3926. 
259  Li, C.; Wang, L.; Li, P.; Zhou, W. Chem. Eur. J. 2011, 17, 10208. 
260  Wu, Y.; Li, B.; Mao, F.; Li, X.; Kwong, F. Y. Org. Lett. 2011, 13, 3528. 
261  Chan, C.-W.; Zhou, Z.; Yu, W.-Y. Adv. Synth. Catal. 2011, 353, 2999. 
262  a) Xiao, F.; Chen, S.; Huang, H.; Deng, G. Eur. J. Org. Chem. 2015, 7919. b) Basle, O.; Bidange, 
J.; Shuai, Q.; Li, C. Adv. Synth. Catal. 2010, 352, 1145. 
263  a) Wang, H.; Guo, L. N.; Duan, X. H. Org. Lett. 2012, 14, 4358. b) Miao, J.; Ge, H. Org. Lett. 
2013, 15, 2930. c) Chen, X.; Cui, X.; Wu, Y. Org. Lett. 2016, 18, 3722. d) Wu, Y.; Sun, L.; Chen, 
Y.; Zhou, Q.; Huang, J.; Miao, H.; Luo, H. J. Org. Chem. 2016, 81, 1244. 
264  a) Yuan, Y.; Chen, D.; Wang, X. Adv. Synth. Catal. 2011, 353, 3373. b) Park, J.; Kim, A.; Sharma, 
S.; Kim, M.; Park, E.; Jeon, Y.; Lee, Y.; Kwak, J. H.; Jung, Y. H.; Kim, I. S. Org. Biomol. Chem. 
2013, 11, 2766. c) Hou, L.; Chen, X.; Li, S.; Cai, S.; Zhao, Y.; Sun, M.; Yang, X. Org. Biomol. 
Chem. 2015, 13, 4160. d) Luo, F.; Yang, J.; Li, Z. K.; Xiang, H. K.; Zhou, X. G. Eur. J. Org. 
Chem. 2015, 2463.  
265  a) Yin, Z.; Sun, P. J. Org. Chem. 2012, 77, 11339. b) Song, H.; Chen, D.; Pi, C.; Cui, X.; Wu, Y. J. 
Org. Chem. 2014, 79, 2955. 
266  Han, S.; Sharma, S.; Park, J.; Kim, M.; Shin, Y.; Mishra, N. K.; Bae, J. J.; Kwak, J. H.; Jung, Y. H.; 
Kim, I. S. J. Org. Chem. 2014, 79, 275. 
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or a bimetallic Pd(III)-Pd(III) complex. Finally, reductive elimination upon III would result 
in the formation of the acylated product and regeneration of the active Pd(II) species to fullfil 
the catalytic cycle. 
 
Scheme 4.28. Pd-catalyzed ortho-acylation of 2-phenylpyridine.  
As mentioned before, 1,2,3-triazole-containing DGs have recently received a great 
deal of attention to accomplish C−H bond functionalizations. In particular, 2-phenyl-1,2,3-
triazoles have been utilized as versatile compounds to perform metal-catalyzed C−H 
acylation processes with aldehydes,
267
 toluene
268
 and benzyl alcohols.
269
 Given the practical 
bonus of easy-assembly of “click” triazoles vs 2-substituted 1,2,3-triazoles, we envisioned 
their alternative use in Pd-catalyzed C−H  acylations with aldehydes. If successful, our 
protocol would complement existing methodologies to produce diaryl ketones featuring the 
unprecedent role of “click” triazoles as versatile D s in C−H acylation events. 
                                                          
267  Wang, Z.; Tian, Q.; Yu, X.; Kuang, C. Adv. Synth. Catal. 2014, 356, 961. 
268  He, P.; Tian, Q.; Kuang, C. Synthesis 2015, 47, 1309. 
269  Premi, C.; Patel, S. S.; Jain, N. Eur. J. Org. Chem. 2016, 3788. 
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Scheme 4.29. Metal-catalyzed C−H acylation processes with 1,2,3-triazoles. 
4.3.2 Results and discussion 
In order to test the feasibility of our approach, we first synthesized triazole 
derivative 80 in 99 % yield upon CuAAC (scheme 4.30).  
 
Scheme 4.30. Synthesis of 1,2,3-triazole 80.   
Having selected triazole 80 as the model substrate, a variety of experimental 
variants such as metal, oxidant, solvent, ligand and temperature were systematically 
examined. Encouraged by our successful results on the development of a Pd-catalyzed C−H 
acetoxylation reaction, we first tested different Pd sources and used commercially available 
4-methylbenzaldehyde 81 as acyl source and TBHP as oxidant in DCE at 100 ºC 
(Table 4.12).  
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Table 4.12. Screening of palladium sources.a   
 
Entry [Pd] catalyst Yield (%)
b
 Entry [Pd] catalyst Yield (%)
b
 
1 Pd(OAc)2 29 6 PdCl2(PPh3)2 0 
2 Pd(TFA)2 34 7 PdCl2(MeCN)2 0 
3 Pd(dba)2 24 8 PdI2 0 
4 PdCl2 0 9 PdCl2(PhCN)2 0 
5 Pd(PPh3)4 0    
aReaction conditions: 80 (0.25 mmol), MePhCHO (2.0 equiv.), THBP (1.0 equiv.), DCE (1 mL) at 100 
ºC for 24 h. bIsolated yield after purification by column chromatography. 
As depicted in Table 4.12, a wide variety of palladium catalysts, including Pd(II) 
and Pd(0) salts were examined in the model reaction. The target acylation process occurred 
when using Pd(OAc)2 (entry 1), Pd(TFA)2 (entry 2) and Pd(dba)2 (entry 3), albeit in low 
yields. Other Pd sources were found inactive under the standard conditions (entries 4-9). 
Accordingly, we further evaluated other reaction parameters utilizing Pd(TFA)2 as the 
catalyst of choice, which provided product 82 in 34 % yield.  
We next evaluated the influence of different oxidants in the reaction outcome. As 
depicted in Table 4.13, the only oxidant capable of promoting the target acylation was found 
to be TBHP, both in decane and aqueous solution (entry 1 and 2, respectively), which 
afforded acylated compound 82 in 34 % yield. Conversely, other peroxides (entries 4-8), 
metal salts (entries 9-12), and persulfates (entries 14-15) were entirely ineffective in the 
tested process. 
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Table 4.13. Screening of oxidants.a   
 
Entry Oxidant Yield (%)
b
 Entry Oxidant Yield (%)
b
 
1 TBHP dec. 34 10 Ag2CO3 0 
2 TBHP aq. 34 (37)
c
 11 AgOAc 0 
3 H2O2 0 12 Cu(OAc)2 0 
4 DTBP n.d. 13 Oxone 0 
5 CHP n.d. 14 K2S2O8 0 
6 BPO n.d. 15 (NH4)2S2O8 0 
7 TBPB n.d. 16 NBS 0 
8 DCP 0 17 DDQ 0 
9 Ag2O 0 18 PIDA 83 (43 %) 
aReaction conditions: 80 (0.25 mmol), MePhCHO (2.0 equiv), Pd(TFA)2 (10 mol %), THBP (1.0 
equiv.), DCE (1 mL) at 100 ºC for 24 h. bIsolated yield after purification by column chromatography. 
cOxidant (4 equiv.) 
It is well-known that C−H functionalization reactions can be dramatically favored 
upon addition of certain additives. For instance, N-protected aminoacids have been 
extensively utilized in Pd-catalyzed C−H functionalization process,270 and diamine-type 
ligands can be also beneficial additives in related processes.
271
 Accordingly, we examined 
the influence of numerous additives in our model reaction. As depicted in Table 4.14, most 
of the additives entirely inhibited the process and starting material was recovered instead. 
                                                          
270  a) Cheng, G.-J.; Yang, Y.-F.; Liu, P.; Chen, P.; Sun, T.-Y.; Li, G.; Zhang, X.; Houk, K. N.; Yu, J.-
Q.; Wu, Y.-D. J. Am. Chem. Soc. 2014, 136, 894. b) Engle, K. M. Pure Appl. Chem. 2016, 88, 119. 
c) Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem. Int. Ed. 2010, 49, 6169. d) Engle, K. M.; 
Wang, D.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 14137. e) Baxter, R. D.; Sale, D.; Engle, K. 
M.; Yu, J.-Q.; Blackmond, D. G. J. Am. Chem. Soc. 2012, 134, 4600. f) Novak, P.; Correa, A.; 
Gallardo-Donaire, J.; Martin, R. Angew. Chem. Int. Ed. 2011, 50, 12236. 
271
  Gao, X.; Wu, B.; Huang, W.-X.; Chen, M.-W.; Zhou, Y.-G. Angew. Chem. Int. Ed. 2015, 54, 
11956. 
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However, certain carboxylic acids (entries 1-6) did not affect the reaction outcome and 
similar results to that obtained in their absence were achieved.  
Table 4.14. Screening of additives.a 
 
Entry Additive Yield (%)
b
 Entry Additive Yield (%)
b
 
1
c
 2,4,6-trimethylbenzoic 
acid 
32 14
c
 KI n.d. 
2
c
 2-(3,5-dimethylphenyl)   
acetic acid 
33 15
c
 N-Acetylglycine 0 
3
c
 PivOH 34 16
d
 Ac-Gly-OH 0 
4
c
 Benzoic acid 33 17
d
 Boc-Phe-OH 0 
5
c
 AcOH 30 18
d
 CBz-Phe-OH 0 
6
c
 AdCO2H 32 19
d
 Boc-Pro-OH 0 
7
c
 2-Nitrobenzoic acid 0 20
d
 Boc-Gly-OH 0 
8
c
 2-Picolinic acid 0 21
d
 Boc-Ala-OH 0 
9
c
 TFA 0 22
d
 CBz-Leu-OH 0 
10
c
 TsOH·H2O 0 23
d
 Boc-Leu-OH 0 
11
c
 TBAB 0. 24
e
 Bipy 0 
12
c
 TBAI n.d. 25
e
 Phen 0 
13
c
 KBr n.d. 26
e
 DMAP 0 
aReaction conditions: 80 (0.25 mmol), MePhCHO (2.0 equiv.), Pd(TFA)2 (10 mol %), THBP (1.0 
equiv.), additive (X equiv.), DCE (1 mL) at 100 ºC for 24 h. bIsolated yield after purification by column 
chromatography. cAdditive (2 equiv.). dAdditive (30 mol %.). eAdditive (20 mol %.). 
Finally, the target process was performed in different solvents and the particular use 
of a combination of DCE and MeCN (Table 4.15, entry 8) afforded slightly better results 
providing acylated triazole 82 in 42 % yield. Remarkably, the performance of the process at 
70 ºC furnished similar results. 
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Table 4.15. Screening of solvents.
a 
 
Entry Solvent Yield (%)
b
 Entry Solvent Yield (%)
b
 
1 DCE 37 8 DCE-MeCN 42 (42)
c
 
2 Toluene n.d. 9 DCE-DMF n.d. 
3 MeCN n.d. 10 DCE-NMP n.d. 
4 Dimethoxyethane n.d. 11 DCE-DMA n.d. 
5 Chlorobenzene n.d. 12 Bn2O n.d. 
6 DMF 0 13 DCE-CCl4 0 
7 1,4-dioxane n.d. 14 DCE-HFIP 0 
aReaction conditions: 80 (0.25 mmol), MePhCHO (2.0 equiv.), Pd(TFA)2 (10 mol %), THBP (1.0 
equiv.), solvent (1 mL) at 100 ºC for 24 h.  bIsolated yield after purification by column chromatography. 
cReaction at 70 ºC. 
Although the catalyst system was far from being optimal, we decided to test the 
influence of using different aldehydes to evaluate if the use of more activated acyl sources 
could result in better yields. Interestingly, the particular use of 4-methoxybenzaldehyde 
provided the corresponding product in 46 % yield (Table 16, entry 5). However, other 
aromatic or aliphatic aldehydes were found less reactive. 
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Table 4.16. Screening of aldehydes for triazole 80.a 
 
Entry Aldehyde Yield (%)
b
 Entry Aldehyde Yield (%)
b
 
1 
 
42 6 
 
n.d. 
2 
 
0 7 
 
32 
3 
 
38 8 
 
n.d. 
4 
 
39 9 
 
n.d. 
5 
 
46 10  n.d. 
aReaction conditions: 80 (0.25 mmol), RCHO (2.0 equiv.), Pd(TFA)2 (10 mol %), TBHP aq. 
(4.0 equiv.), DCE-MeCN (1 mL) at 70 ºC for 24 h. bIsolated yield after purification by column 
chromatography. 
In a final attempt to improve our system, we decided to test the influence of using 
different N1-substituted triazoles. In this respect, the electronic nature of the triazole unit 
acting as DG could be tuned and hence a superior reactivity could be expected for triazoles 
having a higher metal-binding ability. Importantly, the particular use of (4-cyano)benzyl 
substituent resulted in a remarkable 57 % yield of the corresponding coupling product. 
Unfortunately, other N1-substituted triazoles were found even less reactive than the model 
substrate.  
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Table 4.17. Screening of triazoles for aldehyde 85.a 
 
Entry Triazole Yield (%)
b
 
1 
 
29 
2 
 
57 
3 
 
n.d. 
4 
 
27 
5 
 
31 
aReaction conditions: Triazole (0.25 mmol), MeOPhCHO (2.0 equiv.), Pd(TFA)2 (10 mol %), 
TBHP aq. (4.0 equiv.), DCE-MeCN (1 mL) at 70 ºC for 24 h.  bIsolated yield after purification by 
column chromatography. 
To our surprise, at the time we were performing our studies Jiang and coworkers 
reported a similar Pd-catalyzed acylation protocol assisted by “click” triazoles where the 
addition of XPhos as supporting ligand was crucial to obtain a good catalyst performance.
272
  
                                                          
272  a) Zhao, F.; Chen, Z.; Liu, Y.; Xie, K.; Jiang, Y. Eur. J. Org. Chem. 2016, 5971. b) Jiang, Y.; Ma, 
X.; Zhao, F.; Han, C. Synlett 2017, 28, 713. 
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Scheme 4.31. Palladium-catalyzed acylation process reported by Jiang.  
4.3.3 Conclusions 
The use of “click” triazoles as practical D s in Pd-catalyzed C−H acylation events 
has been extensively studied. However, despite of our research efforts, an optimal system 
was not found and in all cases moderate yields were obtained. In any case, our hypothesis 
was found to be valid and the acylation of certain C(sp
2
)–H bonds directed by simple “click” 
triazoles was successfully achieved, albeit in low to moderate yields. Further studies are 
currently under way in our group to explore new synthetic opportunities of 1,2,3-triazoles as 
versatile DGs in the realm of C−H functionalization. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Experimental 
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Experimental 
General Considerations 
Reagents: Commercially available materials were used without further purification. 
Palladium(II) acetate recrystallized (97 % purity), (diacetoxy)iodobenzene (98 % purity), 
bis(tert-butylcarbonyloxy)iodobenzene (97 % purity), and 1,2-dichloroethane 
(spectrophotometric grade, ≥99 %) were purchased from Sigma-Aldrich. AcOH (acetic acid 
glacial, extra pure) was purchased from Scharlau and Ac2O (acetic anhydride) was purchased 
from Panreac.  
Analytical Methods: 
1
H NMR and 
13
C NMR spectra as well as IR, HRMS and 
melting points (where applicable) are included for all new compounds. 
1
H and 
13
C NMR 
spectra were recorded on a Bruker 400 MHz and 500 MHz at 20 ºC. All 
1
H NMR spectra are 
reported in parts per million (ppm) downfield of TMS and were measured relative to the 
signals for CHCl3 (7.26 ppm), unless otherwise indicated. All 
13
C NMR spectra were 
reported in ppm relative to residual CHCl3 (77 ppm), unless otherwise indicated, and were 
obtained with 
1
H decoupling. Coupling constants, J, are reported in hertz. Melting points 
were measured using open glass capillaries in a Büchi SMP-20 apparatus. Mass spectra were 
performed by SGIker and were acquired on a time of flight (TOF) mass spectrometer 
(SYNAPT G2 HDMS from Waters, Milford, MA, USA) equipped with an electrospray 
source in positive mode (ESI
+
). The chromatographic separation was performed using an 
ACQUITY UPLC system from Waters (Milford, MA, USA) equiped with an Acquity UPLC 
BEH C18 1.7 μm, 50 x 2.1 mm column at 30 °C. Mobile phases consisted of 0.1 % formic 
acid in water (A) and 0.1 % formic acid in methanol (B). Separation was carried out in 5 
min: initial conditions were 5 % B, raised to 100 % B over 2.5 min, held at 100 % B until 4 
min, decreased to 5 % B over 0.1 min and held at 5 % B until 5 min for re-equilibration of 
the system. Flow rate was 0.25 mL/min and injection volume was 5 μL. Infrared spectra 
were recorded on a Bruker Alpha P. Flash chromatography was performed with EM Science 
silica gel 60 (230-400 mesh). 
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4.1 Synthesis of the starting materials 
4.1.1 General procedure for the synthesis of 1,2,3-triazoles 
 
General Procedure A: alkyne (1.0 equiv) and the corresponding azide (1.1 equiv) were 
dissolved in a mixture of deoxygenated tBuOH/H2O (4:1, 1 mL/mmol). Then a 
deoxygenated aq. solution of CuSO4·5H2O (10 mol %, 1mL/mmol) followed by a 
deoxygenated aq. solution of sodium ascorbate (40 mol %, 1mL/mmol) was added. The 
resulting mixture was stirred under inert atmosphere at room temperature overnight. The 
solvent was partially evaporated under reduced pressure and the resulting solution was 
washed with aq. NH4OH, extracted with AcOEt and washed with brine. The combined 
organic layers were dried over MgSO4, and concentrated under reduced pressure. The crude 
residue was purified by flash chromatography (hex/AcOEt 7/3) unless otherwise noted. 
 
General Procedure B: 1-bromo-3-methylbutane (1.0 equiv) was drop wise added over a 
solution of NaN3 (1.1 equiv) in HMPA (0.6 mL/mmol). The resulting solution was stirred 
under argon at room temperature for 4 hours. Then, CuI (10 mol %), alkyne (1.0 equiv) and 
DIPEA (5.0 mL/mmol) were subsequently added and the resulting solution was stirred at 
room temperature overnight. Next, it was washed with HCl 10 %, aq. NH4OH, extracted with 
AcOEt and washed with brine. The combined organic layers were dried over MgSO4, and 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (hex/AcOEt 7/3) unless otherwise noted. 
 
General Procedure C: 1-bromo-3-methylbutane (1.0 equiv) was dropwise added over a 
solution of NaN3 (1.1 equiv) in HMPA (0.6 mL/mmol). The resulting solution was stirred 
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under argon at room temperature for 4 h. In a different flask CuI (1.0 equiv) was dissolved in 
MeCN (2.4 mL/mmol) under argon at room temperature. A solution of N-bromosuccinimide 
(1.2 equiv) in MeCN (2.4 mL/mmol) was added and stirred 5 min at room temperature. Later 
on, the previously prepared azide-containing solution along with alkyne (1.0 equiv) and 
DIPEA (1.1 equiv) were subsequently added and the resulting mixture was stirred at room 
temperature overnight. Next, the mixture was washed with HCl 10 %, aq. NH4OH, extracted 
with AcOEt and washed with brine. The combined organic layers were dried over MgSO4, 
and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (hex/AcOEt 7/3) unless otherwise noted. 
 
Methyl 2-methyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl) propanoate (68f). Following the 
general procedure A, using in situ generated methyl 2-azido-2-methylpropanoate (7.4 mmol) 
and phenylacetylene (8.2 mmol, 0.9 mL) provided 216 mg (13 % yield) of 68f as a white 
solid. Mp 101-103 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.91 (s, 1H), 7.84 (d, J = 7.0 Hz, 2H), 
7.41 (t, J = 7.7 Hz, 2H), 7.33 (d, J = 7.4 Hz, 1H), 3.73 (s, 3H), 1.99 (s, 6H). 
13
C NMR (101 
MHz, CDCl3): δ 171.9, 147.5, 130.7, 128.9, 128.2, 125.8, 118.5, 64.6, 53.4, 25.9. IR (neat, 
cm
-1
): 3130, 1739, 1626, 1279, 1163, 1157, 1081, 767, 695. MS (ESI
+
) m/z (%) 246 (M+H). 
HRMS calcd. for (C13H16N3O2): 246.1243, found 246.1240.  
 
1-Mesityl-4-(m-tolyl)-1H-1,2,3-triazole (68m) Following the general procedure A, using 2-
azido-1,3,5-trimethylbenzene
273
 (3.90 mmol, 630 mg) and 3-ethynyltoluene (4.30 mmol, 0.54 
mL) provided 1.05 g (97 % yield) of 68m as a brown solid. Mp 91-92 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.82 (d, J = 12.4 Hz, 2H), 7.71 (d, J = 7.7 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 
7.17 (d, J = 7.7 Hz, 1H), 7.00 (s, 2H), 2.42 (s, 3H), 2.39 (s, 3H), 2.01 (s, 6H). 
13
C NMR (101 
MHz, CDCl3): δ 147.7, 140.0, 138.6, 135.1, 133.5, 130.4, 129.1, 129.0, 128.8, 126.4, 122.9, 
                                                          
273  Abram, S.-L.; Monte-Pérez, I.; Pfaff, F. F.; Farquhar, E. R.; Ray, K. Chem. Commun. 2014, 50, 
9852. 
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121.5, 21.5, 21.2, 17.3. IR (neat, cm
-1
): 2918, 1491, 1378, 1226, 1036, 784, 695. MS (ESI
+
) 
m/z (%) 278 (M+H). HRMS calcd. for (C18H20N3): 278.1657, found 278.1654. 
 
Benzyl 2-(4-(cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)acetate (68n). Following the 
general procedure A, using benzyl 2-azidoacetate
274
 (9.00 mmol, 1.73 g) and 1-
ethynylcyclohexene (10.00 mmol, 1.20 mL) provided 2.30 g (85 % yield) of 68n as a white 
solid. Mp 95-98 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.51 (s, 1H), 7.36 (d, J = 7.3 Hz, 5H), 
6.54 (s, 1H), 5.19 (d, J = 21.5 Hz, 4H), 2.38 (s, 2H), 2.20 (s, 2H), 1.72 (dd, J = 34.5, 5.9 Hz, 
4H). 
13
C NMR (101 MHz, CDCl3): δ 166.4, 150.1, 134.7, 128.9, 128.8, 128.6, 127.1, 125.5, 
119.7, 68.0, 50.9, 26.5, 25.4, 22.5, 22.3. IR (neat, cm
-1
): 2927, 2857, 2831, 1750, 1675, 1454, 
1385, 1195, 942, 748, 698. MS (ESI
+
) m/z (%) 298 (M+H). HRMS calcd. for (C17H20N3O2): 
298.1556, found 298.1552. 
 
4-[(4-Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)methyl]benzonitrile (68o). Following the 
general procedure A, using 4-(azidomethyl)benzonitrile
275
 (8.60 mmol, 1.36 g) and 1-
ethynylcyclohexene (9.50 mmol, 1.00 mL) provided 2.20 g (97 % yield) of 68o as a white 
solid without requiring chromatographic purification. Mp 131-134 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.62 (d, J = 7.9 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J = 7.9 Hz, 2H), 6.50 (s, 1H), 5.56 
(s, 2H), 2.32 (s, 2H), 2.16 (s, 2H), 1.68 (dd, J = 32.6, 5.9 Hz, 4H). 
13
C NMR (101 MHz, 
CDCl3): δ 150.4, 140.3, 132.9, 128.3, 127.0, 125.7, 118.5, 118.3, 112.6, 53.3, 26.4, 25.3, 
22.4, 22.2. IR (neat, cm
-1
): 2934, 2860, 2831, 2232, 1446, 1314, 1197, 1036, 798, 768, 546. 
MS (ESI
+
) m/z (%) 265 (M+H). HRMS calcd. for (C16H17N4): 265.1453, found 265.1452.  
 
 
 
                                                          
274  Pokorski, J. K.; Jenkins, L. M. M.; Feng, H.; Durell, S. R.; Bai, Y.; Appella, D. H. Org. Lett. 2007, 
9, 2381. 
275  Liu, M.; Reiser, O. Org. Lett. 2011, 13, 1102. 
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1-[4-(Tert-butyl)benzyl)]-4-(cyclohex-1-en-1-yl)-1H-1,2,3-triazole (68p). Following the 
general procedure A, using 1-ethynylcyclohex-1-ene (9.42 mmol, 1.10 mL) and 4-(tert-
butyl)benzyl azide
276
 (10.40 mmol, 1.96 g) provided 2.76 g (99 % yield) of 68p as a white 
solid without requiring chromatographic purification. Mp 132-133 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.40 (d, J = 8.0 Hz, 2H), 7.33 (s, 1H), 7.22 (d, J = 7.9 Hz, 2H), 6.50 (t, J = 4.0 Hz, 
1H), 5.48 (s, 2H), 2.37 (dq, J = 6.1, 3.3 Hz, 2H), 2.25-2.12 (m, 2H), 1.82- 1.56 (m, 4H), 1.33 
(s, 9H). 
13
C NMR (101 MHz, CDCl3): δ 151.6, 149.8, 131.9, 127.7, 127.3, 125.9, 124.9, 
118.1, 53.6, 34.5, 31.2, 26.3, 25.2, 22.4, 22.1. IR (neat, cm
-1
): 1433, 1050, 710, 679. MS 
(ESI
+
) m/z (%) 296 (M+H). HRMS calcd. for (C19H26N3): 296.2127, found 296.2129.  
 
2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl 4-methylbenzenesulfonate (68q). 
Following the general procedure A, using 2-(prop-2-yn-1-yl)phenol
277
 (7.20 mmol, 956 mg) 
and benzyl azide (7.20 mmol, 963 mg) provided 1.80 g (95 % yield) of 2-[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]phenol as a white solid. Then, such triazole (1.88 mmol, 500 mg) 
was dissolved in CH2Cl2 (5 mL) and tosyl chloride (2.26 mmol, 431 mg) was added. The 
mixture was cooled to 0 ºC, and triethylamine (2.26 mmol, 0.32 mL) was added. The 
resulting solution was warmed to room temperature and after complete consumption of the 
starting material, the reaction was acidified with HCl (10 %). The aqueous layer was 
extracted with CH2Cl2 and the combined organic layers were dried (anhydrous MgSO4), 
filtered and evaporated under reduced pressure. The crude residue was purified by flash 
chromatography to provide 788 mg (99 %) of 68q as a white solid. Mp 110-114ºC. 
1
H NMR 
(400 MHz, CDCl3): δ 7.74 (d, J = 8.0 Hz, 2H), 7.41-6.99 (m, 12H), 5.48 (s, 2H), 3.93 (s, 
2H), 2.47 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 147.7 146.3, 145.7, 134.9, 133.0, 132.7, 
131.3, 130.0, 129.1, 128.7, 128.43, 128.0, 127.9, 127.4, 122.4, 122.0, 54.2, 26.4, 21.9. IR 
(neat, cm
-1
): 1375, 1191, 1158, 1083, 868, 711, 550. MS (ESI
+
) m/z (%) 420 (M+H). HRMS 
calcd. for (C23H22N3O3S): 420.1304, found 420.1305.   
                                                          
276  Robinson, S. W.; Mustoe, C. L.; White, N. G.; Brown, A.; Thompson, A. L.; Kennepohl, P.; Beer, 
P. D. J. Am. Chem. Soc. 2015, 137, 499. 
277  Zhang, Q.; Takacs, J. M. Org. Lett. 2008, 10, 545. 
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2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl benzoate (68r) To a solution 2-[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]phenol (1.88 mmol, 500 mg) in CH2Cl2 (5 mL) benzoyl 
chloride (2.20 mmol, 0.26 mL) was added. The mixture was cooled to 0 ºC, and 
triethylamine (2.26 mmol, 0.32 mL) was added. The resulting solution was warmed to room 
temperature and after complete consumption of the starting material, the reaction was 
acidified with HCl (10 %). The aqueous layer was extracted with CH2Cl2 and the combined 
organic layers were dried (anhydrous MgSO4), filtered and evaporated under reduced 
pressure. The crude residue was purified by flash chromatography to provide 678 mg (98 % 
yield) of 68r as a white solid. Mp 86-87ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 7.7 
Hz, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.36-7.13 (m, 9H), 7.10 (s, 1H), 
5.40 (s, 2H), 4.07 (s, 2H). 
13
C NMR (101 MHz, CDCl3): δ 165.0, 149.1, 146.7, 134.9, 133.8, 
131.2, 130.9, 130.2, 129.2, 129.1, 128.7, 128.6, 128.1, 128.0, 126.5, 122.7, 121.7, 54.1, 27.1. 
IR (neat, cm
-1
): 1739, 1449, 1214, 1051, 701. MS (ESI
+
) m/z (%) 370 (M+H). HRMS calcd. 
for (C23H20N3O2): 370.1477, found 370.1479. 
 
1-Benzyl-4-(3-methylbenzyl)-1H-1,2,3-triazole (68s). Following the general procedure A, 
using benzyl azide (4.23 mmol, 563 mg) and 3-(m-tolyl)-1-propyne (3.85 mmol, 500 mg) 
provided 778 mg (77 % yield) of 68s as a white solid. Mp 77-78 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.37 (d, J = 5.9 Hz, 3H), 7.32-7.13 (m, 4H), 7.07 (dd, J = 12.0, 6.7 Hz, 3H), 5.48 
(s, 2H), 4.06 (s, 2H), 2.34 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 148.0, 138.8, 138.0, 
134.7, 129.3, 128.9, 128.4, 128.3, 127.8, 127.0, 125.5, 121.2, 53.8, 32.1, 21.2. IR (neat,     
cm
-1
): 1607, 1124, 787, 709. MS (ESI
+
) m/z (%) 264 (M+H). HRMS calcd. for (C17H18N3): 
264.1422, found 264.1422. 
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1-[Bis(trimethylsilyl)methyl]-4-phenyl-1H-1,2,3-triazole (68x) (Table 2). Following the 
general procedure B, using (chloromethylene)bis(trimethylsilane) (5.95 mmol, 1.30 mL) and 
phenylacetylene (5.95 mmol, 0.65 mL) provided 1.53 g (87 % yield) of 68x as a white solid. 
Mp 81-86 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.86-7.79 (m, 2H), 7.54 (s, 1H), 7.41 (t, J = 7.6 
Hz, 2H), 7.34-7.27 (m, 1H), 3.65 (s, 1H), 0.13 (s, 18H). 
13
C NMR (101 MHz, CDCl3):          
δ 147.0, 131.2, 128.9, 128.0, 125.6, 120.2, 46.9, -0.9. IR (neat, cm-1): 2882, 1249, 1045, 842, 
760, 687. MS (ESI
+
) m/z (%) 304 (M+H). HRMS calcd. for (C15H26N3Si2): 304.1665, found 
304.1656. 
 
1-Isopentyl-4-(2-methoxyphenyl)-1H-1,2,3-triazole (68y). Following the general 
procedure B, using 1-ethynyl-2-methoxybenzene (3.78 mmol, 0.49 mL) provided 600 mg (69 
% yield) of 68y as a yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 8.31 (d, J = 7.7 Hz, 1H), 7.97 
(s, 1H), 7.18 (t, J = 7.9 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 4.26 (t, J = 
7.6 Hz, 2H), 3.79 (s, 3H), 1.71 (q, J = 7.3 Hz, 2H), 1.50 (dt, J = 13.4, 6.7 Hz, 1H), 0.85 (d, J 
= 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 155.1, 142.4, 128.3, 126.9, 122.5, 120.3, 
119.0, 110.3, 54.8, 48.0, 38.6, 25.0, 21.7. IR (neat, cm
-1
): 1538, 1243, 1069, 752. MS (ESI
+
) 
m/z (%) 246 (M+H). HRMS calcd. for (C14H20N3O): 246.1606, found 246.1607.  
 
1-Isopentyl-4-[2-(trifluoromethyl)pheny])-1H-1,2,3-triazole (68z). Following the general 
procedure B, using 1-ethynyl-2-(trifluoromethyl)benzene (2.94 mmol, 0.41 mL) provided 
413 mg (50 % yield) of 68z as a white solid. Mp 40-41 ºC. 
1
H NMR (400 MHz, CDCl3):       
δ 7.95 (d, J = 7.8 Hz, 1H), 7.79-7.66 (m, 2H), 7.59 (t, J = 7.7 Hz, 1H), 7.44 (t, J = 7.8 Hz, 
1H), 4.42 (t, J = 7.5 Hz, 2H), 1.83 (q, J = 7.3 Hz, 2H), 1.59 (dt, J = 13.5, 6.7 Hz, 1H), 0.95 
(d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 144.0, 131.9, 131.5, 129.6, 128.1, 127.0 
(d, J = 30 Hz), 125.9 (q, J = 10 Hz), 125.4, 122.6 (q, J = 10 Hz), 48.7, 38.9, 25.4, 22.1. IR 
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(neat, cm
-1
): 1581, 1312, 1100, 767. MS (ESI
+
) m/z (%) 284 (M+H). HRMS calcd. for 
(C14H27N3F3): 284.1375, found 284.1381. 
 
1-Isopentyl-4-(m-tolyl)-1H-1,2,3-triazole (68za). Following the general procedure B, using 
1-ethynyl-3-methylbenzene (8.61 mmol, 1.09 mL) provided 1.70 g (86 % yield) of 68za as a 
white solid. Mp 51-52 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.76 (s, 1H), 7.70 (s, 1H), 7.61 (d, 
J = 7.7 Hz, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 4.39 (t, J = 7.5 Hz, 2H), 
2.40 (s, 3H), 1.83 (q, J = 7.3 Hz, 2H), 1.61 (dt, J = 13.4, 6.7 Hz, 1H), 0.97 (d, J = 6.6 Hz, 
6H). 
13
C NMR (101 MHz, CDCl3): δ 147.6, 138.3, 130.5, 128.6, 128.5, 126.2, 122.6, 119.2, 
48.5, 38.9, 25.3, 22.0, 21.3. IR (neat, cm
-1
): 1433, 1079, 839, 716. MS (ESI
+
) m/z (%) 230 
(M+H). HRMS calcd. for (C14H20N3): 230.1657, found 230.1661. 
 
4-(Cyclohex-1-en-1-yl)-1-isopentyl-1H-1,2,3-triazole (68zb). Following the general 
procedure B, using 1-bromo-3-methylbutane (10.00 mmol, 1.20 mL) and 1-
ethynylcyclohexene (10.00 mmol, 1.30 mL) provided 1.80 g (82 % yield) of 68zb as a white 
solid. Mp 38-42 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.39 (s, 1H), 6.46 (s, 1H), 4.30 (t, J = 7.5 
Hz, 2H), 2.36 (s, 2H), 2.15 (s, 2H), 1.73 (p, J = 6.7, 6.0 Hz, 4H), 1.63 (p, J = 6.1 Hz, 2H), 
1.54 (dt, J = 13.4, 6.6 Hz, 1H), 0.92 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3):          
δ 149.4, 127.4, 124.6, 118.1, 48.5, 39.1, 26.3, 25.4, 25.2, 22.5, 22.2, 22.1. IR (neat, cm-1): 
2951, 2929, 2868, 2837, 1459, 1434, 1216, 1052, 919, 832. MS (ESI
+
) m/z (%) 220 (M+H). 
HRMS calcd. for (C13H22N3): 220.1814, found 220.1804.  
 
4-Benzyl-1-isopentyl-1H-1,2,3-triazole (68zc). Following the general procedure B, using 1-
bromo-3-methylbutane (10.00 mmol, 1.20 mL) and 3-phenyl-1-propyne (10.00 mmol, 1.30 
mL) provided 2.46 g (99 %) of 68zc as a yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 7.31 (dq, 
J = 16.4, 8.0 Hz, 5H), 7.16 (s, 1H), 4.33 (t, J = 7.7 Hz, 2H), 4.11 (s, 2H), 1.78 (q, J = 7.3 Hz, 
2H), 1.61 (dt, J = 13.4, 6.7 Hz, 1H), 0.97 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): 
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δ 146.4, 138.7, 128.0, 127.9, 125.7, 120.8, 47.7, 38.3, 31.5, 24.8, 21.5. IR (neat, cm-1): 2956, 
2870, 1495, 1455, 1216, 1048, 724, 697. MS (ESI
+
) m/z (%) 230 (M+H). HRMS calcd. for 
(C14H20N3): 230.1657, found 230.1674.  
 
5-Iodo-1-isopentyl-4-phenyl-1H-1,2,3-triazole (68ze). Following the general procedure C, 
using phenylacetylene (4.89 mmol, 0.54 mL) provided 1.00 g (66 % yield) of 68ze as a white 
solid. Mp 97-98 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 7.6 Hz, 2H), 7.52-7.33 (m, 
3H), 4.46 (t, J = 7.8 Hz, 2H), 1.93-1.58 (m, 3H), 1.02 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 
MHz, CDCl3): δ 149.6, 130.3, 128.4, 127.4, 76.0, 49.4, 38.6, 25.6, 22.2. IR (neat, cm
-1
): 
1447, 1224, 1064, 985. MS (ESI
+
) m/z (%) 342 (M+H). HRMS calcd. for (C13H17N3I): 
342.0467, found 342.0462.  
 
4-(4-Fluorophenyl)-5-iodo-1-isopentyl-1H-1,2,3-triazole (68zf). Following the general 
procedure C, using 4-fluorophenylacetylene (4.16 mmol, 0.48 mL) provided 790 mg (53 % 
yield) of 68zf as a white solid. Mp 118-120 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.00-7.75 (m, 
2H), 7.13 (t, J = 8.7 Hz, 2H), 4.48-4.30 (m, 2H), 1.82 (ddd, J = 9.5, 7.8, 6.5 Hz, 2H), 1.68 
(dt, J = 13.3, 6.7 Hz, 1H), 1.00 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 162.3 (d, 
J = 247 Hz), 148.9, 129.3 (d, J = 9 Hz), 126.4 (d, J = 10 Hz), 115.4 (d, J = 21 Hz), 75.9, 
49.4, 38.5, 25.6, 22.2. IR (neat, cm
-1
): 1607, 1476, 1223, 838. MS (ESI
+
) m/z (%) 360 
(M+H). HRMS calcd. for (C13H16N3FI): 360.0373, found 360.0373. 
 
5-Iodo-1-isopentyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole (68zg). Following the general 
procedure C, using 4-methoxyphenylacetylene (3.78 mmol, 500 mg) provided 600 mg (43 % 
yield) of 68zg as a white solid. Mp 95-96 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.85 (d, J = 8.3 
Hz, 2H), 6.98 (d, J = 8.3 Hz, 2H), 4.43 (t, J = 7.8 Hz, 2H), 3.84 (s, 3H), 1.95-1.60 (m, 3H), 
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1.00 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 159.7, 149.5, 128.7, 122.8, 113.9, 
75.3, 55.2, 49.4, 38.6, 25.6, 22.2. IR (neat, cm
-1
): 1614, 1339, 1117, 1066. MS (ESI
+
) m/z 
(%) 372 (M+H). HRMS calcd. for (C14H19N3OI): 372.0573, found 372.0565. 
 
4-Benzyl-5-iodo-1-isopentyl-1H-1,2,3-triazole (68zh). Following the general procedure C, 
using 1-bromo-3-methylbutane (10.00 mmol, 1.20 mL) and 3-phenyl-1-propyne (10.00 
mmol, 1.30 mL) provided 1.76 g (50 % yield) of 68zh as a white solid. Mp 114-115 ºC. 
1
H 
NMR (400 MHz, DMSO-d6): δ 7.23 (dd, J = 30.3, 7.2 Hz, 5H), 4.34 (t, J = 7.6 Hz, 2H), 3.95 
(s, 2H), 1.67 (q, J = 7.2 Hz, 2H), 1.53 (dp, J = 13.3, 7.0 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, DMSO-d6): δ 149.6, 138.3, 128.1, 126.0, 82.9, 48.4, 37.9, 31.3, 24.7, 
21.8. IR (neat, cm
-1
): 2955, 2869, 1494, 1453, 1213, 1060, 723, 695. MS (ESI
+
) m/z (%) 356 
(M+H). HRMS calcd. for (C14H19N3I): 356.0624, found 356.0620.  
 
1,4-Dibenzyl-5-iodo-1H-1,2,3-triazole (68zi). Following the general procedure C, using 
benzyl azide (10.00 mmol, 1.30 g) and 3-phenyl-1-propyne (10.00 mmol, 1.30 mL) provided 
1.10 g (30 % yield) of 68zi as a yellowish solid. Mp 131-134 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.43-7.19 (m, 10H), 5.59 (s, 2H), 4.07 (s, 2H). 
13
C NMR (101 MHz, CDCl3):        
δ 151.1, 138.3, 134.5, 129.0, 128.8, 128.6, 128.5, 127.9, 126.6, 78.9, 54.4, 32.5. IR (neat,    
cm
-1
): 3026, 1493, 1454, 1211, 1082, 729, 693. MS (ESI
+
) m/z (%) 376 (M+H). HRMS 
calcd. for (C16H15N3I): 376.0311, found 376.0306. 
 
2-(1-Benzyl-1H-1,2,3-triazol-4-yl)propan-2-amine (75).
213e
 Following the general 
procedure A, using benzyl azide (17.7 mmol, 2.36 g) and 2-methylbut-3-yn-2-amine (19.5 
mmol, 1.62 g) provided 3.10 g (81 % yield) of 75 as a white solid. 
1
H NMR (400 MHz, 
CDCl3): δ 7.40-7.29 (m, 3H), 7.31-7.29 (m, 3H), 5.51 (s, 2H), 1.51 (s, 6H).  
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N-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl)benzamide (76).
123e
 To a solution of 2-
(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-amine (14.20 mmol, 3.10 g) in CH2Cl2 (30 mL) 
triethylamine (43.00 mmol, 6 mL) was added and the mixture was cooled to 0 ºC. Benzoyl 
chloride (14.20 mmol, 1.65 mL) was added and the resulting solution was warmed to room 
temperature overnight. The reaction was quenched with NaHCO3 and the aqueous layer was 
extracted with CH2Cl2. The combined organic layers were washed with HCl (1M), dried 
(anhydrous MgSO4), filtered and evaporated under reduced pressure to provide 4.30 g (94 % 
yield) of 76 as a white solid. 
1
H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 7.3 Hz, 2H), 7.53-
7.44 (m, 1H), 7.40 (dd, J = 13.8, 7.1 Hz, 5H), 7.34-7.22 (m, 2H), 7.01 (s, 1H), 5.52 (s, 2H), 
1.86 (s, 6H). 
 
N-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)propan-2-yl)-2-phenylacetamide (79).
213e
 To a 
solution of 2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-amine (18.00 mmol, 3.50 g) in 
CH2Cl2 (50 mL) triethylamine (54 mmol, 7.50 mL) was added and the mixture was cooled to 
0 ºC. 2-Phenylacetyl chloride (18.00 mmol, 2.40 mL) was added and the resulting solution 
was warmed to room temperature overnight. The reaction was quenched with NaHCO3 and 
the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with 
HCl (1M), dried (anhydrous MgSO4), filtered and evaporated under reduced pressure to 
provide 3.20 g (53 % yield) of 79 as a white solid. Mp 148-150 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.56-7.09 (m, 11H), 6.14 (s, 1H), 5.50 (s, 2H), 3.51 (s, 2H), 1.70 (s, 6H).            
13
C NMR (101 MHz, CDCl3): δ 170.4, 153.7, 135.2, 134.8, 129.4, 129.2, 129.0, 128.8, 
128.2, 127.3, 120.5, 54.3, 51.6, 44.7, 28.0. IR (neat, cm
-1
): 3251, 3128, 1665, 1557, 1333, 
1056, 726, 690. MS (ESI
+
) m/z (%) 335 (M+H). HRMS calcd. for (C20H23N4O): 335.1872, 
found 335.1881. 
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4.2 Pd-catalyzed C(sp2)-H acetoxylation. 
 
General Procedure: A reaction tube containing a stirring bar was charged with the 
corresponding triazole (if solid) (0.25 mmol, 1.00 equiv), PhI(OAc)2 (0.50 mmol, 2.00 equiv) 
and Pd(OAc)2 (10 mol %). The reaction tube was then evacuated and back-filled with dry 
argon (this sequence was repeated up to three times). The triazole (if liquid) (0.25 mmol, 
1.00 equiv), AcOH (0.50 mmol, 2.00 equiv), 1,2-dichloroethane (0.50 mL) and Ac2O (0.50 
mL) were then added under argon atmosphere. The reaction tube was next warmed up to 
90 ºC and stirred for 24 hours. The mixture was then allowed to warm to room temperature, 
filtered off through a pad of celite and washed with CH2Cl2. The resulting mixture was 
concentrated under reduced pressure and the corresponding product was purified by flash 
chromatography (hex/AcOEt 7/3). The yields reported in the thesis refer to isolated yields 
and represent an average of at least two independent runs. 
 
2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69a). Following the general procedure, 
using 1-benzyl-4-phenyl-1H-1,2,3-triazole
278
 (68a) (0.25 mmol, 59 mg) provided 33 mg (45 
% yield) of 69a as a white solid along with 23 mg (25 % yield) of 69a’ as a white solid. 69a: 
Mp 162-163 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 7.4 Hz, 1H), 7.64 (s, 1H), 7.54-
7.25 (m, 7H), 7.16 (d, J = 7.8 Hz, 1H), 5.59 (s, 2H), 2.16 (s, 3H). 
13
C NMR (101 MHz, 
CDCl3): δ 168.8, 147.0, 143.3, 134.4, 129.1, 129.0, 128.8, 128.6, 128.2, 126.3, 123.2, 123.0, 
121.7, 54.2, 21.0. IR (neat, cm
-1
): 1738, 1191, 852. MS (ESI
+
) m/z (%) 294 (M+H). HRMS 
calcd. for (C17H16N3O2): 294.1243, found 294.1243. 69a’: Mp 172-173 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.53 (s, 1H), 7.44-7.34 (m, 3H), 7.29 (dd, J = 7.3, 2.1 Hz, 2H), 7.07 (d, J = 
8.2 Hz, 2H), 5.58 (s, 2H), 2.04 (s, 6H). 
13
C NMR (101 MHz, CDCl3): δ 168.9, 149.0, 139.3, 
                                                          
278  Sharghi, H.; Khalifeh, R.; Doroodmand, M. M. Adv. Synth. Catal. 2009, 351, 207. 
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134.7, 129.1, 129.1, 128.8, 128.1, 123.2, 120.7, 54.1, 20.7. IR (neat, cm
-1
): 1735, 1197, 883. 
MS (ESI
+
) m/z (%) 352 (M+H). HRMS calcd. for (C19H18N3O4): 352.1297, found 352.1292. 
 
2-[1-(4-(Tert-butyl)benzyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69b). Following the 
general procedure, using 1-[4-tert-butyl)benzyl]-4-phenyl-1H-1,2,3-triazole
279
 (68b) (0.25 
mmol, 73 mg) provided 27.9 mg (32 % yield) of 69b as a white solid along with 30.5 mg (30 
% yield) of 69b’ as a white solid. 69b: Mp 163-165 ºC. 1H NMR (400 MHz, CDCl3): δ 8.09 
(d, J = 7.0 Hz, 1H), 7.62 (s, 1H), 7.45 (d, J = 7.9 Hz, 2H), 7.40-7.32 (m, 2H), 7.28 (d, J = 8.0 
Hz, 2H), 7.16 (d, J = 8.1 Hz, 1H), 5.56 (s, 2H), 2.13 (s, 3H), 1.34 (s, 9H). 
13
C NMR (101 
MHz, CDCl3): δ 168.9, 152.2, 147.2, 143.4, 131.6, 129.0, 128.7, 128.2, 126.5, 126.2, 123.5, 
123.1, 121.7, 54.0, 34.8, 31.3, 21.2. IR (neat, cm
-1
): 1750, 1202, 1178, 762. MS (ESI
+
) m/z 
(%) 350 (M+H). HRMS calcd. for (C21H24N3O2): 350.1869, found 350.1869. 69b’: Mp 189-
196 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.51 (s, 1H), 7.45-7.33 (m, 3H), 7.24 (d, J = 8.0 Hz, 
2H), 7.06 (d, J = 8.2 Hz, 2H), 5.53 (s, 2H), 2.02 (s, 6H), 1.31 (s, 9H). 
13
C NMR (101 MHz, 
CDCl3): δ 169.1, 152.3, 149.2, 139.5, 131.9, 129.3, 128.2, 126.3, 123.3, 121.0, 118.2, 54.0, 
34.8, 31.4, 20.9. IR (neat, cm
-1
): 1752, 1750, 1216, 1187, 1028. MS (ESI
+
) m/z (%) 408 
(M+H). HRMS calcd. for (C23H26N3O4): 408.1923, found 408.1927. 
 
2-[1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69c). Following the general 
procedure, using 4-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]benzonitrile
280
 (68c) (0.25 mmol, 
65 mg) provided 35 mg (44 % yield) of 69c as a yellow oil along with 25.1 mg (27 % yield) 
of 69c’ as a white solid. Mp 85-86 ºC 69c: 1H NMR (400 MHz, CDCl3): δ 8.05 (dd, J = 7.5, 
2.1 Hz, 1H), 7.79 (s, 1H), 7.69 (d, J = 8.2 Hz, 2H), 7.46-7.32 (m, 4H), 7.21 (dd, J = 7.7, 1.7 
                                                          
279  Özçubukçu, S.; Ozkal, E.; Jimeno, C.; Pericàs, M. A. Org. Lett. 2009, 11, 4680. 
280 Bidal, Y. D.; Lesieur, M.; Melaimi, M.; Cordes, D. B.; Slawin, A. M. Z.; Bertrand, G.; Cazin, C. S. 
J. Chem. Commun. 2015, 51, 4778. 
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Hz, 1H), 5.65 (s, 2H), 2.28 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 169.1, 147.2, 144.0, 
139.9, 132.9, 129.3, 128.7, 128.4, 126.5, 123.2, 123.1, 122.0, 118.2, 112.7, 53.3, 21.3. IR 
(neat, cm
-1
): 1750, 1216, 1038, 765. MS (ESI
+
) m/z (%) 319 (M+H). HRMS calcd. for 
(C18H15N4O2): 319.1195, found 319.1193. 69c’: Mp 201-206 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.69 (d, J = 8.2 Hz, 2H), 7.62 (s, 1H), 7.41 (t, J = 8.2 Hz, 1H), 7.34 (d, J = 8.1 Hz, 
2H), 7.09 (d, J = 8.2 Hz, 2H), 5.65 (s, 2H), 2.09 (s, 6H). 
13
C NMR (101 MHz, CDCl3):          
δ 169.0, 149.3, 140.1, 133.1, 129.7, 128.4, 123.6, 121.0, 118.1, 117.9, 113.1, 53.5, 31.1, 
21.0. IR (neat, cm
-1
): 1747, 1197, 1026, 884. MS (ESI
+
) m/z (%) 377 (M+H). HRMS calcd. 
for (C20H17N4O4): 377.1250, found 377.1240. 
 
2-[1-(4-Bromobenzyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69d). Following the general 
procedure, using 1-(4-bromobenzyl)-4-phenyl-1H-1,2,3-triazole
281
 (68d) (0.25 mmol, 78 mg) 
provided 34.4 mg (37 % yield) of 69d as a white solid along with 33.3 mg (31 % yield) of 
69d’ as a yellowish solid. 69d: Mp 135-139 ºC. 1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 
7.6 Hz, 1H), 7.66 (s, 1H), 7.54 (d, J = 8.1 Hz, 2H), 7.36 (t, J = 10.0 Hz, 2H), 7.19 (d, J = 9.0 
Hz, 3H), 5.54 (s, 2H), 2.22 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.0, 147.3, 143.9, 
133.7, 132.5, 129.8, 129.2, 128.8, 126.5, 123.3, 123.2, 123.1, 121.7, 53.6, 21.3. IR (neat,   
cm
-1
): 1754, 1199, 1189, 1010, 760. MS (ESI
+
) m/z (%) 372 (M+H). HRMS calcd. for 
(C17H15N3O2Br): 372.0348, found 372.0349. 69d’: Mp 198-199 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.57-7.49 (m, 3H), 7.39 (t, J = 8.2 Hz, 1H), 7.15 (d, J = 8.1 Hz, 2H), 7.07 (d, J = 
8.2 Hz, 2H), 5.52 (s, 2H), 2.07 (s, 6H). 
13
C NMR (126 MHz, CDCl3): δ 169.1, 149.2, 139.8, 
133.9, 132.5, 129.8, 129.5, 123.4, 123.2, 121.0, 118.0, 53.6, 21.0. IR (neat, cm
-1
): 1744, 
1196, 1029, 883. MS (ESI
+
) m/z (%) 430 (M+H). HRMS calcd. for (C19H17N3O4Br): 
430.0402, found 430.0405. 
 
                                                          
281  Bent, S. J.; Mahon, M. F.; Webster, R. L. Dalton Trans 2015, 44, 10253. 
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Methyl 4-[(4-(2-acetoxyphenyl)-1H-1,2,3-triazol-1-yl)methyl]benzoate (69e). Following 
the general procedure, using methyl 4-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]benzoate
282
 
(68e) (0.25 mmol, 73 mg) provided 29 mg (33 % yield) of 69e as a white solid along with 
28 mg (28 % yield) of 69e’ as a white solid. 69e: Mp 162-163 ºC. 1H NMR (400 MHz, 
CDCl3): δ 8.05 (t, J = 7.9 Hz, 3H), 7.70 (s, 1H), 7.35 (q, J = 6.0 Hz, 4H), 7.16 (d, J = 7.9 Hz, 
1H), 5.63 (s, 2H), 3.93 (s, 3H), 2.20 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 168.9, 166.2, 
147.1, 143.7, 139.4, 130.5, 130.3, 129.1, 128.6, 127.7, 126.3, 123.1, 121.7, 53.6, 52.2, 21.1. 
IR (neat, cm
-1
): 1743, 1720, 1196, 726. MS (ESI
+
) m/z (%) 352 (M+H). HRMS calcd. for 
(C19H18N3O4): 352.1297, found 352.1289. 69e’: Mp 172-173 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 8.05 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.31 (d, J = 7.0 Hz, 
2H), 7.07 (d, J = 8.2 Hz, 2H), 5.63 (s, 2H), 3.92 (s, 3H), 2.06 (s, 6H). 
13
C NMR (101 MHz, 
CDCl3): δ 168.9, 166.2, 149.1, 139.7, 139.6, 130.7, 130.4, 129.4, 127.7, 123.4, 120.8, 117.9, 
53.6, 52.3, 20.8. IR (neat, cm
-1
): 1741, 1716, 1194, 729. MS (ESI
+
) m/z (%) 410 (M+H). 
HRMS calcd. for (C21H20N3O6): 410.1352, found 410.1342. 
 
Methyl 2-[4-(2-acetoxyphenyl)-1H-1,2,3-triazol-1-yl]-2-methylpropanoate (69f). 
Following the general procedure, using triazole (68f) (0.25 mmol, 61 mg) at 110 ºC provided 
22.7 mg (30 % yield) of 69f as a yellowish oil along with 46 mg (51 % yield) of 69f’ as a 
pale brown solid. 69f: 
1
H NMR (400 MHz, CDCl3): δ 8.06 (dd, J = 7.6, 2.0 Hz, 1H), 7.93 (s, 
1H), 7.41-7.30 (m, 2H), 7.18 (dd, J = 7.8, 1.6 Hz, 1H), 3.75 (s, 3H), 2.35 (s, 3H), 1.99 (s, 
6H). 
13
C NMR (101 MHz, CDCl3): δ 171.9, 169.2, 147.4, 143.1, 129.2, 128.9, 126.6, 123.6, 
123.2, 120.9, 64.6, 53.5, 26.1, 21.4. IR (neat, cm
-1
): 1751, 1749, 1172, 1009, 831. MS (ESI
+
) 
m/z (%) 304 (M+H). HRMS calcd. for (C15H18N3O4): 304.1297, found 304.1287. 69f’: Mp 
90-94 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.84 (s, 1H), 7.39 (t, J = 8.2 Hz, 1H), 7.09 (d, J = 
8.2 Hz, 2H), 3.73 (s, 3H), 2.20 (s, 6H), 1.96 (s, 6H). 
13
C NMR (101 MHz, CDCl3): δ 171.8, 
                                                          
282 Shin, J.-A.; Lim, Y.-G.; Lee, K.-H. J. Org. Chem. 2012, 77, 4117. 
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169.2, 149.2, 138.6, 129.3, 122.9, 120.9, 118.2, 64.6, 53.4, 25.8, 21.0. IR (neat, cm
-1
): 1743, 
1741, 1186, 1184, 1024. MS (ESI
+
) m/z (%) 362 (M+H). HRMS calcd. for (C17H20N3O6): 
362.1352, found 362.1347. 
 
Benzyl 2-[4-(2-acetoxyphenyl)-1H-1,2,3-triazol-1-yl] acetate (69g). Following the general 
procedure, using benzyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate
283
 (68g) (0.25 mmol, 73 
mg) at 110 ºC provided 41.3 mg (47 % yield) of 69g as a yellowish solid along with 24.6 mg 
(24 % yield) of 69g’ as a white solid. 69g: Mp 81-87 ºC. 1H NMR (400 MHz, CDCl3): δ 8.06 
(d, J = 7.6 Hz, 1H), 7.94 (s, 1H), 7.44-7.28 (m, 7H), 7.18 (d, J = 7.8 Hz, 1H), 5.24 (s, 4H), 
2.30 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 166.2, 147.4, 143.6, 134.6, 129.3, 129.0, 
128.9, 128.8, 128.7, 126.5, 123.4, 123.2, 123.1, 68.2, 51.0, 21.3. IR (neat, cm
-1
): 1749, 1261, 
1175, 696. MS (ESI
+
) m/z (%) 352 (M+H). HRMS calcd. for (C19H18N3O4): 352.1297, found 
352.1292. 69g’: Mp 181-187 ºC. 1H NMR (400 MHz, CDCl3): δ 7.84 (s, 1H), 7.47-7.31 (m, 
6H), 7.10 (d, J = 8.2 Hz, 2H), 5.23 (s, 4H), 2.19 (s, 6H). 
13
C NMR (101 MHz, CDCl3):          
δ 169.3, 166.2, 149.4, 139.4, 134.6, 129.6, 129.0, 128.9, 128.7, 125.2, 120.9, 118.1, 68.2, 
51.0, 21.0. IR (neat, cm
-1
): 1760, 1744, 1222, 1185, 1030. MS (ESI
+
) m/z (%) 410 (M+H). 
HRMS calcd. for (C21H20N3O6): 410.1352, found 410.1353. 
 
2-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69h). Following the general procedure, 
using 1,4-diphenyl-1H-1,2,3-triazole
284
 (68h) (0.25 mmol, 55 mg) provided 21 mg (30 % 
yield) of 69h as a white solid along with 21.1 mg (25 % yield) of 69h’ as a yellowish solid. 
69h: Mp 117-119 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.25 (s, 1H), 8.16 (dd, J = 7.2, 1.9 Hz, 
1H), 7.80 (d, J = 7.2 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.54-7.36 (m, 3H), 7.26 (dd, J = 7.6, 
1.7 Hz, 1H), 2.43 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 169.2, 147.4, 144.0, 137.0, 129.9, 
129.3, 128.9, 128.8, 126.5, 123.3, 123.1, 120.6, 119.8, 21.5. IR (neat, cm
-1
): 1742, 1506, 
                                                          
283  Song, J. H.; Choi, P.; Lee, S. E.; Jeong, K. H.; Kim, T.; Kang, K. S.; Choi, Y. S.; Ham,. J. Eur. J. 
Org. Chem. 2013, 6249. 
284  Deraedt, C.; Pinaud, N.; Astruc, D. J. Am. Chem. Soc. 2014, 136, 12092. 
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1214, 1189, 1036, 753. MS (ESI
+
) m/z (%) 280 (M+H). HRMS calcd. for (C16H14N3O2): 
280.1086, found 280.1083. 69h’: Mp 130-140 ºC. 1H NMR (400 MHz, CDCl3): δ 8.12 (s, 
1H), 7.79-7.73 (m, 2H), 7.55 (t, J = 7.8 Hz, 2H), 7.50-7.39 (m, 2H), 7.13 (d, J = 8.2 Hz, 2H), 
2.24 (s, 6H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 149.3, 139.8, 136.9, 130.0, 129.5, 129.1, 
121.5, 121.1, 120.6, 117.8, 21.2. IR (neat, cm
-1
): 1744, 1368, 1187, 1024, 762. MS (ESI
+
) 
m/z (%) 338 (M+H). HRMS calcd. for (C18H16N3O4): 338.1141, found 338.1139. 
 
2-[1-(4-Cyanophenyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69i). Following the general 
procedure, using 4-(4-phenyl-1H-1,2,3-triazol-1-yl)benzonitrile
285
 (68i) (0.25 mmol, 62 mg) 
provided 29 mg (38 % yield) of 69i as a white solid along with 24.4 mg (27 % yield) of 69i’ 
as a yellowish solid. 69i: Mp 201-207 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 8.07 
(dd, J = 7.6, 1.8 Hz, 1H), 7.90 (dd, J = 33.1, 8.4 Hz, 4H), 7.47-7.33 (m, 2H), 7.23 (d, J = 8.0 
Hz, 1H), 2.38 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 169.1, 147.6, 144.9, 139.8, 134.2, 
129.9, 129.0, 126.7, 123.5, 122.6, 120.7, 119.3, 117.8, 112.7, 21.6. IR (neat, cm
-1
): 2223, 
1748, 1519, 1215, 1185, 1025, 838. MS (ESI
+
) m/z (%) 305 (M+H). HRMS calcd. for 
(C17H13N4O2): 305.1039, found 305.1037. 69i’: Mp 142-158 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 8.19 (s, 1H), 7.95-7.80 (m, 4H), 7.43 (t, J = 8.2 Hz, 1H), 7.12 (d, J = 8.2 Hz, 2H), 
2.22 (s, 6H). 
13
C NMR (126 MHz, CDCl3): δ 169.1, 149.2, 140.4, 139.6, 134.1, 129.9, 121.2, 
121.1, 120.6, 117.8, 117.2, 112.5, 21.1. IR (neat, cm
-1
): 2231, 1754, 1190, 1031, 836. MS 
(ESI
+
) m/z (%) 363 (M+H). HRMS calcd. for (C19H15N4O4): 363.1093, found 363.1082. 
 
2-[1-(3-Methoxyphenyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69j). Following the general 
procedure, using 1-(3-methoxyphenyl)-4-phenyl-1H-1,2,3-triazole
286
 (68j) (0.25 mmol, 
63 mg) provided 30.2 mg (39 % yield) of 69j as a white solid along with 21.1 mg (23 % 
yield) of 69j’ as a yellowish solid. 69j: Mp 117-121 ºC. 1H NMR (400 MHz, CDCl3): δ 8.21 
(s, 1H), 8.14 (dd, J = 7.6, 2.0 Hz, 1H), 7.49-7.35 (m, 4H), 7.27 (ddd, J = 24.7, 7.8, 1.2 Hz, 
                                                          
285  Ramachary, D. B.; Shashank, A. B.; Karthik, S. Angew. Chem. Int. Ed. 2014, 53, 10420. 
286  Chen, Z.; Yan, Q.; Liu, Z.; Xu, Y.; Zhang, Y. Angew. Chem. Int. Ed. 2013, 52, 13324. 
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2H), 7.02 (dd, J = 8.3, 1.9 Hz, 1H), 3.92 (s, 3H), 2.41 (s, 3H). 
13
C NMR (101 MHz, CDCl3): 
δ 169.2, 160.7, 147.4, 143.9, 138.0, 130.7, 129.4, 129.0, 126.5, 123.3, 123.1, 119.9, 114.7, 
112.4, 106.6, 55.7, 21.5. IR (neat, cm
-1
): 1738, 1610, 1499, 1212, 1158, 1040, 754. 
MS (ESI
+
) m/z (%) 310 (M+H). HRMS calcd. for (C17H16N3O3): 310.1192, found 310.1194. 
69j’: Mp 126-132 ºC. 1H NMR (400 MHz, CDCl3): δ 8.16 (s, 1H), 7.48 (t, J = 8.2 Hz, 2H), 
7.43 (t, J = 2.3 Hz, 1H), 7.32 (dd, J = 7.9, 2.0 Hz, 1H), 7.18 (d, J = 8.2 Hz, 2H), 7.05 (dd, J = 
8.3, 2.4 Hz, 1H), 3.94 (s, 3H), 2.29 (s, 6H). 
13
C NMR (126 MHz, CDCl3): δ 169.2, 160.8, 
149.3, 139.7, 137.9, 130.8, 129.5, 121.5, 121.1, 117.8, 114.8, 112.4, 106.5, 55.8, 21.2. 
IR (neat, cm
-1
): 1749, 1747, 1610, 1484, 1195, 1028. MS (ESI
+
) m/z (%) 368 (M+H). HRMS 
calcd. for (C19H18N3O5): 368.1246, found 368.1245. 
 
2-(1-Mesityl-1H-1,2,3-triazol-4-yl)phenyl acetate (69k). Following the general procedure, 
using 1-mesityl-4-phenyl-1H-1,2,3-triazole
287
 (68k) (0.25 mmol, 66 mg) at 110 ºC provided 
19 mg (24 % yield) of 69k as a white solid along with 61.2 mg (64 % yield) of 69k’ as white 
solid. 69k: Mp 107-117 ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.20 (dd, J = 6.8, 2.6 Hz, 1H), 
7.84 (s, 1H), 7.44-7.33 (m, 2H), 7.19 (s, 1H), 7.02 (s, 2H), 2.34 (s, 3H), 2.31 (s, 3H), 2.00 (s, 
6H). 
13
C NMR (101 MHz, CDCl3): δ 168.9, 147.3, 143.0, 140.2, 135.2, 133.4, 129.2, 129.1, 
128.8, 126.5, 123.7, 123.4, 123.1, 21.4, 21.2, 17.4. IR (neat, cm
-1
): 1763, 1481, 1207, 1184, 
1047, 758. MS (ESI
+
) m/z (%) 322 (M+H). HRMS calcd. for (C19H20N3O2): 322.1556, found 
322.1553. 69k’: Mp 163-164 ºC. 1H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H), 7.35 (t, J = 8.2 
Hz, 1H), 7.07 (d, J = 8.2 Hz, 2H), 6.95 (s, 2H), 2.28 (s, 3H), 2.11 (s, 6H), 1.92 (s, 6H).      
13
C NMR (126 MHz, CDCl3): δ 168.5, 149.1, 139.9, 138.5, 134.7, 133.0, 129.2, 128.9, 
125.3, 120.5, 118.0, 20.9, 20.6, 16.9. IR (neat, cm
-1
): 1745, 1496, 1457, 1185, 1024.          
MS (ESI
+
) m/z (%) 380 (M+H). HRMS calcd. for (C21H22N3O4): 380.1610, found 380.1602. 
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2-(1-Benzyl-1H-1,2,3-triazol-4-yl)-3-methylphenyl acetate (69l). Following the general 
procedure, using 1-benzyl-4-(m-tolyl)-1H-1,2,3-triazole
288
 (68l) (0.25 mmol, 62 mg) 
provided 38.4 mg (50 % yield) of 69l as a yellowish solid. Mp 119-122 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.90-7.84 (m, 1H), 7.59 (s, 1H), 7.38 (dt, J = 4.7, 1.7 Hz, 3H), 7.30 (dd, J = 
7.4, 2.2 Hz, 2H), 7.17-7.10 (m, 1H), 7.00 (d, J = 8.2 Hz, 1H), 5.56 (s, 2H), 2.37 (s, 3H), 2.11 
(s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 145.0, 143.6, 136.2, 134.7, 129.8, 129.3, 
129.1, 129.0, 128.3, 123.0, 122.8, 121.7, 54.3, 21.2, 21.0. IR (neat, cm
-1
): 1755, 1496, 1371, 
1182, 1069, 822, 715. MS (ESI
+
) m/z (%) 308 (M+H). HRMS calcd. for (C18H18N3O2): 
308.1399, found 308.1397.  
 
2-(1-Mesityl-1H-1,2,3-triazol-4-yl)-3-methylphenyl acetate (69m). Following the general 
procedure, using1-mesityl-4-(m-tolyl)-1H-1,2,3-triazole (68m) (0.25 mmol, 69 mg) provided 
60.4 mg (72 % yield) of 69m as a yellow solid. Mp 107-109 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 8.03 (d, J = 1.5 Hz, 1H), 7.82 (s, 1H), 7.19 (dd, J = 8.4, 2.1 Hz, 1H), 7.08 (d, J = 
8.2 Hz, 1H), 7.01 (s, 2H), 2.42 (s, 3H), 2.36 (s, 3H), 2.29 (s, 3H), 2.00 (s, 6H). 
13
C NMR 
(101 MHz, CDCl3): δ 169.2, 145.0, 143.6, 136.2, 134.7, 129.8, 129.3, 129.1, 129.0, 128.3, 
123.0, 122.8, 121.7, 54.3, 21.2, 21.0. IR (neat, cm
-1
): 1760, 1494, 1367, 1183, 1039, 908, 
730. MS (ESI
+
) m/z (%) 336 (M+H). HRMS calcd. for (C20H22N3O2): 336.1712, found 
336.1701. 
 
Benzyl 2-[4-(2-acetoxycyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl]acetate (69n). Following 
the general procedure, using benzyl 2-(4-(cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)acetate 
(68n) (0.25 mmol, 74 mg) provided 65.7 mg (74 % yield) of 69n as a yellow solid. Mp 59-66 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.67 (s, 1H), 7.37-7.23 (m, 5H), 5.13 (d, J = 8.0 Hz, 4H), 
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2.64-2.55 (m, 2H), 2.32-2.24 (m, 2H), 2.11 (s, 3H), 1.79-1.65 (m, 4H). 
13
C NMR (101 MHz, 
CDCl3): δ 168.7, 166.2, 145.5, 144.7, 134.5, 128.7, 128.6, 128.4, 122.8, 115.0, 67.7, 50.6, 
27.8, 26.2, 22.4, 21.9, 21.1. IR (neat, cm
-1
): 2937, 1751, 1457, 1188, 1104, 1056, 749, 698. 
MS (ESI
+
) m/z (%) 356 (M+H). HRMS calcd. for (C19H22N3O4): 356.1610, found 356.1601. 
 
2-[1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl]cyclohex-1-en-1-yl acetate (69o). Following 
the general procedure, using 4-[(4-cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-
yl)methyl]benzonitrile (68o) (0.25 mmol, 66 mg) provided 58 mg (72 % yield) of 69o as a 
white solid. Mp 111-117 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.64 (d, J = 8.2 Hz, 2H), 7.44 (s, 
1H), 7.30 (d, J = 8.3 Hz, 2H), 5.57 (s, 2H), 2.64-2.56 (m, 2H), 2.32-2.24 (m, 2H), 2.12 (s, 
3H), 1.81-1.69 (m, 4H). 
13
C NMR (101 MHz, CDCl3): δ 168.7, 145.9, 145.5, 140.2, 132.9, 
128.3, 121.3, 118.2, 115.0, 53.3, 48.6, 28.0, 26.5, 22.6, 22.0, 21.4. IR (neat, cm
-1
): 2941, 
2226, 1738, 1374, 1220, 1097, 765. MS (ESI
+
) m/z (%) 323 (M+H). HRMS calcd. for 
(C18H19N4O2): 323.1508, found 323.1502. 
 
2-[1-(4-(Tert-butyl)benzyl)-1H-1,2,3-triazol-4-yl]cyclohex-1-en-1-yl acetate (69p). 
Following the general procedure, using 1-[4-(tert-butyl)benzyl)]-4-(cyclohex-1-en-1-yl)-1H-
1,2,3-triazole (68p) (0.25 mmol, 74 mg) provided 66 mg (75 % yield) of 69p as a white 
solid. Mp 134-135 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 7.9 Hz, 2H), 7.32 (s, 1H), 
7.20 (d, J = 7.9 Hz, 2H), 5.47 (s, 2H), 2.64 (dd, J = 5.9, 3.3 Hz, 2H), 2.28 (d, J = 6.0 Hz, 
2H), 2.01 (s, 3H), 1.88-1.50 (m, 4H), 1.30 (s, 9H). 
13
C NMR (101 MHz, CDCl3): δ 168.6, 
151.9, 145.2, 144.7, 131.6, 128.1, 128.0, 126.1, 126.0, 121.0, 115.3, 53.7, 34.6, 31.2, 27.8, 
26.2, 22.5, 22.0, 21.1. IR (neat, cm
-1
): 1750, 1213, 1191. MS (ESI
+
) m/z (%) 354 (M+H). 
HRMS calcd. for (C21H28N3O2): 354.2182, found 354.2180. 
 
 259 
 
 
2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-3-(tosyloxy)phenyl acetate (69q). Following 
the general procedure, using 2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl 4-
methylbenzenesulfonate (68q) (0.25 mmol, 104.9 mg) provided 77 mg (65 % yield) of 69q 
as a yellowish oil. 
1
H NMR (400 MHz, CDCl3): δ 7.70 (d, J = 8.0 Hz, 2H), 7.36-7.26 (m, 
5H), 7.24-7.15 (m, 3H), 7.12 (s, 1H), 7.00 (dd, J = 13.1, 8.2 Hz, 2H), 5.38 (s, 2H), 3.89 (s, 
2H), 2.44 (s, 3H), 2.09 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 168.7, 150.1, 148.2, 145.8, 
145.4, 134.8, 132.4, 129.9, 128.8, 128.4, 128.2, 127.7, 127.6, 125.5, 121.9, 121.8, 119.8, 
53.8, 21.6, 21.5, 20.6. IR (neat, cm
-1
): 1752, 1492, 1209, 1168, 727. MS (ESI
+
) m/z (%) 478 
(M+H). HRMS calcd. for (C25H26N3O5S): 478.1358, found 478.1359. 
 
3-Acetoxy-2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl benzoate (69r). Following 
the general procedure, using 2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl benzoate 
(68r) (0.25 mmol, 92.3 mg) provided 66 mg (62 % yield) of 69r as a yellowish solid.        
Mp 116-117ºC. 
1
H NMR (400 MHz, CDCl3): δ 8.03 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.5 Hz, 
1H), 7.45 (t, J = 7.7 Hz, 2H), 7.39-7.28 (m, 4H), 7.20-7.10 (m, 3H), 7.09 (s, 1H), 7.02 (d, J = 
8.1 Hz, 1H), 5.37 (s, 2H), 4.04 (s, 2H), 2.17 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 
165.0, 150.2, 150.1, 145.9, 135.0, 133.9, 130.2, 129.0, 128.9, 128.7, 128.5, 127.9, 124.6, 
121.9, 120.8, 120.5, 54.1, 21.9, 20.8. IR (neat, cm
-1
): 1765, 1731, 1462, 1264, 1173, 1061, 
1025, 702. MS (ESI
+
) m/z (%) 428 (M+H). HRMS calcd. for (C25H22N3O4): 428.1532, found 
428.1533. 
 
2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-methylphenyl acetate (69s). Following the 
general procedure, using 1-benzyl-4-(3-methylbenzyl)-1H-1,2,3-triazole (68s) (0.25 mmol, 
66 mg) provided 52 mg (65 % yield) of 69s as yellow solid. Mp 85-86 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.34 (d, J = 6.3 Hz, 3H), 7.22 (dd, J = 7.1, 2.2 Hz, 2H), 7.06 (t, J = 8.4 Hz, 
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3H), 6.90 (d, J = 7.9 Hz, 1H), 5.43 (s, 2H), 3.95 (s, 2H), 2.28 (s, 3H), 2.15 (s, 3H). 
13
C NMR 
(101 MHz, CDCl3): δ 169.5, 146.8, 146.5, 135.9, 134.8, 131.2, 130.5, 128.9, 128.5, 128.4, 
127.8, 122.3, 121.5, 54.0, 27.1, 20.8, 20.7. IR (neat, cm
-1
): 1752, 1366, 1124, 1052, 635.    
MS (ESI
+
) m/z (%) 322 (M+H). HRMS calcd. for (C19H20N3O2): 322.1477, found 322.1479.   
 
2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]phenyl acetate (69t). Following the general 
procedure, using 1,4-dibenzyl-1H-1,2,3-triazole (68t) (0.25 mmol, 62 mg) provided 12.3 mg 
(16 % yield) of 69t as a yellow oil along with 45.6 mg (50 % yield) of 69t’ as yellowish 
solid. 69t: 
1
H NMR (500 MHz, CDCl3): δ 7.37 (h, J = 5.3 Hz, 3H), 7.32-7.22 (m, 4H), 7.19 
(td, J = 5.7, 2.8 Hz, 1H), 7.11-7.04 (m, 2H), 5.46 (s, 2H), 4.03 (s, 2H), 2.19 (s, 3H).           
13
C NMR (126 MHz, CDCl3): δ 169.5, 149.0, 147.0, 135.0, 131.1, 130.8, 129.2, 128.7, 
128.1, 128.1, 126.4, 122.9, 121.7, 54.2, 27.4, 20.9. IR (neat, cm
-1
): 1747, 1366, 1207, 1172, 
1048, 750, 726. MS (ESI
+
) m/z (%) 308 (M+H). HRMS calcd. for (C18H18N3O2): 308.1399, 
found 308.1388. 69t’: Mp 107-109 ºC. 1H NMR (400 MHz, CDCl3): δ 7.38-7.33 (m, 2H), 
7.32 (s, 1H), 7.29 (d, J = 3.4 Hz, 1H), 7.22 (dd, J = 7.5, 2.2 Hz, 2H), 7.07 (s, 1H), 7.00 (d, J 
= 8.2 Hz, 2H), 5.42 (s, 2H), 4.00 (s, 2H), 2.19 (s, 6H). 
13
C NMR (126 MHz, CDCl3): δ 169.3, 
150.0, 146.0, 135.1, 129.1, 128.6, 128.0, 127.9, 124.5, 122.0, 120.6, 54.2, 21.9, 20.9.          
IR (neat, cm
-1
): 1759, 1463, 1371, 1210, 1200, 1170, 1023, 722. MS (ESI
+
) m/z (%) 366 
(M+H). HRMS calcd. for (C20H20N3O4): 366.1454, found 366.1454. 
 
2-(1-Isopentyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69w). Following the general 
procedure, using 1-(isopentyl)-4-phenyl-1H-1,2,3-triazole
289
 (68w) (0.25 mmol, 54 mg) at 
110 ºC provided 28.7 mg (42 % yield) of 69w as a white solid along with 36.4 mg (44 % 
yield) of 69w’ as a yellowish solid. 69w: Mp 83-90 ºC. 1H NMR (400 MHz, CDCl3): δ 8.02 
(d, J = 6.4 Hz, 1H), 7.72 (s, 1H), 7.32 (p, J = 7.2, 6.7 Hz, 2H), 7.15 (d, J = 7.7 Hz, 1H), 4.38 
(t, J = 7.5 Hz, 2H), 2.32 (s, 3H), 1.80 (q, J = 7.3 Hz, 2H), 1.59 (dt, J = 13.5, 6.7 Hz, 1H), 
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0.95 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 169.1, 147.2, 143.2, 129.0, 128.8, 
126.4, 123.6, 123.1, 121.5, 48.7, 39.1, 25.5, 22.2, 21.4. IR (neat, cm
-1
): 1758, 1371, 1189, 
758. MS (ESI
+
) m/z (%) 274 (M+H). HRMS calcd. for (C15H20N3O2): 274.1556, found 
274.1553. 69w’: Mp 136-144 ºC. 1H NMR (400 MHz, CDCl3): δ 7.64 (s, 1H), 7.39 (t, J = 8.2 
Hz, 1H), 7.09 (d, J = 8.1 Hz, 2H), 4.41 (t, J = 7.4 Hz, 2H), 2.19 (s, 6H), 1.81 (q, J = 7.1 Hz, 
2H), 1.57 (dt, J = 13.3, 6.8 Hz, 1H), 0.96 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): 
δ 169.1, 149.3, 138.9, 129.3, 123.3, 120.9, 118.3, 48.8, 39.2, 25.6, 22.3, 21.1. IR (neat, cm-1): 
1747, 1197, 1027, 883. MS (ESI
+
) m/z (%) 332 (M+H). HRMS calcd. for (C17H22N3O4): 
332.1610, found 332.1622. 
 
2-[1-(Bis(trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl]phenyl acetate (69x). Following the 
general procedure, using 1-[bis(trimethylsilyl)methyl]-4-phenyl-1H-1,2,3-triazole (68x) 
(0.25 mmol, 76 mg) at 110ºC provided 18.9 mg (21 % yield) of 69x as a white solid along 
with 47.2 mg (45 % yield) of 69x’ as a white solid. 69x: Mp 139-143 ºC. 1H NMR (400 
MHz, CDCl3): δ 8.15-8.09 (m, 1H), 7.55 (s, 1H), 7.33 (dt, J = 6.0, 2.5 Hz, 2H), 7.19-7.14 (m, 
1H), 3.68 (s, 1H), 2.32 (s, 3H), 0.12 (s, 18H). 
13
C NMR (126 MHz, CDCl3): δ 168.9, 147.2, 
142.3, 128.8, 126.5, 123.9, 123.0, 122.4, 46.7, 21.5, -1.0. IR (neat, cm
-1
): 1749, 1249, 1197, 
843, 765. MS (ESI
+
) m/z (%) 362 (M+H). HRMS calcd. for (C17H28N3O2Si): 362.1720, 
found 362.1716. 69x’: Mp 137-139 ºC. 1H NMR (400 MHz, CDCl3): δ 7.42-7.34 (m, 2H), 
7.07 (d, J = 8.2 Hz, 2H), 3.66 (s, 1H), 2.13 (s, 6H), 0.10 (s, 18H). 
13
C NMR (126 MHz, 
CDCl3): δ 168.9, 149.4, 138.0, 129.2, 124.0, 120.6, 119.0, 46.6, 21.0, -1.1. IR (neat, cm
-1
): 
1764, 1760, 1217, 1189, 1027, 843. MS (ESI
+
) m/z (%) 420 (M+H). HRMS calcd. for 
(C19H30N3O4Si): 420.1775, found 420.1769. 
 
2-(1-Isopentyl-1H-1,2,3-triazol-4-yl)-3-methoxyphenyl acetate (69y). Following the 
general procedure, using 1-isopentyl-4-(2-methoxyphenyl)-1H-1,2,3-triazole (68y) (0.25 
mmol, 61 mg) provided 71 mg (93 % yield) of 69y as a white solid. Mp 99-100 ºC. 
1
H NMR 
(400 MHz, CDCl3): δ 7.90 (s, 1H), 7.32 (q, J = 7.4, 6.6 Hz, 1H), 6.86 (dd, J = 29.7, 8.3 Hz, 
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2H), 4.41 (t, J = 7.7 Hz, 2H), 3.88 (s, 3H), 2.31 (s, 3H), 1.85 (q, J = 7.3 Hz, 2H), 1.64 (dt, J = 
13.4, 6.7 Hz, 1H), 0.99 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 170.1, 157.3, 
149.2, 139.3, 128.9, 124.2, 116.0, 113.4, 108.5, 55.9, 48.5, 38.9, 25.5, 22.1, 21.1. IR (neat, 
cm
-1
): 1756, 1261, 1074, 737. MS (ESI
+
) m/z (%) 304 (M+H). HRMS calcd. for 
(C16H22N3O3): 304.1661, found 304.1662. 
 
2-(1-Isopentyl-1H-1,2,3-triazol-4-yl)-3-(trifluoromethyl)phenyl acetate (69z). Following 
the general procedure, using 1-isopentyl-4-[2-(trifluoromethyl)pheny])-1H-1,2,3-triazole 
(68z) (0.25 mmol, 71 mg) provided 66 mg (77 % yield) of 69z as a white solid. Mp 60-62 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.66 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 
8.2 Hz, 1H), 4.44 (t, J = 7.3 Hz, 2H), 2.03 (s, 3H), 1.82 (q, J = 7.2 Hz, 2H), 1.55 (dt, J = 
13.4, 6.7 Hz, 1H), 0.95 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 169.0, 150.4, 
138.9, 131.0 (q, J = 30 Hz), 129.8, 126.7, 124.6, 123.7 (q, J = 6Hz), 121.9, 48.7, 38.9, 25.3, 
22.1, 20.4. IR (neat, cm
-1
): 1769, 1319, 1190, 1007, 807. MS (ESI
+
) m/z (%) 342 (M+H). 
HRMS calcd. for (C16H19N3O2F3): 342.1429, found 342.1433. 
 
2-(1-Isopentyl-1H-1,2,3-triazol-4-yl)-4-methylphenyl acetate (69za). Following the 
general procedure, using 1-isopentyl-4-(m-tolyl)-1H-1,2,3-triazole (68za) (0.25 mmol, 
57 mg) provided 59 mg (82 % yield) of 69za as a white solid. Mp 67-69 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.86 (s, 1H), 7.71 (s, 1H), 7.09 (dd, J = 45.9, 8.3 Hz, 2H), 4.40 (t, J = 7.5 
Hz, 2H), 2.38 (s, 3H), 2.31 (s, 3H), 1.82 (q, J = 7.3 Hz, 2H), 1.60 (dt, J = 13.3, 6.5 Hz, 1H), 
0.97 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 144.9, 143.1, 136.1, 129.5, 
129.0, 122.9, 122.7, 121.3, 48.6, 39.0, 25.4, 22.1, 21.2, 20.8. IR (neat, cm
-1
): 1769, 1430, 
1214, 948. MS (ESI
+
) m/z (%) 288 (M+H). HRMS calcd. for (C16H22N3O2): 288.1712, found 
288.1711.   
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2-(1-Isopentyl-1H-1,2,3-triazol-4-yl)cyclohex-1-en-1-yl acetate (69zb). Following the 
general procedure, using 4-(cyclohex-1-en-1-yl)-1-isopentyl-1H-1,2,3-triazole (68zb) (0.25 
mmol, 55 mg) at 110 ºC provided 51.9 mg (75 % yield) of 69zb as a yellow solid. Mp 73-81 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.45 (s, 1H), 4.28 (t, J = 7.4 Hz, 2H), 2.64-2.53 (m, 2H), 
2.26 (t, J = 6.0 Hz, 2H), 2.15 (s, 3H), 1.70 (q, J = 7.1 Hz, 6H), 1.49 (dt, J = 13.4, 6.7 Hz, 
1H), 0.88 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 168.6, 144.9, 144.2, 120.9, 
115.1, 48.3, 38.9, 27.8, 26.2, 25.3, 22.4, 22.0, 21.9, 21.2. IR (neat, cm
-1
): 2938, 2846, 1748, 
1371, 1215, 1198, 1150, 1103, 1058. MS (ESI
+
) m/z (%) 278 (M+H). HRMS calcd. for 
(C15H24N3O2): 278.1869, found 278.1860. 
 
2-[(1-Isopentyl-1H-1,2,3-triazol-4-yl)methyl]phenyl acetate (69zc). Following the general 
procedure, using 4-benzyl-1-isopentyl-1H-1,2,3-triazole (68zc) (0.25 mmol, 57 mg) provided 
12.2 mg (17 % yield) of 69zc as a yellow oil along with 46.6 mg (54 % yield) of 69zc’ as 
white solid. 69zc: 
1
H NMR (400 MHz, CDCl3): δ 7.31 (t, J = 7.0 Hz, 2H), 7.22 (t, J = 7.4 Hz, 
1H), 7.09 (d, J = 10.7 Hz, 2H), 4.34-4.27 (m, 2H), 4.05 (s, 2H), 2.26 (s, 3H), 1.76 (q, J = 7.3 
Hz, 2H), 1.58 (dt, J = 13.4, 6.7 Hz, 1H), 0.96 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, 
CDCl3): δ 169.6, 149.0, 146.5, 131.3, 130.9, 128.1, 126.4, 122.9, 121.5, 48.8, 39.1, 27.3, 
25.7, 22.3, 21.0. IR (neat, cm
-1
): 2957, 1764, 1367, 1202, 1169, 1047, 749. MS (ESI
+
) m/z 
(%) 288 (M+H). HRMS calcd. for (C16H22N3O2): 288.1712, found 288.1713. 69zc’: Mp 96-
100 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.42-7.29 (m, 1H), 7.13-6.97 (m, 3H), 4.37-4.21 (m, 
2H), 4.03 (s, 2H), 2.26 (q, J = 2.1, 1.6 Hz, 6H), 1.79-1.69 (m, 2H), 1.64-1.50 (m, 1H), 1.00-
0.93 (m, 6H). 
13
C NMR (126 MHz, CDCl3): δ 169.3, 150.0, 145.5, 127.8, 124.7, 121.7, 
120.6, 48.7, 39.0, 25.6, 22.2, 21.8, 20.8. IR (neat, cm
-1
): 1757, 1463, 1373, 1199, 1165, 1052, 
1023, 869. MS (ESI
+
) m/z (%) 346 (M+H). HRMS calcd. for (C18H24N3O4): 346.1767, found 
346.1763. 
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2-(1-Benzyl-5-iodo-1H-1,2,3-triazol-4-yl)phenyl acetate (69zd). Following the general 
procedure, using 1-benzyl-5-iodo-4-phenyl-1H-1,2,3-triazole
290
 (68zd) (0.25 mmol, 90 mg) 
provided 71 mg (68 % yield) of 69zd as a white solid. Mp 130-131 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.61 (d, J = 7.7 Hz, 1H), 7.53-7.15 (m, 8H), 5.68 (s, 2H), 2.13 (s, 3H). 
13
C NMR 
(101 MHz, CDCl3): δ 169.0, 148.5, 134.3, 131.0, 130.1, 128.9, 128.5, 127.7, 125.9, 123.3, 
123.1, 79.7, 54.5, 21.0. IR (neat, cm
-1
): 1737, 1195, 912, 761. MS (ESI
+
) m/z (%) 420 
(M+H). HRMS calcd. for (C17H15N3O2I): 420.0209, found 420.0215. 
 
2-(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69ze). Following the general 
procedure, using 5-Iodo-1-isopentyl-4-phenyl-1H-1,2,3-triazole (68ze) (0.25 mmol, 85 mg) 
provided 98 mg (98 % yield) of 69ze as a white solid. Mp 94-95 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.62 (d, J = 7.7 Hz, 1H), 7.48 (t, J = 7.4 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 7.27 (t, 
J = 7.7 Hz, 1H), 4.60-4.36 (m, 2H), 2.20 (s, 3H), 1.88 (q, J = 7.3 Hz, 2H), 1.70 (dq, J = 13.7, 
6.3 Hz, 1H), 1.04 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 169.1, 148.5, 147.7, 
131.1, 130.0, 125.8, 123.4, 123.2, 79.1, 49.6, 38.6, 25.7, 22.3, 21.1. IR (neat, cm
-1
): 1753, 
1197, 907, 768. MS (ESI
+
) m/z (%) 400 (M+H). HRMS calcd. for (C15H19N3O2I): 400.0522, 
found 400.0522. 
 
5-Fluoro-2-(5-iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69zf). Following the 
general procedure, using 4-(4-fluorophenyl)-5-iodo-1-isopentyl-1H-1,2,3-triazole (68zf) 
(0.25 mmol, 90 mg) provided 73 mg (71 % yield) of 69zf as a brown solid. Mp 62-63 ºC.    
1
H NMR (400 MHz, CDCl3): δ 7.55 (dd, J = 8.6, 6.1 Hz, 1H), 7.14-6.89 (m, 2H), 4.45 (t, J = 
7.7 Hz, 2H), 2.17 (s, 3H), 1.84 (q, J = 7.4 Hz, 2H), 1.67 (dt, J = 13.5, 7.2 Hz, 1H), 1.01 (d, J 
= 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 168.6, 162.8 (d, J = 249 Hz), 149.4 (d, J = 11 
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Hz), 147.1, 132.1 (d, J = 10 Hz), 119.6 (d, J = 3 Hz), 113.1 (d, J = 21 Hz), 111.1 (d, J = 25 
Hz), 79.2, 49.6, 38.5, 25.6, 22.2, 21.0. IR (neat, cm
-1
): 1763, 1459, 1200, 833. MS (ESI
+
) m/z 
(%) 418 (M+H). HRMS calcd. for (C15H18N3O2FI): 418.0428, found 418.0441. 
 
2-(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)-5-methoxyphenyl acetate (69zg). Following 
the general procedure, using 5-iodo-1-isopentyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole 
(68zg) (0.25 mmol, 93 mg) provided 77 mg (72 % yield) of 69zg as a white solid. Mp 86-87 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.48 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.7, 2.6 Hz, 1H), 
6.77 (d, J = 2.6 Hz, 1H), 4.43 (t, J = 7.8 Hz, 2H), 3.83 (s, 3H), 2.15 (s, 3H), 1.83 (q, J = 7.3 
Hz, 2H), 1.66 (dt, J = 13.4, 6.7 Hz, 1H), 1.00 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, 
CDCl3): δ 169.0, 160.8, 149.5, 147.6, 131.6, 115.7, 111.8, 108.8, 78.9, 55.5, 49.5, 38.5, 25.6, 
22.2, 21.0. IR (neat, cm
-1
): 1764, 1622, 1187, 1090, 840. MS (ESI
+
) m/z (%) 430 (M+H). 
HRMS calcd. for (C16H21N3O3I): 430.0628, found 430.0632.   
 
2-[(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)methyl]-1,3-phenylene diacetate (69zh’). 
Following the general procedure, using 4-benzyl-5-iodo-1-isopentyl-1H-1,2,3-triazole (68zh) 
(0.25 mmol, 89 mg) provided 84.8 mg (72 % yield) of 69zh’ as yellowish solid. Mp 122-126 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.29 (t, J = 8.2 Hz, 1H), 7.01 (d, J = 8.2 Hz, 2H), 4.36-
4.26 (m, 2H), 3.96 (s, 2H), 2.28 (s, 6H), 1.73 (q, J = 6.9 Hz, 2H), 1.61 (dp, J = 13.4, 6.7 Hz, 
1H), 0.97 (d, J = 6.6 Hz, 6H). 
13
C NMR (126 MHz, CDCl3): δ 168.8, 150.0, 148.4, 127.6, 
122.8, 120.2, 77.5, 49.1, 38.5, 25.5, 22.2, 22.1, 21.2. IR (neat, cm
-1
): 1764, 1466, 1366, 1203, 
1171, 1031, 860, 773, 726. MS (ESI
+
) m/z (%) 472 (M+H). HRMS calcd. for (C18H23N3O4I): 
472.0733, found 472.0742. 
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2-[(1-Benzyl-5-iodo-1H-1,2,3-triazol-4-yl)methyl]phenyl acetate (69zi). Following the 
general procedure, using 1,4-dibenzyl-5-iodo-1H-1,2,3-triazole (68zi) (0.25 mmol, 94 mg) 
and PhI(OAc)2 (0.25 mmol, 83 mg) provided 28 mg (23 % yield) of 69zi’ along with 44.7 
mg (41 % yield) of 69zi as a yellowish solid. Mp 133-138ºC. 
1
H NMR (400 MHz, CDCl3): δ 
7.35 (t, J = 7.0 Hz, 3H), 7.32-7.24 (m, 4H), 7.19 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H), 
5.58 (s, 2H), 4.01 (s, 2H), 2.31 (s, 3H). 
13
C NMR (126 MHz, CDCl3): δ 169.3, 149.8, 149.1, 
134.5, 131.1, 129.9, 129.0, 128.5, 128.0, 127.8, 126.1, 122.7, 78.9, 54.3, 27.5, 21.2. IR (neat, 
cm
-1
): 1752, 1492, 1209, 1168, 1098, 727. MS (ESI
+
) m/z (%) 434 (M+H). HRMS calcd. for 
(C18H17IN3O2): 434.0287, found 434.0288. 
 
2-[(1-Benzyl-5-iodo-1H-1,2,3-triazol-4-yl)methyl]-1,3-phenylene diacetate (69zi’) 
Following the general procedure, using 1,4-dibenzyl-5-iodo-1H-1,2,3-triazole (68zi) (0.25 
mmol, 94 mg) provided 108.1 mg (88 % yield) of 69zi’ as yellow solid. Mp 139-153 ºC. 1H 
NMR (400 MHz, CDCl3): δ 7.33 (t, J = 7.1 Hz, 3H), 7.28 (d, J = 8.2 Hz, 1H), 7.23 (d, J = 6.2 
Hz, 2H), 7.02 (d, J = 8.2 Hz, 2H), 5.52 (s, 2H), 3.97 (s, 2H), 2.25 (s, 6H). 
13
C NMR (101 
MHz, CDCl3): δ 168.8, 149.9, 149.1, 134.4, 128.8, 128.3, 127.6, 122.7, 120.1, 78.1, 54.0, 
22.1, 21.1. IR (neat, cm
-1
): 1761, 1462, 1369, 1203, 1174, 1029, 741. MS (ESI
+
) m/z (%) 492 
(M+H). HRMS calcd. for (C20H19N3O4I): 492.0420, found 492.0410. 
 
2-(1,5-Diphenyl-1H-1,2,3-triazol-4-yl)phenyl acetate (69zj). Following the general 
procedure, using 1,4,5-triphenyl-1H-1,2,3-triazole
71
 (68zj) (0.25 mmol, 74 mg) provided 
40 mg (45 % yield) of 69zj as a white solid along with 36.2 mg (35 % yield) of 69zj’ as 
white solid. 69zj: Mp 137-153 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.47-7.10 (m, 14H), 2.11 
(s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.2, 148.6, 141.7, 136.4, 134.8, 131.1, 129.6, 
129.3, 129.1, 129.0, 128.8, 126.9, 125.8, 125.1, 123.7, 123.1, 20.9. IR (neat, cm
-1
): 1761, 
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1495, 1365, 1198, 1173, 995, 915, 772, 761, 691. MS (ESI
+
) m/z (%) 356 (M+H). HRMS 
calcd. for (C22H18N3O2): 356.1399, found 356.1400. 69zj’: Mp 61-78 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.49-7.09 (m, 13H), 1.97 (s, 6H). 
13
C NMR (126 MHz, CDCl3): δ 168.5, 
150.0, 137.3, 136.8, 136.1, 129.8, 129.5, 129.5, 129.3, 129.1, 129.0, 127.0, 125.4, 120.4, 
117.9, 20.9. IR (neat, cm
-1
): 1759, 1365, 1179, 1026, 996, 755, 696. MS (ESI
+
) m/z (%) 414 
(M+H). HRMS calcd. for (C24H20N3O4): 414.1454, found 414.1449. 
4.3 Pd-catalyzed C(sp2)-H pivaloxylation. 
 
General Procedure: A reaction tube containing a stirring bar was charged with the 
correspoding triazole (0.25 mmol, 1.00 equiv), PhI(OPiv)2 (0.50 mmol, 2.00 equiv), PivOH 
(0.50 mmol, 2.00 equiv) and Pd(OAc)2 (10 mol %). The reaction tube was then evacuated 
and back-filled with dry argon (this sequence was repeated up to three times). Then 1,2-
dichloroethane (1.00 mL) was added under argon atmosphere. The reaction tube was next 
warmed up to 90 ºC and stirred for 24 hours. The mixture was then allowed to warm to room 
temperature, filtered off through a pad of celite and washed with CH2Cl2. The resulting 
mixture was concentrated under reduced pressure and the corresponding product was 
purified by flash chromatography (hex/EtOAc 7/3). The yields reported in the thesis refer to 
isolated yields and represent an average of at least two independent runs. 
 
2-(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)phenyl pivalate (73p). Following the general 
procedure, using 1-[4-(tert-butyl)benzyl)]-4-(cyclohex-1-en-1-yl)-1H-1,2,3-triazole (68p) 
(0.25 mmol, 74 mg) provided 76 mg (77 % yield) of 73p as a white solid. Mp 88-89 ºC. 
1
H 
NMR (400 MHz, CDCl3): δ 7.37 (d, J = 8.0 Hz, 2H), 7.33 (s, 1H), 7.19 (d, J = 8.0 Hz, 2H), 
5.43 (s, 2H), 2.67 (d, J = 5.2 Hz, 2H), 2.19 (t, J = 5.6 Hz, 2H), 1.74 (dt, J = 8.1, 5.3 Hz, 4H), 
1.29 (s, 9H), 1.05 (s, 9H). 
13
C NMR (101 MHz, CDCl3): δ 175.9, 151.8, 145.2, 144.3, 131.2, 
128.2, 126.0, 121.2, 115.4, 53.8, 38.6, 34.5, 31.2, 27.3, 26.9, 26.7, 26.4, 22.5, 22.0. IR (neat, 
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cm
-1
): 1739, 1115, 715. MS (ESI
+
) m/z (%) 396 (M+H). HRMS calcd. for (C24H34N3O2): 
396.2651, found 396.2666. 
 
2-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-methylphenyl pivalate (73s). Following the 
general procedure, using 1-benzyl-4-(3-methylbenzyl)-1H-1,2,3-triazole (68s) (0.25 mmol, 
66 mg) provided 55 mg (60 % yield) of 73s as a yellow solid. Mp 99-100 ºC. 
1
H NMR (400 
MHz, CDCl3): δ 7.36 (d, J = 6.3 Hz, 3H), 7.31-7.21 (m, 2H), 7.13-7.01 (m, 3H), 6.90 (d, J = 
7.9 Hz, 1H), 5.46 (s, 2H), 3.97 (s, 2H), 2.31 (s, 3H), 1.23 (s, 9H). 
13
C NMR (101 MHz, 
CDCl3): δ 177.0, 147.0, 146.9, 135.7, 134.9, 131.3, 130.4, 129.0, 128.5, 128.4, 127.9, 122.1, 
121.7, 54.0, 39.1, 27.2, 20.8. IR (neat, cm
-1
): 1744, 1199, 736. MS (ESI
+
) m/z (%) 396 
(M+H). HRMS calcd. for (C22H26N3O2): 364.1947, found 364.1948. 
 
2-(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)phenyl pivalate (73za). Following the general 
procedure, using1-isopentyl-4-(m-tolyl)-1H-1,2,3-triazole (68za) (0.25 mmol, 57 mg) 
provided 58 mg (70 % yield) of 73za as a white solid. Mp 78-80 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.81 (s, 1H), 7.68 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 4.40 
(t, J = 7.5 Hz, 2H), 2.39 (s, 3H), 1.81 (q, J = 7.3 Hz, 2H), 1.60 (d, J = 5.3 Hz, 1H), 1.36 (s, 
9H), 0.97 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ 176.9, 145.7, 143.2, 135.8, 
129.7, 129.6, 123.3, 122.4, 121.6, 48.6, 39.1, 27.3, 25.4, 22.2, 20.8. IR (neat, cm
-1
): 1742, 
1498, 1110, 790. MS (ESI
+
) m/z (%) 330 (M+H). HRMS calcd. for (C19H28N3O2): 330.2182, 
found 330.2193. 
 
2-(5-Iodo-1-isopentyl-1H-1,2,3-triazol-4-yl)phenyl pivalate (73zd). Following the general 
procedure, using 1-benzyl-5-iodo-4-phenyl-1H-1,2,3-triazole (68zd) (0.25 mmol, 90 mg) 
provided 78 mg (68 % yield) of 73zd as a white solid. Mp 105-107 ºC. 
1
H NMR (400 MHz, 
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CDCl3): δ 7.55-7.43 (m, 3H), 7.42-7.26 (m, 5H), 7.19 (d, J = 8.1 Hz, 1H), 5.67 (s, 2H), 1.12 
(s, 9H). 
13
C NMR (101 MHz, CDCl3): δ 176.3, 149.1, 148.5, 134.2, 131.3, 130.1, 128.8, 
128.4, 127.9, 125.6, 123.6, 122.9, 80.1, 54.4, 38.8, 26.9. IR (neat, cm
-1
): 1747, 1730, 1093, 
731. MS (ESI
+
) m/z (%) 462 (M+H). HRMS calcd. for (C20H21N3O2I): 462.0678, found 
462.0688. 
4.4 Further transformations (Scheme 4.17-4.18) 
 
2-(1-Benzyl-5-(phenylethynyl)-1H-1,2,3-triazol-4-yl)phenyl acetate (70). A reaction tube 
containing a stirring bar was charged with 2-(1-benzyl-5-iodo-1H-1,2,3-triazol-4-yl)phenyl 
acetate (69zd) (0.12 mmol, 50 mg), PdCl2(PPh3)2 (0.012 mmol, 8.20 mg), and K2CO3 (0.18 
mmol, 25 mg). The reaction tube was then evacuated and back-filled with dry argon (this 
sequence was repeated up to three times). Phenylacetylene (0.18 mmol, 20 μL), and THF 
(1.0 mL) were then added under argon atmosphere. The reaction tube was next warmed up to 
80 ºC and stirred 12 hours. The resulting mixture was concentrated under reduced pressure 
and the corresponding product was purified by flash chromatography (hex/EtOAc 8/2) to 
provide 39 mg (83 % yield) of 70 as an orange oil. 
1
H NMR (400 MHz, CDCl3): δ 8.00 (d, J 
= 7.7 Hz, 1H), 7.57-7.34 (m, 11H), 7.34-7.23 (m, 2H), 5.75 (s, 2H), 2.28 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3): δ 169.7, 148.0, 145.34, 134.6, 131.5, 130.0, 130.1, 129.7, 128.9, 128.6, 
128.5, 128.0, 125.9, 123.4, 123.0, 121.2, 119.1, 102.2, 75.0, 53.1, 21.2. IR (neat, cm
-1
): 1763, 
1190, 729, 689. MS (ESI
+
) m/z (%) 394 (M+H). HRMS calcd. for (C25H20N3O2): 394.1556, 
found 394.1566. 
 
Methyl (E)-3-(4-(2-acetoxyphenyl)-1-benzyl-1H-1,2,3-triazol-5-yl)acrylate (71). A 
reaction tube containing a stirring bar was charged with 2-(1-benzyl-5-iodo-1H-1,2,3-triazol-
4-yl)phenyl acetate (69zd) (0.17 mmol, 70 mg), Pd(OAc)2 (0.017 mmol, 1.90 mg), TBAB 
(0.013 mmol, 4.20 mg) and NaHCO3 (0.42 mmol, 35 mg). The reaction tube was then 
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evacuated and back-filled with dry argon (this sequence was repeated up to three times). 
Methyl acrylate (0.42 mmol, 38 μL), and DMF (2.0 mL) were then added under argon 
atmosphere. The reaction tube was next warmed up to 80 ºC and stirred 12 hours. The 
resulting mixture was concentrated under reduced pressure and the corresponding product 
was purified by flash chromatography (hex/EtOAc 7/3) to provide 44 mg (69 % yield) of 71 
as an orange oil. 
1
H NMR (400 MHz, CDCl3): δ 7.63-7.51 (m, 3H), 7.47-7.39 (m, 4H), 7.37-
7.22 (m, 3H), 6.14 (d, J = 16.1 Hz, 1H), 5.77 (s, 2H), 3.78 (s, 3H), 2.08 (s, 3H). 
13
C NMR 
(101 MHz, CDCl3): δ 168.7, 166.1, 148.4, 143.9, 134.4, 131.1, 130.4, 129.5, 129.2, 128.6, 
126.9, 126.8, 126.3, 123.6, 123.4, 123.2, 52.8, 52.0, 20.7. IR (neat, cm
-1
): 1715, 1644, 1176, 
908, 726. MS (ESI
+
) m/z (%) 378 (M+H). HRMS calcd. for (C21H20N3O4): 378.1454, found 
378.1467. 
 
2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenol (72). A reaction tube containing a stirring bar was 
charged with 2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl acetate 69a (0.17 mmol, 50 mg) and 
dissolved in MeOH (4 mL) at 0 ºC. Then Cs2CO3 (0.17 mmol, 55 mg) was added and the 
resulting solution was stirred at room temperature for 5 hours under argon atmosphere. The 
solvent was partially evaporated under reduce pressure and the resulting solution was washed 
with aq. NH4Cl, extracted with CH2Cl2 and washed with brine. The combined organic layers 
were dried over MgSO4, and concentrated under reduced pressure. The crude residue was 
purified by flash chromatography (hex/EtOAc 9/1) to provide 40 mg (94 % yield) of 72 as a 
white solid. Mp 142-144 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.73 (s, 1H), 7.46-7.27 (m, 6H), 
7.21 (t, J = 8 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 6.85 (t, J = 8.0 Hz, 1H), 5.58 (s, 2H). 
13
C 
NMR (101 MHz, CDCl3): δ 155.8, 148.0, 134.0, 129.7, 129.2, 129.0, 128.10, 125.8, 119.4, 
118.8, 117.6, 113.8, 54.5. IR (neat, cm
-1
): 3200, 1210, 690. MS (ESI
+
) m/z (%) 252 (M+H). 
HRMS calcd. for (C15H14N3O): 252.1137, found 252.1149. 
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4.5 Pd-catalyzed C(sp2)-H acylation. 
 
General Procedure: A reaction tube containing a stirring bar was charged with the 
corresponding triazole (0.25 mmol, 1.00 equiv) and Pd(TFA)2 (10 mol %). The reaction tube 
was then evacuated and back-filled with dry argon (this sequence was repeated up to three 
times). Then, 1,2-dichloroethane (1.00 mL), acetonitrile (1.00 mL), aldehyde (0.50 mmol, 
2.00 equiv) and TBHP (70 wt.% in H2O, 0.50 mmol, 2.00 equiv.) were then added under 
argon atmosphere. The reaction tube was next warmed up to 70 ºC and stirred for 24 hours. 
The mixture was then allowed to warm to room temperature, filtered off through a pad of 
celite and washed with CH2Cl2. The resulting mixture was concentrated under reduced 
pressure and the corresponding product was purified by flash chromatography (hex/EtOAc 
7/3). The yields reported in the thesis refer to isolated yields and represent an average of at 
least two independent runs. 
 
2-(1-Benzyl-1H-1,2,3-triazol-4-yl)cyclohex-1-en-1-yl)(4-methoxyphenyl)methanone (82). 
Following the general procedure, using 1-benzyl-4-(cyclohex-1-en-1-yl)-1H-1,2,3-triazole 
(80) (0.25 mmol, 60 mg) and 4-methoxybenzaldehyde (0.5 mmol, 68 mg), provided 43 mg 
(46 % yield) of 82 as a yellowish solid. Mp 146-149 ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.76 
(d, J = 8.8 Hz, 2H), 7.22 (dt, J = 14.3, 7.0 Hz, 3H), 7.14 (s, 1H), 6.88 (d, J = 7.2 Hz, 2H), 
6.77 (d, J = 8.8 Hz, 2H), 5.29 (s, 2H), 3.80 (s, 3H), 2.70 (s, 2H), 2.37 (s, 2H), 1.93-1.73 (m, 
4H). 
13
C NMR (101 MHz, CDCl3): δ 200.0, 163.6, 146.8, 136.5, 134.7, 131.6, 128.8, 128.3, 
127.4, 126.6, 122.1, 113.8, 55.4, 53.6, 28.2, 27.5, 22.2, 21.9. IR (neat, cm
-1
): 3128, 2939, 
2834, 1660, 1596, 1575, 1240, 1165, 1028, 844, 711. MS (ESI
+
) m/z (%) 374 (M+H). HRMS 
calcd. for (C23H24N3O2): 374.1869, found 374.1881. 
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4- [(4-(2-(4- Methoxybenzoyl) cyclohex-1-en-1-yl) -1H-1,2,3-triazol-1-yl) methyl] 
benzonitrile (86b). Following the general procedure, using 4-[(4-(cyclohex-1-en-1-yl)-1H-
1,2,3-triazol-1-yl)methyl]benzonitrile (0.25 mmol, 66 mg) and 4-methoxybenzaldehyde 
(0.50 mmol, 68 mg), provided 57 mg (57 % yield) of 86b as a yellowish solid. Mp 149-151 
ºC. 
1
H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.17 (s, 
1H), 6.89 (d, J = 8.1 Hz, 2H), 6.77 (d, J = 8.8 Hz, 2H), 5.36 (s, 2H), 3.82 (s, 3H), 2.71 (s, 
2H), 2.35 (s, 2H), 1.82 (dq, J = 23.9, 5.1 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 200.0, 
163.6, 147.3, 140.1, 137.1, 132.7, 131.8, 128.2, 127.7, 126.4, 122.4, 118.3, 113.9, 112.3, 
55.6, 53.0, 28.2, 27.5, 22.3, 21.9. IR (neat, cm
-1
): 2943, 2233, 1747, 1594, 1417, 1171, 1153, 
1018, 835, 758. MS (ESI
+
) m/z (%) 374 (M+H). HRMS calcd. for (C24H23N4O2): 299.1821, 
found 399.1819. 
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APPENDIX : 
1
H NMR and 
13
C NMR Spectra 
 
 
Spectrum 4.1. 1H NMR (400 MHz, CDCl3) spectrum of compound 68f. 
 
 
Spectrum 4.2. 13C NMR (101 MHz, CDCl3) spectrum of compound 68f. 
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Spectrum 4.3. 1H NMR (400 MHz, CDCl3) spectrum of compound 68m. 
 
 
Spectrum 4.4. 13C NMR (101 MHz, CDCl3) spectrum of compound 68m. 
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Spectrum 4.5. 1H NMR (400 MHz, CDCl3) spectrum of compound 68n. 
 
 
Spectrum 4.6. 13C NMR (101 MHz, CDCl3) spectrum of compound 68n. 
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Spectrum 4.7. 1H NMR (400 MHz, CDCl3) spectrum of compound 68o. 
 
 
Spectrum 4.8. 13C NMR (101 MHz, CDCl3) spectrum of compound 68o. 
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Spectrum 4.9. 1H NMR (400 MHz, CDCl3) spectrum of compound 68p. 
 
 
Spectrum 4.10. 13C NMR (101 MHz, CDCl3) spectrum of compound 68p. 
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Spectrum 4.11. 1H NMR (400 MHz, CDCl3) spectrum of compound 68q. 
 
 
Spectrum 4.12. 13C NMR (101 MHz, CDCl3) spectrum of compound 68q. 
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Spectrum 4.13. 1H NMR (400 MHz, CDCl3) spectrum of compound 68r. 
 
 
Spectrum 4.14. 13C NMR (101 MHz, CDCl3) spectrum of compound 68r. 
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Spectrum 4.15. 1H NMR (400 MHz, CDCl3) spectrum of compound 68s.  
 
 
Spectrum 4.16. 13C NMR (101 MHz, CDCl3) spectrum of compound 68s. 
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Spectrum 4.17. 1H NMR (400 MHz, CDCl3) spectrum of compound 68x. 
 
 
Spectrum 4.18. 13C NMR (101 MHz, CDCl3) spectrum of compound 68x. 
 284 
 
 
Spectrum 4.19. 1H NMR (400 MHz, CDCl3) spectrum of compound 68y. 
 
 
Spectrum 4.20. 13C NMR (101 MHz, CDCl3) spectrum of compound 68y. 
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Spectrum 4.21. 1H NMR (400 MHz, CDCl3) spectrum of compound 68z. 
 
 
Spectrum 4.22. 13C NMR (101 MHz, CDCl3) spectrum of compound 68z. 
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Spectrum 4.23. 1H NMR (400 MHz, CDCl3) spectrum of compound 68za. 
 
 
Spectrum 4.24. 13C NMR (101 MHz, CDCl3) spectrum of compound 68za. 
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Spectrum 4.25. 1H NMR (400 MHz, CDCl3) spectrum of compound 68zb. 
 
 
Spectrum 4.26. 13C NMR (101 MHz, CDCl3) spectrum of compound 68zb. 
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Spectrum 4.27. 1H NMR (400 MHz, CDCl3) spectrum of compound 68zc. 
 
 
Spectrum 4.28. 13C NMR (101 MHz, CDCl3) spectrum of compound 68zc. 
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Spectrum 4.29. 1H NMR (400 MHz, CDCl3) spectrum of compound 68ze. 
 
 
Spectrum 4.30. 13C NMR (101 MHz, CDCl3) spectrum of compound 68ze. 
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Spectrum 4.31. 1H NMR (400 MHz, CDCl3) spectrum of compound 68zf. 
 
 
Spectrum 4.32. 13C NMR (101 MHz, CDCl3) spectrum of compound 68zf. 
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Spectrum 4.33. 1H NMR (400 MHz, CDCl3) spectrum of compound 68zg. 
 
 
Spectrum 4.34. 13C NMR (101 MHz, CDCl3) spectrum of compound 68zg. 
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Spectrum 4.35. 1H NMR (400 MHz, DMSO-d6) spectrum of compound 68zh. 
 
 
Spectrum 4.36. 13C NMR (101 MHz, DMSO-d6) spectrum of compound 68zh. 
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Spectrum 4.37. 1H NMR (400 MHz, CDCl3) spectrum of compound 68zi. 
 
 
Spectrum 4.38. 13C NMR (101 MHz, CDCl3) spectrum of compound 68zi. 
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Spectrum 4.39. 1H NMR (400 MHz, CDCl3) spectrum of compound 75. 
 
 
Spectrum 4.40. 1H NMR (400 MHz, CDCl3) spectrum of compound 76. 
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Spectrum 4.41. 1H NMR (400 MHz, CDCl3) spectrum of compound 79. 
 
 
Spectrum 4.42. 13C NMR (101 MHz, CDCl3) spectrum of compound 79. 
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Spectrum 4.43. 1H NMR (400 MHz, CDCl3) spectrum of compound 69a. 
 
 
Spectrum 4.44. 13C NMR (101 MHz, CDCl3) spectrum of compound 69a. 
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Spectrum 4.45. 1H NMR (400 MHz, CDCl3) spectrum of compound 69a’. 
 
 
Spectrum 4.46. 13C NMR (101 MHz, CDCl3) spectrum of compound 69a’. 
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Spectrum 4.47. 1H NMR (400 MHz, CDCl3) spectrum of compound 69b. 
 
 
Spectrum 4.48. 13C NMR (101 MHz, CDCl3) spectrum of compound 69b. 
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Spectrum 4.49. 1H NMR (400 MHz, CDCl3) spectrum of compound 69b’. 
 
 
Spectrum 4.50. 13C NMR (101 MHz, CDCl3) spectrum of compound 69b’. 
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Spectrum 4.51. 1H NMR (400 MHz, CDCl3) spectrum of compound 69c. 
 
 
Spectrum 4.52. 13C NMR (126 MHz, CDCl3) spectrum of compound 69c. 
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Spectrum 4.53. 1H NMR (400 MHz, CDCl3) spectrum of compound 69c’. 
 
 
Spectrum 4.54. 13C NMR (126 MHz, CDCl3) spectrum of compound 69c’. 
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Spectrum 4.55. 1H NMR (400 MHz, CDCl3) spectrum of compound 69d. 
 
 
Spectrum 4.56. 13C NMR (101 MHz, CDCl3) spectrum of compound 69d. 
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Spectrum 4.57. 1H NMR (400 MHz, CDCl3) spectrum of compound 69d’. 
 
 
Spectrum 4.58. 13C NMR (101 MHz, CDCl3) spectrum of compound 69d’. 
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Spectrum 4.59. 1H NMR (400 MHz, CDCl3) spectrum of compound 69e.  
 
 
Spectrum 4.60. 13C NMR (101 MHz, CDCl3) spectrum of compound 69e. 
 305 
 
 
Spectrum 4.61. 1H NMR (400 MHz, CDCl3) spectrum of compound 69e’.  
 
 
Spectrum 4.62. 13C NMR (101 MHz, CDCl3) spectrum of compound 69e’. 
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Spectrum 4.63. 1H NMR (400 MHz, CDCl3) spectrum of compound 69f. 
 
 
Spectrum 4.64. 13C NMR (101 MHz, CDCl3) spectrum of compound 69f. 
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Spectrum 4.65. 1H NMR (400 MHz, CDCl3) spectrum of compound 69f’.  
 
 
Spectrum 4.66. 13C NMR (101 MHz, CDCl3) spectrum of compound 69f’. 
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Spectrum 4.67. 1H NMR (400 MHz, CDCl3) spectrum of compound 69g. 
 
 
Spectrum 4.68. 13C NMR (101 MHz, CDCl3) spectrum of compound 69g. 
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Spectrum 69. 1H NMR (400 MHz, CDCl3) spectrum of compound 69g’. 
 
 
Spectrum 4.70. 13C NMR (101 MHz, CDCl3) spectrum of compound 69g’. 
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Spectrum 4.71. 1H NMR (400 MHz, CDCl3) spectrum of compound 69h. 
 
 
Spectrum 4.72. 13C NMR (126 MHz, CDCl3) spectrum of compound 69h. 
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Spectrum 4.73. 1H NMR (400 MHz, CDCl3) spectrum of compound 69h’. 
 
 
Spectrum 4.74. 13C NMR (101 MHz, CDCl3) spectrum of compound 69h’. 
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Spectrum 4.75. 1H NMR (400 MHz, CDCl3) spectrum of compound 69i. 
 
 
Spectrum 4.76. 13C NMR (126 MHz, CDCl3) spectrum of compound 69i. 
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Spectrum 4.77. 1H NMR (400 MHz, CDCl3) spectrum of compound 69i’.  
 
 
Spectrum 4.78. 13C NMR (126 MHz, CDCl3) spectrum of compound 69i’. 
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Spectrum 4.79. 1H NMR (400 MHz, CDCl3) spectrum of compound 69j.  
 
 
Spectrum 4.80. 13C NMR (101 MHz, CDCl3) spectrum of compound 69j. 
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Spectrum 4.81. 1H NMR (400 MHz, CDCl3) spectrum of compound 69j’.   
 
 
Spectrum 4.82. 13C NMR (126 MHz, CDCl3) spectrum of compound 69j’. 
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Spectrum 4.83. 1H NMR (400 MHz, CDCl3) spectrum of compound 69k.    
 
 
Spectrum 4.84. 13C NMR (101 MHz, CDCl3) spectrum of compound 69k. 
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Spectrum 4.85. 1H NMR (400 MHz, CDCl3) spectrum of compound 69k’.  
 
 
Spectrum 4.86. 13C NMR (126 MHz, CDCl3) spectrum of compound 69k’. 
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Spectrum 4.87. 1H NMR (400 MHz, CDCl3) spectrum of compound 69l. 
 
 
Spectrum 4.88. 13C NMR (101 MHz, CDCl3) spectrum of compound 69l. 
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Spectrum 4.89. 1H NMR (400 MHz, CDCl3) spectrum of compound 69m.  
 
 
Spectrum 4.90. 13C NMR (101 MHz, CDCl3) spectrum of compound 69m. 
 320 
 
 
Spectrum 4.91. 1H NMR (400 MHz, CDCl3) spectrum of compound 69n. 
 
 
Spectrum 4.92. 13C NMR (101 MHz, CDCl3) spectrum of compound 69n. 
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Spectrum 4.93. 1H NMR (400 MHz, CDCl3) spectrum of compound 69o.  
 
 
Spectrum 4.94. 13C NMR (101 MHz, CDCl3) spectrum of compound 69o. 
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Spectrum 4.95. 1H NMR (400 MHz, CDCl3) spectrum of compound 69p. 
 
 
Spectrum 4.96. 13C NMR (101 MHz, CDCl3) spectrum of compound 69p. 
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Spectrum 4.97. 1H NMR (400 MHz, CDCl3) spectrum of compound 69q. 
 
 
Spectrum 4.98. 13C NMR (126 MHz, CDCl3) spectrum of compound 69q.  
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Spectrum 4.99. 1H NMR (400 MHz, CDCl3) spectrum of compound 69r. 
 
 
Spectrum 4.100. 13C NMR (101 MHz, CDCl3) spectrum of compound 69r.   
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Spectrum 4.101. 1H NMR (400 MHz, CDCl3) spectrum of compound 69s. 
 
 
Spectrum 4.102. 13C NMR (101 MHz, CDCl3) spectrum of compound 69s.  
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Spectrum 4.103. 1H NMR (500 MHz, CDCl3) spectrum of compound 69t. 
 
 
Spectrum 4.104. 13C NMR (126 MHz, CDCl3) spectrum of compound 69t. 
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Spectrum 4.105. 1H NMR (400 MHz, CDCl3) spectrum of compound 69t’. 
 
   
 
Spectrum 4.106. 13C NMR (126 MHz, CDCl3) spectrum of compound 69t’. 
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Spectrum 4.107. 1H NMR (400 MHz, CDCl3) spectrum of compound 69w. 
 
 
Spectrum 4.108 . 13C NMR (101 MHz, CDCl3) spectrum of compound 69w. 
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Spectrum 4.109. 1H NMR (400 MHz, CDCl3) spectrum of compound 69w’. 
 
 
Spectrum 4.110. 13C NMR (101 MHz, CDCl3) spectrum of compound 69w’. 
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Spectrum 4.111. 1H NMR (400 MHz, CDCl3) spectrum of compound 69x. 
 
 
Spectrum 4.112. 13C NMR (126 MHz, CDCl3) spectrum of compound 69x. 
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Spectrum 4.113. 1H NMR (400 MHz, CDCl3) spectrum of compound 69x’. 
 
 
Spectrum 4.114. 13C NMR (126 MHz, CDCl3) spectrum of compound 69x’. 
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Spectrum 4.115. 1H NMR (400 MHz, CDCl3) spectrum of compound 69y. 
 
 
Spectrum 4.116. 13C NMR (101 MHz, CDCl3) spectrum of compound 69y.  
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Spectrum 4.117. 1H NMR (400 MHz, CDCl3) spectrum of compound 69z. 
 
 
Spectrum 4.118. 13C NMR (101 MHz, CDCl3) spectrum of compound 69z.  
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Spectrum 4.119. 1H NMR (400 MHz, CDCl3) spectrum of compound 69za.  
 
 
Spectrum 4.120 . 13C NMR (101 MHz, CDCl3) spectrum of compound 69za. 
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Spectrum 4.121. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zb. 
 
 
Spectrum 4.122. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zb. 
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Spectrum 4.123. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zc. 
 
 
Spectrum 4.124. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zc. 
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Spectrum 4.125. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zc’. 
 
 
Spectrum 4.126. 13C NMR (126 MHz, CDCl3) spectrum of compound 69zc.  
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Spectrum 4.127. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zd.  
 
 
Spectrum 4.128. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zd. 
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Spectrum 4.129. 1H NMR (400 MHz, CDCl3) spectrum of compound 69ze. 
 
 
Spectrum 4.130. 13C NMR (101 MHz, CDCl3) spectrum of compound 69ze. 
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Spectrum 4.131. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zf. 
 
 
Spectrum 4.132. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zf.  
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Spectrum 4.133. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zg. 
 
 
Spectrum 4.134. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zg. 
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Spectrum 4.135. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zh’. 
 
 
Spectrum 4.136. 13C NMR (126 MHz, CDCl3) spectrum of compound 69zh’.  
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Spectrum 4.137. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zi.  
 
 
Spectrum 4.138. 13C NMR (126 MHz, CDCl3) spectrum of compound 69zi. 
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Spectrum 4.139. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zi’. 
 
 
Spectrum 4.140. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zi’. 
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Spectrum 4.141. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zj. 
 
 
Spectrum 4.142. 13C NMR (101 MHz, CDCl3) spectrum of compound 69zj. 
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Spectrum 4.143. 1H NMR (400 MHz, CDCl3) spectrum of compound 69zj’. 
 
 
Spectrum 4.144. 13C NMR (126 MHz, CDCl3) spectrum of compound 69zj’.  
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Spectrum 4.145. 1H NMR (400 MHz, CDCl3) spectrum of compound 73p. 
 
 
Spectrum 4.146. 13C NMR (101 MHz, CDCl3) spectrum of compound 73p. 
 348 
 
 
Spectrum 4.147. 1H NMR (400 MHz, CDCl3) spectrum of compound 73s. 
 
 
Spectrum 4.148. 13C NMR (101 MHz, CDCl3) spectrum of compound 73s. 
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Spectrum 4.149. 1H NMR (400 MHz, CDCl3) spectrum of compound 73za. 
 
 
Spectrum 4.150. 13C NMR (101 MHz, CDCl3) spectrum of compound 73za. 
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Spectrum 4.151. 1H NMR (400 MHz, CDCl3) spectrum of compound 73zd. 
 
 
Spectrum 4.152. 13C NMR (101 MHz, CDCl3) spectrum of compound 73zd.  
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Spectrum 4.153. 1H NMR (400 MHz, CDCl3) spectrum of compound 70. 
 
 
Spectrum 4.154. 13C NMR (126 MHz, CDCl3) spectrum of compound 70.   
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Spectrum 4.155. 1H NMR (400 MHz, CDCl3) spectrum of compound 71.  
 
 
Spectrum 4.156. 13C NMR (101 MHz, CDCl3) spectrum of compound 71.  
 353 
 
 
Spectrum 4.157. 1H NMR (400 MHz, CDCl3) spectrum of compound 72.  
 
 
Spectrum 4.158. 13C NMR (101 MHz, CDCl3) spectrum of compound 72.    
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Spectrum 4.159. 1H NMR (400 MHz, CDCl3) spectrum of compound 82. 
 
 
Spectrum 4.160. 13C NMR (101 MHz, CDCl3) spectrum of compound 82.    
 355 
 
 
Spectrum 4.161. 1H NMR (400 MHz, CDCl3) spectrum of compound 86b.  
 
 
Spectrum 4.162. 13C NMR (101 MHz, CDCl3) spectrum of compound 86b.    
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